

The Fifth Plot of the Carcinogenic Potency Database: Results of Animal Bioassays Published in the General Literature through 1988 and by the National Toxicology Program through 1989

by Lois Swirsky Gold,^{1,2} Neela B. Manley,² Thomas H. Slone,^{1,2} Georganne Backman Garfinkel,² Lars Rohrbach,¹ and Bruce N. Ames²

This paper is the fifth plot of the Carcinogenic Potency Database (CPDB) that first appeared in this journal in 1984 (1-5). We report here results of carcinogenesis bioassays published in the general literature between January 1987 and December 1988, and in technical reports of the National Toxicology Program between July 1987 and December 1989. This supplement includes results of 412 long-term, chronic experiments of 147 test compounds and reports the same information about each experiment in the same plot format as the earlier papers: the species and strain of test animal, the route and duration of compound administration, dose level and other aspects of experimental protocol, histopathology and tumor incidence, TD₅₀ (carcinogenic potency) and its statistical significance, dose response, author's opinion about carcinogenicity, and literature citation. We refer the reader to the 1984 publications (1,5,6) for a guide to the plot of the database, a complete description of the numerical index of carcinogenic potency, and a discussion of the sources of data, the rationale for the inclusion of particular experiments and particular target sites, and the conventions adopted in summarizing the literature. The five plots of the database are to be used together, as results of individual experiments that were published earlier are not repeated. In all, the five plots include results of 4487 experiments on 1136 chemicals.

Several analyses based on the CPDB that were published earlier are described briefly, and updated results based on all five plots are given for the following earlier analyses: the most potent TD₅₀ value by species, reproducibility of bioassay results, positivity rates, and prediction between species. A new feature of this supplement is that Appendix 14 now provides a summary compendium of positivity and potency, as well as an index to all chemicals in the five plots of the CPDB. It provides the following summary data for each chemical: (a) whether it has been tested in each sex of rats and mice, and positivity results in each group; (b) for positive chemicals, a summary of carcinogenic potency for rats and for mice; (c) an index to the CPDB sorted by chemical name that reports synonyms, CAS number, and the plot numbers that include experiments on the chemical. For readers using the CPDB more extensively, a combined plot of all results from the five separate plot papers, ordered alphabetically by chemical is available from the first author in printed form or on computer tape or diskette. A SAS database is also available.

Background

The Carcinogenic Potency Database (CPDB) is a widely used, standardized resource of results of chronic, long-term carcinogenesis bioassays. The CPDB has been published in plot format in this and four earlier papers. To facilitate its use by other

researchers, we have prepared a printed version of a combined plot that merges results from all five plots organized by chemical, as well as a computer-readable (SAS) database. These are obtainable from the first author.

In this paper we *a)* briefly describe the CPDB and the plot included in this fourth supplement; *b)* refer the reader to our earlier papers; *c)* update some of the earlier published findings using results from all five plots; and *d)* report errata to earlier papers.

Our goal in developing the CPDB over the past 12 years has been to provide a single, standardized and easily accessible resource that includes sufficient information on each experiment to permit investigations in many research areas of carcinogenesis. Therefore, the CPDB provides both qualitative and

¹Cell and Molecular Biology Division, Lawrence Berkeley Laboratory, Berkeley, CA 94720.

²Division of Biochemistry and Molecular Biology, University of California, Berkeley, CA 94720.

Address reprint requests to L. S. Gold, Cell and Molecular Biology Division, Lawrence Berkeley Laboratory, Berkeley, CA 94720.

quantitative information on positive and negative tests (1-4), including for each experiment, the species, strain, and sex of test animal; features of experimental protocol such as route of administration, duration of dosing, dose level(s) in mg/kg body weight/day, and duration of experiment; histopathology and tumor incidence; carcinogenic potency and its statistical significance; shape of the dose-response curve; author's opinion as to carcinogenicity; and literature citation. All experiments in the CPDB meet a specific set of inclusion criteria that are designed to permit the estimation of carcinogenic potency; therefore, reasonable consistency of experimental protocols is assured. Rodent bioassays are included in the database only if the test agent was administered alone, rather than in combination with other substances; if the bioassay included a control group; if the route of administration was diet, water, gavage, inhalation, IV injection or IP injection; and if the length of experiment was at least 1 year with dosing for at least 6 months. Many cancer tests do not meet these rules and are not included, e.g., if route of administration was skin painting or SC injection, or if dosing was not chronic. We do not evaluate whether the results in each experiment provide evidence for carcinogenicity; rather, we report the published opinions of the investigators and the statistical significance of the dose response. The CPDB includes results of all NCI/NTP technical reports published through 1989, with a few exceptions where the chemicals were particulates or the route of administration was skin painting.

A detailed guide to the plot of the database was included in the first published plot in 1984 (1); it described the contents, field by field, and discussed the sources of data, the criteria for the inclusion of particular experiments and particular target sites, and the conventions adopted in summarizing the literature. It is our intention that readers who are not familiar with the CPDB will first read the 1984 paper when using the plot in this paper.

The TD_{50} , our numerical index of carcinogenic potency, has been fully described (1,5,6) and may be briefly defined as follows: For a given target site(s), if there are no tumors in control animals, then TD_{50} is the chronic dose rate in mg/kg body weight/day that would induce tumors in half the test animals at the end of a standard lifespan for the species. Because the tumor(s) of interest often does occur in control animals, TD_{50} is more precisely defined as the chronic dose rate that will halve the probability of remaining tumor-free throughout the standard life span. One reason for choosing TD_{50} is that it is easy to understand the concept, particularly because of the analogy to LD_{50} . Importantly, TD_{50} is often within the range of doses tested; thus the experimental results do not have to be extrapolated far to estimate TD_{50} . The TD_{50} does not indicate anything about carcinogenic effects at low doses because carcinogenesis bioassays are generally conducted at doses at or near the maximum tolerated dose (MTD). In the CPDB, the range of statistically significant TD_{50} values for chemicals that are carcinogenic in rodents is more than 10 millionfold (1).

A new compendium has been prepared for this paper in Appendix 14, which includes summary evaluations of positivity and carcinogenic potency in rats and mice for each chemical in all five plots of the CPDB. This tabulation can be used to investigate associations between rodent potency and other factors such as mutagenicity, teratogenicity, chemical structure, and human, exposure, as well as to obtain summary information on individual

compounds. Methods are described in Appendix 14, and are the same as were used in our earlier publication (7). Appendix 14 lists alphabetically the 1136 chemicals that appear in any of the five plots and indicates which plot includes results of experiments on each chemical. It also lists CAS (Chemical Abstracts Service registry) numbers and common synonyms. In this Appendix 14, four columns have been added that summarize for each chemical whether there are tests in the CPDB in male rats, female rats, male mice, and female mice; for each group we report the strongest level of evidence for carcinogenicity as defined by the opinion of the published author. For chemicals that are classified as positive, two columns report the most potent TD_{50} value in each species that has a positive test in the CPDB. Several footnotes in Appendix 14 give additional information about individual chemicals: e.g., that there is more than one positive test in the species (footnote a); that the TD_{50} values from different positive experiments of the chemical vary by more than 10-fold from one another (footnote f); and that the CPDB includes results in a species other than rats or mice and at least one test is positive (footnote g) or that none are positive (footnote h).

In each of the five plot papers, Appendices 1-13 are in the same format and provide information for the data in that publication. In this paper, Appendices 1-13 apply only to the plot presented here. Appendix 1 lists alphabetically the compounds included in the current plot, their common synonyms, and Chemical Abstracts Service (CAS) registry number; Appendix 2 provides a list of those same compounds ordered by CAS number. The next several appendices provide codes and definitions required for using the plot: strains of test animal (Appendix 3); routes of administration (Appendix 4); sites of tumor induction (Appendix 5); histopathology (Appendix 6); notecodes (Appendix 7); dose-response curve symbols (Appendix 8); reference codes (Appendix 9); NCI/NTP bioassays evaluated as inadequate (Appendix 10); and author's opinion codes (Appendix 11). Appendices 12 and 13 give full bibliographic information for all experiments reported in this plot: a bibliography for the general literature (Appendix 12); and a list of the NTP technical reports (Appendix 13).

Plot in this Supplement

This fifth plot of the CPDB includes results of 412 long-term, chronic experiments on 147 chemicals. It reports results for 47 compounds from technical reports of the NTP published between July 1987 and December 1989, and results for 101 compounds published in the general literature between January 1987 and December 1988. Experiments in rats, mice, and hamsters are reported here for compounds representing a variety of chemical classes and a variety of uses. Some are naturally occurring substances (e.g., catechol, 8-methoxypsoralen, and malonaldehyde); food additives (e.g., potassium bromate and geranyl acetate); industrial chemicals (e.g., 1,3 butadiene, styrene, and pentachlorophenol); and drugs (e.g., ciprofibrate, salbutamol, and diphenhydramine • HCl). Sixty-four of the 147 chemicals in this plot were also included in an earlier plot, and we have flagged these names in this plot with a triple asterisk (***). For some substances, only a few experiments are reported here, but several experiments were reported in earlier plots (e.g., benzene and formaldehyde). The TD_{50} values for the compounds in this plot fall within the 10 million-fold range reported earlier.

Overview and Update of Our Papers That Use the CPDB

The CPDB is exhaustive in that it includes all published tests that meet a set of experimental criteria. There is great diversity in the testing of chemicals reported in the database; while most chemicals have been tested in rats or mice, some have been tested in hamsters, dogs, or monkeys. Experiments with 101 different mouse strains and 74 rat strains are included. For a given chemical, the database may contain only a single experiment or several experiments. For example, among the 857 chemicals tested in rats, 29% have only one rat test and 53% have two tests; however, 15 chemicals have more than 10 tests.

Our group has used the CPDB to address many issues relevant to chemical carcinogenesis and interspecies extrapolation. Below we refer the reader to the appropriate papers. Additionally, because the CPDB now includes many more tests and chemicals than were used in the earlier papers, we have updated several of the original tables from our earlier analyses. Specifically, updated results are reported for the proportion of chemicals that are positive for several datasets, the association between mutagenicity and carcinogenicity, prediction of positivity between species, reproducibility of results in "near-replicate" experiments, carcinogen identification on the basis of two versus four sex-species groups. In each case, the updated findings are similar to those reported earlier, and we refer the reader to the earlier papers for methods and discussion.

Carcinogenic Potency (TD₅₀)

With respect to the measurement of carcinogenic potency, two methods for estimating TD₅₀ from animal bioassays were compared, one based on lifetable data and one based on summary incidence data (8). There is substantial agreement between these two methods of analysis. Second, we have shown that the potency calculated from experimental results (given the usual experimental design and the lack of 100% tumor incidence in dosed animals) is restricted to an approximately 30-fold range surrounding the maximum dose tested in a standard bioassay (9). Third, correlation studies have been conducted of carcinogenic potency between rats and mice (9) and of mutagenic and carcinogenic potencies (10). Fourth, we have shown that, with few exceptions, among chemicals that are positive in more than one test in a species, the most potent TD₅₀ value from among all positive tests is similar to other measures that average TD₅₀ values [harmonic mean, geometric mean, or arithmetic mean] (7). Using the most potent TD₅₀ in rats and in mice, we presented a concise tabulation of TD₅₀ values for positive chemicals, which also includes a summary of positivity in each sex-species group (7). These results are updated in Appendix 14 of this paper and include results for all five plots of the CPDB.

In addition to positivity and potency, other bioassay measures of carcinogenic hazard that we have investigated are whether tumors were induced at more than one site, whether tumors may have caused the death of the animal or instead were found at sacrifice, and whether metastases of induced tumors occurred (11,12).

Reproducibility

Reproducibility of results in animal bioassays has been investigated in "near-replicate" comparisons consisting of two or

more tests of the same chemical administered by the same route and using the same sex and strain of rodent (13). The updated results continue to show good reproducibility. Among 132 comparisons 86% (114/132) have concordant authors' opinions about whether tumors were induced in the individual experiments. In all but 3 of the 69 positive comparisons, at least 1 target site is identical. TD₅₀ values are within a factor of 2 of each other in 51% of the positive comparisons, within a factor of 4 in 77%, and within a factor of 10 in 91%.

Positivity

In several papers we have shown that approximately half the chemicals tested in rats or mice are positive in at least one test, according to the opinion of the published author. Using all data currently in the CPDB, positivity rates are reported in Table 1 separately for chemicals tested in NCI/NTP bioassays, in the general literature, and in either of these sources. Table 2 reports a similar positivity rate for several additional subsets of the CPDB: naturally occurring chemicals, synthetic chemicals, natural pesticides, mold toxins, and chemicals in roasted coffee. We have discussed why it is unlikely that the 50% positivity rate is due simply to selection of suspicious chemical structures (14-16), and show in Table 2 that this rate is similar for chemicals tested before 1979 by NCI and those tested later by NCI/NTP.

Mitogenesis

We have postulated that the high positivity rate is to be expected because the administration of chemicals at the maximum

Table 1. Proportion of CPDB chemicals tested in at least one species that have been evaluated as carcinogenic, by species and reference source.^a

Reference source	Proportion carcinogenic in rats or mice (%)	Proportion carcinogenic in rats (%)	Proportion carcinogenic in mice (%)
NCI/NTP or literature ^b	584/1117 (52%)	424/857 (49%)	324/745 (43%)
NCI/NTP	165/315 (52%)	119/303 (39%)	121/308 (39%)
Literature	448/894 (50%)	321/608 (53%)	216/498 (43%)

^aA chemical is classified as positive if the author of at least one published experiment has evaluated the compound as carcinogenic in that species.

^bThe number of chemicals in the "NCI/NTP or literature" is smaller than the sum of each source separately because some of the chemicals have been reported by both sources.

Table 2. Proportion of chemicals evaluated as carcinogenic for several datasets in the CPDB.^a

Chemicals tested in both rats and mice	288/479 (60%)
Naturally occurring chemicals tested in both rats and mice	56/101 (55%)
Synthetic chemicals tested in both rats and mice	232/378 (61%)
NCI/NTP chemicals ^b	
NCI/NTP chemicals tested before 1979	60/117 (51%)
NCI/NTP chemicals tested after 1979	105/198 (53%)
Chemicals tested in at least 1 species	
Natural pesticides	29/57 (51%)
Mold toxins	12/20 (60%)
Chemicals in roasted coffee	19/26 (73%)

^aA chemical is classified as positive if the author of at least one published experiment evaluated results as evidence that the compound is carcinogenic.

^b94% (296/315) are tested by NCI/NTP in both rats and mice.

tolerated dose (MTD) in standard animal cancer tests increases cell division (mitogenesis), which in turn increases rates of mutagenesis and thus carcinogenesis (15,17). The high rate of endogenous DNA damage contributes to the importance of mitogenesis. A variety of studies on mechanisms of carcinogenesis are consistent with this explanation (17-19). We conclude that at the low doses of most human exposures where cell killing does not occur, the hazards to humans of rodent carcinogens may be much lower than is commonly assumed. Thus, understanding the role of mitogenesis in mutagenesis is critical for clarifying the mechanisms of carcinogenesis and interpreting the results of animal cancer tests (15,17-19).

Mutagenicity

We have also examined mutagenicity rates in the CPDB (14-16) and have updated the results in Table 3. Of the 384 chemicals tested in both rats and mice and for which mutagenicity data in *Salmonella* are available, 72% are either mutagens or carcinogens or both. Overall, mutagens are more often carcinogenic than nonmutagens; however 45% of carcinogens tested in rats and mice are not mutagenic, suggesting the importance of mitogenesis in animal tests at the MTD.

Interspecies Extrapolation

The issue of extrapolating carcinogenesis results from one species to another has been addressed in analyses of prediction between two closely related species, rats and mice (12,14). We have examined how well one can predict carcinogenicity from rats to mice and from mice to rats. The updated results in Table 4 indicate that among chemicals tested in both species, 74% of rat carcinogens are positive in mice, and 72% of mouse carcino-

Table 3. Comparison of mutagenicity and carcinogenicity for 384 CPDB chemicals tested for carcinogenicity in both rats and mice and for mutagenicity in *Salmonella*.^a

		Carcinogenic		Total
		+	-	
Mutagenic	+	131	38	169 ^b
	-	106	109	215
Total		237 ^c	147 ^d	384 ^e

^aA chemical is classified as positive if the author of at least one published experiment evaluated the results as evidence that the compound is carcinogenic. Mutagens are more likely to be carcinogenic 78% (131/169) than nonmutagens 49% (106/215).

^bOf 169 mutagens, 22% are not carcinogenic 38/(131 + 38).

^cOf 237 carcinogens, 45% are not mutagens 106/(131 + 106).

^dOf 147 noncarcinogens, 26% are mutagens 38/(38 + 109).

^eOf 384 chemicals, 44% are mutagens, 62% are carcinogens, and 72% are either mutagens or carcinogens or both (131 + 106 + 38)/384.

Table 4. Comparison of carcinogenic response in rats and mice for 479 CPDB chemicals tested in both species.

		Rats		Total
		+	-	
Mice	+	165	64	229 ^a
	-	59	191	250
Total		224 ^b	255	479 ^c

^aOf 229 mouse carcinogens, 72% are rat carcinogens 165/(165 + 64).

^bOf 224 rat carcinogens, 74% are mouse carcinogens 165/(165 + 59).

^cOf 479 chemicals, 60% are positive in at least one test (165 + 59 + 64)/479.

Table 5. Predictive value of two sex-species groups for CPDB carcinogens tested in both sexes of rats and mice.^a

Sex-species groups used to identify carcinogens	NCI/NTP or literature experiments	NCI/NTP experiments
	Number identified as carcinogenic at least once (N=212) ^{b,c}	Number identified as carcinogenic at least once (N=149) ^c
MM, MR	194 (92%)	135 (91%)
FM, MR	194 (92%)	136 (91%)
MM, FR	183 (86%)	122 (82%)
FM, FR	184 (87%)	124 (83%)
FM, MM	167 (79%)	112 (75%)
FR, MR	162 (76%)	112 (75%)

Abbreviations: FM, female mice, MM, male mice, FR, female rats, MR, male rats.

^aFor chemicals tested in both sexes of rats and mice that were evaluated as carcinogenic in at least one experiment.

^bThe total number of positive chemicals for "NCI/NTP or literature" in this table is 212, while the number in Table 4 is 288. This difference is due to the fact that 76 positive chemicals were tested in both rats and mice, but not in both sexes of rats and mice.

^cPercentage indicates the proportion that would be correctly identified as carcinogens using results from experiments only in the two sex-species groups, considering as positive an evaluation of carcinogenic in either sex-species group.

gens are positive in rats. We earlier discussed three factors that affect the accuracy of prediction: chemical class, mutagenicity, and the dose level at which a chemical is toxic (14).

Target Organ

We have presented a compendium of bioassay results organized by target organ for chemicals that are carcinogenic in at least one species. This compendium reports on 35 target sites and can be used to identify chemicals that induce tumors at particular sites and to determine whether target sites are the same for each chemical that is positive in more than one species (12). Site-specific prediction between rats and mice is less accurate than overall prediction of positivity. Knowing that a chemical is positive at any site in one species gives about a 50% chance that it will be positive at the same site in the other species. Among chemicals with a target site in common between rats and mice, the liver is the most frequent site in common (12). Because the liver is the most common site in both species, we have studied liver carcinogenesis in detail (11,12,14).

Carcinogen Identification by Two Versus Four Sex-Species Groups

We have also addressed the question of how many rodent carcinogens currently identified by performing tests in four sex-species groups would be identified if tests were conducted in only two sex-species groups. The updated results in Table 5 continue to show that few carcinogens would be missed by testing one sex of each species. The greatest number (91-92%) would have been identified by conducting tests only in male rats and male mice/or in male rats and female mice.

Chemicals Selected for Testing

The natural world makes up the vast bulk of chemicals that humans consume each day in both weight and number. Yet, the natural chemicals have never been tested systematically; synthetic chemicals account for 79% (378/479) of the chemicals adequately tested in both rats and mice (Table 2). Because about half

Spe	Strain	Site	Xpo+Xpt	Notes	TD50	2Tailpvi
Sex	Route	Hist			DR	AuOp
BISPHENOL A					1_00ng.....1_ug.....1_0.....1_00.....1_mg.....1_0.....1_00.....1_g.....1_0	
1	M f	b6c	eat	TBA MXB 24m25 t		:> no dre P=1. -
a	M f	b6c	eat	liv MXB 24m25 t		13.1gm * P<.05
b	M f	b6c	eat	lun MXB 24m25 t		41.4gm * P<.6

RefNum	LoConf	UpConf	Cntrl	TDose	TDose	ZDose	Zinc	Citation or Pathology	Brkly Code
BISPHENOL A (4,4'-isopropylidenediphenol) 80-05-7									
1	c50635	2.27gm	n.s.s.	21/50	626.mg	17/50	1.25gm	19/50	
a	c50635	4.53gm	n.s.s.	0/50	626.mg	1/50	1.25gm	3/50	liv:hpa,hpc,ndd.
b	c50635	6.29gm	n.s.s.	1/50	626.mg	1/50	1.25gm	2/50	lun:a/a,a/c.

FIGURE 1. Corrected plot for bisphenol A.

of natural chemicals and half of natural pesticides are positive in animal tests (Table 2), we conclude that our diet is filled with rodent carcinogens as defined by high-dose tests. We have described the concentrations in common foods of natural pesticides that are rodent carcinogens (16). Additionally, we have discussed the toxicological significance of exposures to synthetic chemicals in the context of exposures to naturally occurring chemicals, and we argue that animals have a broad array of inducible general defenses that at low dose are effective against both natural and synthetic toxins (16,20,21). The relatively high and widespread exposure to natural chemicals that are rodent carcinogens, and the 50% positivity rate among natural chemicals that have been tested, indicate that cancer-prevention strategies aimed at chemical carcinogens need to take a broad overview of chemicals, whether synthetic or natural.

Ranking Possible Carcinogenic Hazards

We have proposed a rough index of possible carcinogenic hazard to humans, HERP (Human Exposure Rodent Potency). HERP compares for a given chemical the chronic dose rate at which humans are exposed (mg/kg/day) to the TD₅₀ (mg/kg/day) in rodents. To put possible carcinogenic hazards in perspective, we have used the HERP index to rank a variety of man-made and naturally occurring chemical exposures to humans (22). In a separate analysis a similar index, PERP (Permitted Exposure Rodent Potency) was calculated by using the U.S. Occupational Safety and Health Administration Permitted Exposure Limit (OSHA PEL), and assuming a daily worklife exposure at that limit (23). Permitted worker exposure levels for several rodent carcinogens are close to the dose rate that induces tumors in half the test animals. For high occupational exposures, comparatively little extrapolation is required from the doses used in rodent bioassays, and therefore assumptions about extrapolation from high to low dose are less important.

Errata in Earlier Plots

Some errors and additional information about results reported in earlier plots of the CPDB (1-4) have come to our attention. For two NCI/NTP bioassays in the second plot (2), the route of administration was reported incorrectly: for cytembena the route was reported as diet and should have been IP injection; for vinylidene chloride the reported route was diet and should have been gavage. All other information including dose rates and TD₅₀ values was reported correctly for these two chemicals.

Issues related to the purity of test compounds have resulted in some name changes. For two NCI/NTP bioassays, we have added "technical grade" to the chemical name in the CPDB (Appendix 14) because of impurities in the test agent: 1,1,1-trichloroethane and trifluralin. For 2,3,4,5,6-pentachlorophenol two papers reported results for the technical grade (cited in the plot as Innes et al., 1968/1969 and Schwetz et al., 1975). We now report 2,3,4,5,6-pentachlorophenol (Dowicide EC-7) in Appendix 14 for these papers. The chemical name for the paper of Boberg et al., 1983, remains 2,3,4,5,6-pentachlorophenol.

Two other errors in chemical names have been corrected. Nitro-4-hydroxyphenylarsonic should have been reported as 3-nitro-4-hydroxyphenylarsonic acid (CAS number 121-19-7). Cadmium sulfate should have been reported as cadmium sulfate (1:1) hydrate (3:8).

CAS numbers have been changed for a few chemicals. The CAS number for sodium hypochlorite phosphate has been changed by the American Chemical Society to 11084-85-8. The corrected CAS number for DL- α -tocopheryl acetate is 58-95-7, and the corrected synonym is vitamin E acetate. The corrected CAS number for 1,2-di-N-butylhydrazine • 2HCl is 78776-28-0. The corrected CAS number for propanolol • HCl is 525-66-6.

For several NTP chemicals in the third plot listed below, evaluations for some target tissues were reported as "a," and we have re-assigned the evaluation as "p" indicating the NTP category, "some evidence of carcinogenicity," which NTP defines as a positive category. Our earlier assignment of "a" had been made before current descriptions of the evaluation categories were published by NTP. These sites with opinion "p" should be interpreted as positive. For the chemicals in italics, "p" is the highest level of evidence in the NTP evaluation: benzene, HC Blue No. 1, *chlorobenzene*, *chlorodibromomethane*, *decabromodiphenyl oxide*, *dimethyl morpholinophosphoramidate*, *isophorone*, *methylene chloride*, *1,2-propylene oxide*, *Telone II*, *tetrachloroethylene*, *tris(2-ethylhexyl)phosphate*.

For bisphenol A in female mice, the dose used was incorrect. Therefore, other values such as the TD₅₀ were also incorrect. The corrected plot for this experiment is shown in Figure 1.

There are many people who have provided us with valuable assistance in the course of our work. We thank Jerrold Ward and Leslie Bernstein for their advice on pathology and statistics and Bonnie Stern for suggestions on the manuscript. We also thank Leah Slyder for technical assistance. This work was supported through the University of California, Berkeley, by National Institute of Environmental Health Sciences Center grant ESO1896, and through the Lawrence Berkeley Laboratory by U.S. Department of Energy, contract DE-AC-03-76SF00098 and U.S. Environmental Protection Agency, agreement R-815619-01-0.

REFERENCES

1. Gold, L. S., Sawyer, C. B., Magaw, R., Backman, G. M., de Veciana, M., Levinson, R., Hooper, N. K., Havender, W. R., Bernstein, L., Peto, R., Pike, M. C., and Ames, B. N. A Carcinogenic Potency Database of the standardized results of animal bioassays. *Environ. Health Perspect.* 58: 9-319 (1984).
2. Gold, L. S., de Veciana, M., Backman, G. M., Magaw, R., Lopipero, P., Smith, M., Blumenthal, M., Levinson, R., Bernstein, L., and Ames, B. N. Chronological supplement to the Carcinogenic Potency Database: standardized results of animal bioassays published through December 1982. *Environ. Health Perspect.* 67: 161-200 (1986).
3. Gold, L. S., Slone, T. H., Backman, G. M., Magaw, R., Da Costa, M., Lopipero, P., Blumenthal, M., and Ames, B. N. Second chronological supplement to the Carcinogenic Potency Database: standardized results of animal bioassays published through December 1984 and by the National Toxicology Program through May 1986. *Environ. Health Perspect.* 74: 237-329 (1987).
4. Gold, L. S., Slone, T. H., Backman, G. M., Eisenberg, S., Da Costa, M., Wong, M., Manley, N. B., Rohrbach, L., and Ames, B. N. Third chronological supplement to the Carcinogenic Potency Database: standardized results of animal bioassays published through December 1986 and by the National Toxicology Program through June 1987. *Environ. Health Perspect.* 84: 215-286 (1990).
5. Peto, R., Pike, M. C., Bernstein, L., Gold, L. S., and Ames, B. N. The TD₅₀: a proposed general convention for the numerical description of the carcinogenic potency of chemicals in chronic-exposure animal experiments. *Environ. Health Perspect.* 58: 1-8 (1984).
6. Sawyer, C., Peto, R., Bernstein, L., and Pike, M. C. Calculation of carcinogenic potency from long-term animal carcinogenesis experiments. *Biometrics* 40: 27-40 (1984).
7. Gold, L. S., Slone, T. H., and Bernstein, L. Summary of carcinogenic potency (TD₅₀) and positivity for 492 rodent carcinogens in the Carcinogenic Potency Database. *Environ. Health Perspect.* 79:259-272 (1989).
8. Gold, L. S., Bernstein, L., Kaldor, J., Backman, G. M., and Hoel, D. An empirical comparison of methods used to estimate carcinogenic potency in long-term animal bioassays: lifetable vs. summary incidence data. *Fundam. Appl. Toxicol.* 6: 263-269 (1986).
9. Bernstein, L., Gold, L. S., Ames, B. N., Pike, M. C., and Hoel, D. Some tautologous aspects of the comparison of carcinogenic potency in rats and mice. *Fundam. Appl. Toxicol.* 5: 79-86 (1985).
10. McCann, J., Gold, L. S., Horn, L., McGill, R., Graedel, T. E., and Kaldor, J. Statistical analysis of Salmonella test data and comparison to results of animal cancer tests. *Mutat. Res.* 205: 183-195 (1988).
11. Gold, L. S., Ward, J., Bernstein, L., and Stern, B. Association between carcinogenic potency and tumor pathology in rodent carcinogenesis bioassays. *Fundam. Appl. Toxicol.* 6: 677-690 (1986).
12. Gold, L. S., Slone, T. H., Manley, N. B., and Bernstein, L. Target organs in chronic bioassays of 533 chemical carcinogens. *Environ. Health Perspect.* 93: 233-246 (1991).
13. Gold, L. S., Wright, C., Bernstein, L., and de Veciana, M. Reproducibility of results in 'near-replicate' carcinogenesis bioassays. *J. Natl. Cancer Inst.* 78: 1149-1158 (1987).
14. Gold, L. S., Bernstein, L., Magaw, R., and Slone, T. H. Interspecies extrapolation in carcinogenesis: prediction between rats and mice. *Environ. Health Perspect.* 81: 211-219 (1989).
15. Ames, B. N., and Gold, L. S. Perspective: too many rodent carcinogens: mitogenesis increases mutagenesis. *Science* 249: 970-971 (1990).
16. Ames, B. N., Profet, M., and Gold, L. S. Dietary pesticides (99.99% all natural). *Proc. Natl. Acad. Sci. U.S.A.* 87: 7777-7781 (1990).
17. Ames, B. N., and Gold, L. S. Chemical carcinogenesis: too many rodent carcinogens. *Proc. Natl. Acad. Sci. U.S.A.* 87: 7772-7776 (1990).
18. Ames, B. N., and Gold, L. S. Animal cancer tests and the prevention of cancer. *J. Natl. Cancer Inst. Monogr.* 12: 125-132 (1992).
19. Ames, B. N. Endogenous oxidative DNA damage, aging, and cancer. *Free Rad. Res. Commun.* 7: 121-128 (1989).
20. Ames, B. N., Profet, M., and Gold, L. S. Nature's chemicals and synthetic chemicals: comparative toxicology. *Proc. Natl. Acad. Sci. U.S.A.* 87: 7782-7786 (1990).
21. Ames, B. N., and Gold, L. S. Dietary carcinogens, environmental pollution, and cancer: some misconceptions. *Med. Oncol. Tumor Pharmacother.* 7: 69-85 (1990).
22. Gold, L. S., Slone, T. H., Stern, B. R., Manley, N. B., and Ames, B. N. Rodent carcinogens: setting priorities. *Science* 258: 261-265 (1992).
23. Gold, L. S., Backman, G. M., Hooper, K., and Peto, R. Ranking the potential carcinogenic hazards to workers from exposures to chemicals that are tumorigenic in rodents. *Environ. Health Perspect.* 76: 211-219 (1987).

Carcinogenicity

Spe	Strain	Site	Xpo+Xpt	T050	2Tailpvl
Sex	Route	Hist	Notes	DR	AuOp
ACETALDEHYDE***				100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	
1	R f	wsr inh nac mix	12m24 erv	.	148.mg * P<.0005+
a	R f	wsr inh nac adc	12m24 erv	.	201.mg * P<.0005+
b	R f	wsr inh nac sqc	12m24 erv	.	574.mg * P<.01 +
2	R m	wsr inh nac mix	12m24 erv	.	88.5mg * P<.0005+
a	R m	wsr inh nac adc	12m24 erv	.	190.mg * P<.002 +
b	R m	wsr inh nac sqc	12m24 erv	.	200.mg Z P<.0005+
ACETALDOXIME				100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	
3	R m	f34 wat liv hnd	26m30 e	.	445.mg * P<.4
a	R m	f34 wat adr cca	26m30 e	.	no dre P=1.
2-ACETYLAMINOFLUORENE***				100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	
4	M f	b6c eat liv hpb	24m24 r	.	846.mg * P<.06 +
5	M m	b6c eat liv hpb	24m24 r	.	92.1mg * P<.004 +
6	M f	bcn eat liv hpb	24m24 r	.	3.20gm * P<.5 -
7	M m	bcn eat liv hpb	24m24 r	.	no dre P=1. -
ACROLEIN				100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	
8	R f	f34 wat adr cca	24m31 e	.	93.9mg P<.07
a	R f	f34 wat liv mix	24m31 e	.	188.mg P<.4
b	R f	f34 wat liv hnd	24m31 e	.	388.mg P<.7
c	R f	f34 wat liv hpc	24m31 e	.	433.mg P<.3
9	R m	f34 wat for tum	27m31 ae	.	14.4mg Z P<.002
a	R m	f34 wat liv hpc	27m31 ae	.	1.32gm * P<.9
b	R m	f34 wat adr cca	27m31 ae	.	no dre P=1.
c	R m	f34 wat liv hnd	27m31 ae	.	no dre P=1.
d	R m	f34 wat liv mix	27m31 ae	.	no dre P=1.
ACROLEIN DIETHYLACETAL				100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	
10	R f	f34 wat liv mix	24m30 ae	.	123.mg * P<.06
a	R f	f34 wat liv hnd	24m30 ae	.	131.mg * P<.06
b	R f	f34 wat adr cca	24m30 ae	.	no dre P=1.
c	R f	f34 wat liv hpc	24m30 ae	.	no dre P=1.
11	R m	f34 wat liv hpc	24m30 ae	.	262.mg * P<.1
a	R m	f34 wat liv mix	24m30 ae	.	124.mg * P<.2
b	R m	f34 wat liv hnd	24m30 ae	.	266.mg * P<.4
c	R m	f34 wat adr cca	24m30 ae	.	no dre P=1.
ACROLEIN OXIME				100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	
12	R f	f34 wat liv hnd	7m29 e	.	41.9mg P<.3
a	R f	f34 wat adr cca	7m29 e	.	no dre P=1.
13	R f	f34 wat liv mix	24m30 e	.	27.1mg P<.03
a	R f	f34 wat liv hpc	24m30 e	.	104.mg P<.1
b	R f	f34 wat liv hnd	24m30 e	.	43.8mg P<.2
c	R f	f34 wat adr cca	24m30 e	.	no dre P=1.
14	R m	f34 wat liv mix	7m29 e	.	16.4mg P<.06
a	R m	f34 wat liv hpc	7m29 e	.	50.7mg P<.1
b	R m	f34 wat liv hnd	7m29 e	.	29.3mg P<.3
c	R m	f34 wat adr cca	7m29 e	.	no dre P=1.
15	R m	f34 wat liv hpc	24m30 e	.	72.6mg P<.1
a	R m	f34 wat liv mix	24m30 e	.	30.4mg P<.2
b	R m	f34 wat liv hnd	24m30 e	.	64.9mg P<.4
c	R m	f34 wat adr cca	24m30 e	.	no dre P=1.
ACRYLONITRILE***				100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	
16	R m	cdr wat zym sqc	24m24 es	.	30.1mg * P<.0005+
a	R m	cdr wat for pam	24m24 s	.	97.4mg * P<.003
b	R m	cdr wat pit ade	24m24 es	.	no dre P=1.
c	R m	cdr wat tba mal	24m24 es	.	31.3mg * P<.02
17	R f	sda inh adr phe	12m24	.	1.49mg Z P<.02
a	R f	sda inh bra gli	12m24	.	41.2mg * P<.2 +
b	R f	sda inh liv hpt	12m24	.	no dre P=1.
c	R f	sda inh tba mix	12m24	.	2.09mg Z P<.3
d	R f	sda inh tba mal	12m24	.	no dre P=1.
18	R f	sda gav liv hpt	12m24	.	no dre P=1. -
a	R f	sda gav tba mix	12m24	.	2.97mg P<.3 -
b	R f	sda gav tba mal	12m24	.	no dre P=1. -
19	R f	sda inh mam mix	24m24 g	.	11.7mg P<.003
a	R f	sda inh bra gli	24m24 g	.	132.mg P<.04 +
b	R f	sda inh liv hpt	24m24 g	.	no dre P=1.
c	R f	sda inh tba mal	24m24 g	.	25.2mg P<.008 +
d	R f	sda inh tba mix	24m24 g	.	10.6mg P<.02
20	R m	sda inh bra gli	12m24	.	19.1mg * P<.04 +
a	R m	sda inh liv hpt	12m24	.	no dre P=1.
b	R m	sda inh tba mix	12m24	.	1.30mg * P<.002
c	R m	sda inh tba mal	12m24	.	1.43mg Z P<.04

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	Zinc	Citation or Pathology			Brkly Code				
ACETALDEHYDE*** 75-07-0															
1	1863	85.3mg	288.mg	0/18	50.1mg	1/20	100.mg	7/18	149.mg	11/17	Woutersen;txcy,47,295-305;1987/1986/pers.comm.				
a	1863	110.mg	439.mg	0/18	50.1mg	0/20	100.mg	7/18	149.mg	8/17					
b	1863	234.mg	38.9gm	0/18	50.1mg	1/20	100.mg	0/18	149.mg	5/17					
2	1863	54.4mg	157.mg	0/19	35.1mg	2/20	70.1mg	8/20	104.mg	15/22					
a	1863	102.mg	710.mg	0/19	35.1mg	2/20	70.1mg	6/20	104.mg	6/22					
b	1863	105.mg	463.mg	0/19	35.1mg	0/20	70.1mg	2/20	104.mg	11/22					
ACETALDOXIME 107-29-9															
3	1853	100.mg	n.s.s.	2/20	19.5mg	3/20	50.3mg	4/20	Lijinsky;txih,3,337-345;1987/pers.comm.						
a	1853	323.mg	n.s.s.	1/20	19.5mg	1/20	50.3mg	0/20							
2-ACETYLAMINOFLOURENE*** (N-2-fluorenylacetamide) 53-96-3															
4	1874	345.mg	n.s.s.	0/96	19.5mg	2/96	26.0mg	1/96	32.5mg	3/96	Nonoyama;pavt,25,286-296;1988/pers.comm.				
5	1874	50.6mg	444.mg	0/96	4.80mg	4/96	7.20mg	5/96	9.60mg	6/96					
6	1874	521.mg	n.s.s.	0/96	13.0mg	0/96	16.2mg	1/96	19.5mg	0/96					
7	1874	25.9mg	n.s.s.	1/96	2.40mg	0/96	4.80mg	0/96	7.20mg	0/96					
ACROLEIN 107-02-8															
8	1853	30.8mg	n.s.s.	1/20	20.1mg	5/20	Lijinsky;txih,3,337-345;1987/pers.comm.								
a	1853	39.2mg	n.s.s.	2/20	20.1mg	4/20									
b	1853	48.5mg	n.s.s.	2/20	20.1mg	3/20									
c	1853	70.4mg	n.s.s.	0/20	20.1mg	1/20									
9	1853	7.36mg	55.4mg	0/20	2.64mg	5/20						6.81mg	7/20	14.1mg	3/20
a	1853	57.7mg	n.s.s.	0/20	2.64mg	2/20						6.81mg	0/20	14.1mg	1/20
b	1853	128.mg	n.s.s.	1/20	2.64mg	1/20	6.81mg	0/20	14.1mg	0/20					
c	1853	64.1mg	n.s.s.	2/20	2.64mg	6/20	6.81mg	0/20	14.1mg	2/20					
d	1853	52.1mg	n.s.s.	2/20	2.64mg	8/20	6.81mg	0/20	14.1mg	3/20					
ACROLEIN DIETHYLACETAL 3054-95-3															
10	1853	47.6mg	n.s.s.	2/20	15.4mg	5/20	39.5mg	7/20	Lijinsky;txih,3,337-345;1987/pers.comm.						
a	1853	50.7mg	n.s.s.	2/20	15.4mg	4/20	39.5mg	7/20							
b	1853	129.mg	n.s.s.	1/20	15.4mg	3/20	39.5mg	1/20							
c	1853	197.mg	n.s.s.	0/20	15.4mg	1/20	39.5mg	0/20							
11	1853	79.3mg	n.s.s.	0/20	10.8mg	1/20	27.6mg	2/20							
a	1853	42.6mg	n.s.s.	2/20	10.8mg	3/20	27.6mg	6/20							
b	1853	60.9mg	n.s.s.	2/20	10.8mg	2/20	27.6mg	4/20							
c	1853	49.9mg	n.s.s.	1/20	10.8mg	0/20	27.6mg	0/20							
ACROLEIN OXIME 5314-33-0															
12	1853m	11.3mg	n.s.s.	2/20	7.96mg	5/20	Lijinsky;txih,3,337-345;1987/pers.comm.								
a	1853m	45.9mg	n.s.s.	1/20	7.96mg	0/20									
13	1853n	10.4mg	n.s.s.	2/20	10.4mg	8/20									
a	1853n	25.7mg	n.s.s.	0/20	10.4mg	2/20									
b	1853n	13.8mg	n.s.s.	2/20	10.4mg	6/20									
c	1853n	66.2mg	n.s.s.	1/20	10.4mg	0/20									
14	1853m	5.80mg	n.s.s.	2/20	5.57mg	7/20									
a	1853m	12.5mg	n.s.s.	0/20	5.57mg	2/20									
b	1853m	7.88mg	n.s.s.	2/20	5.57mg	5/20									
c	1853m	19.2mg	n.s.s.	1/20	5.57mg	1/20									
15	1853n	17.8mg	n.s.s.	0/20	7.37mg	2/20									
a	1853n	9.61mg	n.s.s.	2/20	7.37mg	6/20									
b	1853n	13.5mg	n.s.s.	2/20	7.37mg	4/20									
c	1853n	46.0mg	n.s.s.	1/20	7.37mg	0/20									
ACRYLONITRILE*** 107-13-1															
16	1881	14.5mg	77.9mg	0/18	1.00mg	0/20	5.00mg	1/19	25.0mg	9/18	Gallagher;jact,7,603-615;1988				
a	1881	33.6mg	591.mg	0/20	1.00mg	0/20	5.00mg	0/20	25.0mg	4/20					
b	1881	15.4mg	n.s.s.	5/18	1.00mg	3/20	5.00mg	1/19	25.0mg	0/18)					
c	1881	12.6mg	n.s.s.	3/18	1.00mg	1/20	5.00mg	8/20	25.0mg	8/18					
17	bt201	.679mg	n.s.s.	1/30	.271mg	5/30	.542mg	7/30	1.08mg	2/30		Maltoni;anya,534,179-202;1988			
a	bt201	10.1mg	n.s.s.	0/30	.271mg	0/30	.542mg	0/30	1.08mg	1/30					
b	bt201	.893mg	n.s.s.	0/30	.271mg	0/30	.542mg	0/30	1.08mg	0/30					
c	bt201	.623mg	n.s.s.	9/30	.271mg	23/30	.542mg	15/30	1.08mg	17/30					
d	bt201	4.00mg	n.s.s.	3/30	.271mg	12/30	.542mg	6/30	1.08mg	7/30					
18	bt203	8.83mg	n.s.s.	0/75	1.07mg	0/40									
a	bt203	.782mg	n.s.s.	39/75	1.07mg	25/40									
b	bt203	2.33mg	n.s.s.	17/75	1.07mg	9/40									
19	bt4003	5.82mg	75.7mg	24/60	11.1mg	37/54									
a	bt4003	40.1mg	n.s.s.	0/60	11.1mg	3/54									
b	bt4003	123.mg	n.s.s.	0/60	11.1mg	0/54									
c	bt4003	11.7mg	495.mg	9/60	11.1mg	20/54									
d	bt4003	4.69mg	n.s.s.	35/60	11.1mg	43/54									
20	bt201	5.77mg	n.s.s.	0/30	.190mg	0/30	.379mg	0/30	.759mg	1/30	1.52mg 2/30				
a	bt201	.625mg	n.s.s.	0/30	.190mg	0/30	.379mg	0/30	.759mg	0/30					
b	bt201	.674mg	6.77mg	8/30	.190mg	7/30	.379mg	19/30	.759mg	15/30					
c	bt201	.565mg	n.s.s.	3/30	.190mg	0/30	.379mg	10/30	.759mg	9/30					

Spe	Strain	Site	Xpo+Xpt						T050	2Tailpvl	
Sex	Route	Hist	Notes						DR	AuOp	
21	R m	sda	gav	liv	hpt	12m24		.	no dre	P=1.	-
a	R m	sda	gav	tba	mix	12m24			5.59mg	P<.3	-
b	R m	sda	gav	tba	mal	12m24			33.4mg	P<.8	-
AFLOATOXIN B1***							100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10				
22	R f	f34	eat	liv	hpc	24m24	er	.	52.7ug	* P<.06	-
23	R m	f34	eat	liv	hpc	24m24	er	.	49.9ug	* P<.3	-
ALLYL ALCOHOL								100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10			
24	R f	f34	wat	liv	hpc	25m29	e	.	64.2mg	P<.04	
a	R f	f34	wat	liv	mix	25m29	e	.	41.5mg	P<.2	
b	R f	f34	wat	liv	hnd	25m29	e	.	182.mg	P<.7	
c	R f	f34	wat	adr	cca	25m29	e	.	no dre	P=1.	
25	R m	f34	wat	liv	mix	25m29	e	.	128.mg	P<.7	
a	R m	f34	wat	liv	hpc	25m29	e	.	142.mg	P<.3	
b	R m	f34	wat	liv	hnd	25m29	e	.	no dre	P=1.	
c	R m	f34	wat	adr	cca	25m29	e	.	no dre	P=1.	
2-AMINO-3,8-DIMETHYLIMIDAZO[4,5-f]QUINOXALINE							10.....100.....1mg.....10.....100.....1g.....10			
26	M f	cdf	eat	liv	mix	84w84	e	.	14.2mg	P<.0005+	
a	M f	cdf	eat	liv	hpa	84w84	e	.	14.2mg	P<.0005	
b	M f	cdf	eat	liv	hpc	84w84	e	.	27.8mg	P<.0005	
c	M f	cdf	eat	lun	mix	84w84	e	.	77.2mg	P<.002 +	
d	M f	cdf	eat	lun	ade	84w84	e	.	143.mg	P<.02	
e	M f	cdf	eat	lun	adc	84w84	e	.	257.mg	P<.1	
f	M f	cdf	eat	---	mix	84w84	e	.	6.82gm	P<.1	
27	M m	cdf	eat	liv	hpa	84w84	e	.	86.9mg	P<.01	
a	M m	cdf	eat	liv	hpc	84w84	e	.	102.mg	P<.0005	
b	M m	cdf	eat	---	mix	84w84	e	.	109.mg	P<.006	
c	M m	cdf	eat	liv	mix	84w84	e	.	83.8mg	P<.02 +	
d	M m	cdf	eat	lun	mix	84w84	e	.	134.mg	P<.2	
e	M m	cdf	eat	lun	adc	84w84	e	.	236.mg	P<.4	
f	M m	cdf	eat	lun	ade	84w84	e	.	262.mg	P<.2	
28	R f	f3d	eat	cli	sqc	61w61	e	.	4.72mg	P<.0005+	
a	R f	f3d	eat	liv	nnd	61w61	e	.	6.31mg	P<.0005+	
b	R f	f3d	eat	zym	sqc	61w61	e	.	6.31mg	P<.0005+	
c	R f	f3d	eat	ski	sqc	61w61	e	.	87.2mg	P<.3	
29	R m	f3d	eat	liv	mix	61w61	e	.	noT050	P<.0005+	
a	R m	f3d	eat	liv	hpc	61w61	e	.	1.26mg	P<.0005+	
b	R m	f3d	eat	zym	mix	61w61	e	.	2.72mg	P<.0005+	
c	R m	f3d	eat	zym	sqc	61w61	e	.	3.59mg	P<.0005+	
d	R m	f3d	eat	ski	mix	61w61	e	.	8.76mg	P<.002 +	
e	R m	f3d	eat	ski	sqc	61w61	e	.	13.1mg	P<.008 +	
f	R m	f3d	eat	zym	sqc	61w61	e	.	35.8mg	P<.1	
g	R m	f3d	eat	ski	sqc	61w61	e	.	73.5mg	P<.3	
h	R m	f3d	eat	ski	bcc	61w61	e	.	73.5mg	P<.3	
i	R m	f3d	eat	liv	nnd	61w61	e	.	73.5mg	P<.3	
2-AMINO-4-NITROPHENOL								100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10			
30	M f	b6c	gav	TBA	MXB	24m24		.	no dre	P=1.	-
a	M f	b6c	gav	liv	MXB	24m24		.	2.16gm	* P<.5	-
b	M f	b6c	gav	lun	MXB	24m24		.	2.18gm	* P<.5	-
31	M m	b6c	gav	MXA	MXA	24m24		.	798.mg	* P<.007 -	-
a	M m	b6c	gav	TBA	MXB	24m24		.	582.mg	* P<.6	-
b	M m	b6c	gav	liv	MXB	24m24		.	no dre	P=1.	-
c	M m	b6c	gav	lun	MXB	24m24		.	no dre	P=1.	-
32	R f	f34	gav	TBA	MXB	24m24		.	no dre	P=1.	-
a	R f	f34	gav	liv	MXB	24m24		.	no dre	P=1.	-
33	R m	f34	gav	tes	ict	24m24	s	.	68.2mg	* P<.003	
a	R m	f34	gav	k/c	adr	24m24	s	.	839.mg	* P<.01	p
b	R m	f34	gav	sub	MXA	24m24	s	.	458.mg	* P<.05	
c	R m	f34	gav	sub	fib	24m24	s	.	584.mg	* P<.05	
d	R m	f34	gav	liv	MXA	24m24	s	.	1.30gm	* P<.02	
e	R m	f34	gav	TBA	MXB	24m24	s	.	84.1mg	* P<.02	
f	R m	f34	gav	liv	MXB	24m24	s	.	1.30gm	* P<.02	
2-AMINO-5-NITROPHENOL								100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10			
34	M f	b6c	gav	TBA	MXB	24m24	ns	.	5.76gm	* P<.9	-
a	M f	b6c	gav	liv	MXB	24m24	ns	.	no dre	P=1.	-
b	M f	b6c	gav	lun	MXB	24m24	ns	.	807.gm	* P<.1	-
35	M m	b6c	gav	TBA	MXB	24m24	ns	.	no dre	P=1.	-
a	M m	b6c	gav	liv	MXB	24m24	ns	.	no dre	P=1.	-
b	M m	b6c	gav	lun	MXB	24m24	ns	.	no dre	P=1.	-
36	R f	f34	gav	TBA	MXB	24m24		.	no dre	P=1.	-
a	R f	f34	gav	liv	MXB	24m24		.	no dre	P=1.	-
37	R m	f34	gav	tes	ict	24m24	s	.	28.6mg	* P<.0005	
a	R m	f34	gav	pan	MXA	24m24	s	.	107.mg	* P<.0005	

	RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code
21	bt203	8.83mg	n.s.s.	0/75	1.07mg	0/40				
a	bt203	1.55mg	n.s.s.	13/75	1.07mg	11/40				
b	bt203	3.14mg	n.s.s.	6/75	1.07mg	4/40				
AFLATOXIN B1*** 1162-65-8										
22	1824	8.58ug	n.s.s.	0/144	250.ng	0/24	750.ng	0/24	2.25ug	1/24
23	1824	6.83ug	n.s.s.	1/144	200.ng	0/23	600.ng	0/24	1.80ug	1/23
ALLYL ALCOHOL 107-18-6										
24	1853	19.4mg	n.s.s.	0/20	10.4mg	3/20				
a	1853	13.1mg	n.s.s.	2/20	10.4mg	6/20				Lijinsky;txih,3,337-345;1987/pers.comm.
b	1853	22.8mg	n.s.s.	2/20	10.4mg	3/20				
c	1853	62.7mg	n.s.s.	1/20	10.4mg	0/20				
25	1853	16.0mg	n.s.s.	2/20	7.26mg	3/20				
a	1853	23.2mg	n.s.s.	0/20	7.26mg	1/20				
b	1853	20.8mg	n.s.s.	2/20	7.26mg	2/20				
c	1853	43.9mg	n.s.s.	1/20	7.26mg	0/20				
2-AMINO-3,8-DIMETHYLIMIDAZO[4,5-f]QUINOXALINE (MeIQx) 77500-04-0										
26	1820	7.95mg	25.6mg	0/39	78.0mg	32/35				
a	1820	7.95mg	25.6mg	0/39	78.0mg	32/35				
b	1820	16.6mg	50.3mg	0/39	78.0mg	25/35				
c	1820	37.2mg	370.mg	4/39	78.0mg	15/35				
d	1820	59.2mg	n.s.s.	2/39	78.0mg	9/35				
e	1820	83.2mg	n.s.s.	2/39	78.0mg	6/35				
f	1820	83.2mg	n.s.s.	11/39	78.0mg	10/35				
27	1820	38.8mg	10.9gm	5/36	72.0mg	15/37				
a	1820	49.6mg	273.mg	0/36	72.0mg	10/37				
b	1820	48.9mg	1.23gm	2/36	72.0mg	11/37				
c	1820	37.0mg	n.s.s.	6/36	72.0mg	16/37				
d	1820	42.9mg	n.s.s.	10/36	72.0mg	16/37				
e	1820	60.9mg	n.s.s.	7/36	72.0mg	11/37				
f	1820	77.2mg	n.s.s.	3/36	72.0mg	7/37				
28	1867	2.34mg	11.3mg	0/20	20.0mg	12/19				
a	1867	3.00mg	16.4mg	0/20	20.0mg	10/19				
b	1867	3.00mg	16.4mg	0/20	20.0mg	10/19				
c	1867	14.2mg	n.s.s.	0/20	20.0mg	1/19				
29	1867	n.s.s.	2.01mg	0/19	16.0mg	20/20				
a	1867	.518mg	2.88mg	0/19	16.0mg	19/20				
b	1867	1.39mg	6.00mg	0/19	16.0mg	15/20				
c	1867	1.82mg	8.30mg	0/19	16.0mg	13/20				
d	1867	3.75mg	34.5mg	0/19	16.0mg	7/20				
e	1867	4.95mg	197.mg	0/19	16.0mg	5/20				
f	1867	8.79mg	n.s.s.	0/19	16.0mg	2/20				
g	1867	12.0mg	n.s.s.	0/19	16.0mg	1/20				
h	1867	12.0mg	n.s.s.	0/19	16.0mg	1/20				
i	1867	12.0mg	n.s.s.	0/19	16.0mg	1/20				
2-AMINO-4-NITROPHENOL 99-57-0										
30	c55958	181.mg	n.s.s.	32/50	87.6mg	27/50	175.mg	29/50		
a	c55958	449.mg	n.s.s.	2/50	87.6mg	2/50	175.mg	4/50		
b	c55958	450.mg	n.s.s.	2/50	87.6mg	2/50	175.mg	4/50		liv:hpa,hpc,nnd. lun:a/a,a/c.
31	c55958	323.mg	2.80gm	0/50	87.6mg	1/50	175.mg	5/50		abc:hem; liv:hes; mln:hes; pan:hem; spl:hes; sub:hem. S
a	c55958	103.mg	n.s.s.	34/50	87.6mg	39/50	175.mg	35/50		
b	c55958	292.mg	n.s.s.	15/50	87.6mg	18/50	175.mg	10/50		liv:hpa,hpc,nnd. lun:a/a,a/c.
c	c55958	363.mg	n.s.s.	9/50	87.6mg	8/50	175.mg	6/50		
32	c55958	146.mg	n.s.s.	42/50	87.6mg	39/50	175.mg	39/50		
a	c55958	n.s.s.	n.s.s.	0/50	87.6mg	1/50	175.mg	0/50		liv:hpa,hpc,nnd.
33	c55958	35.2mg	387.mg	39/50	87.6mg	39/50	175.mg	36/50		S
a	c55958	286.mg	62.3gm	0/50	87.6mg	1/50	175.mg	3/50		
b	c55958	171.mg	n.s.s.	2/50	87.6mg	6/50	175.mg	4/50		sub: fbs, fib, nfs, srrn. S
c	c55958	213.mg	n.s.s.	1/50	87.6mg	5/50	175.mg	3/50		S
d	c55958	368.mg	n.s.s.	0/50	87.6mg	0/50	175.mg	3/50		liv:hpc,nnd. S
e	c55958	39.6mg	13.1gm	45/50	87.6mg	43/50	175.mg	37/50		
f	c55958	368.mg	n.s.s.	0/50	87.6mg	0/50	175.mg	3/50		liv:hpa,hpc,nnd.
2-AMINO-5-NITROPHENOL 121-88-0										
34	c55970	364.mg	n.s.s.	29/50	283.mg	30/50	566.mg	8/50		
a	c55970	1.48gm	n.s.s.	5/50	283.mg	3/50	566.mg	1/50		liv:hpa,hpc,nnd.
b	c55970	1.14gm	n.s.s.	4/50	283.mg	4/50	566.mg	1/50		lun:a/a,a/c.
35	c55970	550.mg	n.s.s.	31/50	283.mg	32/50	566.mg	8/50		
a	c55970	497.mg	n.s.s.	17/50	283.mg	16/50	(566.mg	1/50)		liv:hpa,hpc,nnd.
b	c55970	1.02gm	n.s.s.	7/50	283.mg	8/50	566.mg	2/50		lun:a/a,a/c.
36	c55970	105.mg	n.s.s.	46/50	70.7mg	45/50	142.mg	38/50		
a	c55970	n.s.s.	n.s.s.	0/50	70.7mg	0/50	142.mg	0/50		liv:hpa,hpc,nnd.
37	c55970	16.8mg	65.2mg	42/50	70.7mg	40/50	142.mg	39/50		S
a	c55970	52.7mg	328.mg	1/50	70.7mg	11/50	142.mg	3/50		pan:acc,ana. S

Spe	Strain	Site	Xpo+Xpt	Notes	TD50	2Tailpvl
Sex	Route	Hist			DR	AuOp
b	R m	f34 gav	pan ana	24m24 s		111.mg * P<.0005p
c	R m	f34 gav	pre can	24m24 s		562.mg / P<.004
d	R m	f34 gav	amd MXA	24m24 s		101.mg * P<.02
e	R m	f34 gav	pre MXA	24m24 s		392.mg * P<.04
f	R m	f34 gav	pni isc	24m24 s		393.mg * P<.04
g	R m	f34 gav	T8A MXB	24m24 s		33.6mg * P<.0005
h	R m	f34 gav	liv MXB	24m24 s		1.56gm * P<.05
L-ASCORBATE, SODIUM					100ng...1ug.....10.....100.....1mg.....10.....100.....1g.....10	
38	R m	f3d eat	eso tum	52w52 er		no dre P=1. -
a	R m	f3d eat	for tum	52w52 er		no dre P=1. -
b	R m	f3d eat	liv tum	52w52 er		no dre P=1. -
AURANOFIN					100ng...1ug.....10.....100.....1mg.....10.....100.....1g.....10	
39	M f	cd1 gav	liv mix	80w81 erv		no dre P=1. -
40	M m	cd1 gav	liv mix	80w81 erv		42.6mg * P<.2 -
5-AZACYTIDINE***					100ng...1ug.....10.....100.....1mg.....10.....100.....1g.....10	
41	M f	bal ipj	lmr mix	50w72 e		56.9ug P<.0005+
a	M f	bal ipj	mgl mix	50w72 e		.432mg P<.002
b	M f	bal ipj	mgl adb	50w72 e		.618mg P<.008 +
c	M f	bal ipj	ski mix	50w72 e		.499mg P<.03 +
d	M f	bal ipj	lun ade	50w72 e		no dre P=1.
e	M f	bal ipj	liv tum	50w72 e		no dre P=1.
f	M f	bal ipj	tba tum	50w72 e		36.4ug P<.0005
42	M m	bal ipj	lun ade	50w67 e		.121mg P<.003 +
a	M m	bal ipj	lmr mix	50w67 e		.285mg P<.01 +
b	M m	bal ipj	ski mix	50w67 e		.980mg P<.04 +
c	M m	bal ipj	liv hpa	50w67 e		1.49mg P<.1
d	M m	bal ipj	tba tum	50w67 e		53.9ug P<.0005
43	R m	f34 ipj	tes tum	52w52 e		.222mg * P<.0005+
a	R m	f34 ipj	liv tum	52w52 e		no dre P=1.
b	R m	f34 ipj	tba tum	52w52 e		.170mg * P<.0005+
6-AZACYTIDINE					100ng...1ug.....10.....100.....1mg.....10.....100.....1g.....10	
44	R m	f34 ipj	liv tum	52w52 e		no dre P=1.
a	R m	f34 ipj	tba tum	52w52 e		no dre P=1. -
AZOXYMETHANE***					100ng...1ug.....10.....100.....1mg.....10.....100.....1g.....10	
45	R m	f34 gav	col tum	30w65 e		.102mg P<.0005+
a	R m	f34 gav	col mal	30w65 e		.171mg P<.0005
b	R m	f34 gav	zym car	30w65 e		.204mg P<.0005+
c	R m	f34 gav	kid mnp	30w65 e		.300mg P<.002 +
d	R m	f34 gav	liv tum	30w65 e		no dre P=1. -
1-AZOXYPROPANE					100ng...1ug.....10.....100.....1mg.....10.....100.....1g.....10	
46	R m	sda gav	ski mix	26w77 ev		noTD50 P<.0005+
a	R m	sda gav	ski ker	26w77 ev		380.ng P<.0005+
b	R m	sda gav	nas mix	26w77 ev		596.ng P<.0005+
c	R m	sda gav	nas ene	26w77 ev		723.ng P<.0005+
d	R m	sda gav	nas pam	26w77 ev		7.36ug P<.1 +
e	R m	sda gav	liv hpc	26w77 ev		7.36ug P<.1
f	R m	sda gav	liv hpa	26w77 ev		no dre P=1.
2-AZOXYPROPANE					100ng...1ug.....10.....100.....1mg.....10.....100.....1g.....10	
47	R m	sda gav	ski ker	26w77 ev		2.68ug P<.04 +
a	R m	sda gav	liv hpc	26w77 ev		7.36ug P<.1
b	R m	sda gav	liv hpa	26w77 ev		no dre P=1.
BENZENE***					100ng...1ug.....10.....100.....1mg.....10.....100.....1g.....10	
48	M f	swi gav	mam car	18m24		279.mg P<.0005+
a	M f	swi gav	lun mix	18m24		453.mg P<.004 +
b	M f	swi gav	lun ata	18m24		1.02gm P<.004
c	M f	swi gav	lun ade	18m24		1.10gm P<.2
d	M f	swi gav	zym car	18m24		6.52gm P<.3 +
e	M f	swi gav	liv hpt	18m24		no dre P=1.
f	M f	swi gav	tba mix	18m24		150.mg P<.0005
g	M f	swi gav	tba mal	18m24		187.mg P<.0005+
49	M m	swi gav	lun mix	18m24		382.mg P<.0005+
a	M m	swi gav	lun ade	18m24		811.mg P<.02
b	M m	swi gav	lun ata	18m24		1.20gm P<.04
c	M m	swi gav	zym car	18m24		1.57gm P<.02 +
d	M m	swi gav	liv hpt	18m24		6.19gm P<.7
e	M m	swi gav	lun adc	18m24		6.52gm P<.3
f	M m	swi gav	tba mix	18m24		370.mg P<.05
g	M m	swi gav	tba mal	18m24		939.mg P<.3 +
50	R f	wis gav	zym sqc	24m24		1.36gm P<.004

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code	
b	c55970	53.8mg	359.mg	1/50	70.7mg	10/50	142.mg	3/50		
c	c55970	163.mg	5.02gm	0/50	70.7mg	0/50	142.mg	4/50		
d	c55970	43.3mg	n.s.s.	20/50	70.7mg	16/50	142.mg	12/50	S	
e	c55970	126.mg	n.s.s.	3/50	70.7mg	2/50	142.mg	5/50	amd:phe,phm. S	
f	c55970	118.mg	n.s.s.	0/50	70.7mg	3/50	142.mg	0/50	pre:adn,can. S	
g	c55970	19.0mg	88.7mg	42/50	70.7mg	44/50	142.mg	34/50		
h	c55970	332.mg	n.s.s.	0/50	70.7mg	0/50	142.mg	2/50	Liv:hpa,hpc,nnnd.	
L-ASCORBATE, SODIUM (vitamin C, sodium) 134-03-2										
38	1900	206.mg	n.s.s.	0/10	400.mg	0/10			Hirose;carc,8,1731-1735;1987/pers.comm.	
a	1900	206.mg	n.s.s.	0/10	400.mg	0/10				
b	1900	206.mg	n.s.s.	0/10	400.mg	0/10				
AURANOFIN ((2,3,4,6-tetra-O-acetyl-1-thio-1-beta-D-glucopyranosato-S) (triethylphosphine) gold) 34031-32-8										
39	1870	130.mg	n.s.s.	4/220	1.00mg	3/110	3.00mg	0/110	7.45mg 0/110	Markiewicz;faat,11,277-284;1988
40	1870	13.8mg	n.s.s.	24/220	1.00mg	21/110	3.00mg	17/110	7.45mg 20/110	
5-AZACYTIDINE*** 320-67-2										
41	1819	35.2ug	.104mg	6/50	.198mg	36/50				Cavaliere;clet,37,51-58;1987
a	1819	.186mg	1.82mg	0/50	.198mg	7/50				
b	1819	.235mg	12.0mg	0/50	.198mg	5/50				
c	1819	.196mg	n.s.s.	1/50	.198mg	7/50				
d	1819	.329mg	n.s.s.	9/50	.198mg	7/50				
e	1819	.980mg	n.s.s.	0/50	.198mg	0/50				
f	1819	21.5ug	69.4ug	14/50	.198mg	44/50				
42	1819	60.4ug	.719mg	12/50	.213mg	27/50				
a	1819	.126mg	41.7mg	3/50	.213mg	12/50				
b	1819	.297mg	n.s.s.	0/50	.213mg	3/50				
c	1819	.365mg	n.s.s.	0/50	.213mg	2/50				
d	1819	31.5ug	.116mg	13/50	.213mg	38/50				
43	1906	.144mg	.404mg	10/49	10.7ug	1/10	.107mg	2/10	1.07mg 56/87	Carr;bjca,57,395-402;1988
a	1906	5.01ug	n.s.s.	0/49	10.7ug	0/10	.107mg	0/10	1.07mg 0/87	
b	1906	.114mg	.282mg	10/49	10.7ug	1/10	.107mg	2/10	1.07mg 63/87	
6-AZACYTIDINE 3131-60-0										
44	1906	.662mg	n.s.s.	0/49	1.07mg	0/12				Carr;bjca,57,395-402;1988
a	1906	.340mg	n.s.s.	10/49	1.07mg	2/12				
AZOXYMETHANE*** (Z-methyl-O,N,N-azoxymethane) 25843-45-2										
45	1864	48.5ug	.249mg	0/19	.527mg	12/16				Lijinsky;canr,47,3968-3972;1987/pers.comm.
a	1864	77.9ug	.474mg	0/19	.527mg	9/16				
b	1864	90.0ug	.610mg	0/19	.527mg	8/16				
c	1864	.121mg	1.26mg	0/19	.527mg	6/16				
d	1864	.679mg	n.s.s.	0/19	.527mg	0/16				
1-AZOXYPROPANE 17697-55-1										
46	1837	n.s.s.	241.ng	1/29	1.40ug	29/29				Fiala;carc,8,1947-1949;1987/pers.comm.
a	1837	214.ng	751.ng	1/29	1.40ug	22/29				
b	1837	330.ng	1.22ug	0/29	1.40ug	17/29				
c	1837	390.ng	1.55ug	0/29	1.40ug	15/29				
d	1837	1.81ug	n.s.s.	0/29	1.40ug	2/29				
e	1837	1.81ug	n.s.s.	0/29	1.40ug	2/29				
f	1837	2.77ug	n.s.s.	1/29	1.40ug	1/29				
2-AZOXYPROPANE 17697-53-9										
47	1837	971.ng	n.s.s.	1/29	1.40ug	6/29				Fiala;carc,8,1947-1949;1987/pers.comm.
a	1837	1.81ug	n.s.s.	0/29	1.40ug	2/29				
b	1837	2.77ug	n.s.s.	1/29	1.40ug	1/29				
BENZENE*** 71-43-2										
48	bt908	154.mg	655.mg	2/40	241.mg	19/40				Maltoni;anya,534,412-426;1988
a	bt908	214.mg	3.43gm	4/40	241.mg	15/40				
b	bt908	414.mg	6.13gm	0/40	241.mg	6/40				
c	bt908	362.mg	n.s.s.	4/40	241.mg	9/40				
d	bt908	1.06gm	n.s.s.	0/40	241.mg	1/40				
e	bt908	1.99gm	n.s.s.	0/40	241.mg	0/40				
f	bt908	77.1mg	523.mg	16/40	241.mg	32/40				
g	bt908	99.1mg	589.mg	11/40	241.mg	28/40				
49	bt908	193.mg	1.39gm	3/40	241.mg	16/40				
a	bt908	330.mg	n.s.s.	2/40	241.mg	9/40				
b	bt908	436.mg	n.s.s.	1/40	241.mg	6/40				
c	bt908	541.mg	n.s.s.	0/40	241.mg	4/40				
d	bt908	756.mg	n.s.s.	2/40	241.mg	3/40				
e	bt908	1.06gm	n.s.s.	0/40	241.mg	1/40				
f	bt908	149.mg	n.s.s.	15/40	241.mg	24/40				
g	bt908	279.mg	n.s.s.	9/40	241.mg	14/40				
50	bt907	552.mg	8.18gm	0/40	321.mg	6/40				

Spe	Strain	Site	Xpo+Xpt	TD50	2Tailpvl
Sex	Route	Hist	Notes	DR	AuOp
a	R f wis	gav	orc sqc 24m24	2.09gm	P<.02
b	R f wis	gav	nas ulc 24m24	8.70gm	P<.3
c	R f wis	gav	tba mal 24m24	482.mg	P<.02
d	R f wis	gav	tba mix 24m24	no dre	P=1.
51	R m wis	gav	zym sqc 24m24	1.14gm	P<.002
a	R m wis	gav	nas ulc 24m24	4.29gm	P<.1
b	R m wis	gav	orc sqc 24m24	8.48gm	P<.6
c	R m wis	gav	tba mal 24m24	523.mg	P<.01
d	R m wis	gav	tba mix 24m24	no dre	P=1.

BENZOFURAN

100ng...1ug...10...100...1mg...10...100...1g...10

52	M f b6c	gav	MXB MXB 24m24	33.4mg	P<.0005
a	M f b6c	gav	liv hpa 24m24	34.4mg	P<.0005c
b	M f b6c	gav	liv MXA 24m24	36.4mg	P<.0005
c	M f b6c	gav	for MXA 24m24	145.mg	P<.003 c
d	M f b6c	gav	for sqp 24m24	172.mg	P<.005
e	M f b6c	gav	lun MXA 24m24	174.mg *	P<.0005c
f	M f b6c	gav	lun a/a 24m24	224.mg *	P<.0005
g	M f b6c	gav	MXA MXA 24m24	322.mg	P<.04
h	M f b6c	gav	TBA MXB 24m24	45.9mg	P<.002
i	M f b6c	gav	liv MXB 24m24	36.4mg	P<.0005
j	M f b6c	gav	lun MXB 24m24	174.mg *	P<.0005
53	M m b6c	gav	liv MXA 24m24	19.8mg	P<.0005c
a	M m b6c	gav	liv hpa 24m24	20.5mg	P<.0005c
b	M m b6c	gav	liv MXA 24m24	21.3mg	P<.0005
c	M m b6c	gav	MXB MXB 24m24	23.9mg	P<.002
d	M m b6c	gav	liv hpb 24m24	102.mg *	P<.0005c
e	M m b6c	gav	for MXA 24m24	108.mg *	P<.002 c
f	M m b6c	gav	liv MXA 24m24	114.mg *	P<.006
g	M m b6c	gav	lun a/a 24m24	136.mg *	P<.004
h	M m b6c	gav	for sqp 24m24	154.mg *	P<.007
i	M m b6c	gav	lun MXA 24m24	160.mg *	P<.04 c
j	M m b6c	gav	for sqc 24m24	383.mg *	P<.03
k	M m b6c	gav	mul mlp 24m24	919.mg *	P<.04
l	M m b6c	gav	TBA MXB 24m24	54.3mg *	P<.02
m	M m b6c	gav	liv MXB 24m24	21.3mg	P<.0005
n	M m b6c	gav	lun MXB 24m24	160.mg *	P<.04
54	R f f34	gav	sub nlm 24m24	98.8mg	P<.005
a	R f f34	gav	lun MXA 24m24	418.mg *	P<.04
b	R f f34	gav	kid uac 24m24	424.mg *	P<.02 p
c	R f f34	gav	lun a/a 24m24	530.mg *	P<.04
d	R f f34	gav	ton sqp 24m24	574.mg *	P<.04
e	R f f34	gav	TBA MXB 24m24	577.mg *	P<.9
f	R f f34	gav	liv MXB 24m24	2.09gm	P<.3
55	R m f34	gav	tes ict 24m24	#8.03mg	P<.004 -
a	R m f34	gav	pit adn 24m24	45.8mg *	P<.03
b	R m f34	gav	MXA MXA 24m24	55.3mg *	P<.02
c	R m f34	gav	lun a/c 24m24	166.mg *	P<.03
d	R m f34	gav	mgl fba 24m24	271.mg *	P<.03
e	R m f34	gav	thy fcc 24m24	389.mg *	P<.03
f	R m f34	gav	TBA MXB 24m24	22.5mg *	P<.02
g	R m f34	gav	liv MXB 24m24	no dre	P=1.

BENZYL ALCOHOL

100ng...1ug...10...100...1mg...10...100...1g...10

56	M f b6c	gav	TBA MXB 24m24	57.5mg *	P<.1 -
a	M f b6c	gav	liv MXB 24m24	1.04gm *	P<.4
b	M f b6c	gav	lun MXB 24m24	no dre	P=1.
57	M m b6c	gav	adr coa 24m24	#1.62gm *	P<.05 -
a	M m b6c	gav	TBA MXB 24m24	no dre	P=1.
b	M m b6c	gav	liv MXB 24m24	588.mg *	P<.4
c	M m b6c	gav	lun MXB 24m24	546.mg *	P<.3
58	R f f34	gav	TBA MXB 24m24 s	885.mg *	P<.7 -
a	R f f34	gav	liv MXB 24m24 s	no dre	P=1.
59	R m f34	gav	mgl MXA 24m24	#1.14gm *	P<.03 -
a	R m f34	gav	mgl fba 24m24	1.38gm *	P<.04
b	R m f34	gav	TBA MXB 24m24	no dre	P=1.
c	R m f34	gav	liv MXB 24m24	no dre	P=1.

HC BLUE NO. 1***

100ng...1ug...10...100...1mg...10...100...1g...10

60	M f b6c	eat	liv mix 9m23 er	41.3mg	P<.0005+
a	M f b6c	eat	liv hpc 9m23 er	114.mg	P<.0005+
b	M f b6c	eat	liv hpa 9m23 er	165.mg	P<.0005
61	M f b6c	eat	liv mix 15m23 er	81.5mg	P<.0005+
a	M f b6c	eat	liv hpc 15m23 er	94.0mg	P<.0005+
b	M f b6c	eat	liv hpa 15m23 er	969.mg	P<.05
62	M f b6c	eat	liv mix 91w91 ekr	85.0mg	P<.0005+
a	M f b6c	eat	liv hpc 91w91 ekr	148.mg	P<.004 +

	RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code
a	bt907	722.mg	n.s.s.	0/40	321.mg	4/40				
b	bt907	1.42gm	n.s.s.	0/40	321.mg	1/40				
c	bt907	217.mg	n.s.s.	10/40	321.mg	21/40				
d	bt907	408.mg	n.s.s.	34/40	321.mg	27/40				
51	bt907	494.mg	4.73gm	0/40	321.mg	7/40				
a	bt907	1.06gm	n.s.s.	0/40	321.mg	2/40				
b	bt907	1.16gm	n.s.s.	1/40	321.mg	2/40				
c	bt907	238.mg	26.9gm	8/40	321.mg	19/40				
d	bt907	490.mg	n.s.s.	30/40	321.mg	25/40				
BENZOFURAN 271-89-6										
52	c56166	18.8mg	73.8mg	5/50	84.9mg	27/50	(170.mg)	29/50)	for:sqc,sqp; liv:hpa; lun:a/a,a/c.	C
a	c56166	19.7mg	71.5mg	1/50	84.9mg	22/50	(170.mg)	21/50)		
b	c56166	20.4mg	80.8mg	4/50	84.9mg	25/50	(170.mg)	22/50)	liv:hpa,hpc.	S
c	c56166	61.8mg	890.mg	2/50	84.9mg	9/50	(170.mg)	5/50)	for:sqc,sqp.	S
d	c56166	69.8mg	1.88gm	2/50	84.9mg	8/50	(170.mg)	5/50)		S
e	c56166	98.1mg	449.mg	2/50	84.9mg	9/50	170.mg	14/50	lun:a/a,a/c.	S
f	c56166	122.mg	565.mg	1/50	84.9mg	5/50	170.mg	13/50		S
g	c56166	101.mg	n.s.s.	1/50	84.9mg	4/50	(170.mg)	1/50)	mul:mlu; spl:mlu.	S
h	c56166	22.3mg	255.mg	27/50	84.9mg	35/50	(170.mg)	35/50)		S
i	c56166	20.4mg	80.8mg	4/50	84.9mg	25/50	(170.mg)	22/50)	liv:hpa,hpc,nnnd.	S
j	c56166	98.1mg	449.mg	2/50	84.9mg	9/50	170.mg	14/50	lun:a/a,a/c.	S
53	c56166	10.7mg	52.5mg	12/50	42.4mg	31/50	(84.9mg)	40/50)	liv:hpa,hpb,hpc.	S
a	c56166	11.5mg	46.9mg	4/50	42.4mg	24/50	(84.9mg)	34/50)		S
b	c56166	11.4mg	58.6mg	12/50	42.4mg	30/50	(84.9mg)	37/50)	liv:hpa,hpc.	S
c	c56166	11.7mg	108.mg	20/50	42.4mg	32/50	(84.9mg)	45/50)	for:sqc,sqp; liv:hpa,hpb,hpc; lun:a/a,a/c.	C
d	c56166	60.1mg	191.mg	0/50	42.4mg	3/50	84.9mg	18/50		S
e	c56166	58.7mg	438.mg	2/50	42.4mg	11/50	84.9mg	13/50	for:sqc,sqp.	S
f	c56166	55.7mg	1.46gm	9/50	42.4mg	10/50	84.9mg	22/50	liv:hpb,hpc.	S
g	c56166	67.8mg	1.08gm	4/50	42.4mg	7/50	84.9mg	15/50		S
h	c56166	74.8mg	2.64gm	2/50	42.4mg	7/50	84.9mg	10/50		S
i	c56166	67.6mg	n.s.s.	10/50	42.4mg	9/50	84.9mg	19/50	lun:a/a,a/c.	S
j	c56166	163.mg	n.s.s.	0/50	42.4mg	4/50	84.9mg	3/50		S
k	c56166	272.mg	n.s.s.	0/50	42.4mg	0/50	84.9mg	3/50		S
l	c56166	25.8mg	n.s.s.	29/50	42.4mg	32/50	84.9mg	45/50		S
m	c56166	11.4mg	58.6mg	12/50	42.4mg	30/50	(84.9mg)	37/50)	liv:hpa,hpc,nnnd.	S
n	c56166	67.6mg	n.s.s.	10/50	42.4mg	9/50	84.9mg	19/50	lun:a/a,a/c.	S
54	c56166	42.7mg	939.mg	1/50	42.4mg	9/50	(84.9mg)	3/50)		S
a	c56166	159.mg	n.s.s.	0/50	42.4mg	2/50	84.9mg	3/50	lun:a/a,a/c.	S
b	c56166	161.mg	n.s.s.	0/50	42.4mg	1/50	84.9mg	4/50		S
c	c56166	183.mg	n.s.s.	0/50	42.4mg	1/50	84.9mg	3/50		S
d	c56166	194.mg	n.s.s.	0/50	42.4mg	1/50	84.9mg	3/50		S
e	c56166	40.0mg	n.s.s.	46/50	42.4mg	48/50	84.9mg	42/50		S
f	c56166	341.mg	n.s.s.	0/50	42.4mg	0/50	84.9mg	1/50	liv:hpa,hpc,nnnd.	S
55	c56166	3.77mg	68.2mg	42/50	21.2mg	40/50	(42.4mg)	41/50)		S
a	c56166	19.5mg	n.s.s.	18/50	21.2mg	16/50	42.4mg	22/50		S
b	c56166	25.4mg	n.s.s.	10/50	21.2mg	13/50	42.4mg	17/50	liv:mn1; mul:mn1.	S
c	c56166	60.0mg	n.s.s.	0/50	21.2mg	3/50	42.4mg	2/50		S
d	c56166	77.8mg	n.s.s.	0/50	21.2mg	0/50	42.4mg	3/50		S
e	c56166	103.mg	n.s.s.	0/50	21.2mg	0/50	42.4mg	3/50		S
f	c56166	10.4mg	n.s.s.	45/50	21.2mg	42/50	42.4mg	46/50		S
g	c56166	147.mg	n.s.s.	1/50	21.2mg	1/50	42.4mg	0/50	liv:hpa,hpc,nnnd.	S
BENZYL ALCOHOL 100-51-6										
56	c06111	120.mg	n.s.s.	27/50	70.7mg	24/50	142.mg	36/50		S
a	c06111	279.mg	n.s.s.	1/50	70.7mg	6/50	142.mg	4/50	liv:hpa,hpc,nnnd.	S
b	c06111	588.mg	n.s.s.	4/50	70.7mg	1/50	142.mg	4/50	lun:a/a,a/c.	S
57	c06111	489.mg	n.s.s.	0/50	70.7mg	0/50	142.mg	3/50		S
a	c06111	134.mg	n.s.s.	34/50	70.7mg	27/50	142.mg	34/50		S
b	c06111	148.mg	n.s.s.	11/50	70.7mg	16/50	142.mg	16/50	liv:hpa,hpc,nnnd.	S
c	c06111	174.mg	n.s.s.	10/50	70.7mg	6/50	142.mg	17/50	lun:a/a,a/c.	S
58	c06111	133.mg	n.s.s.	46/50	142.mg	29/50	283.mg	26/50		S
a	c06111	n.s.s.	n.s.s.	0/50	142.mg	0/50	283.mg	0/50	liv:hpa,hpc,nnnd.	S
59	c06111	465.mg	n.s.s.	0/50	142.mg	3/50	283.mg	3/50	mg1:adn,fba.	S
a	c06111	523.mg	n.s.s.	0/50	142.mg	2/50	283.mg	3/50		S
b	c06111	171.mg	n.s.s.	44/50	142.mg	32/50	283.mg	38/50		S
c	c06111	1.47gm	n.s.s.	2/50	142.mg	0/50	283.mg	1/50	liv:hpa,hpc,nnnd.	S
HC BLUE NO. 1*** 2784-94-3										
60	1860m	19.7mg	91.7mg	3/38	151.mg	20/22			Burnett;fctx,25,703-707;1987/pers.comm.	
a	1860m	56.4mg	302.mg	2/38	151.mg	13/22				
b	1860m	77.2mg	499.mg	1/38	151.mg	10/22				
61	1860n	41.2mg	177.mg	3/38	252.mg	20/23				
a	1860n	48.9mg	201.mg	2/38	252.mg	19/23				
b	1860n	300.mg	n.s.s.	1/38	252.mg	4/23				
62	1860o	33.8mg	291.mg	0/10	195.mg	7/10				
a	1860o	54.2mg	1.03gm	0/10	195.mg	5/10				

Spe	Strain	Site	Xpo+Xpt	Notes	TD50	2Tailpvl
Sex	Route	Hist			DR	AuOp
b	M f	b6c	eat liv hpa	91w91 ekr		287.mg P<.04
63	M f	b6c	eat liv mix	23m23 er	. + .	51.4mg P<.0005+
a	M f	b6c	eat liv hpc	23m23 er		163.mg P<.0005+
b	M f	b6c	eat liv hpa	23m23 er		185.mg P<.0005
64	M f	b6c	eat liv hpc	91w91 ekr		noTD50 P<.0005+
a	M f	b6c	eat liv mix	91w91 ekr		noTD50 P<.0005+
b	M f	b6c	eat liv hpa	91w91 ekr		574.mg P<.04
65	M f	b6c	eat liv mix	23m23 er	<+	noTD50 P<.0005+
a	M f	b6c	eat liv hpc	23m23 er		87.1mg P<.0005+
b	M f	b6c	eat liv hpa	23m23 er		1.30gm P<.02
HC BLUE NO. 1 (PURIFIED) 100ng...1ug...10...100...1mg...10...100...1g...10						
66	M f	b6c	eat liv mix	91w91 ekr	<+	noTD50 P<.0005+
a	M f	b6c	eat liv hpc	91w91 ekr		88.9mg P<.0005+
b	M f	b6c	eat liv hpa	91w91 ekr		917.mg P<.09
67	M f	b6c	eat liv mix	23m23 er	. + .	70.6mg P<.0005+
a	M f	b6c	eat liv hpc	23m23 er		115.mg P<.0005+
b	M f	b6c	eat liv hpa	23m23 er		530.mg P<.0005
BORIC ACID 100ng...1ug...10...100...1mg...10...100...1g...10						
68	M f	b6c	eat TBA	MXB 24m24	>	no dre P=1. -
a	M f	b6c	eat liv	MXB 24m24		31.0gm * P<.9
b	M f	b6c	eat lun	MXB 24m24		4.19gm * P<.3
69	M m	b6c	eat liv	MXA 24m24 s	: +	#638.mg * P<.009 -
a	M m	b6c	eat sub	MXA 24m24 s		706.mg P<.004
b	M m	b6c	eat sub	MXA 24m24 s		1.07gm P<.009
c	M m	b6c	eat liv	hpc 24m24 s		1.12gm * P<.02
d	M m	b6c	eat TBA	MXB 24m24 s		500.mg * P<.03
e	M m	b6c	eat liv	MXB 24m24 s		638.mg * P<.009
f	M m	b6c	eat lun	MXB 24m24 s		38.6gm * P<.1
BROMATE, POTASSIUM*** 100ng...1ug...10...100...1mg...10...100...1g...10						
70	R m	f3d	wat kid mix	6m24 e	. + .	6.67mg P<.0005+
a	R m	f3d	wat kid ade	6m24 e		6.67mg P<.0005
b	R m	f3d	wat per	mso 6m24 e		7.84mg P<.0005
c	R m	f3d	wat thy	fct 6m24 e		11.3mg P<.003
d	R m	f3d	wat kid	adc 6m24 e		79.2mg P<.3
71	R m	f3d	wat kid mix	9m24 e	. + .	4.81mg P<.0005+
a	R m	f3d	wat kid	ade 9m24 e		5.57mg P<.0005
b	R m	f3d	wat per	mso 9m24 e		14.0mg P<.002
c	R m	f3d	wat kid	adc 9m24 e		16.9mg P<.003
72	R m	f3d	wat kid mix	12m24 e	. + .	8.32mg P<.0005+
a	R m	f3d	wat kid	ade 12m24 e		10.1mg P<.0005
b	R m	f3d	wat per	mso 12m24 e		19.4mg P<.003
c	R m	f3d	wat thy	fct 12m24 e		19.4mg P<.003
d	R m	f3d	wat kid	adc 12m24 e		35.5mg P<.02
73	R m	f3d	wat kid	ade 52w52 e	. + .	4.98mg P<.002
a	R m	f3d	wat per	mso 52w52 e		25.6mg P<.2
74	R m	f3d	wat per	mso 24m24 e	. + .	12.4mg P<.0005
a	R m	f3d	wat kid	mix 24m24 e		28.7mg P<.0005+
b	R m	f3d	wat thy	fct 24m24 e		39.8mg P<.002
c	R m	f3d	wat kid	ade 24m24 e		48.0mg P<.004
d	R m	f3d	wat thy	fca 24m24 e		59.5mg P<.008
e	R m	f3d	wat kid	adc 24m24 e		105.mg P<.04
75	R m	f3d	wat per	mso 24m24	. + .	29.1mg * P<.0005
a	R m	f3d	wat kid	rct 24m24		41.6mg * P<.0005+
b	R m	f3d	wat kid	ade 24m24		52.0mg * P<.0005+
c	R m	f3d	wat thy	fct 24m24 e		78.6mg * P<.0005
d	R m	f3d	wat kid	adc 24m24		326.mg * P<.004
e	R m	f3d	wat liv	nnd 24m24		68.2mg Z P<.2
BROMODICHLOROMETHANE*** 100ng...1ug...10...100...1mg...10...100...1g...10						
76	M f	b6c	gav liv	MXA 24m24	: + :	28.9mg * P<.0005c
a	M f	b6c	gav liv	hpa 24m24		36.0mg * P<.0005c
b	M f	b6c	gav liv	hpc 24m24		144.mg * P<.002 c
c	M f	b6c	gav	MXA MXA 24m24		132.mg P<.02
d	M f	b6c	gav	TBA MXB 24m24		62.9mg * P<.04
e	M f	b6c	gav liv	MXB 24m24		28.9mg * P<.0005
f	M f	b6c	gav lun	MXB 24m24		644.mg * P<.2
77	M m	b6c	gav mul	mlp 24m24	: + :	74.2mg P<.008
a	M m	b6c	gav kid	MXA 24m24		137.mg * P<.02 c

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology				Brkly Code		
b	1860a	85.8mg	n.s.s.	0/10	195.mg	3/10								
63	1860r	28.5mg	95.5mg	3/38	195.mg	33/36								
a	1860r	91.4mg	358.mg	2/38	195.mg	20/36								
b	1860r	103.mg	402.mg	1/38	195.mg	18/36								
64	1860s	n.s.s.	162.mg	0/10	390.mg	10/10								
a	1860s	n.s.s.	162.mg	0/10	390.mg	10/10								
b	1860s	172.mg	n.s.s.	0/10	390.mg	3/10								
65	1860u	n.s.s.	106.mg	3/38	390.mg	36/36								
a	1860u	45.8mg	163.mg	2/38	390.mg	34/36								
b	1860u	515.mg	n.s.s.	1/38	390.mg	7/36								
HC BLUE NO. 1 (PURIFIED) 2784-94-3														
66	1860m	n.s.s.	162.mg	0/10	390.mg	10/10					Burnett;fctx,25,703-707;1987/pers.comm.			
a	1860m	31.2mg	277.mg	0/10	390.mg	9/10								
b	1860m	224.mg	n.s.s.	0/10	390.mg	2/10								
67	1860n	31.7mg	141.mg	3/38	390.mg	35/36								
a	1860n	66.1mg	210.mg	2/38	390.mg	32/36								
b	1860n	275.mg	1.41gm	1/38	390.mg	14/36								
BORIC ACID 10043-35-3														
68	c56417	777.mg	n.s.s.	25/50	319.mg	27/50	638.mg	26/50						
a	c56417	1.77gm	n.s.s.	5/50	319.mg	4/50	638.mg	6/50			liv:hpa,hpc,nnnd.			
b	c56417	1.38gm	n.s.s.	1/50	319.mg	5/50	638.mg	4/50			lun:a/a,a/c.			
69	c56417	296.mg	27.8gm	14/50	296.mg	19/50	591.mg	15/50			liv:hpa,hpc.	S		
a	c56417	308.mg	5.24gm	2/50	296.mg	10/50	(591.mg)	2/50			sub: fbs, fib, nfs, srn.	S		
b	c56417	425.mg	45.2gm	1/50	296.mg	7/50	(591.mg)	2/50			sub: fbs, nfs, srn.	S		
c	c56417	500.mg	n.s.s.	5/50	296.mg	12/50	591.mg	8/50				S		
d	c56417	218.mg	n.s.s.	31/50	296.mg	37/50	591.mg	23/50						
e	c56417	296.mg	27.8gm	14/50	296.mg	19/50	591.mg	15/50			liv:hpa,hpc,nnnd.			
f	c56417	799.mg	n.s.s.	11/50	296.mg	11/50	591.mg	4/50			lun:a/a,a/c.			
BROMATE, POTASSIUM*** 7758-01-2														
70	1814m	3.08mg	18.8mg	0/19	6.25mg	9/19					Kurokawa;gann,78,358-364;1987			
a	1814m	3.08mg	18.8mg	0/19	6.25mg	9/19								
b	1814m	3.50mg	24.7mg	0/19	6.25mg	8/19								
c	1814m	4.57mg	58.1mg	0/19	6.25mg	6/19								
d	1814m	12.9mg	n.s.s.	0/19	6.25mg	1/19								
71	1814n	2.42mg	10.9mg	0/19	9.38mg	14/19								
a	1814n	2.79mg	12.9mg	0/19	9.38mg	13/19								
b	1814n	5.97mg	52.5mg	0/19	9.38mg	7/19								
c	1814n	6.85mg	87.2mg	0/19	9.38mg	6/19								
72	1814o	3.72mg	23.3mg	0/19	12.5mg	9/14								
a	1814o	4.41mg	30.2mg	0/19	12.5mg	8/14								
b	1814o	7.26mg	103.mg	0/19	12.5mg	5/14								
c	1814o	7.26mg	103.mg	0/19	12.5mg	5/14								
d	1814o	10.7mg	n.s.s.	0/19	12.5mg	3/14								
73	1814r	2.66mg	14.9mg	0/8	25.0mg	15/26								
a	1814r	8.84mg	n.s.s.	0/8	25.0mg	4/26								
74	1814s	6.33mg	27.2mg	0/19	25.0mg	15/20								
a	1814s	13.3mg	81.8mg	0/19	25.0mg	9/20								
b	1814s	17.0mg	156.mg	0/19	25.0mg	7/20								
c	1814s	19.4mg	271.mg	0/19	25.0mg	6/20								
d	1814s	22.5mg	895.mg	0/19	25.0mg	5/20								
e	1814s	31.8mg	n.s.s.	0/19	25.0mg	3/20								
75	1851	17.0mg	64.2mg	0/20	.900mg	0/20	1.70mg	3/20	3.30mg	4/24	7.30mg	2/24	16.0mg	3/20
					43.4mg	15/20								
a	1851	24.4mg	82.5mg	0/20	.900mg	0/20	1.70mg	0/20	3.30mg	1/24	7.30mg	5/24	16.0mg	5/20
					43.4mg	9/20								
b	1851	29.4mg	133.mg	0/20	.900mg	0/20	1.70mg	0/20	3.30mg	1/24	7.30mg	5/24	16.0mg	5/20
					43.4mg	6/20								
c	1851	39.3mg	199.mg	0/16	.900mg	0/19	1.70mg	0/20	3.30mg	1/24	7.30mg	0/24	16.0mg	3/20
					43.4mg	7/19								
d	1851	98.7mg	2.93gm	0/20	.900mg	0/20	1.70mg	0/20	3.30mg	0/24	7.30mg	0/24	16.0mg	0/20
					43.4mg	3/20								
e	1851	19.1mg	n.s.s.	2/20	.900mg	0/20	1.70mg	4/20	3.30mg	7/24	7.30mg	0/24	16.0mg	6/20
					(43.4mg)	5/20								
BROMODICHLOROMETHANE*** (dichlorobromomethane) 75-27-4														
76	c55243	18.6mg	52.2mg	3/50	52.0mg	18/50	104.mg	29/50				liv:hpa,hpc.		
a	c55243	22.8mg	65.0mg	1/50	52.0mg	13/50	104.mg	23/50						
b	c55243	69.9mg	734.mg	2/50	52.0mg	5/50	104.mg	10/50						
c	c55243	47.5mg	n.s.s.	2/50	52.0mg	7/50	(104.mg)	1/50			mul:mih; spl:mlh.	S		
d	c55243	26.3mg	n.s.s.	34/50	52.0mg	31/50	104.mg	35/50						
e	c55243	18.6mg	52.2mg	3/50	52.0mg	18/50	104.mg	29/50			liv:hpa,hpc,nnnd.			
f	c55243	176.mg	n.s.s.	1/50	52.0mg	2/50	104.mg	3/50			lun:a/a,a/c.			
77	c55243	28.1mg	1.51gm	0/50	17.5mg	5/50	(35.0mg)	3/50				S		
a	c55243	61.8mg	n.s.s.	1/50	17.5mg	2/50	35.0mg	9/50			kid:tla,uac.			

Spe	Strain	Site	Xpo+Xpt	TD50	2Tailpvl
Sex	Route	Hist	Notes	DR	AuOp
b	M m	b6c	gav kid tla 24m24	215.mg	* P<.09 c
c	M m	b6c	gav kid uac 24m24	336.mg	* P<.03 c
d	M m	b6c	gav TBA MXB 24m24	no dre	P=1.
e	M m	b6c	gav liv MXB 24m24	no dre	P=1.
f	M m	b6c	gav lun MXB 24m24	no dre	P=1.
78	R f	f34	gav MXB MXB 24m24	84.8mg /	P<.0005
a	R f	f34	gav kid MXA 24m24	143.mg	* P<.0005c
b	R f	f34	gav col MXA 24m24	200.mg /	P<.0005c
c	R f	f34	gav kid uac 24m24	272.mg	* P<.002 c
d	R f	f34	gav kid tla 24m24	351.mg	* P<.008 c
e	R f	f34	gav col apn 24m24	364.mg	* P<.004 c
f	R f	f34	gav col acn 24m24	411.mg	* P<.007 c
g	R f	f34	gav TBA MXB 24m24	no dre	P=1.
h	R f	f34	gav liv MXB 24m24	no dre	P=1.
79	R m	f34	gav MXB MXB 24m24	30.3mg /	P<.0005
a	R m	f34	gav MXA MXA 24m24	30.7mg /	P<.0005c
b	R m	f34	gav MXA MXA 24m24	35.6mg /	P<.0005c
c	R m	f34	gav MXA MXA 24m24	55.6mg /	P<.0005c
d	R m	f34	gav kid MXA 24m24	152.mg /	P<.0005c
e	R m	f34	gav kid uac 24m24	213.mg /	P<.0005c
f	R m	f34	gav tn timer 24m24	350.mg	* P<.05
g	R m	f34	gav lun MXA 24m24	366.mg	* P<.02
h	R m	f34	gav lun a/a 24m24	447.mg	* P<.05
i	R m	f34	gav kid tla 24m24	583.mg	* P<.05 c
j	R m	f34	gav TBA MXB 24m24	267.mg	* P<.7
k	R m	f34	gav liv MXB 24m24	747.mg	* P<.2
BROMOETHANE				100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	
80	M f	b6c	inh ute MXA 24m24	535.mg Z	P<.0005c
a	M f	b6c	inh ute MXA 24m24	596.mg Z	P<.0005
b	M f	b6c	inh ute MXA 24m24	681.mg Z	P<.0005
c	M f	b6c	inh ute acn 24m24	822.mg Z	P<.0005
d	M f	b6c	inh ute adn 24m24	2.61gm	* P<.002
e	M f	b6c	inh ute sqc 24m24	4.44gm	* P<.03
f	M f	b6c	inh TBA MXB 24m24	571.mg	* P<.009
g	M f	b6c	inh liv MXB 24m24	no dre	P=1.
h	M f	b6c	inh lun MXB 24m24	5.81gm	* P<.5
81	M m	b6c	inh lun MXA 24m24	1.10gm	* P<.03 e
a	M m	b6c	inh lun a/c 24m24	2.39gm	* P<.04
b	M m	b6c	inh TBA MXB 24m24	1.63gm	* P<.5
c	M m	b6c	inh liv MXB 24m24	3.67gm	* P<.7
d	M m	b6c	inh lun MXB 24m24	1.10gm	* P<.03
82	R f	f34	inh bra gln 24m25	1.02gm	* P<.05 e
a	R f	f34	inh lun a/a 24m25	1.28gm	* P<.03 e
b	R f	f34	inh TBA MXB 24m25	no dre	P=1.
c	R f	f34	inh liv MXB 24m25	670.mg Z	P<.3
83	R m	f34	inh liv nnd 24m25	1.14gm	* P<.03
a	R m	f34	inh amd MXA 24m25	149.mg	* P<.2 p
b	R m	f34	inh MXB MXB 24m25	151.mg Z	P<.2
c	R m	f34	inh lun MXA 24m25	+hist 582.mg	* P<.2 p
d	R m	f34	inh bra gcl 24m25	+hist 80.7gm	* P<.1 p
e	R m	f34	inh bra MXA 24m25	+hist no dre	P=1. p
f	R m	f34	inh TBA MXB 24m25	no dre	P=1.
g	R m	f34	inh liv MXB 24m25	2.28gm Z	P<.6
1,3-BUTADIENE***				100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	
84	R f	cdr	inh mgl mix 24m24 e	133.mg	P<.0005+
a	R f	cdr	inh mgl ben 24m24 e	182.mg	P<.0005
b	R f	cdr	inh thy fca 24m24 e	8.27gm	* P<.0005
c	R f	cdr	inh mgl mal 24m24 e	7.72gm	* P<.07
d	R f	cdr	inh tba tum 24m24 e	no dre	P=1.
85	R m	cdr	inh tes ldc 26m26 e	+ 7.55gm	* P<.003 +
a	R m	cdr	inh pan exa 26m26 e	9.31gm	* P<.006
b	R m	cdr	inh tba tum 26m26 e	1.47gm	* P<.08
BUTYLATED HYDROXYANISOLE***				100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	
86	R m	f34	eat for car 6m24 e	no dre	P=1.
a	R m	f34	eat for pam 6m24 e	no dre	P=1.
b	R m	f34	eat liv tum 6m24 e	no dre	P=1.
87	R m	f34	eat for sqc 12m24 e	4.06gm	* P<.04 +
a	R m	f34	eat fls pam 12m24 e	4.06gm	* P<.04
b	R m	f34	eat fgr pam 12m24 e	12.5gm	* P<.3
c	R m	f34	eat liv tum 12m24 e	no dre	P=1.
88	R m	f34	eat fgr pam 24m24 e	298.mg	* P<.0005
a	R m	f34	eat fls pam 24m24 e	298.mg	* P<.0005
b	R m	f34	eat for sqc 24m24 e	7.76gm	* P<.04 +
c	R m	f34	eat liv tum 24m24 e	no dre	P=1.

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code
b	c55243	80.4mg n.s.s.	1/50	17.5mg	2/50	35.0mg	6/50		
c	c55243	116.mg n.s.s.	0/50	17.5mg	0/50	35.0mg	4/50		
d	c55243	42.5mg n.s.s.	38/50	17.5mg	36/50	35.0mg	35/50		
e	c55243	51.4mg n.s.s.	17/50	17.5mg	16/50	35.0mg	20/50	liv:hpa,hpc,nnnd.	
f	c55243	158.mg n.s.s.	12/50	17.5mg	3/50	35.0mg	7/50	lun:a/a,a/c.	
78	c55243	52.7mg 150.mg	0/50	34.7mg	1/50	70.1mg	24/50	col:acn,apn; kid:tla,uac.	C
a	c55243	79.8mg 294.mg	0/50	34.7mg	1/50	70.1mg	15/50	kid:tla,uac.	
b	c55243	103.mg 505.mg	0/50	34.7mg	0/50	70.1mg	12/50	col:acn,apn.	
c	c55243	128.mg 934.mg	0/50	34.7mg	0/50	70.1mg	9/50		
d	c55243	152.mg 5.11gm	0/50	34.7mg	1/50	70.1mg	6/50		
e	c55243	157.mg 2.04gm	0/50	34.7mg	0/50	70.1mg	7/50		
f	c55243	168.mg 4.92gm	0/50	34.7mg	0/50	70.1mg	6/50		
g	c55243	73.5mg n.s.s.	48/50	34.7mg	43/50	70.1mg	43/50		
h	c55243	303.mg n.s.s.	1/50	34.7mg	3/50	70.1mg	1/50	liv:hpa,hpc,nnnd.	
79	c55243	21.7mg 43.8mg	0/50	35.0mg	13/50	70.1mg	46/50	col:acn,apn; kid:tla,uac; rec:acn,apn.	C
a	c55243	22.0mg 44.5mg	0/50	35.0mg	13/50	70.1mg	45/50	col:acn,apn; rec:acn,apn.	
b	c55243	24.9mg 53.3mg	0/50	35.0mg	11/50	70.1mg	38/50	col:acn; rec:acn.	
c	c55243	36.8mg 89.2mg	0/50	35.0mg	3/50	70.1mg	33/50	col:apn; rec:apn.	
d	c55243	81.6mg 345.mg	0/50	35.0mg	1/50	70.1mg	13/50	kid:tla,uac.	
e	c55243	103.mg 603.mg	0/50	35.0mg	0/50	70.1mg	10/50		
f	c55243	143.mg n.s.s.	0/50	35.0mg	3/50	70.1mg	3/50		S
g	c55243	149.mg n.s.s.	0/50	35.0mg	2/50	70.1mg	4/50	lun:a/a,a/c.	S
h	c55243	169.mg n.s.s.	0/50	35.0mg	2/50	70.1mg	3/50		S
i	c55243	201.mg n.s.s.	0/50	35.0mg	1/50	70.1mg	3/50		
j	c55243	37.0mg n.s.s.	43/50	35.0mg	41/50	70.1mg	47/50		
k	c55243	207.mg n.s.s.	1/50	35.0mg	0/50	70.1mg	4/50	liv:hpa,hpc,nnnd.	
BROMOETHANE (ethyl bromide) 74-96-4									
80	c55481	356.mg 855.mg	0/50	137.mg	4/50	275.mg	5/50	550.mg 27/50	ute:acn,adn,sgc.
a	c55481	387.mg 981.mg	0/50	137.mg	3/50	275.mg	4/50	550.mg 25/50	ute:acn,adn.
b	c55481	434.mg 1.15gm	0/50	137.mg	3/50	275.mg	4/50	550.mg 22/50	ute:acn,sgc.
c	c55481	503.mg 1.47gm	0/50	137.mg	2/50	275.mg	3/50	550.mg 19/50	S
d	c55481	1.17gm 11.3gm	0/50	137.mg	1/50	275.mg	1/50	550.mg 6/50	S
e	c55481	1.67gm n.s.s.	0/50	137.mg	1/50	275.mg	1/50	550.mg 3/50	S
f	c55481	275.mg 16.5gm	27/50	137.mg	24/50	275.mg	29/50	550.mg 37/50	
g	c55481	1.47gm n.s.s.	5/50	137.mg	6/50	275.mg	6/50	550.mg 3/50	liv:hpa,hpc,nnnd.
h	c55481	1.19gm n.s.s.	6/50	137.mg	3/50	275.mg	5/50	550.mg 6/50	lun:a/a,a/c.
81	c55481	481.mg n.s.s.	7/50	115.mg	6/50	229.mg	12/50	458.mg 15/50	lun:a/a,a/c.
a	c55481	965.mg n.s.s.	2/50	115.mg	0/50	229.mg	5/50	458.mg 6/50	S
b	c55481	328.mg n.s.s.	30/50	115.mg	30/50	229.mg	34/50	458.mg 33/50	
c	c55481	537.mg n.s.s.	21/50	115.mg	18/50	229.mg	20/50	458.mg 22/50	liv:hpa,hpc,nnnd.
d	c55481	481.mg n.s.s.	7/50	115.mg	6/50	229.mg	12/50	458.mg 15/50	lun:a/a,a/c.
82	c55481	373.mg n.s.s.	0/50	32.7mg	1/50	65.5mg	1/50	131.mg 3/50	
a	c55481	388.mg n.s.s.	0/50	32.7mg	0/50	65.5mg	0/50	131.mg 3/50	
b	c55481	99.5mg n.s.s.	49/50	32.7mg	46/50	65.5mg	40/50	131.mg 44/50	
c	c55481	178.mg n.s.s.	1/50	32.7mg	0/50	65.5mg	4/50	(131.mg 0/50)	liv:hpa,hpc,nnnd.
83	c55481	339.mg n.s.s.	0/50	22.9mg	0/50	45.8mg	0/50	91.7mg 3/50	S
a	c55481	49.7mg n.s.s.	8/50	22.9mg	23/50	45.8mg	18/50	91.7mg 21/50	amd:phe,phm.
b	c55481	47.4mg n.s.s.	8/50	22.9mg	28/50	45.8mg	21/50	91.7mg 22/50	amd:phe,phm; bra:ast,gcl,glu,oli; lun:a/a,a/c.
c	c55481	219.mg n.s.s.	0/50	22.9mg	0/50	45.8mg	4/50	91.7mg 1/50	lun:a/a,a/c.
d	c55481	259.mg n.s.s.	0/50	22.9mg	3/50	45.8mg	1/50	91.7mg 1/50	
e	c55481	557.mg n.s.s.	0/50	22.9mg	3/50	45.8mg	0/50	91.7mg 0/50	bra:ast,glu,oli.
f	c55481	63.2mg n.s.s.	43/50	22.9mg	47/50	45.8mg	47/50	91.7mg 43/50	
g	c55481	358.mg n.s.s.	2/50	22.9mg	0/50	45.8mg	0/50	91.7mg 3/50	liv:hpa,hpc,nnnd.
1,3-BUTADIENE*** 106-99-0									
84	1829	78.0mg 341.mg	50/100	166.mg	79/100	(1.32gm	81/100)		Owen;amih,48,407-413;1987
a	1829	110.mg 428.mg	32/100	166.mg	64/100	(1.32gm	55/100)		
b	1829	4.26gm 24.8gm	0/100	166.mg	2/100	1.32gm	10/100		
c	1829	2.91gm n.s.s.	18/100	166.mg	15/100	1.32gm	26/100		
d	1829	893.mg n.s.s.	97/100	166.mg	98/100	1.32gm	94/100		
85	1829	3.58gm 52.9gm	0/100	116.mg	3/100	927.mg	8/100		
a	1829	3.98gm 136.gm	3/100	116.mg	1/100	927.mg	10/100		
b	1829	550.mg n.s.s.	84/100	116.mg	70/100	927.mg	87/100		
BUTYLATED HYDROXYANISOLE*** (BHA, 2(3)-tert-butyl-4-hydroxyanisole) 25013-16-5									
86	1902m	2.06gm n.s.s.	0/50	200.mg	0/50				Nera;txcy,53,251-268;1988
a	1902m	2.06gm n.s.s.	0/50	200.mg	0/50				
b	1902m	2.06gm n.s.s.	0/50	200.mg	0/50				
87	1902n	1.23gm n.s.s.	0/50	400.mg	3/46				
a	1902n	1.23gm n.s.s.	0/50	400.mg	3/46				
b	1902n	2.03gm n.s.s.	0/50	400.mg	1/46				
c	1902n	3.79gm n.s.s.	0/50	400.mg	0/46				
88	1902o	186.mg 495.mg	0/50	800.mg	37/44				
a	1902o	186.mg 495.mg	0/50	800.mg	37/44				
b	1902o	2.35gm n.s.s.	0/50	800.mg	3/44				
c	1902o	7.25gm n.s.s.	0/50	800.mg	0/44				

Spe	Strain	Site	Xpo+Xpt								TD50	2Tailpvl
Sex	Route	Hist	Notes								DR	AuOp
89	R m	f3d eat	for mix	52w52								1.30gm * P<.08
a	R m	f3d eat	for pam	52w52								1.99gm * P<.2 -
b	R m	f3d eat	for sqc	52w52								4.04gm * P<.4 -
c	R m	f3d eat	liv tum	52w52								no dre P=1. -
90	R m	f3d eat	eso tum	52w52 er								no dre P=1. -
a	R m	f3d eat	for tum	52w52 er								no dre P=1. -
b	R m	f3d eat	liv tum	52w52 er								no dre P=1. -
BUTYLATED HYDROXYTOLUENE***				100ng...1ug...:10.....100.....1mg.....10.....100.....1g.....:10								
91	M f	b6c eat	lun a/c	24m28 e								71.3gm * P<.6
a	M f	b6c eat	liv hem	24m28 e								126. gm * P<.3
b	M f	b6c eat	liv hpc	24m28 e								no dre P=1.
c	M f	b6c eat	liv hpa	24m28 e								no dre P=1.
d	M f	b6c eat	lun a/a	24m28 e								no dre P=1.
e	M f	b6c eat	liv hct	24m28 e								no dre P=1. -
f	M f	b6c eat	tba tum	24m28 e								no dre P=1.
92	M m	b6c eat	liv hpa	24m28 e								3.45gm * P<.003
a	M m	b6c eat	liv hct	24m28 e								2.90gm * P<.02 +
b	M m	b6c eat	lun a/a	24m28 e								18.5gm * P<.3
c	M m	b6c eat	liv ang	24m28 e								128. gm * P<.3
d	M m	b6c eat	liv hpc	24m28 e								no dre P=1.
e	M m	b6c eat	liv hem	24m28 e								no dre P=1.
f	M m	b6c eat	lun a/c	24m28 e								no dre P=1.
g	M m	b6c eat	tba tum	24m28 e								no dre P=1.
93	R m	f3d eat	eso tum	52w52 er								no dre P=1. -
a	R m	f3d eat	for tum	52w52 er								no dre P=1. -
b	R m	f3d eat	liv tum	52w52 er								no dre P=1. -
CADMIUM CHLORIDE				100ng...1ug...:10.....100.....1mg.....10.....100.....1g.....:10								
94	R m	wis inh	lun car	18m31 eo								12.7ug * P<.0005+
a	R m	wis inh	lun adc	18m31 eo								22.0ug * P<.0005
b	R m	wis inh	lun epc	18m31 eo								58.8ug * P<.0005
c	R m	wis inh	lun mec	18m31 eo								.315mg * P<.03
d	R m	wis inh	lun ade	18m31 eo								.563mg * P<.5
e	R m	wis inh	adr pbm	18m31 eo								.591mg * P<.8
CATECHOL***				100ng...1ug...:10.....100.....1mg.....10.....100.....1g.....:10								
95	R m	f3d eat	stg ade	51w52 rv								noTD50 P<.0005
a	R m	f3d eat	stg adc	51w52 rv								257. mg P<.07 +
b	R m	f3d eat	for pam	51w52 rv								833. mg P<.4
p-CHLOROANILINE.HCL				100ng...1ug...:10.....100.....1mg.....10.....100.....1g.....:10								
96	M f	b6c gav	TBA MXB	24m24								no dre P=1. -
a	M f	b6c gav	liv MXB	24m24								176. mg * P<.5
b	M f	b6c gav	lun MXB	24m24								no dre P=1.
97	M m	b6c gav	liv hpc	24m24								33.8mg * P<.002
a	M m	b6c gav	--- hes	24m24								89.5mg * P<.04 p
b	M m	b6c gav	liv MXA	24m24								49.3mg * P<.2 p
c	M m	b6c gav	MXB MXB	24m24								56.0mg * P<.2
d	M m	b6c gav	TBA MXB	24m24								83.7mg * P<.6
e	M m	b6c gav	liv MXB	24m24								49.3mg * P<.2
f	M m	b6c gav	lun MXB	24m24								2.78gm * P<.1.
98	R f	f34 gav	amd pob	24m24								105. mg * P<.2 e
a	R f	f34 gav	spl MXA	24m24								232. mg * P<.3 e
b	R f	f34 gav	TBA MXB	24m24								145. mg Z P<.9
c	R f	f34 gav	liv MXB	24m24								no dre P=1.
99	R m	f34 gav	spl MXA	24m24								7.62mg Z P<.0005c
a	R m	f34 gav	spl MXA	24m24								7.90mg Z P<.0005
b	R m	f34 gav	amd MXA	24m24								13.3mg Z P<.009 e
c	R m	f34 gav	spl ost	24m24								15.5mg Z P<.0005
d	R m	f34 gav	spl MXA	24m24								16.9mg * P<.0005
e	R m	f34 gav	spl fbs	24m24								19.0mg * P<.0005
f	R m	f34 gav	spl hes	24m24								107. mg * P<.005
g	R m	f34 gav	amd MXA	24m24								14.8mg Z P<.02
h	R m	f34 gav	TBA MXB	24m24								20.8mg Z P<.4
i	R m	f34 gav	liv MXB	24m24								no dre P=1.
CHLORODIFLUOROMETHANE				100ng...1ug...:10.....100.....1mg.....10.....100.....1g.....:10								
100	M f	swi inh	lun ade	18m24								no dre P=1. -
a	M f	swi inh	tba mal	18m24								no dre P=1. -
b	M f	swi inh	tba mix	18m24								no dre P=1. -
101	M m	swi inh	lun ade	18m24								no dre P=1. -
a	M m	swi inh	tba mix	18m24								no dre P=1. -
b	M m	swi inh	tba mal	18m24								98.3gm * P<.8
102	R f	sda inh	liv ang	24m24								no dre P=1. -
a	R f	sda inh	tba mix	24m24								26.0gm * P<.1. -
b	R f	sda inh	tba mal	24m24								20.1gm * P<.8 -

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code		
89	1883	393.mg	n.s.s.	0/10	400.mg	0/20	800.mg	3/20	Hasegawa;gann,79,320-328;1988/pers.comm.		
a	1883	488.mg	n.s.s.	0/10	400.mg	0/20	800.mg	2/20			
b	1883	658.mg	n.s.s.	0/10	400.mg	0/20	800.mg	1/20			
c	1883	275.mg	n.s.s.	0/10	400.mg	0/20	800.mg	0/20			
90	1900	206.mg	n.s.s.	0/10	400.mg	0/15	800.mg	0/15	Hirose;carc,8,1731-1735;1987/pers.comm.		
a	1900	206.mg	n.s.s.	0/10	400.mg	0/15	800.mg	0/15			
b	1900	206.mg	n.s.s.	0/10	400.mg	0/15	800.mg	0/15			
BUTYLATED HYDROXYTOLUENE*** (BHT, 2,6-DI-tert-butyl-p-cresol) 128-37-0											
91	1882	12.3gm	n.s.s.	1/41	1.13gm	2/44	2.25gm	2/40	Inai;gann,79,49-58;1988		
a	1882	20.6gm	n.s.s.	0/41	1.13gm	0/44	2.25gm	1/40			
b	1882	29.7gm	n.s.s.	2/41	1.13gm	1/44	2.25gm	0/40			
c	1882	13.0gm	n.s.s.	5/41	1.13gm	7/44	2.25gm	2/40			
d	1882	16.4gm	n.s.s.	4/41	1.13gm	5/44	2.25gm	1/40			
e	1882	14.6gm	n.s.s.	7/41	1.13gm	8/44	2.25gm	2/40			
f	1882	6.04gm	n.s.s.	35/41	1.13gm	33/44	2.25gm	22/40			
92	1882	1.90gm	17.7gm	6/32	1.04gm	16/42	2.08gm	25/47			
a	1882	1.42gm	n.s.s.	12/32	1.04gm	26/42	2.08gm	31/47			
b	1882	5.38gm	n.s.s.	4/32	1.04gm	6/42	2.08gm	10/47			
c	1882	20.9gm	n.s.s.	0/32	1.04gm	0/42	2.08gm	1/47			
d	1882	7.51gm	n.s.s.	7/32	1.04gm	11/42	2.08gm	8/47			
e	1882	21.5gm	n.s.s.	4/32	1.04gm	3/42	2.08gm	1/47			
f	1882	19.0gm	n.s.s.	1/32	1.04gm	3/42	2.08gm	0/47			
g	1882	1.72gm	n.s.s.	27/32	1.04gm	36/42	2.08gm	38/47			
93	1900	144.mg	n.s.s.	0/10	280.mg	0/10	280.mg	0/10	Hirose;carc,8,1731-1735;1987/pers.comm.		
a	1900	144.mg	n.s.s.	0/10	280.mg	0/10	280.mg	0/10			
b	1900	144.mg	n.s.s.	0/10	280.mg	0/10	280.mg	0/10			
CADMIUM CHLORIDE 10108-64-2											
94	1907	8.89ug	18.8ug	0/38	3.34ug	6/39	6.68ug	20/38	13.4ug	25/35	Takenaka;jnci,70,367-373;1983
a	1907	14.6ug	35.9ug	0/38	3.34ug	4/39	6.68ug	16/38	13.4ug	15/35	
b	1907	32.3ug	158mg	0/38	3.34ug	2/39	6.68ug	5/38	13.4ug	8/35	
c	1907	95.5ug	n.s.s.	0/38	3.34ug	0/39	6.68ug	0/38	13.4ug	3/35	
d	1907	118mg	n.s.s.	0/38	3.34ug	1/39	6.68ug	0/38	13.4ug	1/35	
e	1907	49.7ug	n.s.s.	2/38	3.34ug	8/39	6.68ug	4/38	13.4ug	4/35	
CATECHOL*** (1,2-dihydroxybenzene)*** 120-80-9											
95	1845	n.s.s.	35.6mg	0/10	335.mg	15/15					Hirose;gann,78,1144-1149;1987/pers.comm.
a	1845	77.6mg	n.s.s.	0/10	335.mg	3/15					
b	1845	135.mg	n.s.s.	0/10	335.mg	1/15					
p-CHLOROANILINE.HCl 20265-96-7											
96	c02038	28.9mg	n.s.s.	36/50	2.11mg	26/50	7.04mg	21/50	21.1mg	31/50	
a	c02038	33.4mg	n.s.s.	6/50	2.11mg	9/50	7.04mg	8/50	21.1mg	11/50	liv:hpa,hpc,ndd.
b	c02038	88.7mg	n.s.s.	6/50	2.11mg	2/50	7.04mg	1/50	21.1mg	4/50	lun:a/a,a/c.
97	c02038	17.3mg	146.mg	3/50	2.11mg	7/50	7.04mg	11/50	21.1mg	17/50	S
a	c02038	33.5mg	n.s.s.	4/50	2.11mg	4/50	7.04mg	1/50	21.1mg	10/50	
b	c02038	16.4mg	n.s.s.	11/50	2.11mg	21/50	7.04mg	20/50	21.1mg	21/50	liv:hpa,hpc.
c	c02038	16.8mg	n.s.s.	14/50	2.11mg	24/50	7.04mg	21/50	21.1mg	23/50	---:hes; liv:hpa,hpc. P
d	c02038	14.6mg	n.s.s.	40/50	2.11mg	30/50	7.04mg	35/50	21.1mg	36/50	
e	c02038	16.4mg	n.s.s.	11/50	2.11mg	21/50	7.04mg	20/50	21.1mg	21/50	liv:hpa,hpc,ndd.
f	c02038	43.1mg	n.s.s.	8/50	2.11mg	5/50	7.04mg	7/50	21.1mg	6/50	lun:a/a,a/c.
98	c02038	29.5mg	n.s.s.	2/50	1.40mg	3/50	4.20mg	1/50	12.6mg	6/50	
a	c02038	57.0mg	n.s.s.	0/50	1.40mg	0/50	4.20mg	1/50	12.6mg	1/50	spl:fbs,ost.
b	c02038	10.8mg	n.s.s.	37/50	1.40mg	30/50	4.20mg	34/50	12.6mg	40/50	
c	c02038	130.mg	n.s.s.	1/50	1.40mg	1/50	4.20mg	0/50	12.6mg	0/50	liv:hpa,hpc,ndd.
99	c02038	5.14mg	11.8mg	0/49	1.40mg	1/50	4.20mg	3/50	12.6mg	38/50	spl:fbs,hes,ost.
a	c02038	5.28mg	12.4mg	0/49	1.40mg	1/50	4.20mg	3/50	12.6mg	36/50	spl:fbs,ost. S
b	c02038	6.01mg	494.mg	13/49	1.40mg	14/50	4.20mg	15/50	12.6mg	26/50	amd:pbb,phm,pob.
c	c02038	9.01mg	29.7mg	0/49	1.40mg	0/50	4.20mg	1/50	12.6mg	19/50	S
d	c02038	10.1mg	31.2mg	0/49	1.40mg	1/50	4.20mg	2/50	12.6mg	19/50	spl:fbs, fib. S
e	c02038	11.0mg	36.3mg	0/49	1.40mg	1/50	4.20mg	2/50	12.6mg	17/50	S
f	c02038	36.3mg	1.04gm	0/49	1.40mg	0/50	4.20mg	0/50	12.6mg	4/50	S
g	c02038	6.47mg	n.s.s.	13/49	1.40mg	14/50	4.20mg	14/50	12.6mg	25/50	amd:pbb,pob. S
h	c02038	5.46mg	n.s.s.	42/49	1.40mg	42/50	4.20mg	39/50	12.6mg	48/50	
i	c02038	42.8mg	n.s.s.	1/49	1.40mg	6/50	4.20mg	5/50	12.6mg	0/50	liv:hpa,hpc,ndd.
CHLORODIFLUOROMETHANE (fluorocarbon 22) 75-45-6											
100	bt606	30.0gm	n.s.s.	2/60	556.mg	3/60	2.78gm	0/60			Maltoni;anya,534,261-282;1988
a	bt606	8.72gm	n.s.s.	12/60	556.mg	13/60	2.78gm	11/60			
b	bt606	10.4gm	n.s.s.	14/60	556.mg	19/60	2.78gm	11/60			
101	bt606	13.0gm	n.s.s.	6/60	463.mg	2/60	2.32gm	4/60			
a	bt606	8.02gm	n.s.s.	10/60	463.mg	10/60	2.32gm	9/60			
b	bt606	9.13gm	n.s.s.	1/60	463.mg	5/60	2.32gm	3/60			
102	bt605	10.6gm	n.s.s.	1/60	176.mg	1/60	882.mg	0/60			
a	bt605	718.mg	n.s.s.	45/60	176.mg	44/60	882.mg	45/60			
b	bt605	2.06gm	n.s.s.	13/60	176.mg	12/60	882.mg	14/60			

Spe	Strain	Site	Xpo+Xpt	Notes	TD50	2Tailpvl
Sex	Route	Hist			OR	AuOp
103	R m	sda inh	liv ang	24m24	.	no dre P=1. -
a	R m	sda inh	tba mix	24m24		6.54gm * P<.6 -
b	R m	sda inh	tba mal	24m24		no dre P=1. -
CHLOROETHANE*					100ng...1ug.....10.....100.....1mg.....10.....100.....1g.....10	
104	M f	b6c inh	ute car	23m23	:	1.81gm P<.0005c
a	M f	b6c inh	liv MXA	23m23	:	7.22gm P<.0005e
b	M f	b6c inh	liv hpc	23m23		7.58gm P<.0005
c	M f	b6c inh	--- MXA	23m23		9.96gm P<.002
d	M f	b6c inh	lun MXA	23m23		8.64gm P<.02
e	M f	b6c inh	TBA MXB	23m23		1.38gm P<.0005
f	M f	b6c inh	liv MXB	23m23		7.22gm P<.0005
g	M f	b6c inh	lun MXB	23m23		8.64gm P<.02
105	M m	b6c inh	lun MXA	23m23 s	:	#9.91gm P<.005
a	M m	b6c inh	lun a/a	23m23 s		12.7gm P<.005
b	M m	b6c inh	TBA MXB	23m23 s		10.1gm P<.2
c	M m	b6c inh	liv MXB	23m23 s		34.1gm P<.5
d	M m	b6c inh	lun MXB	23m23 s		9.91gm P<.005
106	R f	f34 inh	ute pst	24m24	:	10.2gm P<.05
a	R f	f34 inh	bra a/sl	24m24		21.0gm P<.04 e
b	R f	f34 inh	TBA MXB	24m24		2.66gm P<.2
c	R f	f34 inh	liv MXB	24m24		no dre P=1.
107	R m	f34 inh	ski MXA	24m24	:	3.21gm P<.004 e
a	R m	f34 inh	ski bcc	24m24		4.97gm P<.02
b	R m	f34 inh	TBA MXB	24m24		1.60gm P<.3
c	R m	f34 inh	liv MXB	24m24		47.7gm P<.8
3-(p-CHLOROPHENYL)-1,1-DIMETHYLUREA***					...1ug.....10.....100.....1mg.....10.....100.....1g.....10	
108	M f	b6c eat	TBA MXB	24m24	:	no dre P=1. -
a	M f	b6c eat	liv MXB	24m24		no dre P=1.
b	M f	b6c eat	lun MXB	24m24		no dre P=1.
109	M m	b6c eat	sub MXA	24m24	:	#2.10gm P<.02 -
a	M m	b6c eat	sub MXA	24m24		2.21gm P<.04
b	M m	b6c eat	TBA MXB	24m24		no dre P=1.
c	M m	b6c eat	liv MXB	24m24		no dre P=1.
d	M m	b6c eat	lun MXB	24m24		17.6gm * P<.7
110	R f	f34 eat	TBA MXB	24m24	:	no dre P=1. -
a	R f	f34 eat	liv MXB	24m24		no dre P=1.
111	R m	f34 eat	MXB MXB	24m24	:	86.3gm * P<.0005
a	R m	f34 eat	kid MXA	24m24	:	131.mg * P<.0005c
b	R m	f34 eat	kid tla	24m24		272.mg * P<.006 c
c	R m	f34 eat	kid uac	24m24		281.mg * P<.003 c
d	R m	f34 eat	liv MXA	24m24		201.mg * P<.04 c
e	R m	f34 eat	TBA MXB	24m24		no dre P=1.
f	R m	f34 eat	liv MXB	24m24		201.mg * P<.04
CIPROFIBRATE***					100ng...1ug.....10.....100.....1mg.....10.....100.....1g.....10	
112	M m	c5n eat	liv mix	78w78 e	:	4.17gm P<.0005+
a	M m	c5n eat	liv hpa	78w78 e		5.89gm P<.002 +
b	M m	c5n eat	liv hpc	78w78 e		12.3gm P<.02 +
c	M m	c5n eat	lun tum	78w78 e		no dre P=1.
113	M m	c5n eat	liv mix	89w91 ev	:	12.1gm P<.0005+
a	M m	c5n eat	liv hpa	89w91 ev		19.2gm P<.002 +
b	M m	c5n eat	liv hpc	89w91 ev		46.4gm P<.04 +
CYCLOHEXANONE					100ng...1ug.....10.....100.....1mg.....10.....100.....1g.....10	
114	M f	b6c wat	--- mly	24m25 ers	:	3.69gm Z P<.03
a	M f	b6c wat	liv mix	24m25 ers		no dre P=1.
b	M f	b6c wat	lun mix	24m25 ers		no dre P=1.
115	M m	b6c wat	liv mix	24m25 er	:	no dre P=1.
a	M m	b6c wat	lun mix	24m25 er		no dre P=1.
116	R f	f34 wat	liv nnd	24m25 e	:	6.30gm * P<.5
117	R m	f34 wat	adr cca	24m25 e	:	929.mg P<.03
a	R m	f34 wat	liv car	24m25 e		no dre P=1.
b	R m	f34 wat	liv mix	24m25 e		no dre P=1.
3-DIAZOTYRAMINE.HCL					100ng...1ug.....10.....100.....1mg.....10.....100.....1g.....10	
118	R m	f3d wat	orc sqc	27m27 e	:	37.6gm P<.0005+
DICHLORODIFLUOROMETHANE					100ng...1ug.....10.....100.....1mg.....10.....100.....1g.....10	
119	M f	swi inh	--- Leu	18m24	:	4.10gm P<.06 -
a	M f	swi inh	lun ade	18m24		91.9gm * P<.4 -
b	M f	swi inh	tba mal	18m24		3.32gm P<.03 -
c	M f	swi inh	tba mix	18m24		59.0gm * P<.7 -
120	M m	swi inh	lun ade	18m24	:	41.9gm * P<.2 -
a	M m	swi inh	tba mix	18m24		12.1gm * P<.02 -
b	M m	swi inh	tba mal	18m24		33.1gm * P<.2 -

RefNum	LoConf	UpConf	Cntri	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code	
103	bt605	1.27gm	n.s.s.	0/60	124.mg	0/60	618.mg			
a	bt605	1.11gm	n.s.s.	19/60	124.mg	14/60	618.mg			
b	bt605	2.23gm	n.s.s.	9/60	124.mg	6/60	618.mg			
CHLOROETHANE* (ethyl chloride) 75-00-3										
104	c06224	823.mg	3.55gm	1/50	12.4gm	43/50				
a	c06224	2.24gm	38.5gm	3/50	12.4gm	8/50			liv:hpa,hpc.	
b	c06224	2.29gm	46.7gm	3/50	12.4gm	7/50			S	
c	c06224	2.82gm	59.7gm	4/50	12.4gm	10/50		---:mlh,mlm,mlp,mlu,mly.	S	
d	c06224	1.97gm	n.s.s.	5/50	12.4gm	4/50			lun:a/a,a/c.	
e	c06224	721.mg	2.85gm	28/50	12.4gm	47/50				
f	c06224	2.24gm	38.5gm	3/50	12.4gm	8/50			liv:hpa,hpc,nnd.	
g	c06224	1.97gm	n.s.s.	5/50	12.4gm	4/50			lun:a/a,a/c.	
105	c06224	4.00gm	107.gm	5/50	10.4gm	10/50			lun:a/a,a/c.	
a	c06224	4.89gm	159.gm	3/50	10.4gm	8/50			S	
b	c06224	3.22gm	n.s.s.	27/50	10.4gm	20/50				
c	c06224	6.36gm	n.s.s.	15/50	10.4gm	10/50			liv:hpa,hpc,nnd.	
d	c06224	4.00gm	107.gm	5/50	10.4gm	10/50			lun:a/a,a/c.	
106	c06224	3.58gm	n.s.s.	2/50	2.88gm	7/50			S	
a	c06224	6.08gm	n.s.s.	0/50	2.88gm	3/50				
b	c06224	936.mg	n.s.s.	45/50	2.88gm	48/50				
c	c06224	13.6gm	n.s.s.	1/50	2.88gm	0/50			liv:hpa,hpc,nnd.	
107	c06224	1.15gm	20.6gm	0/50	2.01gm	5/50			ski:bcc,sla,tri.	
a	c06224	1.39gm	n.s.s.	0/50	2.01gm	3/50			S	
b	c06224	468.mg	n.s.s.	48/50	2.01gm	47/50				
c	c06224	2.58gm	n.s.s.	1/50	2.01gm	1/50			liv:hpa,hpc,nnd.	
3-(p-CHLOROPHENYL)-1,1-DIMETHYLUREA*** (Telvar, monuron) 150-68-5										
108	c02846	656.mg	n.s.s.	30/50	638.mg	21/50	(1.29gm	14/50)		
a	c02846	7.79gm	n.s.s.	6/50	638.mg	0/50	1.29gm	3/50	liv:hpa,hpc,nnd.	
b	c02846	5.33gm	n.s.s.	6/50	638.mg	7/50	1.29gm	3/50	lun:a/a,a/c.	
109	c02846	864.mg	n.s.s.	1/50	589.mg	8/50	(1.19gm	1/50)	sub:fbs, fib.	
a	c02846	870.mg	n.s.s.	2/50	589.mg	9/50	(1.19gm	2/50)	sub:fbs, fib, srrn.	
b	c02846	1.01gm	n.s.s.	30/50	589.mg	22/50	(1.19gm	19/50)		
c	c02846	1.57gm	n.s.s.	12/50	589.mg	8/50	(1.19gm	6/50)	liv:hpa,hpc,nnd.	
d	c02846	2.72gm	n.s.s.	6/50	589.mg	5/50	1.19gm	10/50	lun:a/a,a/c.	
110	c02846	79.7mg	n.s.s.	41/50	36.8mg	45/50	73.6mg	37/50		
a	c02846	527.mg	n.s.s.	4/50	36.8mg	1/50	73.6mg	2/50	liv:hpa,hpc,nnd.	
111	c02846	52.1mg	225.mg	1/50	29.4mg	8/50	58.9mg	20/50	kid:tla,uac; liv:hpc,nnd.	
a	c02846	75.2mg	286.mg	0/50	29.4mg	3/50	58.9mg	15/50	kid:tla,uac.	
b	c02846	128.mg	2.64gm	0/50	29.4mg	2/50	58.9mg	7/50		
c	c02846	132.mg	764.mg	0/50	29.4mg	1/50	58.9mg	8/50		
d	c02846	93.9mg	n.s.s.	1/50	29.4mg	6/50	58.9mg	9/50	liv:hpc,nnd.	
e	c02846	78.4mg	n.s.s.	36/50	29.4mg	41/50	58.9mg	36/50		
f	c02846	93.9mg	n.s.s.	1/50	29.4mg	6/50	58.9mg	9/50	liv:hpa,hpc,nnd.	
CIPROFIBRATE*** 52214-84-3										
112	1895m	1.50mg	15.8mg	0/12	15.0mg	6/8			Rao;bjca,58,46-51;1988/pers.comm.	
a	1895m	2.09mg	26.4mg	0/12	15.0mg	5/8				
b	1895m	3.65mg	n.s.s.	0/12	15.0mg	3/8				
c	1895m	13.9mg	n.s.s.	0/12	15.0mg	0/8				
113	1895n	5.16mg	37.1mg	0/12	25.4mg	8/12				
a	1895n	7.63mg	86.4mg	0/12	25.4mg	6/12				
b	1895n	13.9mg	n.s.s.	0/12	25.4mg	3/12				
CYCLOHEXANONE 108-94-1										
114	1850	1.54gm	n.s.s.	8/52	1.26gm	17/50	(2.53gm	4/50	4.86gm	0/41)
a	1850	24.1gm	n.s.s.	3/52	1.26gm	6/50	2.53gm	3/50	4.86gm	2/41
b	1850	36.8gm	n.s.s.	3/52	1.26gm	2/50	2.53gm	2/50	4.86gm	1/41
115	1850	3.72gm	n.s.s.	16/52	1.05gm	25/51	2.11gm	13/46		
a	1850	4.90gm	n.s.s.	13/52	1.05gm	7/51	(2.11gm	3/47)		
116	1850	1.32gm	n.s.s.	3/52	183.mg	4/52	361.mg	5/52		
117	1850	364.mg	n.s.s.	1/52	160.mg	7/52	(316.mg	1/51)		
a	1850	1.20gm	n.s.s.	2/52	160.mg	0/52	316.mg	0/51		
b	1850	1.66gm	n.s.s.	6/52	160.mg	5/52	316.mg	4/51		
3-DIAZOTYRAMINE.HCl (4-(2-aminoethyl)-6-diazo-2,4-cyclohexadienone.HCl) ---										
118	1825	21.1mg	74.3mg	0/16	50.0mg	19/28			Fujita;carc,8,527-529;1987	
DICHLORODIFLUOROMETHANE (fluorocarbon 12) 75-71-8										
119	bt602	1.51gm	n.s.s.	8/90	777.mg	12/60	(3.89gm	6/60)		
a	bt602	19.1gm	n.s.s.	2/90	777.mg	1/60	3.89gm	3/60	Maltoni ;anya,534,261-282;1988	
b	bt602	1.33gm	n.s.s.	9/90	777.mg	14/60	(3.89gm	6/60)		
c	bt602	8.68gm	n.s.s.	15/90	777.mg	15/60	3.89gm	13/60		
120	bt602	11.1gm	n.s.s.	3/90	648.mg	3/60	3.24gm	5/60		
a	bt602	5.11gm	n.s.s.	9/90	648.mg	9/60	3.24gm	15/60		
b	bt602	9.46gm	n.s.s.	5/90	648.mg	4/60	3.24gm	7/60		

Spe	Strain	Site	Xpo+Xpt	Notes	TD50	2Tailpvl
Sex	Route	Hist			DR	AuOp
121	R f	sda inh	Liv ang	24m24		.31.3gm * P<.2 -
a	R f	sda inh	tba mal	24m24		no dre P=1. -
b	R f	sda inh	tba mix	24m24		no dre P=1. -
122	R m	sda inh	adr phe	24m24		1.32gm P<.02 -
a	R m	sda inh	liv ang	24m24		no dre P=1. -
b	R m	sda inh	tba mix	24m24		555.mg P<.06 -
c	R m	sda inh	tba mal	24m24		no dre P=1. -
2,4-DICHLOROPHENOL					100ng...1ug...10...100...1mg...10...100...1g...10	
123	M f	b6c eat	TBA MXB	24m24		:> no dre P=1. -
a	M f	b6c eat	liv MXB	24m24		no dre P=1. -
b	M f	b6c eat	lun MXB	24m24		no dre P=1. -
124	M m	b6c eat	for MXA	24m24		: #12.4gm * P<.04 -
a	M m	b6c eat	TBA MXB	24m24		no dre P=1. -
b	M m	b6c eat	liv MXB	24m24		458.gm * P<.1. -
c	M m	b6c eat	lun MXB	24m24		13.3gm * P<.5 -
125	R f	f34 eat	TBA MXB	24m24		:> no dre P=1. -
a	R f	f34 eat	liv MXB	24m24		no dre P=1. -
126	R m	f34 eat	TBA MXB	24m24		:> no dre P=1. -
a	R m	f34 eat	liv MXB	24m24		no dre P=1. -
DICHLOROVOS***					100ng...1ug...10...100...1mg...10...100...1g...10	
127	M f	b6c gav	for MXA	24m24		: ± 56.3mg * P<.02
a	M f	b6c gav	for sqp	24m24		61.3mg * P<.03 c
b	M f	b6c gav	TBA MXB	24m24		no dre P=1. -
c	M f	b6c gav	liv MXB	24m24		no dre P=1. -
d	M f	b6c gav	lun MXB	24m24		32.1mg * P<.5 -
128	M m	b6c gav	for sqp	24m24		: ± 82.8mg * P<.07 p
a	M m	b6c gav	TBA MXB	24m24		38.2mg * P<.6 -
b	M m	b6c gav	liv MXB	24m24		43.4mg * P<.3 -
c	M m	b6c gav	lun MXB	24m24		12.1mg * P<.7 -
129	R f	f34 gav	mgl fba	24m24		: ± 3.97mg P<.03 e
a	R f	f34 gav	mgl MXA	24m24		8.51mg * P<.05 -
b	R f	f34 gav	sub MXA	24m24		27.3mg * P<.03 -
c	R f	f34 gav	pan ade	24m24		44.6mg * P<.2 e
d	R f	f34 gav	TBA MXB	24m24		13.9mg * P<.6 -
e	R f	f34 gav	liv MXB	24m24		83.9mg * P<.3 -
130	R m	f34 gav	MXB MXB	24m24		: + : 3.21mg * P<.005
a	R m	f34 gav	pan ade	24m24		4.16mg * P<.005 p
b	R m	f34 gav	--- mnl	24m24		6.89mg * P<.02 p
c	R m	f34 gav	lun a/a	24m24		52.2mg * P<.04 -
d	R m	f34 gav	TBA MXB	24m24		12.3mg * P<.6 -
e	R m	f34 gav	liv MXB	24m24		56.2mg * P<.4 -
DIETHYLSTILBESTROL***					100ng...1ug...10...100...1mg...10...100...1g...10	
131	M f	c3v eat	mgl mix	25m25 e		.+ . 24.7ug P<.0005+
a	M f	c3v eat	mgl adb	25m25 e		30.2ug P<.0005 -
b	M f	c3v eat	mgl ada	25m25 e		2.63mg P<.5 -
c	M f	c3v eat	lun act	25m25 e		no dre P=1. -
d	M f	c3v eat	liv ade	25m25 e		no dre P=1. -
e	M f	c3v eat	liv adc	25m25 e		no dre P=1. -
132	M f	c3v eat	mgl mix	26m26 e		.+ . 42.7ug P<.0005+
a	M f	c3v eat	mgl adb	26m26 e		43.4ug P<.0005 -
b	M f	c3v eat	--- mso	26m26 e		.928mg P<.003 -
c	M f	c3v eat	ute ena	26m26 e		2.05mg P<.05 -
d	M f	c3v eat	cvu adc	26m26 e		2.47mg P<.07 -
e	M f	c3v eat	liv ade	26m26 e		no dre P=1. -
f	M f	c3v eat	mgl ada	26m26 e		no dre P=1. -
g	M f	c3v eat	liv adc	26m26 e		no dre P=1. -
h	M f	c3v eat	lun act	26m26 e		no dre P=1. -
133	M f	c3v eat	mgl mix	29m29 e		.+ . 87.2ug P<.0005+
a	M f	c3v eat	mgl adb	29m29 e		95.6ug P<.0005 -
b	M f	c3v eat	--- mso	29m29 e		.520mg P<.0005 -
c	M f	c3v eat	cvu adc	29m29 e		1.17mg P<.004 -
d	M f	c3v eat	ute ena	29m29 e		1.71mg P<.02 -
e	M f	c3v eat	mgl ada	29m29 e		2.10mg P<.3 -
f	M f	c3v eat	liv ade	29m29 e		no dre P=1. -
g	M f	c3v eat	liv adc	29m29 e		no dre P=1. -
h	M f	c3v eat	lun act	29m29 e		no dre P=1. -
134	M f	c3v eat	mgl mix	29m29 e		.+ . .115mg P<.0005+
a	M f	c3v eat	mgl adb	29m29 e		.118mg P<.0005 -
b	M f	c3v eat	--- mso	29m29 e		.487mg P<.0005 -
c	M f	c3v eat	cvu adc	29m29 e		1.66mg P<.02 -
d	M f	c3v eat	ute ena	29m29 e		1.87mg P<.02 -
e	M f	c3v eat	mgl ada	29m29 e		4.39mg P<.5 -
f	M f	c3v eat	liv ade	29m29 e		no dre P=1. -
g	M f	c3v eat	liv adc	29m29 e		no dre P=1. -
h	M f	c3v eat	lun act	29m29 e		no dre P=1. -

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code
121	bt601	8.46gm	n.s.s.	1/150	247.mg	1/90	1.23gm	3/90	
a	bt601	6.91gm	n.s.s.	43/150	247.mg	24/90	1.23gm	18/90	
b	bt601	1.34gm	n.s.s.	124/150	247.mg	71/90	1.23gm	72/90	
122	bt601	529.mg	n.s.s.	6/150	173.mg	11/90	(864.mg	5/90)	
a	bt601	2.67gm	n.s.s.	1/150	173.mg	0/90	864.mg	0/90	
b	bt601	221.mg	n.s.s.	51/150	173.mg	42/90	(864.mg	27/90)	
c	bt601	6.54gm	n.s.s.	25/150	173.mg	16/90	864.mg	9/90	

2,4-DICHLOROPHENOL 120-83-2

123	c55345	2.31gm	n.s.s.	26/50	638.mg	18/50	1.29gm	21/50	
a	c55345	8.98gm	n.s.s.	2/50	638.mg	3/50	1.29gm	0/50	liv:hpa,hpc,nnnd.
b	c55345	7.95gm	n.s.s.	3/50	638.mg	1/50	1.29gm	2/50	lun:a/a,a/c.
124	c55345	3.77gm	n.s.s.	0/50	589.mg	0/50	1.19gm	3/50	for:sqc,scp. S
a	c55345	1.20gm	n.s.s.	29/50	589.mg	29/50	1.19gm	24/50	
b	c55345	1.93gm	n.s.s.	10/50	589.mg	12/50	1.19gm	9/50	liv:hpa,hpc,nnnd.
c	c55345	2.85gm	n.s.s.	3/50	589.mg	2/50	1.19gm	5/50	lun:a/a,a/c.
125	c55345	254.mg	n.s.s.	47/50	123.mg	36/50	248.mg	44/50	
a	c55345	n.s.s.	n.s.s.	0/50	123.mg	1/50	248.mg	0/50	liv:hpa,hpc,nnnd.
126	c55345	343.mg	n.s.s.	48/50	196.mg	38/50	396.mg	41/50	
a	c55345	748.mg	n.s.s.	5/50	196.mg	1/50	(396.mg	1/50)	liv:hpa,hpc,nnnd.

DICHLORVQS*** (DDVP, Vapona) 62-73-7

127	c00113	26.8mg	n.s.s.	5/50	14.0mg	6/50	28.0mg	19/50	for:sqc,scp. S
a	c00113	28.2mg	n.s.s.	5/50	14.0mg	6/50	28.0mg	18/50	
b	c00113	31.8mg	n.s.s.	37/50	14.0mg	26/50	28.0mg	37/50	
c	c00113	75.7mg	n.s.s.	6/50	14.0mg	4/50	28.0mg	7/50	liv:hpa,hpc,nnnd.
d	c00113	63.6mg	n.s.s.	3/50	14.0mg	3/50	28.0mg	6/50	lun:a/a,a/c.
128	c00113	28.9mg	n.s.s.	1/50	7.01mg	1/50	14.0mg	5/50	
a	c00113	7.52mg	n.s.s.	37/50	7.01mg	41/50	14.0mg	37/50	
b	c00113	12.5mg	n.s.s.	16/50	7.01mg	18/50	14.0mg	20/50	liv:hpa,hpc,nnnd.
c	c00113	17.2mg	n.s.s.	10/50	7.01mg	15/50	14.0mg	10/50	lun:a/a,a/c.
129	c00113	1.65mg	n.s.s.	9/50	2.80mg	19/50	(5.61mg	16/50)	
a	c00113	3.66mg	n.s.s.	9/50	2.80mg	19/50	5.61mg	17/50	mgl:ade,fba. S
b	c00113	11.1mg	n.s.s.	0/50	2.80mg	3/50	5.61mg	3/50	sub:fbs, fib. S
c	c00113	13.6mg	n.s.s.	1/50	2.80mg	1/50	5.61mg	4/50	
d	c00113	2.62mg	n.s.s.	47/50	2.80mg	46/50	5.61mg	46/50	
e	c00113	20.5mg	n.s.s.	0/50	2.80mg	1/50	5.61mg	1/50	liv:hpa,hpc,nnnd.
130	c00113	1.62mg	31.1mg	25/50	2.80mg	37/50	5.61mg	41/50	---:mml; pan:ade. P
a	c00113	2.09mg	44.6mg	16/50	2.80mg	25/50	5.61mg	30/50	
b	c00113	3.24mg	n.s.s.	11/50	2.80mg	20/50	5.61mg	21/50	
c	c00113	15.5mg	n.s.s.	0/50	2.80mg	0/50	5.61mg	3/50	S
d	c00113	2.34mg	n.s.s.	48/50	2.80mg	45/50	5.61mg	45/50	
e	c00113	12.7mg	n.s.s.	1/50	2.80mg	3/50	5.61mg	2/50	liv:hpa,hpc,nnnd.

DIETHYLSTILBESTROL*** (DES) 56-53-1

131	1852m	19.0ug	32.3ug	4/73	83.2ug	167/182			Greenman;jnci,77,891-898;1986/pers.comm.
a	1852m	23.7ug	38.9ug	2/73	83.2ug	158/182			
b	1852m	.673mg	n.s.s.	2/73	83.2ug	9/182			
c	1852m	1.97mg	n.s.s.	5/75	83.2ug	3/182			
d	1852m	3.29mg	n.s.s.	3/77	83.2ug	0/181			
e	1852m	2.93mg	n.s.s.	10/77	83.2ug	1/181			
132	1852n	33.7ug	55.3ug	4/73	83.2ug	151/189			
a	1852n	34.3ug	55.6ug	2/73	83.2ug	149/189			
b	1852n	.490mg	4.06mg	0/77	83.2ug	13/189			
c	1852n	.836mg	n.s.s.	0/77	83.2ug	6/189			
d	1852n	.936mg	n.s.s.	0/77	83.2ug	5/189			
e	1852n	3.74mg	n.s.s.	3/77	83.2ug	0/188			
f	1852n	2.13mg	n.s.s.	2/73	83.2ug	2/189			
g	1852n	2.24mg	n.s.s.	10/77	83.2ug	5/188			
h	1852n	1.71mg	n.s.s.	5/75	83.2ug	5/189			
133	1852o	67.3ug	.118mg	4/73	83.2ug	117/185			
a	1852o	73.9ug	.128mg	2/73	83.2ug	109/185			
b	1852o	.331mg	.932mg	0/77	83.2ug	28/191			
c	1852o	.616mg	5.24mg	0/77	83.2ug	13/191			
d	1852o	.804mg	n.s.s.	0/77	83.2ug	9/191			
e	1852o	.737mg	n.s.s.	2/73	83.2ug	12/185			
f	1852o	2.05mg	n.s.s.	3/77	83.2ug	4/191			
g	1852o	1.85mg	n.s.s.	10/77	83.2ug	10/191			
h	1852o	1.70mg	n.s.s.	5/75	83.2ug	7/191			
134	1852r	86.3ug	.164mg	4/73	83.2ug	96/182			
a	1852r	89.3ug	.163mg	2/73	83.2ug	92/182			
b	1852r	.312mg	.860mg	0/77	83.2ug	29/192			
c	1852r	.783mg	n.s.s.	0/77	83.2ug	9/192			
d	1852r	.849mg	n.s.s.	0/77	83.2ug	8/192			
e	1852r	1.04mg	n.s.s.	2/96	83.2ug	7/182			
f	1852r	2.00mg	n.s.s.	3/77	83.2ug	4/192			
g	1852r	1.81mg	n.s.s.	10/77	83.2ug	10/192			
h	1852r	1.00mg	n.s.s.	5/75	83.2ug	12/192			

Spe	Strain	Site	Xpo	Xpt	Notes	TD50	2Tailpvl
Sex	Route	Hist				DR	AuOp
5,6-DIHYDRO-5-AZACYTIDINE						100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	
135	R m	f34 ipj	liv	tum	52w52 e	.	no dre P=1.
a	R m	f34 ipj	tba	tum	52w52 e		20.7mg P<.5
DIMETHOXANE, COMMERCIAL GRADE						100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	
136	M f	b6c gav	TBA	MXB	24m24	:	3.38gm * P<.8 -
a	M f	b6c gav	liv	MXB	24m24		no dre P=1.
b	M f	b6c gav	lun	MXB	24m24		10.4gm * P<.8
137	M m	b6c gav	for	MXA	24m24	:	1.44gm * P<.04 e
a	M m	b6c gav	TBA	MXB	24m24		1.82gm * P<.7
b	M m	b6c gav	liv	MXB	24m24		1.18gm * P<.3
c	M m	b6c gav	lun	MXB	24m24		1.45gm * P<.2
138	R f	f34 gav	TBA	MXB	24m24	:	no dre P=1. -
a	R f	f34 gav	liv	MXB	24m24		2.43gm * P<.2
139	R m	f34 gav	TBA	MXB	24m24	:	no dre P=1. -
a	R m	f34 gav	liv	MXB	24m24		no dre P=1.
5,6-DIMETHOXYSTERIGMATOCYSTIN						100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	
140	R m	ain eat	liv	nnd	38w80 e	<+	noTD50 P<.002
a	R m	ain eat	liv	mix	38w80 e		noTD50 P<.002 +
b	R m	ain eat	liv	hpc	38w80 e		.400mg P<.002
c	R m	ain eat	liv	hms	38w80 e		.566mg P<.006
d	R m	ain eat	bon	ost	38w80 e		1.36gm P<.06
DIMETHYL METHYLPHOSPHONATE*						100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	
141	M f	b6c gav	lun	a/a	24m24 as	:	#4.09gm * P<.04 -
a	M f	b6c gav	TBA	MXB	24m24 as		851.mg * P<.02
b	M f	b6c gav	liv	MXB	24m24 as		6.56gm * P<.4
c	M f	b6c gav	lun	MXB	24m24 as		7.25gm * P<.3
142	M m	b6c gav	liv	MXA	23m24 as	:	#458.mg * P<.002
a	M m	b6c gav	liv	hpa	23m24 as		563.mg * P<.003
b	M m	b6c gav	TBA	MXB	23m24 as		370.mg / P<.002
c	M m	b6c gav	liv	MXB	23m24 as		458.mg * P<.002
d	M m	b6c gav	lun	MXB	23m24 as		7.27gm / P<.5
143	R f	f34 gav	TBA	MXB	24m24	:	868.mg * P<.3 -
a	R f	f34 gav	liv	MXB	24m24		no dre P=1.
144	R m	f34 gav	tes	ict	24m24	:	169.mg * P<.0005
a	R m	f34 gav	amd	MXA	24m24		306.mg * P<.0005
b	R m	f34 gav	MXA	MXA	24m24		453.mg / P<.0005
c	R m	f34 gav	MXB	MXB	24m24		520.mg * P<.0005
d	R m	f34 gav	k/p	MXA	24m24		608.mg * P<.0005
e	R m	f34 gav	k/p	tpp	24m24		700.mg * P<.0005p
f	R m	f34 gav	thy	ccr	24m24		983.mg * P<.005
g	R m	f34 gav	trv	men	24m24		1.01gm * P<.0005
h	R m	f34 gav	MXA	MXA	24m24		1.02gm * P<.005
i	R m	f34 gav	thy	MXA	24m24		1.66gm * P<.004
j	R m	f34 gav	kid	uac	24m24		2.24gm * P<.008 p
k	R m	f34 gav	thy	MXA	24m24		1.14gm * P<.04
l	R m	f34 gav	amd	phm	24m24		2.02gm * P<.05
m	R m	f34 gav	TBA	MXB	24m24		178.mg * P<.0005
n	R m	f34 gav	liv	MXB	24m24		1.63gm * P<.09
6-DIMETHYLAMINO-4,4-DIPHENYL-3-HEPTANOL ACETATE.HCL					10.....100.....1mg.....10.....100.....1g.....10	
145	M f	b6c eat	liv	hct	25m25 e	.	1.85gm * P<.9
a	M f	b6c eat	lun	mix	25m25 e		no dre P=1.
146	M m	b6c eat	liv	hct	25m25 e	.	no dre P=1.
a	M m	b6c eat	lun	mix	25m25 e		no dre P=1.
147	R f	f34 eat	ute	esp	25m25 e	.	43.3gm * P<.006
a	R f	f34 eat	liv	nnd	25m25 e		60.7gm * P<.007 +
b	R f	f34 eat	liv	hpc	25m25 e		+hist 260.mg * P<.1 +
148	R m	f34 eat	liv	nnd	25m25 e	.	77.3gm * P<.09 +
a	R m	f34 eat	liv	hpc	25m25 e		+hist 110.mg * P<.02 +
6-DIMETHYLAMINO-4,4-DIPHENYL-3-HEPTANONE.HCL					10.....100.....1mg.....10.....100.....1g.....10	
149	M f	b6c eat	pta	ade	25m25 e	.	42.5gm P<.02 -
a	M f	b6c eat	lun	a/a	25m25 e		371.mg * P<.09 -
b	M f	b6c eat	liv	hpa	25m25 e		385.mg * P<.2 -
c	M f	b6c eat	liv	hpc	25m25 e		no dre P=1. -
d	M f	b6c eat	lun	a/c	25m25 e		no dre P=1. -
150	M m	b6c eat	liv	hpc	25m25 e	.	281.mg * P<.2 -
a	M m	b6c eat	liv	hpa	25m25 e		2.13gm / P<.8 -
b	M m	b6c eat	lun	a/a	25m25 e		no dre P=1. -
c	M m	b6c eat	lun	a/c	25m25 e		no dre P=1. -
151	R f	f34 eat	liv	nnd	25m25 e	.	1.42gm * P<.4 -
152	R m	f34 eat	liv	hpc	25m25 e	.	1.09gm * P<.3 -
a	R m	f34 eat	liv	nnd	25m25 e		no dre P=1. -

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code
5,6-DIHYDRO-5-AZACYTIDINE (DHAC) 62488-57-7									
135	1906	9.94mg	n.s.s.	0/49	21.4mg	0/9		Carr;bjca,57,395-402;1988	
a	1906	3.21mg	n.s.s.	10/49	21.4mg	3/9			
DIMETHOXANE, COMMERCIAL GRADE 828-00-2									
136	c56213	322.mg	n.s.s.	32/50	176.mg	26/50	352.mg	33/50	
a	c56213	1.39gm	n.s.s.	8/50	176.mg	5/50	352.mg	4/50	liv:hpa,hpc,nnd.
b	c56213	1.15gm	n.s.s.	4/50	176.mg	1/50	352.mg	5/50	lun:a/a,a/c.
137	c56213	584.mg	n.s.s.	2/50	176.mg	3/50	352.mg	8/50	for:psq,sgc.
a	c56213	237.mg	n.s.s.	38/50	176.mg	31/50	352.mg	37/50	
b	c56213	355.mg	n.s.s.	14/50	176.mg	12/50	352.mg	19/50	liv:hpa,hpc,nnd.
c	c56213	462.mg	n.s.s.	8/50	176.mg	4/50	352.mg	13/50	lun:a/a,a/c.
138	c56213	135.mg	n.s.s.	41/50	88.1mg	37/50	176.mg	32/50	
a	c56213	598.mg	n.s.s.	0/50	88.1mg	1/50	176.mg	1/50	liv:hpa,hpc,nnd.
139	c56213	58.7mg	n.s.s.	39/50	44.0mg	36/50	88.1mg	32/50	
a	c56213	n.s.s.	n.s.s.	0/50	44.0mg	1/50	88.1mg	0/50	liv:hpa,hpc,nnd.
5,6-DIMETHOXYSTERIGMATOCYSTIN 65176-75-2									
140	1889	n.s.s.	.364mg	0/10	.967mg	8/8		Mori;carc,9,1039-1042;1988	
a	1889	n.s.s.	.364mg	0/10	.967mg	8/8			
b	1889	.142mg	1.94mg	0/10	.967mg	5/8			
c	1889	.188mg	5.90mg	0/10	.967mg	4/8			
d	1889	.332mg	n.s.s.	0/10	.967mg	2/8			
DIMETHYL METHYLPHOSPHONATE* (DMMP) 756-79-6									
141	c54762	1.41gm	n.s.s.	1/50	701.mg	5/50	1.40gm	1/50	S
a	c54762	382.mg	n.s.s.	27/50	701.mg	31/50	1.40gm	8/50	
b	c54762	1.40gm	n.s.s.	3/50	701.mg	5/50	1.40gm	0/50	liv:hpa,hpc,nnd.
c	c54762	1.69gm	n.s.s.	3/50	701.mg	5/50	1.40gm	1/50	lun:a/a,a/c.
142	c54762	211.mg	2.42gm	17/50	701.mg	21/50	1.43gm	4/50	liv:hpa,hpc,S
a	c54762	242.mg	4.34gm	12/50	701.mg	15/50	1.43gm	3/50	S
b	c54762	178.mg	1.95gm	34/50	701.mg	27/50	1.43gm	10/50	
c	c54762	211.mg	2.42gm	17/50	701.mg	21/50	1.43gm	4/50	liv:hpa,hpc,nnd.
d	c54762	1.05gm	n.s.s.	6/50	701.mg	0/50	1.43gm	3/50	lun:a/a,a/c.
143	c54762	280.mg	n.s.s.	40/50	350.mg	42/50	701.mg	40/50	
a	c54762	n.s.s.	n.s.s.	0/50	350.mg	2/50	701.mg	0/50	liv:hpa,hpc,nnd.
144	c54762	93.5mg	500.mg	41/50	350.mg	39/50	701.mg	39/50	S
a	c54762	163.mg	899.mg	12/50	350.mg	18/50	701.mg	18/50	amd:phe,phm.S
b	c54762	227.mg	1.58gm	10/50	350.mg	11/50	701.mg	17/50	mul:mnl; spl:mnl.S
c	c54762	267.mg	1.18gm	0/50	350.mg	9/50	701.mg	6/50	k/p:tpg; kid:uac.P
d	c54762	292.mg	1.66gm	0/50	350.mg	8/50	701.mg	3/50	k/p:tcc, tpp.S
e	c54762	324.mg	2.07gm	0/50	350.mg	7/50	701.mg	3/50	
f	c54762	384.mg	9.77gm	1/50	350.mg	4/50	701.mg	4/50	S
g	c54762	438.mg	3.03gm	0/50	350.mg	4/50	701.mg	6/50	S
h	c54762	415.mg	10.2gm	2/50	350.mg	5/50	701.mg	6/50	mul:men,msm; tnv:men.S
i	c54762	591.mg	11.5gm	0/50	350.mg	2/50	701.mg	3/50	thy:fca, fcc.S
j	c54762	737.mg	44.7gm	0/50	350.mg	2/50	701.mg	3/50	
k	c54762	398.mg	n.s.s.	4/50	350.mg	4/50	701.mg	5/50	thy:cca, ccr.S
l	c54762	647.mg	n.s.s.	0/50	350.mg	4/50	701.mg	0/50	S
m	c54762	97.5mg	549.mg	40/50	350.mg	36/50	701.mg	37/50	
n	c54762	498.mg	n.s.s.	1/50	350.mg	4/50	701.mg	1/50	liv:hpa,hpc,nnd.
6-DIMETHYLAMINO-4,4-DIPHENYL-3-HEPTANOL ACETATE.HCl (L-alpha-acetylmetadol.HCl, LAAM) ---									
145	1894	85.3mg	n.s.s.	6/50	7.60mg	8/50	30.0mg	7/50	Rosenkrantz;faat,11,626-639;1988/pers.comm.
a	1894	186.mg	n.s.s.	5/50	7.60mg	0/50	30.0mg	3/50	
146	1894	13.4mg	n.s.s.	18/50	7.60mg	18/50	30.0mg	5/50	
a	1894	182.mg	n.s.s.	11/50	7.60mg	8/50	30.0mg	4/50	
147	1894	21.6mg	520.mg	2/50	5.70mg	10/50	16.6mg	12/50	
a	1894	28.2mg	999.mg	3/50	5.70mg	4/50	16.6mg	12/50	
b	1894	78.7mg	n.s.s.	0/50	5.70mg	1/50	16.6mg	2/50	
148	1894	27.2mg	n.s.s.	1/50	3.10mg	3/50	9.70mg	5/50	
a	1894	38.1mg	19.3gm	0/50	3.10mg	0/50	9.70mg	4/50	
6-DIMETHYLAMINO-4,4-DIPHENYL-3-HEPTANONE.HCl (DL-methadone.HCl) 1095-90-5									
149	1893	19.0mg	n.s.s.	5/50	15.0mg	15/50	60.0mg	4/50	Rosenkrantz;faat,11,640-651;1988/pers.comm.
a	1893	132.mg	n.s.s.	1/50	15.0mg	5/50	60.0mg	6/50	
b	1893	124.mg	n.s.s.	3/50	15.0mg	6/50	60.0mg	8/50	
c	1893	217.mg	n.s.s.	5/50	15.0mg	6/50	60.0mg	5/50	
d	1893	128.mg	n.s.s.	1/50	15.0mg	0/50	60.0mg	0/50	
150	1893	86.0mg	n.s.s.	12/50	15.0mg	11/50	60.0mg	17/50	
a	1893	196.mg	n.s.s.	9/50	15.0mg	2/50	60.0mg	8/50	
b	1893	384.mg	n.s.s.	8/50	15.0mg	5/50	60.0mg	3/50	
c	1893	607.mg	n.s.s.	5/50	15.0mg	0/50	60.0mg	1/50	
151	1893	328.mg	n.s.s.	3/50	28.0mg	1/50	88.0mg	5/50	
152	1893	269.mg	n.s.s.	0/50	16.0mg	1/50	46.0mg	1/50	
a	1893	155.mg	n.s.s.	10/50	16.0mg	9/50	46.0mg	8/50	

Spe	Strain	Site	Xpo+Xpt	Notes	TD50	2Tailpvl							
Sex	Route	Hist			DR	AuOp							
2-DIMETHYLAMINOETHANOL													
100ng			1ug	10	100	1mg	10	100	1g	10			
153	M f	c3j	wat	liv	tum	29m29	e		.	>	6.72gm	P<.7	-
a	M f	c3j	wat	tba	tum	29m29	e				no dre	P=1.	-
154	M f	cen	wat	liv	tum	24m24	e		.	>	2.99gm	P<.6	-
a	M f	cen	wat	tba	tum	24m24	e				1.66gm	P<.8	-
N,N-DIMETHYLANILINE													
100ng			1ug	10	100	1mg	10	100	1g	10			
155	M f	b6c	gav	for	sqp	24m24			:	±	99.3mg	* P<.05	e
a	M f	b6c	gav	TBA	MXB	24m24					108.mg	/ P<.7	
b	M f	b6c	gav	liv	MXB	24m24					163.mg	* P<.4	
c	M f	b6c	gav	lun	MXB	24m24					276.mg	* P<.5	
156	M m	b6c	gav	TBA	MXB	24m24			:	>	489.mg	* P<1.	-
a	M m	b6c	gav	liv	MXB	24m24					216.mg	* P<.7	
b	M m	b6c	gav	lun	MXB	24m24					102.mg	* P<.4	
157	R f	f34	gav	TBA	MXB	24m24			:	>	no dre	P=1.	-
a	R f	f34	gav	liv	MXB	24m24					no dre	P=1.	-
158	R m	f34	gav	srp	MXA	24m24			:	+	125.mg	* P<.005	p
a	R m	f34	gav	srp	srn	24m24					175.mg	* P<.02	
b	R m	f34	gav	TBA	MXB	24m24					93.2mg	* P<.7	
c	R m	f34	gav	liv	MXB	24m24					no dre	P=1.	
2,4-DINITROTOLUENE (PURIFIED)													
100ng			1ug	10	100	1mg	10	100	1g	10			
159	R m	f34	eat	liv	mix	52w52	er		.	>	90.2mg	P<.3	-
a	R m	f34	eat	liv	nnd	52w52	er				90.2mg	P<.3	-
2,6-DINITROTOLUENE													
100ng			1ug	10	100	1mg	10	100	1g	10			
160	R m	f34	eat	liv	thc	52w52	er		.	+	.574mg	* P<.0005	
a	R m	f34	eat	liv	hpc	52w52	er				.574mg	* P<.0005+	
b	R m	f34	eat	liv	nnd	52w52	er				.964mg	* P<.0005+	
c	R m	f34	eat	liv	clc	52w52	er				34.2mg	* P<.8	
d	R m	f34	eat	liv	hpd	52w52	er				68.9mg	* P<.9	
DINITROTOLUENE, TECHNICAL GRADE (2,4 (77%)- and 2,6 (19%)-)													
100ng			1ug	10	100	1mg	10	100	1g	10			
161	R m	f34	eat	liv	nnd	52w52	er		.	+	8.02mg	P<.0005+	
a	R m	f34	eat	liv	thc	52w52	er				9.34mg	P<.0005+	
b	R m	f34	eat	liv	clc	52w52	er				53.9mg	P<.09	
DIPENTYLNITROSAMINE													
100ng			1ug	10	100	1mg	10	100	1g	10			
162	R f	f34	eat	liv	hpc	23m24	er		.	+	7.57mg	* P<.0005+	
163	R m	f34	eat	liv	hpc	21m24	er		.	+	2.75mg	* P<.0005+	
DIPHENHYDRAMINE.HCl***													
100ng			1ug	10	100	1mg	10	100	1g	10			
164	M f	b6c	eat	TBA	MXB	24m24			:	>	no dre	P=1.	-
a	M f	b6c	eat	liv	MXB	24m24					363.mg	* P<.5	
b	M f	b6c	eat	lun	MXB	24m24					357.mg	* P<.3	
165	M m	b6c	eat	liv	hpc	24m25			:	±	#37.3mg	P<.02	-
a	M m	b6c	eat	TBA	MXB	24m25					no dre	P=1.	
b	M m	b6c	eat	liv	MXB	24m25					201.mg	* P<.6	
c	M m	b6c	eat	lun	MXB	24m25					447.mg	P<.9	
166	R f	f34	eat	pta	adn	24m24			:	±	20.5mg	* P<.06	e
a	R f	f34	eat	TBA	MXB	24m24					65.1mg	* P<.8	
b	R f	f34	eat	liv	MXB	24m24					no dre	P=1.	
167	R m	f34	eat	lun	a/a	24m24			:	+	66.1mg	* P<.009	
a	R m	f34	eat	bra	ast	24m24					140.mg	/ P<.01	
b	R m	f34	eat	lun	MXA	24m24					57.3mg	* P<.02	e
c	R m	f34	eat	bra	MXA	24m24					143.mg	/ P<.05	e
d	R m	f34	eat	TBA	MXB	24m24					17.8mg	* P<.07	
e	R m	f34	eat	liv	MXB	24m24					243.mg	* P<.2	
5,5-DIPHENYLHYDANTOIN***													
100ng			1ug	10	100	1mg	10	100	1g	10			
168	M f	b6c	eat	liv	hct	78w86	e		.	>	151.mg	* P<.3	-
a	M f	b6c	eat	liv	hpa	78w86	e				229.mg	* P<.8	-
b	M f	b6c	eat	liv	hpc	78w86	e				457.mg	* P<.3	-
c	M f	b6c	eat	lun	act	78w86	e				2.06gm	* P<1.	-
d	M f	b6c	eat	liv	hem	78w86	e				no dre	P=1.	-
169	M m	b6c	eat	liv	hem	78w86	e		.	>	321.mg	* P<.7	-
a	M m	b6c	eat	liv	hct	78w86	e				no dre	P=1.	-
b	M m	b6c	eat	liv	hpa	78w86	e				no dre	P=1.	-
c	M m	b6c	eat	liv	hpc	78w86	e				no dre	P=1.	-
d	M m	b6c	eat	lun	act	78w86	e				no dre	P=1.	-
170	R f	f3d	eat	liv	nnd	24m26	e		.	>	47.8gm	* P<1.	-
a	R f	f3d	eat	liv	hpc	24m26	e				no dre	P=1.	-
b	R f	f3d	eat	tba	mal	24m26	e				110.mg	* P<.2	-
171	R m	f3d	eat	liv	hpc	24m26	e		.	>	1.08gm	* P<.3	-
a	R m	f3d	eat	liv	nnd	24m26	e				no dre	P=1.	-
b	R m	f3d	eat	tba	mal	24m26	e				98.7mg	* P<.5	-

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code
2-DIMETHYLAMINOETHANOL 108-01-0									
153	1877	931.mg	n.s.s.	4/44	268.mg	5/40		Stenback;made,42,129-138;1988	
a	1877	166.mg	n.s.s.	39/44	268.mg	35/40			
154	1877	478.mg	n.s.s.	6/58	178.mg	7/50			
a	1877	177.mg	n.s.s.	33/58	178.mg	30/50			
N,N-DIMETHYLANILINE 121-69-7									
155	c56428	39.3mg	n.s.s.	2/50	10.6mg	2/50	21.2mg 8/50		
a	c56428	15.7mg	n.s.s.	39/50	10.6mg	27/50	21.2mg 41/50		
b	c56428	40.2mg	n.s.s.	5/50	10.6mg	5/50	21.2mg 8/50	liv:hpa,hpc,nnd.	
c	c56428	54.8mg	n.s.s.	4/50	10.6mg	3/50	21.2mg 6/50	lun:a/a,a/c.	
156	c56428	17.4mg	n.s.s.	32/50	10.6mg	37/50	21.2mg 33/50		
a	c56428	28.3mg	n.s.s.	11/50	10.6mg	16/50	21.2mg 13/50	liv:hpa,hpc,nnd.	
b	c56428	26.7mg	n.s.s.	7/50	10.6mg	12/50	21.2mg 11/50	lun:a/a,a/c.	
157	c56428	2.41mg	n.s.s.	48/50	2.12mg	42/50	(21.2mg 42/50)		
a	c56428	n.s.s.	n.s.s.	0/50	2.12mg	0/50	21.2mg 0/50	liv:hpa,hpc,nnd.	
158	c56428	42.5mg	1.09gm	0/50	2.12mg	0/50	21.2mg 4/50	srp:ost,srn.	S
a	c56428	52.3mg	n.s.s.	0/50	2.12mg	0/50	21.2mg 3/50		
b	c56428	12.8mg	n.s.s.	42/50	2.12mg	35/50	21.2mg 39/50		
c	c56428	126.mg	n.s.s.	1/50	2.12mg	1/50	21.2mg 0/50	liv:hpa,hpc,nnd.	
2,4-DINITROTOLUENE (PURIFIED) 121-14-2									
159	1834	14.7mg	n.s.s.	0/20	27.0mg	1/20		Leonard;jnci,79,1313-1319;1987/pers.comm.	
a	1834	14.7mg	n.s.s.	0/20	27.0mg	1/20			
2,6-DINITROTOLUENE 606-20-2									
160	1834	.305mg	1.06mg	0/20	7.00mg	17/20	14.0mg 19/19	Leonard;jnci,79,1313-1319;1987/pers.comm.	
a	1834	.305mg	1.06mg	0/20	7.00mg	17/20	14.0mg 19/19		
b	1834	.587mg	1.65mg	0/20	7.00mg	18/20	14.0mg 15/19		
c	1834	8.41mg	n.s.s.	0/20	7.00mg	2/20	14.0mg 0/19		
d	1834	11.2mg	n.s.s.	0/20	7.00mg	1/20	14.0mg 0/19		
DINITROTOLUENE, TECHNICAL GRADE (2,4 (77%)- and 2,6 (19%)-) ---									
161	1834	3.82mg	20.9mg	0/20	35.0mg	10/19		Leonard;jnci,79,1313-1319;1987/pers.comm.	
a	1834	4.32mg	26.1mg	0/20	35.0mg	9/19			
b	1834	13.2mg	n.s.s.	0/20	35.0mg	2/19			
DIPENTYLNITROSAMINE 13256-06-9									
162	1824	4.75mg	12.7mg	0/144	2.50mg	3/24	7.50mg 8/24 22.5mg 24/24	Elashoff;jnci,79,509-526;1987	
163	1824	1.74mg	4.46mg	1/144	2.00mg	7/24	6.00mg 22/24 18.0mg 23/24		
DIPHENHYDRAMINE.HCl*** (Benadryl) 147-24-0									
164	c56075	33.1mg	n.s.s.	37/50	20.1mg	39/50	40.3mg 32/50		
a	c56075	80.6mg	n.s.s.	5/50	20.1mg	5/50	40.3mg 7/50	liv:hpa,hpc,nnd.	
b	c56075	98.7mg	n.s.s.	3/50	20.1mg	2/50	40.3mg 6/50	lun:a/a,a/c.	
165	c56075	16.0mg	n.s.s.	4/50	18.5mg	14/50	(37.2mg 5/50)		S
a	c56075	31.3mg	n.s.s.	30/50	18.5mg	32/50	37.2mg 22/50		
b	c56075	34.1mg	n.s.s.	12/50	18.5mg	18/50	37.2mg 12/50	liv:hpa,hpc,nnd.	
c	c56075	31.8mg	n.s.s.	6/50	18.5mg	7/50	(37.2mg 0/50)	lun:a/a,a/c.	
166	c56075	8.55mg	n.s.s.	23/50	7.62mg	26/50	15.4mg 35/50		
a	c56075	8.16mg	n.s.s.	47/50	7.62mg	46/50	15.4mg 46/50		
b	c56075	n.s.s.	n.s.s.	0/50	7.62mg	0/50	15.4mg 0/50	liv:hpa,hpc,nnd.	
167	c56075	29.3mg	1.71gm	0/50	12.3mg	5/50	24.6mg 3/50		S
a	c56075	46.0mg	6.01gm	0/50	12.3mg	0/50	24.6mg 4/50		S
b	c56075	25.0mg	n.s.s.	1/50	12.3mg	6/50	24.6mg 5/50	lun:a/a,a/c.	
c	c56075	45.5mg	n.s.s.	1/50	12.3mg	0/50	24.6mg 5/50	bra:ast,gln.	
d	c56075	7.16mg	n.s.s.	47/50	12.3mg	49/50	24.6mg 47/50		
e	c56075	59.7mg	n.s.s.	0/50	12.3mg	1/50	24.6mg 1/50	liv:hpa,hpc,nnd.	
5,5-DIPHENYLHYDANTOIN*** (phenytoin) 57-41-0									
168	1887	45.8mg	n.s.s.	0/49	7.07mg	2/49	14.1mg 1/45	Maeda;jtxe,24,111-119;1988	
a	1887	56.3mg	n.s.s.	0/49	7.07mg	2/49	14.1mg 0/45		
b	1887	74.5mg	n.s.s.	0/49	7.07mg	0/49	14.1mg 1/45		
c	1887	55.4mg	n.s.s.	1/49	7.07mg	2/49	14.1mg 1/45		
d	1887	97.3mg	n.s.s.	1/49	7.07mg	1/49	14.1mg 0/45		
169	1887	41.0mg	n.s.s.	3/47	6.53mg	0/44	13.1mg 4/43		
a	1887	22.3mg	n.s.s.	26/47	6.53mg	20/44	13.1mg 16/43		
b	1887	28.9mg	n.s.s.	19/47	6.53mg	12/44	13.1mg 11/43		
c	1887	28.7mg	n.s.s.	7/47	6.53mg	8/44	13.1mg 5/43		
d	1887	58.2mg	n.s.s.	6/47	6.53mg	3/44	13.1mg 2/43		
170	1855	241.mg	n.s.s.	1/50	11.6mg	0/47	23.2mg 1/48	Jang;fctx,25,697-702;1987	
a	1855	87.5mg	n.s.s.	0/50	11.6mg	0/47	23.2mg 0/48		
b	1855	37.0mg	n.s.s.	13/50	11.6mg	11/50	23.2mg 19/48		
171	1855	177.mg	n.s.s.	0/50	9.29mg	0/48	18.6mg 1/50		
a	1855	133.mg	n.s.s.	1/50	9.29mg	2/48	18.6mg 1/50		
b	1855	22.8mg	n.s.s.	22/50	9.29mg	22/48	18.6mg 26/50		

Spe	Strain	Site	Xpo+Xpt						TD50	2Tailpvl		
Sex	Route	Hist	Notes						DR	AuOp		
1,2-EPOXYBUTANE				100ng	1ug	10	100	1mg	10	100	1g	10
172	M f	b6c	inh TBA MXB 24m24 s						:			
	a	M f	b6c inh liv MXB 24m24 s							141. mg	* P<.4	-
	b	M f	b6c inh lun MXB 24m24 s							445. mg	* P<.3	
										834. mg	* P<.6	
173	M m	b6c	inh TBA MXB 24m24						:			
	a	M m	b6c inh liv MXB 24m24							2.47gm	* P<.1	-
	b	M m	b6c inh lun MXB 24m24							8.60gm	* P<.1	
										no dre	P=1.	
174	R f	f34	inh pta adn 24m24						:			
	a	R f	f34 inh thy MXA 24m24							83.8mg	* P<.05	
	b	R f	f34 inh ova MXA 24m24							509. mg	* P<.03	
	c	R f	f34 inh nas ppa 24m24							545. mg	* P<.03	
	d	R f	f34 inh TBA MXB 24m24							1.73gm	* P<.09	e
	e	R f	f34 inh liv MXB 24m24							78.0mg	* P<.2	
										no dre	P=1.	
175	R m	f34	inh MXB MXB 24m24						:			
	a	R m	f34 inh lun MXA 24m24							106. mg	* P<.0005	
	b	R m	f34 inh nas ppa 24m24							220. mg	* P<.006	c
	c	R m	f34 inh MXA MXA 24m24							220. mg	* P<.002	c
	d	R m	f34 inh lun a/c 24m24							30.7mg	P<.04	
	e	R m	f34 inh TBA MXB 24m24							314. mg	* P<.02	c
	f	R m	f34 inh Liv MXB 24m24							79.6mg	* P<.3	
										622. mg	* P<.5	
ERYTHROMYCIN STEARATE				100ng	1ug	10	100	1mg	10	100	1g	10
176	M f	b6c	eat TBA MXB 24m24						:			
	a	M f	b6c eat liv MXB 24m24							no dre	P=1.	-
	b	M f	b6c eat lun MXB 24m24							no dre	P=1.	
										no dre	P=1.	
177	M m	b6c	eat TBA MXB 24m24						:			
	a	M m	b6c eat liv MXB 24m24							no dre	P=1.	-
	b	M m	b6c eat lun MXB 24m24							no dre	P=1.	
										no dre	P=1.	
178	R f	f34	eat TBA MXB 24m24						:			
	a	R f	f34 eat liv MXB 24m24							no dre	P=1.	-
										5.85gm	* P<.2	
179	R m	f34	eat TBA MXB 24m24						:			
	a	R m	f34 eat liv MXB 24m24							2.02gm	* P<.8	-
										3.95gm	* P<.3	
ETHOXYQUIN***				100ng	1ug	10	100	1mg	10	100	1g	10
180	R m	f3d	eat eso tum 52w52 er						:			
	a	R m	f3d eat for tum 52w52 er							no dre	P=1.	-
	b	R m	f3d eat liv tum 52w52 er							no dre	P=1.	-
										no dre	P=1.	-
ETHYLENE OXIDE***				100ng	1ug	10	100	1mg	10	100	1g	10
181	M f	b6c	inh MXB MXB 24m24						:			
										39.2mg	* P<.002	
	a	M f	b6c inh MXB MXB 24m24							45.8mg	* P<.0005	
	b	M f	b6c inh lun MXA 24m24							61.8mg	* P<.0005	c
	c	M f	b6c inh lun a/a 24m24							87.5mg	* P<.002	c
	d	M f	b6c inh lun a/c 24m24							200. mg	* P<.004	c
	e	M f	b6c inh liv hpa 24m24							75.8mg	P<.02	
	f	M f	b6c inh mgl MXA 24m24							76.3mg	P<.02	p
	g	M f	b6c inh MXB MXB 24m24							79.2mg	* P<.02	
	h	M f	b6c inh MXA MXA 24m24							139. mg	* P<.06	p
	i	M f	b6c inh hag pcy 24m24							142. mg	* P<.04	c
	j	M f	b6c inh ute MXA 24m24							250. mg	* P<.02	p
	k	M f	b6c inh ute acn 24m24							297. mg	* P<.02	p
	l	M f	b6c inh TBA MXB 24m24							103. mg	* P<.4	
	m	M f	b6c inh liv MXB 24m24							149. mg	P<.4	
	n	M f	b6c inh lun MXB 24m24							61.8mg	* P<.0005	
182	M m	b6c	inh MXB MXB 24m24						:			
	a	M m	b6c inh lun MXA 24m24							51.2mg	* P<.04	
	b	M m	b6c inh lun a/c 24m24							65.7mg	* P<.06	c
	c	M m	b6c inh hag pcy 24m24							110. mg	* P<.08	c
	d	M m	b6c inh lun a/a 24m24							110. mg	* P<.04	c
	e	M m	b6c inh TBA MXB 24m24							181. mg	* P<.3	c
	f	M m	b6c inh liv MXB 24m24							108. mg	* P<.5	
	g	M m	b6c inh lun MXB 24m24							273. mg	* P<.6	
										65.7mg	* P<.06	
DI(2-ETHYLHEXYL)PHTHALATE***				100ng	1ug	10	100	1mg	10	100	1g	10
183	R m	f34	eat liv mix 95w95 er						.			
	a	R m	f34 eat liv hpc 95w95 er							499. mg	P<.003	+
	b	R m	f34 eat liv hpn 95w95 er							895. mg	P<.02	
										2.05gm	P<.2	
ETHYNDIOL DIACETATE***				100ng	1ug	10	100	1mg	10	100	1g	10
184	R f	win	gav liv tum 60w60 er						:			
										no dre	P=1.	-
FORMALDEHYDE***				100ng	1ug	10	100	1mg	10	100	1g	10
185	R f	sda	wat --- Leu 24m34 er						.			
										815. mg	* P<.04	+

Spe	Strain	Site	Xpo+Xpt					TD50	2Tailpvl
Sex	Route	Hist	Notes					DR	AuOp
a	R f	sda wat	---	lls	24m34	er		996.mg	* P<.03 +
b	R f	sda wat	git mix	24m34	er			2.96gm	* P<.2 +
186	R m	sda wat	---	lls	24m34	er	. + .	424.mg	* P<.0005+
a	R m	sda wat	---	leu	24m34	er		480.mg	* P<.01 +
b	R m	sda wat	git mix	24m34	er			1.41gm	* P<.02 +
FUROSEMIDE				100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10					
187	M f	b6c	eat	mgl	MXA	24m24		732.mg	* P<.004 p
a	M f	b6c	eat	mgl	mtm	24m24		845.mg	* P<.004
b	M f	b6c	eat	thy	fca	24m24		703.mg	* P<.02
c	M f	b6c	eat	TBA	MXB	24m24		136.mg	* P<.02
d	M f	b6c	eat	liv	MXB	24m24		3.97gm	* P<.8
e	M f	b6c	eat	lun	MXB	24m24		2.71gm	* P<.6
188	M m	b6c	eat	TBA	MXB	24m24	:	393.mg	* P<.5 -
a	M m	b6c	eat	liv	MXB	24m24	:	405.mg	* P<.2
b	M m	b6c	eat	lun	MXB	24m24		no dre	P=1.
189	R f	f34	eat	thy	MXA	24m24	:	47.1mg	* P<.003 -
a	R f	f34	eat	thy	cca	24m24	:	51.4mg	* P<.004
b	R f	f34	eat	TBA	MXB	24m24		20.9mg	/ P<.04
c	R f	f34	eat	liv	MXB	24m24		no dre	P=1.
190	R m	f34	eat	pta	adn	24m24	:	27.0mg	P<.05
a	R m	f34	eat	kid	MXA	24m24	:	370.mg	* P<.7 e
b	R m	f34	eat	brm	mng	24m24		no dre	P=1. e
c	R m	f34	eat	TBA	MXB	24m24		no dre	P=1.
d	R m	f34	eat	liv	MXB	24m24		no dre	P=1.
GERANYL ACETATE, FOOD GRADE (71% GERANYL ACETATE, 29% CITRONELLYL ACETATE)			10.....100.....1g.....10					
191	M f	b6c	gav	TBA	MXB	23m24	as	353.mg	* P<.02 -
a	M f	b6c	gav	liv	MXB	23m24	as	2.73gm	* P<.4
b	M f	b6c	gav	lun	MXB	23m24	as	5.30gm	* P<.4
192	M m	b6c	gav	TBA	MXB	23m24	as	485.mg	/ P<.04 -
a	M m	b6c	gav	liv	MXB	23m24	as	647.mg	/ P<.005
b	M m	b6c	gav	lun	MXB	23m24	as	5.26gm	* P<.6
193	R f	f34	gav	TBA	MXB	24m24		no dre	P=1. -
a	R f	f34	gav	liv	MXB	24m24		45.1gm	* P<.3
194	R m	f34	gav	tes	ict	24m24	s	772.mg	* P<.03
a	R m	f34	gav	ski	MXA	24m24	s	5.05gm	* P<.05
b	R m	f34	gav	ski	sqp	24m24	s	6.12gm	* P<.06 e
c	R m	f34	gav	kid	tla	24m24	s	20.2gm	* P<.5 e
d	R m	f34	gav	TBA	MXB	24m24	s	9.26gm	* P<.8
e	R m	f34	gav	liv	MXB	24m24	s	15.4gm	* P<.2
N2-gamma-GLUTAMYL-p-HYDRAZINOBENZOIC ACID				..1ug.....10.....100.....1mg.....10.....100.....1g.....10					
195	M f	swa	gav	liv	mix	12m31	e	41.4gm	P<1.
a	M f	swa	gav	lun	mix	12m31	e	no dre	P=1.
b	M f	swa	gav	sub	mix	12m31	e	no dre	P=1.
196	M m	swa	gav	sub	fb	12m31	e	277.mg	P<.0005+
a	M m	swa	gav	lun	mix	12m31	e	250.mg	P<.05
b	M m	swa	gav	liv	mix	12m31	e	no dre	P=1.
HEXACHLORO BENZENE***				100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10					
197	R m	cdr	eat	liv	nnd	28m28	be	27.3mg	P<.1
a	R m	cdr	eat	liv	hpc	28m28	be	55.3mg	P<.3
b	R m	cdr	eat	liv	bic	28m28	be	55.3mg	P<.3
198	R m	cdr	eat	liv	nnd	28m28	e	17.9mg	P<.05
a	R m	cdr	eat	liv	kcs	28m28	e	55.3mg	P<.3
gamma-1,2,3,4,5,6-HEXACHLOROCYCLOHEXANE***				..1ug.....10.....100.....1mg.....10.....100.....1g.....10					
199	M f	baa	eat	lun	tum	26w52	er	1.26gm	P<1.
a	M f	baa	eat	liv	hpc	26w52	er	no dre	P=1. -
b	M f	baa	eat	liv	hpa	26w52	er	no dre	P=1. -
200	M f	baa	eat	lun	tum	6m24	er	15.9gm	P<1.
a	M f	baa	eat	liv	hpc	6m24	er	no dre	P=1. -
b	M f	baa	eat	liv	hpa	6m24	er	no dre	P=1. -
201	M f	baa	eat	liv	hpa	52w52	er	no dre	P=1. -
a	M f	baa	eat	liv	hpc	52w52	er	no dre	P=1. -
b	M f	baa	eat	lun	tum	52w52	er	no dre	P=1.
202	M f	baa	eat	lun	tum	24m24	er	1.33gm	P<.7 -
a	M f	baa	eat	liv	hpc	24m24	er	no dre	P=1. -
b	M f	baa	eat	liv	hpa	24m24	er	no dre	P=1. -
c	M f	baa	eat	liv	mix	24m24	er	no dre	P=1. -
203	M f	pva	eat	lun	tum	52w52	er	no dre	P=1.

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology					Brkly Code		
a	bt7001	386.mg	n.s.s.	1/50	.410mg	1/50	2.05mg	3/50	4.10mg	2/50	20.5mg	2/50	41.0mg	5/50	
					61.5mg	5/50									
b	bt7001	753.mg	n.s.s.	0/50	.410mg	1/50	2.05mg	2/50	4.10mg	0/50	20.5mg	0/50	41.0mg	1/50	
					61.5mg	3/50									
186	bt7001	213.mg	1.73gm	4/50	.359mg	0/50	1.79mg	2/50	3.59mg	4/50	17.9mg	4/50	35.9mg	6/50	
					53.8mg	11/50									
a	bt7001	213.mg	63.8gm	5/50	.359mg	1/50	1.79mg	5/50	3.59mg	5/50	17.9mg	8/50	35.9mg	6/50	
					53.8mg	11/50									
b	bt7001	517.mg	n.s.s.	0/50	.359mg	2/50	1.79mg	0/50	3.59mg	0/50	17.9mg	0/50	35.9mg	1/50	
					53.8mg	5/50									
FUROSEMIDE 54-31-9															
187	c55936	310.mg	4.35gm	0/50	89.3mg	2/50	180.mg	5/50							mgI:acc,mtm.
a	c55936	337.mg	5.57gm	0/50	89.3mg	1/50	180.mg	5/50							S
b	c55936	292.mg	n.s.s.	0/50	89.3mg	4/50	180.mg	3/50							S
c	c55936	62.7mg	n.s.s.	34/50	89.3mg	35/50	180.mg	39/50							
d	c55936	380.mg	n.s.s.	6/50	89.3mg	4/50	180.mg	5/50							liv:hpa,hpc,nnd.
e	c55936	416.mg	n.s.s.	3/50	89.3mg	2/50	180.mg	3/50							lun:a/a,a/c.
188	c55936	89.7mg	n.s.s.	33/50	82.4mg	34/50	166.mg	34/50							
a	c55936	133.mg	n.s.s.	15/50	82.4mg	16/50	166.mg	20/50							liv:hpa,hpc,nnd.
b	c55936	471.mg	n.s.s.	5/50	82.4mg	3/50	166.mg	4/50							lun:a/a,a/c.
189	c55936	22.2mg	296.mg	4/50	17.2mg	7/50	34.5mg	11/50							thy:cca,ccr. S
a	c55936	23.6mg	375.mg	4/50	17.2mg	6/50	34.5mg	11/50							S
b	c55936	8.91mg	n.s.s.	48/50	17.2mg	45/50	34.5mg	46/50							
c	c55936	n.s.s.	n.s.s.	0/50	17.2mg	0/50	34.5mg	0/50							liv:hpa,hpc,nnd.
190	c55936	10.0mg	n.s.s.	4/50	13.7mg	11/50	27.7mg	8/50							S
a	c55936	48.3mg	n.s.s.	1/50	13.7mg	4/50	27.7mg	2/50							kid:tla,uac.
b	c55936	n.s.s.	n.s.s.	0/50	13.7mg	3/50	27.7mg	0/50							
c	c55936	15.6mg	n.s.s.	47/50	13.7mg	44/50	27.7mg	46/50							
d	c55936	n.s.s.	n.s.s.	0/50	13.7mg	0/50	27.7mg	0/50							liv:hpa,hpc,nnd.
GERANYL ACETATE, FOOD GRADE (71% GERANYL ACETATE, 29% CITRONELLYL ACETATE) (CAS# 105-87-3 and 150-84-5) mixture															
191	c54728	146.mg	n.s.s.	20/50	354.mg	20/50	714.mg	6/50							
a	c54728	520.mg	n.s.s.	5/50	354.mg	4/50	714.mg	2/50							liv:hpa,hpc,nnd.
b	c54728	779.mg	n.s.s.	1/50	354.mg	1/50	714.mg	1/50							lun:a/a,a/c.
192	c54728	197.mg	n.s.s.	33/50	354.mg	33/50	714.mg	21/50							
a	c54728	296.mg	7.59gm	13/50	354.mg	17/50	714.mg	15/50							liv:hpa,hpc,nnd.
b	c54728	766.mg	n.s.s.	6/50	354.mg	6/50	714.mg	3/50							lun:a/a,a/c.
193	c54728	1.61gm	n.s.s.	38/50	707.mg	31/50	1.41gm	28/50							
a	c54728	7.34gm	n.s.s.	0/50	707.mg	0/50	1.41gm	1/50							liv:hpa,hpc,nnd.
194	c54728	353.mg	n.s.s.	43/50	707.mg	44/50	1.41gm	44/50							S
a	c54728	2.06gm	n.s.s.	0/50	707.mg	5/50	1.41gm	1/50							ski:sqc,sgp. S
b	c54728	2.32gm	n.s.s.	0/50	707.mg	4/50	1.41gm	1/50							
c	c54728	4.71gm	n.s.s.	0/50	707.mg	2/50	1.41gm	0/50							
d	c54728	867.mg	n.s.s.	36/50	707.mg	33/50	1.41gm	23/50							
e	c54728	3.79gm	n.s.s.	0/50	707.mg	1/50	1.41gm	1/50							liv:hpa,hpc,nnd.
N2-gamma-GLUTAMYL-p-HYDRAZINOBENZOIC ACID (N2-[gamma-L(+)-GLUTAMYL]-4-CARBOXYPHENYLHYDRAZINE) 69644-85-5															
195	1832	666.mg	n.s.s.	1/46	78.2mg			1/42							Toth;acnr,6,917-920;1986
a	1832	264.mg	n.s.s.	12/47	78.2mg			12/47							
b	1832	585.mg	n.s.s.	3/43	78.2mg			1/32							
196	1832	146.mg	632.mg	0/43	78.2mg			13/48							
a	1832	101.mg	n.s.s.	15/49	78.2mg			23/45							
b	1832	443.mg	n.s.s.	7/40	78.2mg			3/32							
HEXACHLOROBENZENE*** (HCB) 118-74-1															
197	1833m	6.71mg	n.s.s.	0/39	1.60mg			2/39							Arnold;fctx,23,779-793;1985
a	1833m	9.00mg	n.s.s.	0/39	1.60mg			1/39							
b	1833m	9.00mg	n.s.s.	0/39	1.60mg			1/39							
198	1833n	5.43mg	n.s.s.	0/38	1.60mg			3/39							
a	1833n	9.00mg	n.s.s.	0/38	1.60mg			1/39							
gamma-1,2,3,4,5,6-HEXACHLOROCYCLOHEXANE*** (lindane) 58-89-9															
199	1828m	14.6mg	n.s.s.	1/48	10.4mg			1/45							Wolff;carc,8,1889-1897;1987
a	1828m	24.1mg	n.s.s.	0/48	10.4mg			0/45							
b	1828m	24.1mg	n.s.s.	0/48	10.4mg			0/45							
200	1828n	50.4mg	n.s.s.	2/96	5.20mg			2/95							
a	1828n	55.5mg	n.s.s.	3/96	5.20mg			2/95							
b	1828n	54.8mg	n.s.s.	6/96	5.20mg			3/95							
201	1828o	51.4mg	n.s.s.	0/48	20.8mg			0/48							
a	1828o	51.4mg	n.s.s.	0/48	20.8mg			0/48							
b	1828o	51.4mg	n.s.s.	1/48	20.8mg			0/48							
202	1828r	160.mg	n.s.s.	2/96	20.8mg			3/96							
a	1828r	297.mg	n.s.s.	3/96	20.8mg			1/96							
b	1828r	222.mg	n.s.s.	6/96	20.8mg			3/96							
c	1828r	219.mg	n.s.s.	9/96	20.8mg			4/96							
203	1828o	49.3mg	n.s.s.	1/46	20.8mg			0/46							

Spe	Strain	Site	Xpo+Xpt							TDSO	2Tailpvl
Sex	Route	Hist	Notes							DR	AuOp
a	M f	pva eat	liv hpc	52w52	er					no dre	P=1. -
b	M f	pva eat	liv hpa	52w52	er					no dre	P=1. -
204	M f	pva eat	liv mix	24m24	er	.	±			132.mg	P<.05 +
a	M f	pva eat	lun tum	24m24	er					170.mg	P<.09 +
b	M f	pva eat	liv hpa	24m24	er					207.mg	P<.2
c	M f	pva eat	liv hpc	24m24	er					435.mg	P<.3
205	M f	yva eat	lun tum	26w52	er	.	>			84.6mg	P<.3
a	M f	yva eat	liv hpc	26w52	er					no dre	P=1. -
b	M f	yva eat	liv hpa	26w52	er					no dre	P=1. -
206	M f	yva eat	lun tum	6m24	er	.	±			52.2mg	P<.1
a	M f	yva eat	liv hpa	6m24	er					62.3mg	P<.3 -
b	M f	yva eat	liv hpc	6m24	er					396.mg	P<.9 -
207	M f	yva eat	liv hpa	52w52	er	.	>			162.mg	P<.7
a	M f	yva eat	lun tum	52w52	er					169.mg	P<.3
b	M f	yva eat	liv hpc	52w52	er					no dre	P=1. -
208	M f	yva eat	liv mix	24m24	er	.	+	.		28.8mg	P<.0005+
a	M f	yva eat	liv hpa	24m24	er					41.6mg	P<.0005+
b	M f	yva eat	lun tum	24m24	er					85.3mg	P<.002 +
c	M f	yva eat	liv hpc	24m24	er					294.mg	P<.5 -
HEXACHLOROETHANE***				100ng...1ug.....10.....100.....1mg.....10.....100.....1g.....10							
209	R f	f34 gav	TBA MXB	24m24						no dre	P=1. -
a	R f	f34 gav	liv MXB	24m24						276.gm *	P<.1
210	R m	f34 gav	MXA MXA	24m24		.	±			8.02mg	P<.03 e
a	R m	f34 gav	MXA MXA	24m24						9.05mg	P<.04
b	R m	f34 gav	kid MXA	24m24						55.4mg *	P<.02 c
c	R m	f34 gav	kid ruc	24m24						159.mg *	P<.04
d	R m	f34 gav	TBA MXB	24m24						28.0mg *	P<.5
e	R m	f34 gav	liv MXB	24m24						1.34gm *	P<.9
4-HEXYLRESORCINOL				100ng...1ug.....10.....100.....1mg.....10.....100.....1g.....10							
211	M f	b6c gav	TBA MXB	24m24						no dre	P=1. -
a	M f	b6c gav	liv MXB	24m24						no dre	P=1. -
b	M f	b6c gav	lun MXB	24m24						no dre	P=1. -
212	M m	b6c gav	hag MXA	24m24		.	±			368.mg *	P<.03 e
a	M m	b6c gav	amd phe	24m24						519.mg *	P<.07 e
b	M m	b6c gav	TBA MXB	24m24						no dre	P=1. -
c	M m	b6c gav	liv MXB	24m24						no dre	P=1. -
d	M m	b6c gav	lun MXB	24m24						no dre	P=1. -
213	R f	f34 gav	TBA MXB	24m24						no dre	P=1. -
a	R f	f34 gav	liv MXB	24m24						128.gm *	P<.1
214	R m	f34 gav	TBA MXB	24m24		.	>			615.mg	P<.1 -
a	R m	f34 gav	liv MXB	24m24						1.53gm *	P<.3
HYDRAZINE SULFATE***				100ng...1ug.....10.....100.....1mg.....10.....100.....1g.....10							
215	H m	syg wat	liv hpc	24m24	er	.	+	.		181.mg *	P<.0005+
a	H m	syg wat	liv mhs	24m24	er					2.58gm *	P<.3
b	H m	syg wat	liv hpa	24m24	er					2.59gm *	P<.5
c	H m	syg wat	liv rts	24m24	er					2.59gm *	P<.5
p-HYDRAZINOBENZOIC ACID.HCl				100ng...1ug.....10.....100.....1mg.....10.....100.....1g.....10							
216	M f	swa wat	aol mix	28m28	e	.	+	.		1.07gm	P<.0005+
a	M f	swa wat	aol lei	28m28	e					1.97gm	P<.01 +
b	M f	swa wat	lun ade	28m28	e					1.17gm	P<.04
c	M f	swa wat	aol ley	28m28	e					2.66gm	P<.03 +
d	M f	swa wat	lun mix	28m28	e					1.14gm	P<.2
e	M f	swa wat	lun adc	28m28	e					11.2gm	P<.9
217	M m	swa wat	aol mix	28m28	e	.	+	.		380.mg	P<.0005+
a	M m	swa wat	aol lei	28m28	e					609.mg	P<.002 +
b	M m	swa wat	aol ley	28m28	e					1.49gm	P<.005 +
c	M m	swa wat	lun ade	28m28	e					597.mg	P<.07
d	M m	swa wat	lun mix	28m28	e					675.mg	P<.3
e	M m	swa wat	lun adc	28m28	e					no dre	P=1. -
HYDROCHLOROTHIAZIDE				100ng...1ug.....10.....100.....1mg.....10.....100.....1g.....10							
218	M f	b6c eat	TBA MXB	24m24						no dre	P=1. -
a	M f	b6c eat	liv MXB	24m24						no dre	P=1. -
b	M f	b6c eat	lun MXB	24m24						no dre	P=1. -
219	M m	b6c eat	liv MXA	24m24		.	+			1.23gm *	P<.008 e
a	M m	b6c eat	liv hpa	24m24						1.49gm *	P<.007
b	M m	b6c eat	TBA MXB	24m24						3.82gm /	P<.7
c	M m	b6c eat	liv MXB	24m24						1.23gm *	P<.008
d	M m	b6c eat	lun MXB	24m24						19.8gm *	P<.9
220	R f	f34 eat	TBA MXB	24m25						no dre	P=1. -
a	R f	f34 eat	liv MXB	24m25		.	>			no dre	P=1. -
221	R f	f34 eat	pit mix	24m30		.	+	.		33.9mg	P<.0005
a	R f	f34 eat	adr phe	24m30						100.mg	P<.0005

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code
a	1828o	51.4mg	n.s.s.	0/48	20.8mg	0/48			
b	1828o	51.4mg	n.s.s.	0/46	20.8mg	0/48			
204	1828r	53.5mg	n.s.s.	7/95	20.8mg	16/95			
a	1828r	62.5mg	n.s.s.	6/95	20.8mg	13/94			
b	1828r	71.0mg	n.s.s.	5/95	20.8mg	11/95			
c	1828r	113.mg	n.s.s.	2/95	20.8mg	5/95			
205	1828m	13.8mg	n.s.s.	0/48	10.4mg	1/48			
a	1828m	25.7mg	n.s.s.	0/48	10.4mg	0/48			
b	1828m	25.7mg	n.s.s.	2/48	10.4mg	0/48			
206	1828n	18.4mg	n.s.s.	4/95	5.20mg	10/95			
a	1828n	17.4mg	n.s.s.	8/93	5.20mg	13/95			
b	1828n	21.5mg	n.s.s.	12/93	5.20mg	13/95			
207	1828o	19.7mg	n.s.s.	2/48	20.8mg	3/48			
a	1828o	27.6mg	n.s.s.	0/48	20.8mg	1/48			
b	1828o	51.4mg	n.s.s.	0/48	20.8mg	0/48			
208	1828r	17.1mg	71.0mg	20/93	20.8mg	49/94			
a	1828r	24.6mg	97.7mg	8/93	20.8mg	33/94			
b	1828r	43.3mg	383.mg	4/95	20.8mg	18/95			
c	1828r	65.1mg	n.s.s.	12/93	20.8mg	16/94			
HEXACHLOROETHANE*** 67-72-1									
209	c04605	89.8mg	n.s.s.	50/50	56.1mg	44/50	111.mg	43/50	
a	c04605	384.mg	n.s.s.	1/50	56.1mg	3/50	111.mg	1/50	liv:hpa,hpc,nnd.
210	c04605	3.35mg	n.s.s.	15/50	7.01mg	28/50	(14.0mg	21/50)	adr:pob; amd:pbp,phc,phm,pob.
a	c04605	3.70mg	n.s.s.	14/50	7.01mg	26/50	(14.0mg	19/50)	adr:pob; amd:pbp,pob.
b	c04605	23.3mg	n.s.s.	1/50	7.01mg	2/50	14.0mg	7/50	kid:ade,rua,ruc.
c	c04605	47.3mg	n.s.s.	0/50	7.01mg	0/50	14.0mg	3/50	
d	c04605	6.04mg	n.s.s.	45/50	7.01mg	48/50	14.0mg	45/50	
e	c04605	53.9mg	n.s.s.	2/50	7.01mg	1/50	14.0mg	2/50	liv:hpa,hpc,nnd.
4-HEXYLRESORCINOL 136-77-6									
211	c55787	124.mg	n.s.s.	39/50	43.8mg	22/50	87.6mg	31/50	
a	c55787	699.mg	n.s.s.	3/50	43.8mg	0/50	87.6mg	1/50	liv:hpa,hpc,nnd.
b	c55787	585.mg	n.s.s.	5/50	43.8mg	0/50	87.6mg	2/50	lun:a/a,a/c.
212	c55787	158.mg	n.s.s.	0/50	43.8mg	4/50	87.6mg	3/50	hag:adn,can.
a	c55787	187.mg	n.s.s.	1/50	43.8mg	2/50	87.6mg	5/50	
b	c55787	72.4mg	n.s.s.	36/50	43.8mg	34/50	87.6mg	30/50	
c	c55787	115.mg	n.s.s.	21/50	43.8mg	9/50	(87.6mg	9/50)	liv:hpa,hpc,nnd.
d	c55787	225.mg	n.s.s.	10/50	43.8mg	9/50	87.6mg	5/50	lun:a/a,a/c.
213	c55787	76.1mg	n.s.s.	44/50	44.2mg	39/50	88.4mg	35/50	
a	c55787	548.mg	n.s.s.	1/50	44.2mg	0/50	88.4mg	1/50	liv:hpa,hpc,nnd.
214	c55787	22.8mg	n.s.s.	44/50	44.2mg	44/50	(88.4mg	36/50)	
a	c55787	376.mg	n.s.s.	0/50	44.2mg	1/50	88.4mg	1/50	liv:hpa,hpc,nnd.
HYDRAZINE SULFATE*** 10034-93-2									
215	1821	95.1mg	431.mg	0/31	20.4mg	0/31	40.8mg	4/31	61.2mg 9/31
a	1821	420.mg	n.s.s.	0/31	20.4mg	0/31	40.8mg	0/31	61.2mg 1/31
b	1821	421.mg	n.s.s.	0/31	20.4mg	0/31	40.8mg	1/31	61.2mg 0/31
c	1821	421.mg	n.s.s.	0/31	20.4mg	0/31	40.8mg	1/31	61.2mg 0/31
p-HYDRAZINOBENZOIC ACID.HCL 24589-77-3									
216	1741	462.mg	3.77gm	0/45	250.mg	7/36			McManus;livt,57,78-85;1987
a	1741	680.mg	212.gm	0/45	250.mg	4/36			
b	1741	469.mg	n.s.s.	5/48	250.mg	13/49			
c	1741	806.mg	n.s.s.	0/45	250.mg	3/36			
d	1741	385.mg	n.s.s.	12/48	250.mg	19/49			
e	1741	865.mg	n.s.s.	7/48	250.mg	8/49			
217	1741	216.mg	862.mg	2/46	208.mg	21/50			
a	1741	309.mg	2.24gm	2/46	208.mg	15/50			
b	1741	606.mg	11.3gm	0/46	208.mg	6/50			
c	1741	219.mg	n.s.s.	10/40	208.mg	15/33			
d	1741	191.mg	n.s.s.	15/39	208.mg	15/28			
e	1741	652.mg	n.s.s.	9/40	208.mg	6/33			
HYDROCHLOROTHIAZIDE 58-93-5									
218	c55925	846.mg	n.s.s.	36/50	320.mg	35/50	638.mg	27/50	
a	c55925	2.74gm	n.s.s.	3/50	320.mg	5/50	638.mg	1/50	liv:hpa,hpc,nnd.
b	c55925	3.18gm	n.s.s.	4/50	320.mg	3/50	638.mg	2/50	lun:a/a,a/c.
219	c55925	612.mg	24.4gm	7/50	296.mg	10/50	589.mg	21/50	liv:hpa,hpc.
a	c55925	747.mg	20.3gm	3/50	296.mg	8/50	589.mg	14/50	
b	c55925	610.mg	n.s.s.	30/50	296.mg	20/50	589.mg	34/50	
c	c55925	612.mg	24.4gm	7/50	296.mg	10/50	589.mg	21/50	liv:hpa,hpc,nnd.
d	c55925	1.59gm	n.s.s.	8/50	296.mg	4/50	589.mg	9/50	lun:a/a,a/c.
220	c55925	88.0mg	n.s.s.	49/50	12.4mg	39/50	24.6mg	39/50	99.1mg 37/50
a	c55925	n.s.s.	n.s.s.	0/50	12.4mg	0/50	24.6mg	0/50	99.1mg 0/50
221	1854	18.4mg	69.4mg	0/24	44.0mg	18/24			liv:hpa,hpc,nnd.
a	1854	46.7mg	285.mg	0/24	44.0mg	9/24			Lijinsky;txih,3,413-422;1987/pers.comm.

Spe	Strain	Site	Xpo+Xpt	T050	2Tailpvl
Sex	Route	Hist	Notes	DR	AuOp
b	R f	f34 eat liv hpc	24m30	1.11gm	P<.3
c	R f	f34 eat liv nnd	24m30	no dre	P=1.
d	R f	f34 eat liv mix	24m30	no dre	P=1.
222	R m	f34 eat TBA MXB	24m25	274.mg *	P<.7 -
a	R m	f34 eat liv MXB	24m25	771.mg *	P<.3
223	R m	f34 eat tes car	24m30	35.6mg	P<.0005
a	R m	f34 eat pit mix	24m30	71.3mg	P<.0005
b	R m	f34 eat adr phe	24m30	271.mg	P<.4
c	R m	f34 eat liv mix	24m30	no dre	P=1.
d	R m	f34 eat liv hpc	24m30	no dre	P=1.
e	R m	f34 eat liv nnd	24m30	no dre	P=1.
HYDROQUINONE				100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	
224	M f	b6c gav liv hpa	24m24	65.0mg	P<.002
a	M f	b6c gav liv MXA	24m24	122.mg *	P<.009 p
b	M f	b6c gav TBA MXB	24m24	no dre	P=1.
c	M f	b6c gav liv MXB	24m24	122.mg *	P<.009
d	M f	b6c gav lun MXB	24m24	19.2gm *	P<.1
225	M m	b6c gav TBA MXB	24m24	497.mg *	P<.8 -
a	M m	b6c gav liv MXB	24m24	383.mg *	P<.7
b	M m	b6c gav lun MXB	24m24	no dre	P=1.
226	R f	f34 gav --- mnl	24m24	55.8mg *	P<.006 p
a	R f	f34 gav TBA MXB	24m24	51.6mg *	P<.3
b	R f	f34 gav liv MXB	24m24	no dre	P=1.
227	R m	f34 gav kid rua	24m24	64.7mg *	P<.0005p
a	R m	f34 gav amd MXA	24m24	40.4mg *	P<.03
b	R m	f34 gav amd MXA	24m24	48.2mg *	P<.05
c	R m	f34 gav TBA MXB	24m24	41.8mg *	P<.3
d	R m	f34 gav liv MXB	24m24	5.71gm *	P<.1
3-HYDROXY-p-BUTYROPHENETIDIDE				100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	
228	M f	b6c eat liv hpa	72w84 ae	4.00gm	P<.02
a	M f	b6c eat lun act	72w84 ae	11.3gm *	P<.4
b	M f	b6c eat liv hpc	72w84 ae	no dre	P=1.
229	M m	b6c eat kid rcc	70w84 ae	5.53gm *	P<.004 +
a	M m	b6c eat --- lkm	70w84 ae	2.74gm	P<.04
b	M m	b6c eat kid rca	70w84 ae	5.58gm *	P<.02 +
c	M m	b6c eat lun act	70w84 ae	5.28gm *	P<.3
d	M m	b6c eat liv hpa	70w84 ae	17.5gm	P<.9
e	M m	b6c eat ubl pam	70w84 ae	46.4gm *	P<.3
f	M m	b6c eat liv hem	70w84 ae	406.gm *	P<.1
g	M m	b6c eat liv hpc	70w84 ae	no dre	P=1.
1-(2-HYDROXYETHYL)-1-NITROSOUREA***			1ug.....10.....100.....1mg.....10.....100.....1g.....10	
230	R f	f34 gav mgl adc	37w60 j	.452mg	P<.003 +
a	R f	f34 gav col ade	37w60 j	1.53mg	P<.1
b	R f	f34 gav for sqc	37w60 j	3.15mg	P<.3
c	R f	f34 gav zym car	37w60 j	3.15mg	P<.3
d	R f	f34 gav for mix	37w60 j	no dre	P=1.
e	R f	f34 gav lun a/a	37w60 j	no dre	P=1.
231	R m	f34 gav lun mix	37w55 j	77.6ug	P<.0005+
a	R m	f34 gav for mix	37w55 j	.203mg	P<.0005+
b	R m	f34 gav col mix	37w55 j	.240mg	P<.002 +
c	R m	f34 gav for sqc	37w55 j	.637mg	P<.04
d	R m	f34 gav col adc	37w55 j	.983mg	P<.1
e	R m	f34 gav zym mix	37w55 j	.568mg	P<.3
f	R m	f34 gav lun mal	37w55 j	.602mg	P<.2
g	R m	f34 gav zym car	37w55 j	.879mg	P<.4
ISOFLURANE				100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	
232	M f	sww inh lun ala	78w81	.30.0gm *	P<.3 -
a	M f	sww inh liv bsa	78w81	no dre	P=1. -
233	M m	sww inh lun ala	78w81	no dre	P=1. -
a	M m	sww inh liv bsa	78w81	no dre	P=1. -
LASIOCARPINE***				100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	
234	R f	f34 eat liv hpc	21m24 er	.938mg Z	P<.0005+
235	R m	f34 eat liv hpc	23m24 er	.800mg *	P<.0005+
MALONALDEHYDE, SODIUM SALT***				100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	
236	M f	b6c gav TBA MXB	24m24	274.mg *	P<.5 -
a	M f	b6c gav liv MXB	24m24	568.mg *	P<.2
b	M f	b6c gav lun MXB	24m24	4.41gm *	P<.9
237	M m	b6c gav TBA MXB	24m24	217.mg *	P<.6 -
a	M m	b6c gav liv MXB	24m24	230.mg *	P<.4
b	M m	b6c gav lun MXB	24m24	1.13gm *	P<.8
238	R f	f34 gav thy MXA	24m24	252.mg /	P<.02 c

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code
b	1854	180.mg	n.s.s.	0/24	44.0mg	1/24			
c	1854	194.mg	n.s.s.	4/24	44.0mg	2/24			
d	1854	152.mg	n.s.s.	4/24	44.0mg	3/24			
222	c55925	29.2mg	n.s.s.	50/50	9.91mg	43/50	19.8mg 44/50 79.2mg 45/50		
a	c55925	143.mg	n.s.s.	1/50	9.91mg	0/50	19.8mg 1/50 79.2mg 2/50		liv:hpa,hpc,nnd.
223	1854	19.3mg	72.9mg	0/24	46.2mg	18/24		Lijinsky;txih,3,413-422;1987/pers.comm.	
a	1854	36.1mg	169.mg	0/24	46.2mg	12/24			
b	1854	64.1mg	n.s.s.	6/24	46.2mg	9/24			
c	1854	357.mg	n.s.s.	3/24	46.2mg	0/24			
d	1854	357.mg	n.s.s.	1/24	46.2mg	0/24			
e	1854	357.mg	n.s.s.	2/24	46.2mg	0/24			
HYDROQUINONE 123-31-9									
224	c55834	32.3mg	305.mg	2/55	35.0mg	15/55	(70.0mg 12/55)		S
a	c55834	62.8mg	4.53gm	3/55	35.0mg	16/55	70.0mg 13/55		liv:hpa,hpc.
b	c55834	63.5mg	n.s.s.	43/55	35.0mg	42/55	70.0mg 39/55		
c	c55834	62.8mg	4.53gm	3/55	35.0mg	16/55	70.0mg 13/55		liv:hpa,hpc,nnd.
d	c55834	203.mg	n.s.s.	4/55	35.0mg	6/55	70.0mg 4/55		lun:a/a,a/c.
225	c55834	45.4mg	n.s.s.	39/55	35.3mg	46/55	70.5mg 44/55		
a	c55834	63.4mg	n.s.s.	20/55	35.3mg	29/55	70.5mg 25/55		liv:hpa,hpc,nnd.
b	c55834	183.mg	n.s.s.	14/55	35.3mg	11/55	70.5mg 10/55		lun:a/a,a/c.
226	c55834	27.9mg	747.mg	9/55	17.6mg	15/55	35.3mg 22/55		
a	c55834	15.6mg	n.s.s.	47/55	17.6mg	49/55	35.3mg 50/55		
b	c55834	n.s.s.	n.s.s.	0/55	17.6mg	0/55	35.3mg 0/55		liv:hpa,hpc,nnd.
227	c55834	32.1mg	181.mg	0/55	17.6mg	4/55	35.2mg 8/55		
a	c55834	17.7mg	n.s.s.	14/55	17.6mg	19/55	35.2mg 21/55		amd:pbb,phm,pob. S
b	c55834	19.9mg	n.s.s.	13/55	17.6mg	17/55	35.2mg 19/55		amd:pbb,pob. S
c	c55834	12.7mg	n.s.s.	49/55	17.6mg	46/55	35.2mg 48/55		
d	c55834	82.6mg	n.s.s.	3/55	17.6mg	2/55	35.2mg 2/55		liv:hpa,hpc,nnd.
3-HYDROXY-p-BUTYROPHENETIDIDE (betadid, bucetin) 1083-57-4									
228	1835	1.38gm	n.s.s.	0/46	795.mg	4/47	(1.76gm 0/46)		Togei;jnci,79,1151-1158;1987
a	1835	3.06gm	n.s.s.	1/46	795.mg	6/47	1.76gm 3/46		
b	1835	8.72gm	n.s.s.	0/46	795.mg	1/47	1.76gm 0/46		
229	1835	2.50gm	32.0gm	0/47	745.mg	2/45	1.54gm 6/46		
a	1835	997.mg	n.s.s.	1/47	745.mg	6/45	(1.54gm 1/46)		
b	1835	2.53gm	n.s.s.	0/47	745.mg	4/45	1.54gm 4/46		
c	1835	1.60gm	n.s.s.	6/47	745.mg	12/45	1.54gm 10/46		
d	1835	833.mg	n.s.s.	14/47	745.mg	14/45	(1.54gm 0/46)		
e	1835	7.55gm	n.s.s.	0/47	745.mg	0/45	1.54gm 1/46		
f	1835	5.29gm	n.s.s.	3/47	745.mg	1/45	1.54gm 3/46		
g	1835	6.91gm	n.s.s.	7/47	745.mg	4/45	1.54gm 2/46		
1-(2-HYDROXYETHYL)-1-NITROSOUREA*** (N-nitroso-2-hydroxyethylurea, NHEU) 13743-07-2									
230	1792m	.183mg	2.36mg	0/20	.707mg	6/20		Lijinsky;gann,79,181-186;1988/1986	
a	1792m	.376mg	n.s.s.	0/20	.707mg	2/20			
b	1792m	.512mg	n.s.s.	0/20	.707mg	1/20			
c	1792m	.512mg	n.s.s.	0/20	.707mg	1/20			
d	1792m	.461mg	n.s.s.	2/20	.707mg	2/20			
e	1792m	.581mg	n.s.s.	1/20	.707mg	1/20			
231	1792m	38.9ug	.188mg	1/20	.540mg	15/20			
a	1792m	90.6ug	.641mg	0/20	.540mg	8/20			
b	1792m	.103mg	.910mg	0/20	.540mg	7/20			
c	1792m	.192mg	n.s.s.	0/20	.540mg	3/20			
d	1792m	.241mg	n.s.s.	0/20	.540mg	2/20			
e	1792m	.153mg	n.s.s.	2/20	.540mg	5/20			
f	1792m	.170mg	n.s.s.	1/20	.540mg	4/20			
g	1792m	.183mg	n.s.s.	2/20	.540mg	4/20			
ISDIFLURANE 26675-46-7									
232	1879	8.67gm	n.s.s.	15/92	1.52gm	14/83	6.09gm 19/83		Baden;anes,69,750-753;1988
a	1879	36.0gm	n.s.s.	1/92	1.52gm	2/83	6.09gm 1/83		
233	1879	16.1gm	n.s.s.	18/89	1.27gm	23/84	5.08gm 12/82		
a	1879	27.2gm	n.s.s.	4/89	1.27gm	7/84	5.08gm 2/82		
LASIOCARPINE*** 303-34-4									
234	1824	.521mg	1.94mg	0/144	.350mg	9/24	.750mg 7/24 (1.50mg 3/23)		Elashoff;jnci,79,509-526;1987
235	1824	.507mg	1.36mg	1/144	.280mg	5/24	.600mg 11/24 1.20mg 14/23		
MALONALDEHYDE, SODIUM SALT*** (3-hydroxy-2-propenal, sodium salt) 24382-04-5									
236	c54842	64.5mg	n.s.s.	27/50	42.0mg	31/50	84.9mg 26/50		
a	c54842	184.mg	n.s.s.	2/50	42.0mg	3/50	84.9mg 5/50		liv:hpa,hpc,nnd.
b	c54842	200.mg	n.s.s.	5/50	42.0mg	7/50	84.9mg 4/50		lun:a/a,a/c.
237	c54842	36.0mg	n.s.s.	39/50	42.4mg	37/50	84.9mg 31/50		
a	c54842	55.8mg	n.s.s.	17/50	42.4mg	21/50	84.9mg 17/50		liv:hpa,hpc,nnd.
b	c54842	102.mg	n.s.s.	10/50	42.4mg	5/50	84.9mg 8/50		lun:a/a,a/c.
238	c54842	98.7mg	n.s.s.	2/50	35.0mg	1/50	70.7mg 7/50		thy:fca,fcc.

Spe	Strain	Site	Xpo+Xpt	T050	2Tailpvl
Sex	Route	Hist	Notes	DR	AuOp
a	R f	f34 gav	TBA MXB 24m24		164.mg * P<.5
b	R f	f34 gav	liv MXB 24m24		1.95gm * P<.2
239	R m	f34 gav	MXB MXB 24m24		67.7mg * P<.0005
a	R m	f34 gav	pni isa 24m24	: + :	80.5mg P<.0005c
b	R m	f34 gav	pni MXA 24m24		90.3mg P<.005
c	R m	f34 gav	thy MXA 24m24		113.mg * P<.002 c
d	R m	f34 gav	tes ict 24m24		39.8mg * P<.02
e	R m	f34 gav	amd phe 24m24		184.mg * P<.05
f	R m	f34 gav	sub MXA 24m24		195.mg * P<.04
g	R m	f34 gav	thy fca 24m24		206.mg * P<.02
h	R m	f34 gav	thy fcc 24m24		236.mg * P<.02
i	R m	f34 gav	adr coa 24m24		566.mg * P<.03
j	R m	f34 gav	TBA MXB 24m24		41.8mg / P<.008
k	R m	f34 gav	liv MXB 24m24		665.mg * P<.4
2-MERCAPTOBENZOTHIAZOLE***					
100ng...1ug...:10.....100.....1mg.....10.....100.....1g.....10					
240	M f	b6c gav	liv MXA 24m24	:	2.16gm * P<.3 e
a	M f	b6c gav	TBA MXB 24m24		no dre P=1.
b	M f	b6c gav	liv MXB 24m24		2.16gm * P<.3
c	M f	b6c gav	lun MXB 24m24		no dre P=1.
241	M m	b6c gav	TBA MXB 24m24	:	3.33gm * P<.8 ~
a	M m	b6c gav	liv MXB 24m24		3.70gm * P<.7
b	M m	b6c gav	lun MXB 24m24		no dre P=1.
242	R f	f34 gav	MXB MXB 24m24	:	247.mg * P<.03
a	R f	f34 gav	pta adn 24m24	: ±	343.mg * P<.07 p
b	R f	f34 gav	amd phe 24m24		805.mg * P<.04 p
c	R f	f34 gav	TBA MXB 24m24		576.mg * P<.6
d	R f	f34 gav	liv MXB 24m24		no dre P=1.
243	R m	f34 gav	MXB MXB 24m24	:	157.mg P<.0005
a	R m	f34 gav	tes ict 24m24	: + :	240.mg * P<.005
b	R m	f34 gav	pta adn 24m24		333.mg P<.009
c	R m	f34 gav	pan ana 24m24		345.mg P<.0005p
d	R m	f34 gav	amd MXA 24m24		394.mg * P<.003 p
e	R m	f34 gav	mul mnl 24m24		401.mg P<.004 p
f	R m	f34 gav	pre adn 24m24		1.71gm * P<.004
g	R m	f34 gav	pre MXA 24m24		1.58gm * P<.02 p
h	R m	f34 gav	sub MXA 24m24		1.73gm * P<.04
i	R m	f34 gav	sub MXA 24m24		1.90gm * P<.03
j	R m	f34 gav	sub fib 24m24		2.20gm * P<.04
k	R m	f34 gav	MXA MXA 24m24		3.20gm * P<.02
l	R m	f34 gav	TBA MXB 24m24		136.mg P<.002
m	R m	f34 gav	liv MXB 24m24		no dre P=1.
8-METHOXYPSORALEN					
100ng...1ug...:10.....100.....1mg.....10.....100.....1g.....10					
244	R f	f34 gav	MXA MXA 24m24	:	#333.mg * P<.02 -
a	R f	f34 gav	TBA MXB 24m24	: ±	45.6mg * P<.09
b	R f	f34 gav	liv MXB 24m24		5.14gm * P<.9
245	R m	f34 gav	tes ict 24m24	:	14.6mg * P<.0005
a	R m	f34 gav	MXB MXB 24m24	: + :	27.3mg * P<.0005
b	R m	f34 gav	kid MXA 24m24		32.4mg * P<.0005c
c	R m	f34 gav	kid tla 24m24		43.2mg * P<.0005c
d	R m	f34 gav	lun a/a 24m24		57.1mg * P<.003 e
e	R m	f34 gav	sub MXA 24m24		70.2mg * P<.0005
f	R m	f34 gav	sub fib 24m24		72.6mg * P<.002 e
g	R m	f34 gav	kid uac 24m24		167.mg * P<.008 c
h	R m	f34 gav	zym MXA 24m24		101.mg * P<.02 c
i	R m	f34 gav	pan ana 24m24		113.mg * P<.04
j	R m	f34 gav	TBA MXB 24m24		16.1mg * P<.002
k	R m	f34 gav	liv MXB 24m24		no dre P=1.
METHYL CARBAMATE					
100ng...1ug...:10.....100.....1mg.....10.....100.....1g.....10					
246	M f	b6c gav	TBA MXB 24m24	:	no dre P=1. -
a	M f	b6c gav	liv MXB 24m24	:	4.70gm * P<.4
b	M f	b6c gav	lun MXB 24m24		no dre P=1.
247	M m	b6c gav	TBA MXB 24m24	:	5.22gm * P<.8 -
a	M m	b6c gav	liv MXB 24m24	:	5.08gm * P<.7
b	M m	b6c gav	lun MXB 24m24		no dre P=1.
248	R f	f34 gav	liv MXA 24m24	:	:839.mg * P<.006 c
a	R f	f34 gav	liv nnd 24m24	: +	979.mg * P<.02
b	R f	f34 gav	TBA MXB 24m24		no dre P=1.
c	R f	f34 gav	liv MXB 24m24		839.mg * P<.006
249	R m	f34 gav	liv MXA 24m24	:	2.03gm / P<.6 c
a	R m	f34 gav	TBA MXB 24m24	:	no dre P=1.
b	R m	f34 gav	liv MXB 24m24	:	2.03gm / P<.6
N-METHYL-N'-NITRO-N-NITROSOGUANIDINE***					
100ng...1ug...:10.....100.....1mg.....10.....100.....1g.....10					
250	R m	wis wat	duo adc 75w75 e	:	.910gm P<.0005+

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code	
a	c54842	34.5mg	n.s.s.	37/50	35.0mg	37/50	70.7mg	21/50		
b	c54842	318.mg	n.s.s.	0/50	35.0mg	0/50	70.7mg	1/50	liv:hpa,hpc,nnnd.	
239	a	c54842	37.4mg	216.mg	4/50	35.4mg	17/50	70.7mg	13/50	pni:isa; thy:fca,fcc. C
										1/50)
a	c54842	37.9mg	219.mg	0/50	35.4mg	9/50	(70.7mg	1/50)		
b	c54842	39.6mg	876.mg	1/50	35.4mg	9/50	(70.7mg	1/50)	pni:isa,isc. S	
c	c54842	56.2mg	545.mg	4/50	35.4mg	8/50	70.7mg	13/50	thy:fca,fcc. S	
d	c54842	18.5mg	n.s.s.	40/50	35.4mg	45/50	70.7mg	36/50	S	
e	c54842	70.8mg	n.s.s.	5/50	35.4mg	6/50	70.7mg	8/50	S	
f	c54842	81.3mg	n.s.s.	1/50	35.4mg	7/50	70.7mg	3/50	sub:fbf,fbf. S	
g	c54842	86.5mg	n.s.s.	3/50	35.4mg	3/50	70.7mg	9/50	S	
h	c54842	98.2mg	n.s.s.	1/50	35.4mg	5/50	70.7mg	5/50	S	
i	c54842	186.mg	n.s.s.	0/50	35.4mg	1/50	70.7mg	3/50	S	
j	c54842	20.2mg	889.mg	40/50	35.4mg	40/50	70.7mg	41/50		
k	c54842	133.mg	n.s.s.	3/50	35.4mg	2/50	70.7mg	3/50	liv:hpa,hpc,nnnd.	
2-MERCAPTOBENZOTHIAZOLE*** (Captax, rotax)				149-30-4						
240	a	c56519	629.mg	n.s.s.	4/50	265.mg	12/50	531.mg	4/50	liv:hpa,hpc.
										15/50)
a	c56519	697.mg	n.s.s.	38/50	265.mg	33/50	531.mg	15/50		
b	c56519	629.mg	n.s.s.	4/50	265.mg	12/50	531.mg	4/50	liv:hpa,hpc,nnnd.	
c	c56519	2.14gm	n.s.s.	3/50	265.mg	1/50	531.mg	2/50	lun:a/a,a/c.	
241	a	c56519	359.mg	n.s.s.	31/50	265.mg	39/50	531.mg	25/50	
										14/50)
a	c56519	557.mg	n.s.s.	16/50	265.mg	21/50	531.mg	14/50	liv:hpa,hpc,nnnd.	
b	c56519	1.06gm	n.s.s.	7/50	265.mg	9/50	531.mg	5/50	lun:a/a,a/c.	
242	a	c56519	112.mg	n.s.s.	16/50	133.mg	28/50	265.mg	29/50	amd:phe; pta:adn. P
										25/50)
a	c56519	140.mg	n.s.s.	15/50	133.mg	24/50	265.mg	25/50		
b	c56519	347.mg	n.s.s.	1/50	133.mg	5/50	265.mg	6/50		
c	c56519	116.mg	n.s.s.	37/50	133.mg	46/50	265.mg	40/50		
d	c56519	3.30gm	n.s.s.	1/50	133.mg	0/50	265.mg	0/50	liv:hpa,hpc,nnnd.	
243	a	c56519	82.2mg	543.mg	24/50	265.mg	38/50	(531.mg	31/50)	amd:phe,phm; mul:mnl; pan:ana; pre:adn,can. P
										48/50)
a	c56519	121.mg	2.27gm	48/50	265.mg	48/50	531.mg	48/50		
b	c56519	146.mg	13.6gm	14/50	265.mg	21/50	(531.mg	12/50)	S	
c	c56519	167.mg	1.10gm	2/50	265.mg	13/50	(531.mg	6/50)		
d	c56519	203.mg	2.31gm	18/50	265.mg	27/50	531.mg	24/50	amd:phe,phm.	
e	c56519	183.mg	2.99gm	7/50	265.mg	16/50	(531.mg	3/50)		
f	c56519	749.mg	10.5gm	0/50	265.mg	4/50	531.mg	4/50	S	
g	c56519	684.mg	n.s.s.	1/50	265.mg	6/50	531.mg	5/50	pre:adn,can.	
h	c56519	686.mg	n.s.s.	3/50	265.mg	6/50	531.mg	7/50	sub:fbf,fbf,nfm,snr. S	
i	c56519	744.mg	n.s.s.	2/50	265.mg	4/50	531.mg	6/50	sub:fbf,nfm. S	
j	c56519	822.mg	n.s.s.	2/50	265.mg	3/50	531.mg	6/50	S	
k	c56519	1.14gm	n.s.s.	0/50	265.mg	2/50	531.mg	3/50	mul:mfm; tna:men. S	
l	c56519	69.9mg	617.mg	37/50	265.mg	47/50	(531.mg	41/50)		
m	c56519	1.94gm	n.s.s.	3/50	265.mg	2/50	531.mg	1/50	liv:hpa,hpc,nnnd.	
8-METHOXYPSORALEN (8-MOP)				298-81-7						
244	a	c55903	108.mg	n.s.s.	0/50	26.3mg	1/50	52.8mg	3/50	pal:sqp; ton:sqp. S
										37/50)
a	c55903	17.5mg	n.s.s.	46/50	26.3mg	43/50	52.8mg	37/50		
b	c55903	240.mg	n.s.s.	1/50	26.3mg	0/50	52.8mg	1/50	liv:hpa,hpc,nnnd.	
245	a	c55903	8.08mg	43.1mg	38/50	26.3mg	44/50	52.8mg	43/50	S
										14/50)
a	c55903	15.5mg	59.4mg	2/50	26.3mg	16/50	52.8mg	14/50	kid:tla,uac; zym:can,sgc. C	
b	c55903	17.6mg	73.7mg	1/50	26.3mg	12/50	52.8mg	11/50	kid:tla,uac.	
c	c55903	22.2mg	120.mg	1/50	26.3mg	11/50	52.8mg	8/50		
d	c55903	25.5mg	397.mg	4/50	26.3mg	9/50	52.8mg	9/50		
e	c55903	32.1mg	265.mg	1/50	26.3mg	5/50	52.8mg	8/50	sub:fbf,snr. S	
f	c55903	32.6mg	316.mg	1/50	26.3mg	5/50	52.8mg	7/50		
g	c55903	52.4mg	3.38gm	0/50	26.3mg	1/50	52.8mg	3/50		
h	c55903	41.2mg	n.s.s.	1/50	26.3mg	7/50	52.8mg	4/50	zym:can,sgc.	
i	c55903	39.2mg	n.s.s.	2/50	26.3mg	3/50	52.8mg	4/50	S	
j	c55903	8.23mg	76.0mg	44/50	26.3mg	41/50	52.8mg	41/50		
k	c55903	n.s.s.	n.s.s.	0/50	26.3mg	0/50	52.8mg	0/50	liv:hpa,hpc,nnnd.	
METHYL CARBAMATE				598-55-0						
246	a	c55594	700.mg	n.s.s.	32/50	354.mg	28/50	707.mg	27/50	
										6/50)
a	c55594	1.20gm	n.s.s.	4/50	354.mg	7/50	707.mg	6/50	liv:hpa,hpc,nnnd.	
b	c55594	2.30gm	n.s.s.	7/50	354.mg	5/50	707.mg	4/50	lun:a/a,a/c.	
247	a	c55594	495.mg	n.s.s.	27/50	354.mg	35/50	707.mg	28/50	
										16/50)
a	c55594	780.mg	n.s.s.	14/50	354.mg	17/50	707.mg	16/50	liv:hpa,hpc,nnnd.	
b	c55594	1.61gm	n.s.s.	11/50	354.mg	8/50	707.mg	8/50	lun:a/a,a/c.	
248	a	c55594	342.mg	8.57gm	0/50	70.7mg	0/50	142.mg	6/50	liv:hpc,nnnd.
										5/50)
a	c55594	372.mg	n.s.s.	0/50	70.7mg	0/50	142.mg	5/50		
b	c55594	146.mg	n.s.s.	47/50	70.7mg	43/50	142.mg	42/50	S	
c	c55594	342.mg	8.57gm	0/50	70.7mg	0/50	142.mg	6/50		
249	a	c55594	357.mg	n.s.s.	4/50	70.7mg	0/50	142.mg	7/50	liv:hpa,hpc,nnnd.
										liv:hpc,nnnd.
a	c55594	56.6mg	n.s.s.	47/50	70.7mg	45/50	(142.mg	40/50)		
b	c55594	357.mg	n.s.s.	4/50	70.7mg	0/50	142.mg	7/50	liv:hpa,hpc,nnnd.	
N-METHYL-N'-NITRO-N-NITROSOGUANIDINE*** (MNNG)				70-25-7						
250	1822	.505mg	1.85mg	0/30	2.13mg	17/30			Fujii;nutc,9,185-193;1987	

Spe	Strain	Site	Xpo+Xpt							T050	2Tailpvl						
Sex	Route	Hist	Notes							OR	AuOp						
a	R m	wis wat	gam adc	75w75	e					5.31mg	P<.02	+					
b	R m	wis wat	eso sqc	75w75	e					11.0mg	P<.1	+					
c	R m	wis wat	liv tum	75w75	e					no dre	P=1.						
d	R m	wis wat	tba mix	75w75	e					no dre	P=1.						
N-METHYL-2-PYRROLIDONE				100ng	...	1ug	...	10	...	100	...	1g	...	10			
251	R f	cdr inh	liv tum	24m24	e					.	>	no dre	P=1.	-			
252	R m	cdr inh	liv tum	24m24	e					.	>	no dre	P=1.	-			
alpha-METHYLDOPA SESQUIHYDRATE				100ng	...	1ug	...	10	...	100	...	1g	...	10			
253	M f	b6c eat	TBA MXB	24m24						.	>	no dre	P=1.	-			
a	M f	b6c eat	liv MXB	24m24								no dre	P=1.	-			
b	M f	b6c eat	lun MXB	24m24								25.0gm	* P<.5				
254	M m	b6c eat	kid MXA	24m24						.	>	20.1gm	* P<.2	e			
a	M m	b6c eat	TBA MXB	24m24								no dre	P=1.	-			
b	M m	b6c eat	liv MXB	24m24								no dre	P=1.	-			
c	M m	b6c eat	lun MXB	24m24								no dre	P=1.	-			
255	R f	f34 eat	TBA MXB	24m24						.	>	592.mg	* P<.5	-			
a	R f	f34 eat	liv MXB	24m24								no dre	P=1.	-			
256	R m	f34 eat	TBA MXB	24m24						.	>	no dre	P=1.	-			
a	R m	f34 eat	liv MXB	24m24								no dre	P=1.	-			
N-METHYLDOPAMINE, O,O'-DIISOBUTYROYL ESTER.HCL				...	10	...	1mg	...	10	...	100	...	1g	...	10		
257	R f	cdr gav	adr cca	24m24						.	>	no dre	P=1.	-			
a	R f	cdr gav	pit ade	24m24								no dre	P=1.	-			
b	R f	cdr gav	mgl adc	24m24								no dre	P=1.	-			
c	R f	cdr gav	mgl ade	24m24								no dre	P=1.	-			
d	R f	cdr gav	adr phm	24m24								no dre	P=1.	-			
258	R m	cdr gav	pit ade	24m24						.	+	30.2mg	Z P<.002	-			
a	R m	cdr gav	adr phm	24m24								no dre	P=1.	-			
b	R m	cdr gav	adr cca	24m24								no dre	P=1.	-			
METHYLENE CHLORIDE***				100ng	...	1ug	...	10	...	100	...	1g	...	10			
259	M f	swi gav	lun ade	15m24	s					.	>	7.05gm	* P<.9				
a	M f	swi gav	liv hpt	15m24	s							no dre	P=1.	-			
b	M f	swi gav	tba mal	15m24	s							no dre	P=1.	-			
c	M f	swi gav	tba mix	15m24	s							no dre	P=1.	-			
260	M m	swi gav	lun ade	15m24	s					.	±	916.mg	* P<.05				
a	M m	swi gav	liv hpt	15m24	s							no dre	P=1.	-			
b	M m	swi gav	tba mal	15m24	s							no dre	P=1.	-			
c	M m	swi gav	tba mix	15m24	s							no dre	P=1.	-			
261	R f	sda gav	mam mal	15m24	s					.	±	1.13gm	* P<.07				
a	R f	sda gav	mam mix	15m24	s							1.03gm	* P<.7				
b	R f	sda gav	tba mal	15m24	s							1.74gm	* P<.6				
c	R f	sda gav	tba mix	15m24	s							no dre	P=1.	-			
262	R f	sda inh	mam mix	24m24	gv					.	+	37.8mg	P<.009				
a	R f	sda inh	tba mix	24m24	gv							32.1mg	P<.03				
b	R f	sda inh	tba mal	24m24	gv							477.mg	P<.7				
263	R m	sda gav	tba mix	15m24	s					.	>	no dre	P=1.	-			
a	R m	sda gav	tba mal	15m24	s							935.mg	P<.9				
264	R f	sss inh	mgl fba	24m24	e					.	>	631.mg	* P<.7				
a	R f	sss inh	mgl ben	24m24	e							1.55gm	* P<.9				
b	R f	sss inh	liv kcs	24m24	e							9.34gm	* P<.8	-			
c	R f	sss inh	liv hpc	24m24	e							9.52gm	* P<.7	-			
d	R f	sss inh	liv nnd	24m24	e							no dre	P=1.	-			
e	R f	sss inh	mgl adc	24m24	e							no dre	P=1.	-			
265	R f	sss inh	mgl fba	12m24	e					.	±	37.7mg	P<.05				
a	R f	sss inh	mgl ben	12m24	e							38.1mg	P<.05				
b	R f	sss inh	mgl adc	12m24	e							1.14gm	P<.6	-			
c	R f	sss inh	liv nnd	12m24	e							no dre	P=1.	-			
d	R f	sss inh	liv hpc	12m24	e							no dre	P=1.	-			
266	R m	sss inh	liv tum	86w86	e					.	>	no dre	P=1.	-			
4-(METHYLNITROSAMINO)-1-(3-PYRRIDYL)-1-BUTANOL				...	10	...	100	...	1mg	...	10	...	100	...	1g	...	10
267	R m	f34 wat	lun mix	26m26						.	+	.103mg	P<.0005+				
a	R m	f34 wat	lun adc	26m26								.409mg	P<.0005				
b	R m	f34 wat	lun adq	26m26								.577mg	P<.0005				
c	R m	f34 wat	pae mix	26m26								.668mg	P<.0005+				
d	R m	f34 wat	pae aod	26m26								1.09mg	P<.0005				
e	R m	f34 wat	amd tum	26m26								1.39mg	P<.002				
f	R m	f34 wat	lun ade	26m26								1.38mg	P<.04				
g	R m	f34 wat	pae ana	26m26								2.14mg	P<.05				
h	R m	f34 wat	liv hpt	26m26								5.86mg	P<.2				
i	R m	f34 wat	liv mix	26m26								7.25mg	P<.7				
j	R m	f34 wat	liv ade	26m26								no dre	P=1.	-			

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code
a	1822	1.83mg	n.s.s.	0/30	2.13mg	4/30			
b	1822	2.71mg	n.s.s.	0/30	2.13mg	2/30			
c	1822	6.86mg	n.s.s.	0/30	2.13mg	0/30			
d	1822	.764mg	n.s.s.	20/30	2.13mg	20/30			
N-METHYL-2-PYRROLIDONE 872-50-4									
251	1818	513.mg	n.s.s.	0/83	30.4mg	0/82		Lee;faat,9,222-235;1987/pers.comm.	
252	1818	372.mg	n.s.s.	0/82	21.2mg	0/85			
alpha-METHYLDOPA SESQUIHYDRATE 41372-08-1									
253	c55721	3.22gm	n.s.s.	33/50	811.mg	22/50	1.61gm	21/50	
a	c55721	5.13gm	n.s.s.	4/50	811.mg	1/50	(1.61gm	0/50)	liv:hpa,hpc,nnid.
b	c55721	4.97gm	n.s.s.	4/50	811.mg	1/50	1.61gm	6/50	lun:a/a,a/c.
254	c55721	6.08gm	n.s.s.	0/50	749.mg	2/50	1.49gm	1/50	kid:tla,uac.
a	c55721	4.11gm	n.s.s.	32/50	749.mg	15/50	1.49gm	17/50	
b	c55721	7.29gm	n.s.s.	15/50	749.mg	5/50	1.49gm	6/50	liv:hpa,hpc,nnid.
c	c55721	4.94gm	n.s.s.	10/50	749.mg	5/50	1.49gm	7/50	lun:a/a,a/c.
255	c55721	140.mg	n.s.s.	45/50	154.mg	47/50	312.mg	47/50	
a	c55721	n.s.s.	n.s.s.	0/50	154.mg	1/50	312.mg	0/50	liv:hpa,hpc,nnid.
256	c55721	216.mg	n.s.s.	46/50	123.mg	31/50	250.mg	42/50	
a	c55721	351.mg	n.s.s.	6/50	123.mg	3/50	(250.mg	1/50)	liv:hpa,hpc,nnid.
N-METHYLDOPAMINE, O,O'-DIISOBUTYROYL ESTER.HCl (ibopamine.HCl) 75011-65-3									
257	1875	164.mg	n.s.s.	71/200	30.0mg	26/100(90.0mg	22/100	180.mg	19/100)
a	1875	249.mg	n.s.s.	163/200	30.0mg	83/100	90.0mg	92/100	180.mg
b	1875	626.mg	n.s.s.	31/200	30.0mg	17/100	90.0mg	11/100(180.mg	1/100)
c	1875	1.22gm	n.s.s.	67/200	30.0mg	30/100	90.0mg	27/100	180.mg
d	1875	2.59gm	n.s.s.	11/200	30.0mg	1/100	90.0mg	3/100	180.mg
258	1875	15.3mg	142.mg	125/200	30.0mg	81/100(90.0mg	59/100	180.mg	41/100)
a	1875	850.mg	n.s.s.	45/200	30.0mg	11/100	90.0mg	13/100(180.mg	7/100)
b	1875	145.mg	n.s.s.	50/200	30.0mg	21/100(90.0mg	11/100	180.mg	10/100)
METHYLENE CHLORIDE*** (dichloromethane, Freon 30) 75-09-2									
259	bt3003	502.mg	n.s.s.	10/60	39.6mg	8/50	198.mg	9/50	Maltoni;anya,534,352-366;1988
a	bt3003	340.mg	n.s.s.	0/60	39.6mg	0/50	198.mg	0/50	
b	bt3003	586.mg	n.s.s.	15/60	39.6mg	8/50	198.mg	10/50	
c	bt3003	427.mg	n.s.s.	31/60	39.6mg	17/50	198.mg	20/50	
260	bt3003	345.mg	n.s.s.	3/60	39.6mg	6/50	198.mg	9/50	
a	bt3003	1.27gm	n.s.s.	5/60	39.6mg	2/50	198.mg	2/50	
b	bt3003	1.18gm	n.s.s.	12/60	39.6mg	4/50	198.mg	4/50	
c	bt3003	477.mg	n.s.s.	18/60	39.6mg	10/50	198.mg	13/50	
261	bt3002	403.mg	n.s.s.	4/50	39.6mg	3/50	198.mg	9/50	
a	bt3002	151.mg	n.s.s.	28/50	39.6mg	37/50	198.mg	33/50	
b	bt3002	320.mg	n.s.s.	14/50	39.6mg	12/50	198.mg	16/50	
c	bt3002	141.mg	n.s.s.	39/50	39.6mg	41/50	198.mg	39/50	
262	bt4005	17.7mg	1.23gm	24/60	29.4mg	35/54			
a	bt4005	13.6mg	n.s.s.	35/60	29.4mg	42/54			
b	bt4005	70.6mg	n.s.s.	9/60	29.4mg	10/54			
263	bt3002	47.0mg	n.s.s.	37/50	39.6mg	33/50	(198.mg	22/50)	
a	bt3002	68.6mg	n.s.s.	15/50	39.6mg	16/50	(198.mg	6/50)	
264	1890m	84.1mg	n.s.s.	51/69	13.0mg	57/69	52.0mg	60/69	130.mg
a	1890m	93.8mg	n.s.s.	52/70	13.0mg	58/70	52.0mg	61/70	130.mg
b	1890m	1.52gm	n.s.s.	0/70	13.0mg	0/70	52.0mg	1/70	130.mg
c	1890m	1.09gm	n.s.s.	1/70	13.0mg	0/70	52.0mg	2/70	130.mg
d	1890m	813.mg	n.s.s.	4/70	13.0mg	4/70	52.0mg	3/70	130.mg
e	1890m	859.mg	n.s.s.	3/69	13.0mg	5/69	52.0mg	4/69	130.mg
265	1890n	11.8mg	n.s.s.	51/69	65.0mg	23/25			
a	1890n	11.9mg	n.s.s.	52/70	65.0mg	23/25			
b	1890n	149.mg	n.s.s.	3/69	65.0mg	2/25			
c	1890n	220.mg	n.s.s.	4/70	65.0mg	1/25			
d	1890n	335.mg	n.s.s.	1/70	65.0mg	0/25			
266	1890m	66.5mg	n.s.s.	0/70	9.10mg	0/70	36.4mg	0/70	91.0mg
4-(METHYLNITROSAMINO)-1-(3-PYRRIDYL)-1-BUTANOL ---									
267	1866	56.5ug	.199mg	6/80	.250mg	26/30			Rivenson;canr,48,6912-6917;1988/pers.comm.
a	1866	.203mg	1.07mg	2/80	.250mg	12/30			
b	1866	.265mg	1.76mg	1/80	.250mg	9/30			
c	1866	.294mg	2.29mg	1/80	.250mg	8/30			
d	1866	.413mg	4.54mg	0/80	.250mg	5/30			
e	1866	.479mg	7.65mg	0/80	.250mg	4/30			
f	1866	.445mg	n.s.s.	3/80	.250mg	5/30			
g	1866	.589mg	n.s.s.	1/80	.250mg	3/30			
h	1866	.954mg	n.s.s.	0/80	.250mg	1/30			
i	1866	.712mg	n.s.s.	6/80	.250mg	3/30			
j	1866	.935mg	n.s.s.	6/80	.250mg	2/30			

Spe	Strain	Site	Xpo+Xpt						TD50	2Tailpvl
Sex	Route	Hist	Notes						DR	AuOp
4-(METHYLNITROSAMINO)-1-(3-PYRRIDYL)-1-(BUTANONE).....10.....100.....1mg.....10.....100.....1g.....10										
268	R m	f34 wat	lun mix	27m30					.182mg	* P<.0005+
a	R m	f34 wat	lun ade	27m30					.343mg	Z P<.002
b	R m	f34 wat	pae mix	27m30					.490mg	Z P<.006 +
c	R m	f34 wat	liv mix	27m30					.651mg	* P<.0005+
d	R m	f34 wat	lun adc	27m30					.672mg	* P<.0005
e	R m	f34 wat	liv ade	27m30					.871mg	* P<.0005
f	R m	f34 wat	lun adq	27m30					1.46mg	Z P<.0005
g	R m	f34 wat	nas mix	27m30					1.66mg	* P<.0005
h	R m	f34 wat	lun sqc	27m30					3.40mg	* P<.005
i	R m	f34 wat	--- mix	27m30					.140mg	Z P<.02
j	R m	f34 wat	liv hpt	27m30					2.74mg	* P<.03
k	R m	f34 wat	pae aod	27m30					6.93mg	* P<.08
l	R m	f34 wat	pae ana	27m30					29.2mg	* P<.1
N-METHYLOLACRYLAMIDE 100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10										
269	M f	b6c gav	MXB MXB	24m24					27.8mg	* P<.0005
a	M f	b6c gav	hag MXA	24m24					44.6mg	* P<.0005
b	M f	b6c gav	hag MXA	24m24					55.5mg	* P<.002 c
c	M f	b6c gav	liv hpa	24m24					66.9mg	/ P<.0005c
d	M f	b6c gav	liv MXA	24m24					74.8mg	* P<.009
e	M f	b6c gav	ova gcb	24m24					119. mg	* P<.006 c
f	M f	b6c gav	lun MXA	24m24					111. mg	* P<.06 c
g	M f	b6c gav	TBA MXB	24m24					30.9mg	* P<.03
h	M f	b6c gav	liv MXB	24m24					74.8mg	* P<.009
i	M f	b6c gav	lun MXB	24m24					111. mg	* P<.06
270	M m	b6c gav	MXB MXB	24m24					13.3mg	* P<.0005
a	M m	b6c gav	hag MXA	24m24					17.4mg	* P<.0005
b	M m	b6c gav	hag ade	24m24					17.5mg	* P<.0005c
c	M m	b6c gav	liv MXA	24m24					29.4mg	* P<.003 c
d	M m	b6c gav	lun MXA	24m24					38.5mg	* P<.002 c
e	M m	b6c gav	liv hpa	24m24					50.2mg	/ P<.008
f	M m	b6c gav	lun a/a	24m24					66.0mg	* P<.009
g	M m	b6c gav	lun a/c	24m24					75.1mg	* P<.006
h	M m	b6c gav	liv hpc	24m24					63.4mg	* P<.05
i	M m	b6c gav	TBA MXB	24m24					22.3mg	* P<.02
j	M m	b6c gav	liv MXB	24m24					29.4mg	* P<.003
k	M m	b6c gav	lun MXB	24m24					38.5mg	* P<.002
271	R f	f34 gav	TBA MXB	24m24					no dre	P=1. -
a	R f	f34 gav	liv MXB	24m24					no dre	P=1. -
272	R m	f34 gav	ski ker	24m24					#13.0mg	P<.03 -
a	R m	f34 gav	TBA MXB	24m24					3.12gm	* P<.1
b	R m	f34 gav	liv MXB	24m24					no dre	P=1. -
p-METHYLSTYRENE 100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10										
273	M f	swi gav	lun ade	78w83					616. mg	* P<.2 -
a	M f	swi gav	liv hpt	78w83					no dre	P=1. -
b	M f	swi gav	tba mix	78w83					343. mg	* P<.2 -
c	M f	swi gav	tba mal	78w83					no dre	P=1. -
274	M m	swi gav	lun ade	78w83					962. mg	* P<.3 -
a	M m	swi gav	liv hpt	78w83					no dre	P=1. -
b	M m	swi gav	tba mal	78w83					no dre	P=1. -
c	M m	swi gav	tba mix	78w83					no dre	P=1. -
MISOPROSTOL 100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10										
275	M f	cd1 gav	lun ala	91w91 e					2.35gm	* P<.9 -
a	M f	cd1 gav	liv hpa	91w91 e					no dre	P=1. -
b	M f	cd1 gav	liv hem	91w91 e					no dre	P=1. -
c	M f	cd1 gav	lun alc	91w91 e					no dre	P=1. -
d	M f	cd1 gav	tba mix	91w91 e					.130mg	Z P<.0005-
276	M m	cd1 gav	liv hpa	91w91 e					no dre	P=1. -
a	M m	cd1 gav	liv hpc	91w91 e					no dre	P=1. -
b	M m	cd1 gav	lun ala	91w91 e					no dre	P=1. -
c	M m	cd1 gav	lun alc	91w91 e					no dre	P=1. -
d	M m	cd1 gav	liv hem	91w91 e					no dre	P=1. -
e	M m	cd1 gav	tba mix	91w91 e					no dre	P=1. -
277	R f	cdr gav	liv hcs	24m24 e					9.53gm	* P<.1. -
a	R f	cdr gav	liv hpc	24m24 e					no dre	P=1. -
b	R f	cdr gav	agl fba	24m24 e					no dre	P=1. -
c	R f	cdr gav	tba mix	24m24 e					no dre	P=1. -
278	R m	cdr gav	liv hcs	24m24 e					no dre	P=1. -
a	R m	cdr gav	tba mix	24m24 e					no dre	P=1. -
NALIDIXIC ACID 100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10										
279	M f	b6c eat	and phe	24m24					#3.63gm	* P<.03 -
a	M f	b6c eat	TBA MXB	24m24					1.69gm	* P<.6
b	M f	b6c eat	liv MXB	24m24					3.16gm	* P<.3

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code		
4-(METHYLNITROSAMINO)-1-(3-PYRRIDYL)-1-(BUTANONE) 64091-91-4											
268	1866	.123mg	.297mg	6/80	25.0ug	9/80	50.0ug	20/80	.250mg	27/30	Rivenson; canr, 48, 6912-6917; 1988/pers. comm.
a	1866	.181mg	1.52mg	3/80	25.0ug	5/80	50.0ug	16/80	(.250mg)	2/30	
b	1866	.241mg	5.70mg	1/80	25.0ug	5/80	50.0ug	9/80	(.250mg)	2/30	
c	1866	.345mg	1.90mg	6/80	25.0ug	3/80	50.0ug	11/80	.250mg	12/30	
d	1866	.375mg	1.53mg	2/80	25.0ug	3/80	50.0ug	4/80	.250mg	13/30	
e	1866	.427mg	3.37mg	6/80	25.0ug	2/80	50.0ug	9/80	.250mg	10/30	
f	1866	.677mg	4.26mg	1/80	25.0ug	0/80	50.0ug	0/80	.250mg	9/30	
g	1866	.757mg	5.90mg	0/80	25.0ug	1/80	50.0ug	2/80	.250mg	5/30	
h	1866	1.17mg	4.2.2mg	0/80	25.0ug	1/80	50.0ug	0/80	.250mg	3/30	
i	1866	63.5ug	n.s.s.	9/80	25.0ug	21/80	(50.0ug)	10/80	.250mg	2/30	
j	1866	1.04mg	n.s.s.	0/80	25.0ug	1/80	50.0ug	2/80	.250mg	2/30	
k	1866	1.70mg	n.s.s.	0/80	25.0ug	0/80	50.0ug	1/80	.250mg	1/30	
l	1866	.859mg	n.s.s.	1/80	25.0ug	5/80	50.0ug	8/80	.250mg	1/30	
N-METHYLOLACRYLAMIDE (N-(hydroxymethyl)-acrylamide) 924-42-5											
269	c60333	15.8mg	89.4mg	14/50	17.5mg	20/50	35.0mg	37/50			hag:ade,anb; (liv:hpa; lun:a/a,a/c; ova:gcb. C
a	c60333	25.3mg	141.1mg	5/50	17.5mg	11/50	35.0mg	22/50			hag:ade,anb,car. S
b	c60333	29.9mg	222.1mg	5/50	17.5mg	8/50	35.0mg	20/50			hag:ade,anb. S
c	c60333	35.6mg	241.1mg	3/50	17.5mg	4/50	35.0mg	17/50			
d	c60333	35.7mg	2.08gm	6/50	17.5mg	7/50	35.0mg	17/50			liv:hpa,hpc. S
e	c60333	58.1mg	996.1mg	0/50	17.5mg	5/50	35.0mg	5/50			
f	c60333	45.2mg	n.s.s.	6/50	17.5mg	8/50	35.0mg	13/50			lun:a/a,a/c. S
g	c60333	13.9mg	n.s.s.	33/50	17.5mg	41/50	35.0mg	47/50			
h	c60333	35.7mg	2.08gm	6/50	17.5mg	7/50	35.0mg	17/50			liv:hpa,hpc,nnd. S
i	c60333	45.2mg	n.s.s.	6/50	17.5mg	8/50	35.0mg	13/50			lun:a/a,a/c. S
270	c60333	8.07mg	32.0mg	16/50	17.5mg	30/50	35.0mg	43/50			hag:ade; (liv:hpa,hpc; lun:a/a,a/c. C
a	c60333	11.4mg	30.6mg	2/50	17.5mg	14/50	35.0mg	30/50			hag:ade,car. S
b	c60333	11.7mg	29.4mg	1/50	17.5mg	14/50	35.0mg	29/50			
c	c60333	15.2mg	186.1mg	12/50	17.5mg	17/50	35.0mg	26/50			liv:hpa,hpc. S
d	c60333	20.4mg	163.1mg	5/50	17.5mg	10/50	35.0mg	18/50			lun:a/a,a/c. S
e	c60333	23.3mg	1.15gm	8/50	17.5mg	4/50	35.0mg	19/50			S
f	c60333	30.7mg	2.27gm	3/50	17.5mg	6/50	35.0mg	11/50			S
g	c60333	35.1mg	897.1mg	2/50	17.5mg	4/50	35.0mg	10/50			S
h	c60333	27.1mg	n.s.s.	6/50	17.5mg	13/50	35.0mg	12/50			S
i	c60333	10.2mg	n.s.s.	35/50	17.5mg	39/50	35.0mg	47/50			
j	c60333	15.2mg	186.1mg	12/50	17.5mg	17/50	35.0mg	26/50			liv:hpa,hpc,nnd. S
k	c60333	20.4mg	163.1mg	5/50	17.5mg	10/50	35.0mg	18/50			lun:a/a,a/c. S
271	c60333	6.33mg	n.s.s.	45/50	4.20mg	36/50	8.41mg	42/50			
a	c60333	n.s.s.	n.s.s.	0/50	4.20mg	0/50	8.41mg	0/50			liv:hpa,hpc,nnd. S
272	c60333	4.72mg	n.s.s.	1/50	4.20mg	6/50	(8.41mg)	3/50			
a	c60333	5.39mg	n.s.s.	45/50	4.20mg	40/50	8.41mg	45/50			
b	c60333	11.0mg	n.s.s.	4/50	4.20mg	2/50	(8.41mg)	0/50			liv:hpa,hpc,nnd. S
p-METHYLSTYRENE 622-97-9											
273	bt107	200.1mg	n.s.s.	13/60	6.71mg	5/60	33.6mg	10/60	168.1mg	15/60	Conti;anya, 534, 203-234; 1988
a	bt107	42.6mg	n.s.s.	0/60	6.71mg	0/60	33.6mg	0/60	168.1mg	0/60	
b	bt107	104.1mg	n.s.s.	33/60	6.71mg	18/60	33.6mg	33/60	168.1mg	33/60	
c	bt107	343.1mg	n.s.s.	19/60	6.71mg	10/60	33.6mg	20/60	168.1mg	13/60	
274	bt107	262.1mg	n.s.s.	7/60	6.71mg	5/60	33.6mg	7/60	168.1mg	10/60	
a	bt107	793.1mg	n.s.s.	5/60	6.71mg	4/60	33.6mg	6/60	168.1mg	2/60	
b	bt107	583.1mg	n.s.s.	12/60	6.71mg	7/60	33.6mg	9/60	168.1mg	6/60	
c	bt107	320.1mg	n.s.s.	20/60	6.71mg	14/60	33.6mg	18/60	168.1mg	15/60	
MISOPROSTOL 59122-46-2											
275	1841	106.1mg	n.s.s.	1/64	.160mg	1/64	1.60mg	0/64	16.0mg	1/64	Port;txpy, 15, 134-142; 1987/pers. comm.
a	1841	110.1mg	n.s.s.	0/64	.160mg	3/64	1.60mg	0/64	16.0mg	1/64	
b	1841	176.1mg	n.s.s.	2/64	.160mg	2/64	1.60mg	0/64	16.0mg	0/64	
c	1841	96.2mg	n.s.s.	0/64	.160mg	2/64	1.60mg	2/64	16.0mg	1/64	
d	1841	69.7ug	.481mg	22/64	.160mg	42/64	(1.60mg)	21/64	16.0mg	18/64	
276	1841	5.97mg	n.s.s.	15/64	.160mg	11/64	1.60mg	9/64	(16.0mg)	2/64	
a	1841	109.1mg	n.s.s.	2/64	.160mg	1/64	1.60mg	1/64	16.0mg	1/64	
b	1841	148.1mg	n.s.s.	0/64	.160mg	1/64	1.60mg	1/64	16.0mg	0/64	
c	1841	167.1mg	n.s.s.	2/64	.160mg	4/64	1.60mg	1/64	16.0mg	0/64	
d	1841	176.1mg	n.s.s.	1/64	.160mg	1/64	1.60mg	0/64	16.0mg	0/64	
e	1841	2.86mg	n.s.s.	34/64	.160mg	27/64	1.60mg	27/64	(16.0mg)	15/64	
277	1840	18.1mg	n.s.s.	0/60	24.0ug	2/60	.240mg	1/59	2.40mg	1/60	Dodd;txpy, 15, 125-133; 1987/pers. comm.
a	1840	22.4mg	n.s.s.	0/60	24.0ug	0/60	.240mg	1/59	2.40mg	0/60	
b	1840	5.70mg	n.s.s.	23/60	24.0ug	27/60	.240mg	37/59	2.40mg	24/60	
c	1840	2.28mg	n.s.s.	56/60	24.0ug	58/60	.240mg	54/59	2.40mg	52/60	
278	1840	18.8mg	n.s.s.	2/60	24.0ug	0/60	.240mg	1/60	2.40mg	1/60	
a	1840	.350mg	n.s.s.	47/60	24.0ug	49/60	.240mg	42/60	(2.40mg)	24/60	
NALIDIXIC ACID 389-08-2											
279	c56199	1.38gm	n.s.s.	0/50	258.1mg	2/50	515.1mg	3/50			S
a	c56199	344.1mg	n.s.s.	36/50	258.1mg	39/50	515.1mg	35/50			
b	c56199	963.1mg	n.s.s.	4/50	258.1mg	6/50	515.1mg	7/50			liv:hpa,hpc,nnd. S

Spe	Strain	Site	Xpo+Xpt	TD50	2Tailpvl
Sex	Route	Hist	Notes	DR	AuOp
c	M f b6c	eat lun	MXB 24m24	4.90gm	* P<.4
280	M m b6c	eat sub	MXA 24m24	1.21gm	* P<.04 e
a	M m b6c	eat TBA	MXB 24m24	1.33gm	* P<.4
b	M m b6c	eat liv	MXB 24m24	no dre	P=1.
c	M m b6c	eat lun	MXB 24m24	4.60gm	* P<.6
281	R f f34	eat cli	MXA 24m24	372.mg	* P<.05 c
a	R f f34	eat TBA	MXB 24m24	no dre	P=1.
b	R f f34	eat liv	MXB 24m24	no dre	P=1.
282	R m f34	eat pre	MXA 24m24	138.mg	* P<.0005c
a	R m f34	eat pre	can 24m24	211.mg	* P<.0005
b	R m f34	eat pre	adn 24m24	301.mg	* P<.02
c	R m f34	eat pre	MXA 24m24	358.mg	* P<.05
d	R m f34	eat TBA	MXB 24m24	7.60gm	* P<.1
e	R m f34	eat liv	MXB 24m24	no dre	P=1.
NEOSUGAR				100ng.....1ug.....:10.....:100.....:1mg.....:10.....:100.....:1g.....:10	
283	R f f3d	eat spl	leu 24m24	> 25.5gm	* P<.5 -
a	R f f3d	eat pit	ade 24m24	no dre	P=1.
284	R m f3d	eat pit	ade 24m24	3.55gm	* P<.007 -
NITRITE, SODIUM***				100ng.....1ug.....:10.....:100.....:1mg.....:10.....:100.....:1g.....:10	
285	H f syg	eat liv	cgf 97w97 e	no dre	P=1.
a	H f syg	eat tba	tum 97w97 e	477.mg	P<.6
286	H m syg	eat liv	tum 24m24 e	no dre	P=1.
a	H m syg	eat tba	tum 24m24 e	no dre	P=1.
287	R f f34	eat liv	mix 24m30	136.mg	P<.003
a	R f f34	eat liv	nnd 24m30	218.mg	P<.03
b	R f f34	eat liv	hpc 24m30	516.mg	P<.02
288	R m f34	eat liv	mix 24m30	641.mg	P<.3
a	R m f34	eat liv	nnd 24m30	674.mg	P<.3
b	R m f34	eat liv	hpc 24m30	no dre	P=1.
5-NITRO-2-FURALDEHYDE SEMICARBAZONE***			1ug.....:10.....:100.....:1mg.....:10.....:100.....:1g.....:10	
289	M f b6c	eat ova	MXB 24m24	22.4mg	* P<.0005
a	M f b6c	eat ova	MXA 24m24	29.8mg	* P<.0005
b	M f b6c	eat ova	mtb 24m24	30.8mg	* P<.0005c
c	M f b6c	eat ova	gct 24m24	124.mg	* P<.005 c
d	M f b6c	eat TBA	MXB 24m24	66.2mg	* P<.3
e	M f b6c	eat liv	MXB 24m24	no dre	P=1.
f	M f b6c	eat lun	MXB 24m24	241.mg	* P<.3
290	M m b6c	eat sub	MXA 24m24	#154.mg	* P<.05 ~
a	M m b6c	eat TBA	MXB 24m24	89.3mg	* P<.4
b	M m b6c	eat liv	MXB 24m24	152.mg	P<.7
c	M m b6c	eat lun	MXB 24m24	1.38gm	* P<.9
291	R f f34	eat mgl	fbp 24m24	15.7mg	* P<.0005c
a	R f f34	eat TBA	MXB 24m24	no dre	P=1.
b	R f f34	eat liv	MXB 24m24	253.mg	* P<.2
292	R m f34	eat tnv	MXA 24m24	44.0mg	* P<.003 e
a	R m f34	eat ski	MXA 24m24	151.mg	* P<.006 e
b	R m f34	eat pre	car 24m24	65.5mg	* P<.03 e
c	R m f34	eat ski	sea 24m24	177.mg	* P<.02
d	R m f34	eat TBA	MXB 24m24	33.8mg	* P<.3
e	R m f34	eat liv	MXB 24m24	no dre	P=1.
3-NITRO-4-HYDROXYPHENYLARSONIC ACID***			1ug.....:10.....:100.....:1mg.....:10.....:100.....:1g.....:10	
293	M f b6c	eat TBA	MXB 24m24	no dre	P=1. -
a	M f b6c	eat liv	MXB 24m24	no dre	P=1.
b	M f b6c	eat lun	MXB 24m24	193.mg	* P<.6
294	M m b6c	eat MXA	MXA 24m24	#138.mg	* P<.03 -
a	M m b6c	eat TBA	MXB 24m24	no dre	P=1.
b	M m b6c	eat liv	MXB 24m24	no dre	P=1.
c	M m b6c	eat lun	MXB 24m24	no dre	P=1.
295	R f f34	eat TBA	MXB 24m24	no dre	P=1. -
a	R f f34	eat liv	MXB 24m24	no dre	P=1.
296	R m f34	eat pit	pdp 24m24	3.40gm	* P<.05
a	R m f34	eat pni	ade 24m24	16.5mg	* P<.02
b	R m f34	eat pan	ade 24m24	19.0mg	* P<.07 e
c	R m f34	eat TBA	MXB 24m24	7.20gm	* P<.5
d	R m f34	eat liv	MXB 24m24	no dre	P=1.
1-[(5-NITROFURFURYLIDENE)AMINO]HYDANTOIN***			1ug.....:10.....:100.....:1mg.....:10.....:100.....:1g.....:10	
297	M f b6c	eat ova	MXB 24m24 s	866.mg	* P<.003
a	M f b6c	eat ova	MXA 24m24 s	1.40gm	/ P<.004 c
b	M f b6c	eat ova	tua 24m24 s	2.53gm	* P<.03 c
c	M f b6c	eat ova	mtb 24m24 s	3.38gm	* P<.05 c
d	M f b6c	eat ova	MXA 24m24 s	+hist 2.56gm	* P<.4 c
e	M f b6c	eat ova	gcb 24m24 s	+hist 8.47gm	* P<.9 c

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Bkly Code		
c	c56199	1.27gm	n.s.s.	1/50	258.mg	5/50	515.mg		lun:a/a,a/c.		
280	c56199	536.mg	n.s.s.	5/50	238.mg	9/50	475.mg		sub: fbs, fib.		
a	c56199	342.mg	n.s.s.	26/50	238.mg	24/50	475.mg				
b	c56199	1.07gm	n.s.s.	10/50	238.mg	12/50	475.mg		liv:hpa,hpc,nnd.		
c	c56199	848.mg	n.s.s.	6/50	238.mg	5/50	475.mg		lun:a/a,a/c.		
281	c56199	165.mg	n.s.s.	5/50	99.0mg	15/50	198.mg		cli: adn, can, ppc, ppn.		
a	c56199	102.mg	n.s.s.	47/50	99.0mg	43/50	198.mg	(198.mg	41/50)		
b	c56199	1.14gm	n.s.s.	1/50	99.0mg	0/50	198.mg		liv:hpa,hpc,nnd.		
282	c56199	82.0mg	416.mg	3/50	79.2mg	19/50	159.mg		pre: adn, can, ppn.		
a	c56199	126.mg	458.mg	0/50	79.2mg	10/50	159.mg		S		
b	c56199	145.mg	n.s.s.	2/50	79.2mg	10/50	159.mg		S		
c	c56199	155.mg	n.s.s.	3/50	79.2mg	10/50	159.mg		pre: adn, ppn.		
d	c56199	94.9mg	n.s.s.	44/50	79.2mg	45/50	159.mg		S		
e	c56199	746.mg	n.s.s.	2/50	79.2mg	1/50	159.mg		liv:hpa,hpc,nnd.		
NEOSUGAR 88385-81-3											
283	1880	5.05gm	n.s.s.	4/50	400.mg	7/50	1.00gm	12/50	2.50gm	7/50	Clevenger; jact, 7, 643-662; 1988
a	1880	8.67gm	n.s.s.	24/50	400.mg	19/50	1.00gm	19/50	2.50gm	14/50	
284	1880	1.71gm	59.6gm	10/50	320.mg	13/50	800.mg	19/50	2.00gm	22/50	
NITRITE, SODIUM*** 7632-00-0											
285	1831	402.mg	n.s.s.	1/14	149.mg	0/15					Ernst; carc, 8, 1843-1845; 1987/pers.comm.
a	1831	78.7mg	n.s.s.	5/14	149.mg	7/15					
286	1831	391.mg	n.s.s.	0/16	131.mg	0/15					
a	1831	134.mg	n.s.s.	10/16	131.mg	6/15					
287	1854	62.3mg	897.mg	4/24	87.9mg	14/24					Lijinsky; txih, 3, 413-422; 1987/pers.comm.
a	1854	86.7mg	n.s.s.	4/24	87.9mg	11/24					
b	1854	178.mg	n.s.s.	0/24	87.9mg	4/24					
288	1854	164.mg	n.s.s.	3/24	92.3mg	6/24					
a	1854	180.mg	n.s.s.	2/24	92.3mg	5/24					
b	1854	429.mg	n.s.s.	1/24	92.3mg	1/24					
5-NITRO-2-FURALDEHYDE SEMICARBAZONE*** (nitrofurazone) 59-87-0											
289	c56064	15.4mg	37.7mg	1/50	19.3mg	20/50	39.9mg	29/50			ova: gct, mtb. C
a	c56064	20.1mg	48.8mg	0/50	19.3mg	18/50	39.9mg	20/50			ova: mtb, tua. S
b	c56064	20.7mg	50.6mg	0/50	19.3mg	17/50	39.9mg	20/50			
c	c56064	60.2mg	1.14gm	1/50	19.3mg	4/50	39.9mg	9/50			
d	c56064	19.9mg	n.s.s.	36/50	19.3mg	43/50	39.9mg	42/50			
e	c56064	214.mg	n.s.s.	3/50	19.3mg	3/50	39.9mg	1/50			liv:hpa,hpc,nnd.
f	c56064	73.0mg	n.s.s.	3/50	19.3mg	7/50	39.9mg	6/50			lun:a/a,a/c.
290	c56064	60.1mg	n.s.s.	3/50	17.8mg	3/50	36.8mg	8/50			sub: fbs, fib, nts, srrn. S
a	c56064	23.9mg	n.s.s.	28/50	17.8mg	26/50	36.8mg	26/50			
b	c56064	20.2mg	n.s.s.	16/50	17.8mg	15/50	36.8mg	5/50			liv:hpa,hpc,nnd.
c	c56064	69.1mg	n.s.s.	8/50	17.8mg	7/50	36.8mg	6/50			lun:a/a,a/c.
291	c56064	9.47mg	44.2mg	8/50	15.4mg	36/50	30.7mg	36/50			
a	c56064	20.3mg	n.s.s.	44/50	15.4mg	47/50	30.7mg	46/50			
b	c56064	87.3mg	n.s.s.	0/50	15.4mg	2/50	30.7mg	2/50			liv:hpa,hpc,nnd.
292	c56064	18.8mg	195.mg	0/50	12.3mg	7/50	24.6mg	2/50			tnv: men, msn.
a	c56064	55.2mg	548.mg	0/50	12.3mg	0/50	24.6mg	5/50			ski: sea, tri.
b	c56064	29.4mg	n.s.s.	1/50	12.3mg	8/50	24.6mg	5/50			
c	c56064	59.1mg	n.s.s.	0/50	12.3mg	0/50	24.6mg	4/50			S
d	c56064	9.75mg	n.s.s.	47/50	12.3mg	46/50	24.6mg	40/50			
e	c56064	73.2mg	n.s.s.	7/50	12.3mg	4/50	24.6mg	3/50			liv:hpa,hpc,nnd.
3-NITRO-4-HYDROXYPHENYLARSONIC ACID*** (roxarsone) 121-19-7											
293	c56508	32.7mg	n.s.s.	24/50	12.8mg	11/50	25.5mg	18/50			
a	c56508	196.mg	n.s.s.	3/50	12.8mg	0/50	25.5mg	0/50			liv:hpa,hpc,nnd.
b	c56508	34.8mg	n.s.s.	3/50	12.8mg	4/50	25.5mg	5/50			lun:a/a,a/c.
294	c56508	56.5mg	n.s.s.	0/50	11.8mg	2/50	23.5mg	4/50			acx: csa; adr: cca. S
a	c56508	29.5mg	n.s.s.	35/50	11.8mg	30/50	23.5mg	34/50			
b	c56508	71.9mg	n.s.s.	12/50	11.8mg	15/50	23.5mg	7/50			liv:hpa,hpc,nnd.
c	c56508	63.0mg	n.s.s.	11/50	11.8mg	5/50	23.5mg	10/50			lun:a/a,a/c.
295	c56508	4.18mg	n.s.s.	48/50	2.45mg	47/50	4.93mg	46/50			
a	c56508	n.s.s.	n.s.s.	0/50	2.45mg	1/50	4.93mg	0/50			liv:hpa,hpc,nnd.
296	c56508	1.28mg	n.s.s.	6/50	1.96mg	13/50	3.92mg	8/50			S
a	c56508	6.87mg	n.s.s.	0/50	1.96mg	3/50	3.92mg	4/50			S
b	c56508	6.46mg	n.s.s.	1/50	1.96mg	1/50	3.92mg	5/50			
c	c56508	1.58mg	n.s.s.	46/50	1.96mg	48/50	3.92mg	47/50			
d	c56508	18.5mg	n.s.s.	2/50	1.96mg	2/50	3.92mg	1/50			liv:hpa,hpc,nnd.
1-[(5-NITROFURFURYLIDENE)AMINO]HYDANTOIN*** (macrofantin, nitrofurantoin) 67-20-9											
297	c55196	466.mg	3.57gm	0/50	166.mg	3/50	319.mg	11/50			ova: gcb, gcm, mtb, tua. C
a	c55196	660.mg	3.82gm	0/50	166.mg	0/50	319.mg	9/50			ova: mtb, tua.
b	c55196	960.mg	n.s.s.	0/50	166.mg	0/50	319.mg	5/50			
c	c55196	1.16gm	n.s.s.	0/50	166.mg	0/50	319.mg	4/50			
d	c55196	972.mg	n.s.s.	0/50	166.mg	3/50	319.mg	2/50			ova: gcb, gcm.
e	c55196	1.12gm	n.s.s.	0/50	166.mg	3/50	319.mg	1/50			

Spe	Strain	Site	Xpo+Xpt	Notes	TD50	2Tailpvl
Sex	Route	Hist			QR	AuQp
f	M f	b6c eat	TBA MXB	24m24 s		no dre P=1.
g	M f	b6c eat	liv MXB	24m24 s		2.33gm * P<.2
h	M f	b6c eat	lun MXB	24m24 s		no dre P=1.
298	M m	b6c eat	TBA MXB	24m24		no dre P=1. -
a	M m	b6c eat	liv MXB	24m24		no dre P=1.
b	M m	b6c eat	lun MXB	24m24		no dre P=1.
299	R f	f34 eat	cli ade	24m24	: ±	#93.7mg P<.03 -
a	R f	f34 eat	TBA MXB	24m24		no dre P=1.
b	R f	f34 eat	liv MXB	24m24		no dre P=1.
300	R m	f34 eat	sub fib	24m24	: ±	303.mg * P<.02
a	R m	f34 eat	kid MXA	24m24		+hist 698.mg * P<.05 p
b	R m	f34 eat	TBA MXB	24m24		no dre P=1.
c	R m	f34 eat	liv MXB	24m24		332.mg P<.2
1-NITROPROPANE***					100ng...1ug...10...100...1mg...10...100...1g...10	
301	R m	sda gav	liv hpa	26w77 ev	>	.872mg P<1. -
3-NITROSO-2-OXAZOLIDINONE					100ng...1ug...10...100...1mg...10...100...1g...10	
302	R m	mrw wat	itm mix	64w64 e	<+	noTD50 P<.0005+
a	R m	mrw wat	liv mix	64w64 e		.582mg P<.0005+
b	R m	mrw wat	tba tum	64w64 e		noTD50 P<.0005
303	R m	mrw wat	itm mix	70w70 ev	. + .	.729mg P<.0005+
a	R m	mrw wat	liv mix	70w70 ev		1.15mg P<.0005+
b	R m	mrw wat	tba tum	70w70 ev		.335mg P<.0005
N-NITROSODIETHANOLAMINE***					100ng...1ug...10...100...1mg...10...100...1g...10	
304	R m	sda wat	liv mix	38m39 a	.	38.4mg * P<.0005+
a	R m	sda wat	liv hpc	38m39 a	+	70.4mg * P<.0005+
b	R m	sda wat	liv hmb	38m39 a		126.mg * P<.06 +
c	R m	sda wat	ner tum	38m39 a		42.5mg * P<.3 +
d	R m	sda wat	--- tum	38m39 a		55.6mg * P<.2 +
e	R m	sda wat	git mix	38m39 a		143.mg * P<.6 +
f	R m	sda wat	liv hpa	38m39 a		347.mg * P<.3 +
g	R m	sda wat	tba ben	38m39 a		7.93mg * P<.2
h	R m	sda wat	tba mal	38m39 a		23.5mg * P<.3 +
N-NITROSODIETHYLAMINE***					100ng...1ug...10...100...1mg...10...100...1g...10	
305	R m	sda wat	liv mix	35m37 a	. + .	.270mg Z P<.0005+
a	R m	sda wat	git mix	35m37 a		.401mg * P<.0005+
b	R m	sda wat	liv hpc	35m37 a		.541mg Z P<.0005+
c	R m	sda wat	eso pam	35m37 a		.715mg Z P<.0005+
d	R m	sda wat	liv hmb	35m37 a		.719mg * P<.0005+
e	R m	sda wat	eso sqc	35m37 a		3.38mg * P<.002 +
f	R m	sda wat	unt tum	35m37 a		6.51mg * P<.3 +
g	R m	sda wat	tba mal	35m37 a		.188mg * P<.0005+
h	R m	sda wat	tba ben	35m37 a		no dre P=1.
N-NITROSODIMETHYLAMINE***					100ng...1ug...10...100...1mg...10...100...1g...10	
306	R m	f34 gav	lun mix	30w65 e	. + .	76.5ug P<.0005+
a	R m	f34 gav	lun a/a	30w65 e		.106mg P<.0005+
b	R m	f34 gav	kid mnp	30w65 e		.189mg P<.0005+
c	R m	f34 gav	liv mix	30w65 e		.189mg P<.0005+
d	R m	f34 gav	liv bht	30w65 e		.372mg P<.003
e	R m	f34 gav	lun sqc	30w65 e		.372mg P<.003
f	R m	f34 gav	liv cab	30w65 e		.822mg P<.04
g	R m	f34 gav	liv hes	30w65 e		.822mg P<.04
N-NITROSODITHIAZINE					100ng...1ug...10...100...1mg...10...100...1g...10	
307	R f	f34 gav	nac car	11m26 e	.	5.11mg P<.1
a	R f	f34 gav	liv hpc	11m26 e	±	10.5mg P<.3 -
NITROETHYLMETHYLAMINE***					100ng...1ug...10...100...1mg...10...100...1g...10	
308	R m	f34 gav	liv bht	30w55 e	.	50.3ug P<.0005
a	R m	f34 gav	liv mix	30w55 e	. + .	50.3ug P<.0005+
b	R m	f34 gav	liv hes	30w55 e		.120mg P<.0005
c	R m	f34 gav	nac tum	30w55 e		.201mg P<.0005+
d	R m	f34 gav	lun a/a	30w55 e		.242mg P<.0005+
N-NITROSOGLUCOLINE					100ng...1ug...10...100...1mg...10...100...1g...10	
309	R m	f34 wat	pae ana	30m30	.	7.95mg P<.02
a	R m	f34 wat	liv ade	30m30	±	no dre P=1.
N-NITROSOMETHYL-(2-HYDROXYETHYL)AMINE					100ng...1ug...10...100...1mg...10...100...1g...10	
310	R m	f34 gav	liv hpc	69w69 es	.	1.29mg P<.003 +
a	R m	f34 gav	nas sqc	69w69 es	. + .	2.06mg P<.02 +
b	R m	f34 gav	liv hes	69w69 es		8.97mg P<.3
c	R m	f34 gav	nas sqc	69w69 es		8.97mg P<.3
d	R m	f34 gav	liv nnd	69w69 es		no dre P=1.

RefNum	LoConf	UpConf	Cntrl	1dose	1inc	2dose	2inc	Citation or Pathology	Brkly Code
f	c55196	368.mg n.s.s.	30/50	166.mg	35/50	319.mg	41/50		
g	c55196	764.mg n.s.s.	2/50	166.mg	2/50	319.mg	8/50		
h	c55196	822.mg n.s.s.	3/50	166.mg	2/50	(319.mg)	0/50)		liv:hpa,hpc,nnd. Lun:a/a,a/c.
298	c55196	357.mg n.s.s.	31/50	153.mg	27/50	294.mg	33/50		
a	c55196	567.mg n.s.s.	10/50	153.mg	12/50	294.mg	11/50		liv:hpa,hpc,nnd. Lun:a/a,a/c.
b	c55196	787.mg n.s.s.	6/50	153.mg	4/50	294.mg	7/50		
299	c55196	36.2mg n.s.s.	1/50	29.4mg	7/50	(63.8mg)	4/50)		S
a	c55196	45.2mg n.s.s.	49/50	29.4mg	48/50	63.8mg	46/50		
b	c55196	n.s.s. n.s.s.	0/50	29.4mg	1/50	63.8mg	0/50		liv:hpa,hpc,nnd.
300	c55196	142.mg n.s.s.	0/50	51.3mg	5/50	98.1mg	4/50		S
a	c55196	240.mg n.s.s.	0/50	51.3mg	1/50	98.1mg	3/50		kid:rua,ruc.
b	c55196	62.1mg n.s.s.	48/50	51.3mg	47/50	98.1mg	45/50		
c	c55196	90.0mg n.s.s.	1/50	51.3mg	4/50	(98.1mg)	0/50)		liv:hpa,hpc,nnd.
1-NITROPROPANE*** 108-03-2									
301	1837	16.8ug n.s.s.	1/29	9.59ug	1/26			Fiala;carc,8,1947-1949;1987/pers.comm.	
3-NITROSO-2-OXAZOLIDINONE 38347-74-9									
302	1813m	n.s.s. .262mg	0/17	2.14mg	26/26			Mirvish;jnci,78,387-393;1987/pers.comm.	
a	1813m	.315mg 1.22mg	0/17	2.14mg	16/26				
b	1813m	n.s.s. .281mg	2/17	2.14mg	26/26				
303	1813n	.389mg 1.57mg	0/17	2.15mg	15/25				
a	1813n	.571mg 3.09mg	0/17	2.15mg	11/25				
b	1813n	.171mg .750mg	2/17	2.15mg	22/25				
N-NITROSODIETHANOLAMINE*** 1116-54-7									
304	1838	16.0mg 201.mg	3/500	.143mg	2/80	.450mg	1/80	1.43mg	6/80
a	1838	24.3mg 368.mg	0/500	.143mg	0/80	.450mg	1/80	1.43mg	3/80
b	1838	30.8mg n.s.s.	1/500	.143mg	1/80	.450mg	0/80	1.43mg	2/80
c	1838	11.5mg n.s.s.	54/500	.143mg	8/80	.450mg	16/80	1.43mg	11/80
d	1838	15.3mg n.s.s.	23/500	.143mg	8/80	.450mg	5/80	1.43mg	7/80
e	1838	20.7mg n.s.s.	26/500	.143mg	7/80	.450mg	3/80	1.43mg	6/80
f	1838	47.6mg n.s.s.	1/500	.143mg	0/80	.450mg	0/80	1.43mg	1/80
g	1838	2.58mg n.s.s.	362/500	.143mg	61/80	.450mg	60/80	1.43mg	64/80
h	1838	6.85mg n.s.s.	144/500	.143mg	29/80	.450mg	29/80	1.43mg	28/80
N-NITROSODIETHYLAMINE*** (DEN) 55-18-5									
305	1838	.183mg .422mg	3/500	7.14ug	2/80	22.9ug	3/80	71.4ug	36/80
a	1838	.241mg .807mg	26/500	7.14ug	9/80	22.9ug	7/80	71.4ug	25/80
b	1838	.326mg .991mg	0/500	7.14ug	1/80	22.9ug	0/80	71.4ug	21/80
c	1838	.405mg 1.44mg	0/500	7.14ug	0/80	22.9ug	0/80	71.4ug	17/80
d	1838	.408mg 1.45mg	0/500	7.14ug	0/80	22.9ug	2/80	71.4ug	15/80
e	1838	1.13mg 26.3mg	1/500	7.14ug	0/80	22.9ug	0/80	71.4ug	4/80
f	1838	1.32mg n.s.s.	1/500	7.14ug	2/80	22.9ug	1/80	71.4ug	1/80
g	1838	.118mg .370mg	144/500	7.14ug	23/80	22.9ug	27/80	71.4ug	52/80
h	1838	.368mg n.s.s.	362/500	7.14ug	58/80	22.9ug	54/80	71.4ug	53/80
N-NITROSODIMETHYLAMINE*** (DMN) 62-75-9									
306	1864	37.7ug .169mg	0/19	.527mg	16/19				
a	1864	53.3ug .240mg	0/19	.527mg	14/19				Lijinsky;canr,47,3968-3972;1987/pers.comm.
b	1864	89.9ug .494mg	0/19	.527mg	10/19				
c	1864	89.9ug .494mg	0/19	.527mg	10/19				
d	1864	.151mg 1.92mg	0/19	.527mg	6/19				
e	1864	.151mg 1.92mg	0/19	.527mg	6/19				
f	1864	.248mg n.s.s.	0/19	.527mg	3/19				
g	1864	.248mg n.s.s.	0/19	.527mg	3/19				
N-NITROSODITHIAZINE 114282-83-6									
307	1884	1.25mg n.s.s.	0/20	.702mg	2/20				
a	1884	1.71mg n.s.s.	0/20	.702mg	1/20				Lijinsky;fttx,26,3-7;1988
NITROSOETHYLMETHYLAMINE*** (N-nitrosomethylethylamine) 10595-95-6									
308	1864	19.8ug .125mg	0/19	.727mg	15/16				
a	1864	19.8ug .125mg	0/19	.727mg	15/16				Lijinsky;canr,47,3968-3972;1987/pers.comm.
b	1864	56.8ug .302mg	0/19	.727mg	11/16				
c	1864	88.9ug .602mg	0/19	.727mg	8/16				
d	1864	.103mg .821mg	0/19	.727mg	7/16				
N-NITROSOGUVACOLINE 55557-02-3									
309	1866	2.57mg n.s.s.	1/80	1.00mg	4/30				
a	1866	9.37mg n.s.s.	6/80	1.00mg	0/30				Rivenson;canr,48,6912-6917;1988/pers.comm.
N-NITROSOMETHYL-(2-HYDROXYETHYL)AMINE 26921-68-6									
310	1904	.522mg 6.74mg	0/20	1.53mg	6/20				
a	1904	.710mg n.s.s.	0/20	1.53mg	4/20				Koepke;canr,48,1533-1536;1988/pers.comm.
b	1904	1.46mg n.s.s.	0/20	1.53mg	1/20				
c	1904	1.46mg n.s.s.	0/20	1.53mg	1/20				
d	1904	1.45mg n.s.s.	3/20	1.53mg	2/20				

Spe	Strain	Site	Xpo+Xpt	Sex	Route	Hist	Notes	TD50	2Tailpvl
								DR	Au0p
N-NITROSOMETHYL-(3-HYDROXYPROPYL)AMINE								100	10
311	R f	f34	gav	liv	nnd	30m30	e	3.48mg	P<.004 +
a	R f	f34	gav	lun	mix	30m30	e	8.06mg	P<.06 +
b	R f	f34	gav	lun	a/c	30m30	e	24.9mg	P<.1 +
c	R f	f34	gav	lun	a/a	30m30	e	14.4mg	P<.3
312	R m	f34	gav	lun	mix	30m30	e	1.09mg	P<.0005+
a	R m	f34	gav	tes	ict	30m30	e	2.26mg	P<.0005
b	R m	f34	gav	lun	a/c	30m30	e	2.46mg	P<.0005+
c	R m	f34	gav	liv	nnd	30m30	e	4.78mg	P<.06 +
d	R m	f34	gav	lun	a/a	30m30	e	8.46mg	P<.3
N-NITROSOMETHYL-(2-TOSYLOXYETHYL)AMINE								100	10
313	R f	f34	gav	liv	mix	28m28	e	3.47mg	P<.0005+
a	R f	f34	gav	liv	hpc	28m28	e	7.55mg	P<.0005+
b	R f	f34	gav	liv	hes	28m28	e	12.8mg	P<.003 +
c	R f	f34	gav	liv	nnd	28m28	e	22.3mg	P<.3
314	R m	f34	gav	liv	hes	28m28	e	11.8mg	P<.007 +
a	R m	f34	gav	liv	mix	28m28	e	7.79mg	P<.04 +
b	R m	f34	gav	tes	ict	28m28	e	11.1mg	P<.04
c	R m	f34	gav	pit	ade	28m28	e	11.1mg	P<.04
d	R m	f34	gav	liv	hpc	28m28	e	32.2mg	P<.1 +
e	R m	f34	gav	liv	nnd	28m28	e	12.6mg	P<.2
N-NITROSOMORPHOLINE***								100	10
315	R f	f34	wat	liv	mix	10m29	es	.140mg	* P<.0005+
a	R f	f34	wat	amd	phe	10m29	es	.325mg	Z P<.007
b	R f	f34	wat	thy	ccr	10m29	es	.363mg	Z P<.0005
c	R f	f34	wat	liv	hpc	10m29	es	.564mg	Z P<.0005+
d	R f	f34	wat	liv	hes	10m29	es	.666mg	* P<.0005+
e	R f	f34	wat	liv	nnd	10m29	es	1.28mg	Z P<.0005+
f	R f	f34	wat	eso	mix	10m29	es	1.97mg	Z P<.0005
g	R f	f34	wat	eso	sqp	10m29	es	2.53mg	Z P<.0005
h	R f	f34	wat	ton	mix	10m29	es	6.54mg	Z P<.003
i	R f	f34	wat	ton	sqp	10m29	es	50.2mg	* P<.3
j	R f	f34	wat	thy	fca	10m29	es	no dre	P=1.
316	R f	f34	wat	liv	mix	23m29	e	.127mg	* P<.0005+
a	R f	f34	wat	liv	nnd	23m29	e	.239mg	* P<.0005+
b	R f	f34	wat	liv	hpc	23m29	e	.431mg	* P<.0005+
c	R f	f34	wat	thy	fca	23m29	e	.581mg	Z P<.0005
d	R f	f34	wat	liv	hes	23m29	e	.630mg	* P<.0005+
e	R f	f34	wat	amd	phe	23m29	e	1.07mg	* P<.06
f	R f	f34	wat	ton	sqp	23m29	e	3.49mg	* P<.02
N-NITROSOPYRROLIDINE***								100	10
317	R m	sda	wat	liv	mix	37m38	a	2.43mg	* P<.0005+
a	R m	sda	wat	liv	hpc	37m38	a	4.06mg	* P<.0005+
b	R m	sda	wat	liv	hpa	37m38	a	8.13mg	* P<.0005+
c	R m	sda	wat	unt	tum	37m38	a	7.03mg	Z P<.1 +
d	R m	sda	wat	git	mix	37m38	a	14.9mg	* P<.4 +
e	R m	sda	wat	liv	hmm	37m38	a	55.7mg	* P<.3
f	R m	sda	wat	tba	mal	37m38	a	2.03mg	* P<.007 +
g	R m	sda	wat	tba	ben	37m38	a	no dre	P=1.
N-NITROSOTHIALDINE								100	10
318	R f	f34	gav	eso	sqc	43w90	e	.483mg	P<.0005+
a	R f	f34	gav	eso	sqc	43w90	e	1.63mg	P<.003
b	R f	f34	gav	ton	sqc	43w90	e	1.53mg	P<.02 +
c	R f	f34	gav	liv	hpa	43w90	e	2.61mg	P<.02 +
d	R f	f34	gav	liv	cho	43w90	e	3.58mg	P<.04 +
e	R f	f34	gav	ton	sqc	43w90	e	no dre	P=1.

Spe	Strain	Site	Xpo+Xpt	Notes	T050	2Tailpvl
Sex	Route	Hist			DR	Au0p
OCHRATOXIN A***					100ng...1ug.....10.....100.....1mg.....10.....100.....1g.....10	
319	R f	f34 gav	kid MXA	24m24	:	+.485mg * P<.0005c
a	R f	f34 gav	kid rva	24m24	:	.813mg * P<.003 c
b	R f	f34 gav	kid ruc	24m24	:	1.31mg * P<.02 c
c	R f	f34 gav	MXB MXB	24m24	:	.386mg * P<.3
d	R f	f34 gav	mgl fba	24m24	:	.550mg * P<.5 c
e	R f	f34 gav	TBA MXB	24m24	:	no dre P=1.
f	R f	f34 gav	liv MXB	24m24	:	no dre P=1.
320	R m	f34 gav	kid MXA	24m24	:	57.9ug * P<.0005c
a	R m	f34 gav	kid MXA	24m24	:	75.6ug * P<.0005c
b	R m	f34 gav	kid MXA	24m24	:	.241mg * P<.0005c
c	R m	f34 gav	TBA MXB	24m24	:	86.3ug * P<.007
d	R m	f34 gav	liv MXB	24m24	:	2.50mg * P<.3
C.I. ACID ORANGE 3					100ng...1ug.....10.....100.....1mg.....10.....100.....1g.....10	
321	M f	b6c gav	lun a/a	24m24	:	#2.59mg * P<.05 -
a	M f	b6c gav	TBA MXB	24m24	:	no dre P=1.
b	M f	b6c gav	liv MXB	24m24	:	7.55mg * P<.8
c	M f	b6c gav	lun MXB	24m24	:	11.6mg * P<.8
322	M m	b6c gav	liv hpc	24m24	:	#184.mg P<.02 -
a	M m	b6c gav	TBA MXB	24m24	:	372.mg * P<.4
b	M m	b6c gav	liv MXB	24m24	:	no dre P=1.
c	M m	b6c gav	lun MXB	24m24	:	5.86mg * P<.9
323	R f	f34 gav	kid tcc	24m24 s	:	1.71mg / P<.0005c
a	R f	f34 gav	TBA MXB	24m24 s	:	361.mg * P<.05
b	R f	f34 gav	liv MXB	24m24 s	:	5.09mg * P<.5
324	R m	f34 gav	TBA MXB	23m24 ans	:	270.mg / P<.03 -
a	R m	f34 gav	liv MXB	23m24 ans	:	no dre P=1.
C.I. ACID ORANGE 10					100ng...1ug.....10.....100.....1mg.....10.....100.....1g.....10	
325	M f	b6c eat	TBA MXB	24m24	:	no dre P=1. -
a	M f	b6c eat	liv MXB	24m24	:	no dre P=1.
b	M f	b6c eat	lun MXB	24m24	:	no dre P=1.
326	M m	b6c eat	TBA MXB	24m24	:	no dre P=1. -
a	M m	b6c eat	liv MXB	24m24	:	no dre P=1.
b	M m	b6c eat	lun MXB	24m24	:	22.0mg * P<.8
327	R f	f34 eat	TBA MXB	24m24	:	no dre P=1. -
a	R f	f34 eat	liv MXB	24m24	:	no dre P=1.
328	R m	f34 eat	tnv MXA	24m24	:	#915.mg * P<.05 -
a	R m	f34 eat	TBA MXB	24m24	:	2.71mg * P<.9
b	R m	f34 eat	liv MXB	24m24	:	620.mg * P<.06
PENICILLIN VK					100ng...1ug.....10.....100.....1mg.....10.....100.....1g.....10	
329	M f	b6c gav	TBA MXB	24m24	:	no dre P=1. -
a	M f	b6c gav	liv MXB	24m24	:	10.2mg * P<.6
b	M f	b6c gav	lun MXB	24m24	:	16.6mg * P<.7
330	M m	b6c gav	TBA MXB	24m24	:	no dre P=1. -
a	M m	b6c gav	liv MXB	24m24	:	no dre P=1.
b	M m	b6c gav	lun MXB	24m24	:	no dre P=1.
331	R f	f34 gav	thy MXA	24m24 s	:	#1.36mg * P<.03 -
a	R f	f34 gav	thy cca	24m24 s	:	1.62mg * P<.05
b	R f	f34 gav	cli adn	24m24 s	:	3.65mg * P<.02
c	R f	f34 gav	TBA MXB	24m24 s	:	503.mg * P<.08
d	R f	f34 gav	liv MXB	24m24 s	:	no dre P=1.
332	R m	f34 gav	pta MXA	24m24 s	:	#874.mg * P<.02 -
a	R m	f34 gav	pta edn	24m24 s	:	949.mg * P<.03
b	R m	f34 gav	TBA MXB	24m24 s	:	544.mg * P<.08
c	R m	f34 gav	liv MXB	24m24 s	:	12.2mg * P<.5
2,3,4,5,6-PENTACHLOROPHENOL (Dowicide EC-7)***				10.....100.....1mg.....10.....100.....1g.....10	
333	M f	b6c eat	MXB MXB	24m24	:	28.7mg * P<.0005
a	M f	b6c eat	liv MXA	24m24	:	38.3mg * P<.0005c
b	M f	b6c eat	amd MXA	24m24	:	38.8mg Z P<.0005c
c	M f	b6c eat	amd MXA	24m24	:	40.3mg Z P<.0005
d	M f	b6c eat	liv hpa	24m24	:	40.6mg * P<.0005
e	M f	b6c eat	--- MXA	24m24	:	187.mg * P<.0005
f	M f	b6c eat	--- hes	24m24	:	200.mg * P<.0002 c
g	M f	b6c eat	TBA MXB	24m24	:	86.1mg Z P<.2
h	M f	b6c eat	liv MXB	24m24	:	38.3mg * P<.0005
i	M f	b6c eat	lun MXB	24m24	:	12.8mg * P<.1
334	M m	b6c eat	amd MXA	24m24	:	17.4mg * P<.0005
a	M m	b6c eat	amd MXA	24m24	:	17.5mg * P<.0005c
b	M m	b6c eat	MXB MXB	24m24	:	24.9mg Z P<.0005
c	M m	b6c eat	liv hpa	24m24	:	36.2mg * P<.0005
d	M m	b6c eat	liv MXA	24m24	:	38.3mg Z P<.003 c
e	M m	b6c eat	TBA MXB	24m24	:	57.8mg * P<.09
f	M m	b6c eat	liv MXB	24m24	:	38.3mg Z P<.003
g	M m	b6c eat	lun MXB	24m24	:	1.94mg * P<.9

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology		Brkly Code		
OCHRATOXIN A*** 303-47-9												
319	c56586	.235mg	1.40mg	0/50	14.8ug	0/51	49.4ug	2/50	.148mg	8/50	kid:rua,ruc.	
	a	c56586	.331mg	4.82mg	0/50	14.8ug	0/51	49.4ug	1/50	.148mg	5/50	
	b	c56586	.448mg	n.s.s.	0/50	14.8ug	0/51	49.4ug	1/50	.148mg	3/50	
	c	c56586	.103mg	n.s.s.	17/50	14.8ug	23/51	49.4ug	24/50	.148mg	30/50	kid:rua,ruc; mgl:fba. C
	d	c56586	.116mg	n.s.s.	17/50	14.8ug	23/51	49.4ug	22/50	.148mg	28/50	
	e	c56586	.117mg	n.s.s.	39/50	14.8ug	44/51	49.4ug	40/50	.148mg	45/50	
	f	c56586	n.s.s.	n.s.s.	0/50	14.8ug	0/51	49.4ug	0/50	.148mg	0/50	liv:hpa,hpc,nnnd.
320	c56586	40.6ug	87.9ug	1/50	14.8ug	1/51	49.3ug	20/51	.148mg	36/50	kid:rua,ruc,rue,tcb.	
	a	c56586	51.8ug	.115mg	0/50	14.8ug	0/51	49.3ug	16/51	.148mg	30/50	kid:ruc,tcb.
	b	c56586	.127mg	.729mg	1/50	14.8ug	1/51	49.3ug	6/51	.148mg	10/50	kid:rua,rue.
	c	c56586	40.9ug	1.42mg	43/50	14.8ug	38/51	49.3ug	44/51	.148mg	50/50	
	d	c56586	.495mg	n.s.s.	1/50	14.8ug	0/51	49.3ug	0/51	.148mg	2/50	liv:hpa,hpc,nnnd.
C.I. ACID ORANGE 3 6373-74-6												
321	c54911	868.mg	n.s.s.	0/50	177.mg	1/50	354.mg	3/50				
	a	c54911	165.mg	n.s.s.	35/50	177.mg	27/50	(354.mg)	23/50			S
	b	c54911	707.mg	n.s.s.	3/50	177.mg	4/50	354.mg	4/50			liv:hpa,hpc,nnnd.
	c	c54911	1.10gm	n.s.s.	2/50	177.mg	2/50	354.mg	3/50			lun:a/a,a/c.
322	c54911	79.4mg	n.s.s.	7/50	88.4mg	16/50	(177.mg)	10/50				S
	a	c54911	96.8mg	n.s.s.	42/50	88.4mg	36/50	177.mg	39/50			
	b	c54911	224.mg	n.s.s.	21/50	88.4mg	20/50	177.mg	15/50			liv:hpa,hpc,nnnd.
	c	c54911	266.mg	n.s.s.	13/50	88.4mg	9/50	177.mg	10/50			lun:a/a,a/c.
323	c54911	683.mg	6.26gm	0/50	264.mg	0/50	531.mg	6/50				
	a	c54911	149.mg	n.s.s.	45/50	264.mg	44/50	531.mg	19/50			
	b	c54911	945.mg	n.s.s.	1/50	264.mg	3/50	531.mg	0/50			liv:hpa,hpc,nnnd.
324	c54911	113.mg	n.s.s.	42/50	265.mg	33/50	536.mg	13/50				
	a	c54911	1.65gm	n.s.s.	2/50	265.mg	0/50	536.mg	0/50			liv:hpa,hpc,nnnd.
C.I. ACID ORANGE 10 1936-15-8												
325	c53838	709.mg	n.s.s.	25/50	386.mg	27/50	(773.mg)	19/50				
	a	c53838	3.72gm	n.s.s.	3/50	386.mg	3/50	773.mg	3/50			liv:hpa,hpc,nnnd.
	b	c53838	2.15gm	n.s.s.	2/50	386.mg	1/50	(773.mg)	0/50			lun:a/a,a/c.
326	c53838	1.45gm	n.s.s.	30/50	360.mg	19/50	720.mg	25/50				
	a	c53838	2.09gm	n.s.s.	15/50	360.mg	7/50	720.mg	12/50			liv:hpa,hpc,nnnd.
	b	c53838	2.56gm	n.s.s.	1/50	360.mg	3/50	720.mg	2/50			lun:a/a,a/c.
327	c53838	89.9mg	n.s.s.	68/90	49.5mg	33/50	(149.mg)	31/50				
	a	c53838	967.mg	n.s.s.	3/90	49.5mg	2/50	149.mg	1/50			liv:hpa,hpc,nnnd.
328	c53838	346.mg	n.s.s.	0/90	39.6mg	3/50	119.mg	2/50			trv:men,msm. S	
	a	c53838	125.mg	n.s.s.	61/90	39.6mg	31/50	119.mg	34/50			
	b	c53838	223.mg	n.s.s.	5/90	39.6mg	3/50	119.mg	8/50			liv:hpa,hpc,nnnd.
PENICILLIN VK 132-98-9												
329	c56100	754.mg	n.s.s.	38/50	357.mg	26/50	714.mg	30/50				
	a	c56100	1.66gm	n.s.s.	3/50	357.mg	4/50	714.mg	4/50			liv:hpa,hpc,nnnd.
	b	c56100	2.19gm	n.s.s.	4/50	357.mg	1/50	714.mg	5/50			lun:a/a,a/c.
330	c56100	719.mg	n.s.s.	36/50	357.mg	35/50	714.mg	29/50				
	a	c56100	657.mg	n.s.s.	19/50	357.mg	18/50	(714.mg)	8/50			liv:hpa,hpc,nnnd.
	b	c56100	1.81gm	n.s.s.	10/50	357.mg	9/50	714.mg	6/50			lun:a/a,a/c.
331	c56100	576.mg	n.s.s.	6/50	354.mg	7/50	707.mg	11/50			thy:cca,ccr. S	
	a	c56100	638.mg	n.s.s.	6/50	354.mg	6/50	707.mg	10/50			S
	b	c56100	1.25gm	n.s.s.	0/50	354.mg	1/50	707.mg	3/50			S
	c	c56100	197.mg	n.s.s.	44/50	354.mg	45/50	707.mg	38/50			
	d	c56100	n.s.s.	n.s.s.	0/50	354.mg	1/50	707.mg	0/50			liv:hpa,hpc,nnnd.
332	c56100	390.mg	n.s.s.	10/50	354.mg	11/50	707.mg	14/50			pta:adn,can. S	
	a	c56100	406.mg	n.s.s.	10/50	354.mg	11/50	707.mg	13/50			S
	b	c56100	210.mg	n.s.s.	42/50	354.mg	40/50	707.mg	31/50			
	c	c56100	1.99gm	n.s.s.	0/50	354.mg	1/50	707.mg	0/50			liv:hpa,hpc,nnnd.
2,3,4,5,6-PENTACHLOROPHENOL (Dowicide EC-7)*** (Dowicide 7, penta, PCP) 87-86-5												
333	c55389	19.4mg	47.8mg	1/35	12.8mg	6/50	25.6mg	9/50	76.9mg	42/50	---:hes; amd:pbb,phm,pob; liv:hpa,hpc. C	
	a	c55389	24.4mg	71.6mg	1/35	12.8mg	4/50	25.6mg	6/50	76.9mg	31/50	liv:hpa,hpc.
	b	c55389	25.7mg	61.2mg	0/35	12.8mg	2/50	25.6mg	2/50	76.9mg	38/50	amd:pbb,phm,pob.
	c	c55389	26.6mg	64.0mg	0/35	12.8mg	1/50	25.6mg	2/50	76.9mg	38/50	amd:pbb,pob. S
	d	c55389	25.8mg	75.3mg	1/35	12.8mg	3/50	25.6mg	6/50	76.9mg	30/50	S
	e	c55389	93.8mg	646.mg	0/35	12.8mg	1/50	25.6mg	3/50	76.9mg	9/50	---:hem,hes. S
	f	c55389	97.8mg	878.mg	0/35	12.8mg	1/50	25.6mg	3/50	76.9mg	8/50	
	g	c55389	29.6mg	n.s.s.	24/35	12.8mg	29/50	25.6mg	25/50	76.9mg	46/50	
	h	c55389	24.4mg	71.6mg	1/35	12.8mg	4/50	25.6mg	6/50	76.9mg	31/50	liv:hpa,hpc,nnnd.
	i	c55389	221.mg	n.s.s.	2/35	12.8mg	3/50	25.6mg	1/50	76.9mg	3/50	lun:a/a,a/c.
334	c55389	12.4mg	25.6mg	0/35	11.8mg	4/50	23.7mg	21/50	71.0mg	44/50	amd:pbb,pob. S	
	a	c55389	12.2mg	28.2mg	1/35	11.8mg	4/50	23.7mg	21/50	71.0mg	45/50	amd:pbb,phm,pmb,pob.
	b	c55389	13.9mg	72.0mg	7/35	11.8mg	21/50	23.7mg	27/50	71.0mg	45/50	amd:pbb,phm,pmb,pob; liv:hpa,hpc. C
	c	c55389	19.2mg	128.mg	5/35	11.8mg	13/50	23.7mg	17/50	71.0mg	32/50	S
	d	c55389	18.8mg	224.mg	6/35	11.8mg	19/50	23.7mg	21/50	71.0mg	34/50	liv:hpa,hpc.
	e	c55389	21.2mg	n.s.s.	20/35	11.8mg	32/50	23.7mg	33/50	71.0mg	46/50	
	f	c55389	18.8mg	224.mg	6/35	11.8mg	19/50	23.7mg	21/50	71.0mg	34/50	liv:hpa,hpc,nnnd.
	g	c55389	143.mg	n.s.s.	5/35	11.8mg	1/50	23.7mg	2/50	71.0mg	5/50	lun:a/a,a/c.

Spe	Strain	Site	Xpo+Xpt	Notes	T050	2Tailpvl	
Sex	Route	Hist			DR	AuOp	
2,3,4,5,6-PENTACHLOROPHENOL, TECHNICAL GRADE10.....100.....1mg.....10.....100.....1g.....10							
335	M f	b6c	eat	--- hes 24m24	:	+	106.6mg * P<.007 p
	a	M f	b6c	eat MXB MXB 24m24		:	50.4mg * P<.02
	b	M f	b6c	eat liv MXA 24m24			90.1mg * P<.2 p
	c	M f	b6c	eat TBA MXB 24m24			79.3mg / P<.5
	d	M f	b6c	eat liv MXB 24m24			90.1mg * P<.2
	e	M f	b6c	eat lun MXB 24m24			395.6mg * P<.4
336	M m	b6c	eat	MXB MXB 24m24	:	+	10.5mg * P<.002
	a	M m	b6c	eat amd MXA 24m24			12.9mg * P<.0005c
	b	M m	b6c	eat liv hpa 24m24			13.5mg * P<.002
	c	M m	b6c	eat liv MXA 24m24			13.7mg * P<.005 c
	d	M m	b6c	eat TBA MXB 24m24			22.6mg * P<.2
	e	M m	b6c	eat liv MXB 24m24			13.7mg * P<.005
	f	M m	b6c	eat lun MXB 24m24			154.4mg * P<.5
PENTAERYTHRITOL TETRANITRATE WITH 80% D-LACTOSE MONOHYDRATE100.....1mg.....10.....100.....1g.....10							
337	M f	b6c	eat	TBA MXB 24m24			:no dre P=1. -
	a	M f	b6c	eat liv MXB 24m24			no dre P=1.
	b	M f	b6c	eat lun MXB 24m24			82.0gm * P<.5
338	M m	b6c	eat	TBA MXB 24m24			no dre P=1. -
	a	M m	b6c	eat liv MXB 24m24			no dre P=1.
	b	M m	b6c	eat lun MXB 24m24			no dre P=1.
339	R f	f34	eat	zym MXA 24m25	:	±	5.03gm * P<.04 e
	a	R f	f34	eat thy MXA 24m25			5.80gm * P<.03
	b	R f	f34	eat zym ade 24m25			11.1gm * P<.1 e
	c	R f	f34	eat zym car 24m25			9.20gm * P<.2 e
	d	R f	f34	eat TBA MXB 24m25			416.6mg * P<.04
	e	R f	f34	eat liv MXB 24m25			no dre P=1.
340	R m	f34	eat	amd phm 24m25	:		12.2gm * P<.04
	a	R m	f34	eat zym MXA 24m25			13.6gm * P<.2 e
	b	R m	f34	eat zym car 24m25			20.6gm * P<.2 e
	c	R m	f34	eat zym ade 24m25			no dre P=1. e
	d	R m	f34	eat TBA MXB 24m25			24.0gm / P<.1
	e	R m	f34	eat liv MXB 24m25			no dre P=1.
PENTANAL METHYLFORMYLHYDRAZONE 100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10							
341	M f	swa	gav	lun mix 12m33 e	:	+	3.12mg P<.0005+
	a	M f	swa	gav lun ade 12m33 e			5.64mg P<.0005
	b	M f	swa	gav lun adc 12m33 e			9.29mg P<.0005
	c	M f	swa	gav liv bhp 12m33 e			11.8mg P<.003 +
342	M m	swa	gav	lun mix 12m31 e	:	+	3.79mg P<.0005+
	a	M m	swa	gav lun ade 12m31 e			5.52mg P<.002
	b	M m	swa	gav pre mix 12m31 e			16.2mg P<.007 +
	c	M m	swa	gav lun adc 12m31 e			11.0mg P<.02
	d	M m	swa	gav pre sqc 12m31 e			19.8mg P<.02
	e	M m	swa	gav liv hpt 12m31 e			33.1mg P<.3 +
	f	M m	swa	gav pre sqp 12m31 e			106.6mg P<.3
PHENOBARBITAL*** 100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10							
343	M m	chg	eat	liv tum 52w52 r	:	+	5.56mg P<.002 +
344	M m	chh	eat	liv tum 52w52 r			noTD50 P<.09
345	R m	f34	eat	liv mix 52w52 er		.	no dre P=1. -
PHENYL-beta-NAPHTHYLAMINE*** 100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10							
346	M f	b6c	eat	kid MXA 24m24	:		10.8mg * P<.1 e
	a	M f	b6c	eat TBA MXB 24m24			no dre P=1.
	b	M f	b6c	eat liv MXB 24m24			5.63gm * P<.4
	c	M f	b6c	eat lun MXB 24m24			no dre P=1.
347	M m	b6c	eat	sub MXA 24m24	:	±	#2.38gm * P<.04 -
	a	M m	b6c	eat TBA MXB 24m24			4.51gm * P<.8
	b	M m	b6c	eat liv MXB 24m24			1.35gm * P<.2
	c	M m	b6c	eat lun MXB 24m24			no dre P=1.
348	R f	f34	eat	TBA MXB 24m24	:	>	no dre P=1. -
	a	R f	f34	eat liv MXB 24m24			no dre P=1.
349	R m	f34	eat	TBA MXB 24m24	:	>	no dre P=1. -
	a	R m	f34	eat liv MXB 24m24			no dre P=1.
PHENYLBUTAZONE 100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10							
350	R f	don	eat	adr phe 24m26 e	:	±	707.7mg * P<.03 -
	a	R f	don	eat liv nnd 24m26 e			1.14gm * P<.06 -
	b	R f	don	eat kid tum 24m26 e			no dre P=1. -
	c	R f	don	eat tba mix 24m26 e			no dre P=1. -
351	R m	don	eat	kid tum 24m26 e		.	no dre P=1. -
	a	R m	don	eat liv hpc 24m26 e		.	no dre P=1. -
	b	R m	don	eat liv nnd 24m26 e		.	no dre P=1. -
	c	R m	don	eat tba mix 24m26 e		.	no dre P=1. -

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code
2,3,4,5,6-PENTACHLOROPHENOL, TECHNICAL GRADE (penta, PCP) 87-86-5									
335	c55378	49.9mg	1.32gm	0/35	12.8mg	3/50	25.5mg	6/50	
a	c55378	25.0mg	n.s.s.	3/35	12.8mg	11/50	25.5mg	14/50	---:hes; liv:hpa,hpc. P
b	c55378	34.1mg	n.s.s.	3/35	12.8mg	9/50	25.5mg	9/50	liv:hpa,hpc.
c	c55378	17.5mg	n.s.s.	27/35	12.8mg	30/50	25.5mg	37/50	
d	c55378	34.1mg	n.s.s.	3/35	12.8mg	9/50	25.5mg	9/50	liv:hpa,hpc,nnd.
e	c55378	89.9mg	n.s.s.	1/35	12.8mg	1/50	25.5mg	3/50	lun:a/a,a/c.
336	c55378	5.89mg	51.5mg	7/35	11.8mg	29/50	23.5mg	41/50	amd:pbb,pob; liv:hpa,hpc. C
a	c55378	8.42mg	24.2mg	0/35	11.8mg	10/50	23.5mg	23/50	amd:pbb,pob.
b	c55378	7.57mg	66.9mg	5/35	11.8mg	20/50	23.5mg	33/50	S
c	c55378	7.30mg	123.mg	7/35	11.8mg	26/50	23.5mg	37/50	liv:hpa,hpc.
d	c55378	7.67mg	n.s.s.	17/35	11.8mg	38/50	23.5mg	45/50	
e	c55378	7.30mg	123.mg	7/35	11.8mg	26/50	23.5mg	37/50	liv:hpa,hpc,nnd.
f	c55378	36.5mg	n.s.s.	2/35	11.8mg	2/50	23.5mg	6/50	lun:a/a,a/c.
PENTAERYTHRYL TETRANITRATE WITH 80% D-LACTOSE MONOHYDRATE (PETN, NF) 78-11-5									
337	c55743	9.43gm	n.s.s.	37/50	3.19gm	29/50	6.38gm	28/50	
a	c55743	13.6gm	n.s.s.	6/50	3.19gm	2/50	6.38gm	1/50	(liv:hpa,hpc,nnd.
b	c55743	17.0gm	n.s.s.	3/50	3.19gm	3/50	6.38gm	5/50	lun:a/a,a/c.
338	c55743	10.4gm	n.s.s.	36/50	2.94gm	28/50	5.89gm	32/50	
a	c55743	14.5gm	n.s.s.	11/50	2.94gm	11/50	5.89gm	11/50	liv:hpa,hpc,nnd.
b	c55743	9.00gm	n.s.s.	11/50	2.94gm	8/50	5.89gm	7/50	lun:a/a,a/c.
339	c55743	1.66gm	n.s.s.	0/50	304.mg	1/50	616.mg	3/50	zym:ade,car.
a	c55743	1.71gm	n.s.s.	0/50	304.mg	0/50	616.mg	3/50	thy:fcø,fcc. S
b	c55743	2.72gm	n.s.s.	0/50	304.mg	0/50	616.mg	2/50	
c	c55743	2.10gm	n.s.s.	0/50	304.mg	1/50	616.mg	1/50	
d	c55743	182.mg	n.s.s.	46/50	304.mg	47/50	616.mg	50/50	
e	c55743	n.s.s.	n.s.s.	0/50	304.mg	0/50	616.mg	0/50	liv:hpa,hpc,nnd.
340	c55743	4.24gm	n.s.s.	0/50	981.mg	2/50	1.97gm	3/50	S
a	c55743	4.84gm	n.s.s.	0/50	981.mg	3/50	1.97gm	2/50	zym:ade,car.
b	c55743	7.00gm	n.s.s.	0/50	981.mg	2/50	1.97gm	2/50	
c	c55743	n.s.s.	n.s.s.	0/50	981.mg	1/50	1.97gm	0/50	
d	c55743	1.02gm	n.s.s.	47/50	981.mg	43/50	1.97gm	48/50	
e	c55743	11.4gm	n.s.s.	3/50	981.mg	0/50	1.97gm	1/50	liv:hpa,hpc,nnd.
PENTANAL METHYLFORMYLHYDRAZONE 57590-20-2									
341	1859	1.80mg	6.98mg	13/50	2.58mg	36/48			Toth;myco,98,83-89;1987/pers.comm.
a	1859	2.94mg	22.1mg	12/50	2.58mg	28/48			
b	1859	4.88mg	26.7mg	2/50	2.58mg	16/48			
c	1859	5.31mg	52.3mg	0/23	2.58mg	8/32			
342	1859	2.04mg	11.7mg	11/41	2.77mg	30/44			
a	1859	2.84mg	23.2mg	8/41	2.77mg	24/44			
b	1859	6.61mg	193.mg	0/27	2.77mg	6/34			
c	1859	4.82mg	n.s.s.	5/41	2.77mg	15/44			
d	1859	7.52mg	n.s.s.	0/27	2.77mg	5/34			
e	1859	5.38mg	n.s.s.	0/8	2.77mg	1/11			
f	1859	17.2mg	n.s.s.	0/27	2.77mg	1/34			
PHENOBARBITAL*** (phenobarbitone) 50-06-6									
343	1891	2.31mg	38.5mg	42/139	24.0mg	14/21			Mizutani;clet,39,233-237;1988
344	1891	n.s.s.	n.s.s.	42/56	24.0mg	31/31			
345	1834	20.6mg	n.s.s.	0/20	20.0mg	0/20			Leonard;jnci,79,1313-1319;1987/pers.comm.
PHENYL-beta-NAPHTHYLAMINE*** (Agerite powder, N-phenyl-2-naphthylamine) 135-88-6									
346	c02915	2.66gm	n.s.s.	0/50	322.mg	0/50	644.mg	2/50	kid:tla,uac.
a	c02915	830.mg	n.s.s.	42/50	322.mg	23/50	644.mg	33/50	
b	c02915	1.41gm	n.s.s.	4/50	322.mg	3/50	644.mg	7/50	liv:hpa,hpc,nnd.
c	c02915	3.31gm	n.s.s.	5/50	322.mg	1/50	644.mg	3/50	lun:a/a,a/c.
347	c02915	992.mg	n.s.s.	2/50	297.mg	4/50	594.mg	8/50	sub:fbs,nfs,srn. S
a	c02915	437.mg	n.s.s.	34/50	297.mg	30/50	594.mg	32/50	
b	c02915	487.mg	n.s.s.	11/50	297.mg	16/50	594.mg	17/50	liv:hpa,hpc,nnd.
c	c02915	1.36gm	n.s.s.	11/50	297.mg	9/50	594.mg	7/50	lun:a/a,a/c.
348	c02915	175.mg	n.s.s.	46/50	124.mg	38/50	248.mg	33/50	
a	c02915	3.10gm	n.s.s.	2/50	124.mg	0/50	248.mg	0/50	liv:hpa,hpc,nnd.
349	c02915	108.mg	n.s.s.	48/50	99.0mg	40/50	198.mg	42/50	
a	c02915	1.11gm	n.s.s.	2/50	99.0mg	3/50	198.mg	0/50	liv:hpa,hpc,nnd.
PHENYLBUTAZONE 50-33-9									
350	1815	283.mg	n.s.s.	4/96	59.1mg	6/50	118.mg	6/42	Maekawa;jnci,79,577-584;1987/pers.comm.
a	1815	396.mg	n.s.s.	2/96	59.1mg	3/50	118.mg	4/42	
b	1815	427.mg	n.s.s.	0/96	59.1mg	0/50	118.mg	0/42	
c	1815	151.mg	n.s.s.	85/96	59.1mg	43/50	118.mg	32/42	
351	1815	335.mg	n.s.s.	0/93	47.3mg	0/47	95.4mg	0/44	
a	1815	335.mg	n.s.s.	1/93	47.3mg	0/47	95.4mg	0/44	
b	1815	778.mg	n.s.s.	4/93	47.3mg	0/47	95.4mg	2/44	
c	1815	159.mg	n.s.s.	69/93	47.3mg	36/47	95.4mg	27/44	

Spe	Strain	Site	Xpo+Xpt	Notes	T050	2Tailpvl	
Sex	Route	Mist			DR	AuOp	
m-PHENYLENEDIAMINE					100ng...1ug...10...100...1mg...10...100...1g...10		
352	M f	b6c	wat	liv hem 78w84 e	.	916.mg * P<.2 -	
	a	M f	b6c	wat	liv hct 78w84 e	no dre P=1. -	
	b	M f	b6c	wat	liv hnd 78w84 e	no dre P=1. -	
	c	M f	b6c	wat	lun ade 78w84 e	no dre P=1. -	
353	M m	b6c	wat	liv hem 78w84 e	.	2.73gm * P<.9 -	
	a	M m	b6c	wat	liv hct 78w84 e	no dre P=1. -	
	b	M m	b6c	wat	liv hnd 78w84 e	no dre P=1. -	
	c	M m	b6c	wat	lun ade 78w84 e	no dre P=1. -	
PROPYL GALLATE***					100ng...1ug...10...100...1mg...10...100...1g...10		
354	R m	f3d	eat	eso tum 52w52 er	.	no dre P=1. -	
	a	R m	f3d	eat	for tum 52w52 er	no dre P=1. -	
	b	R m	f3d	eat	liv tum 52w52 er	no dre P=1. -	
PROPYLENE***					100ng...1ug...10...100...1mg...10...100...1g...10		
355	M f	swi	inh	lun ade 18m24	.	19.8gm * P<.09 -	
	a	M f	swi	inh	liv hpt 18m24	286.gm * P<.6 -	
	b	M f	swi	inh	lun adc 18m24	1.17kg P<.9 -	
	c	M f	swi	inh	tba mix 18m24	10.1gm * P<.08 -	
	d	M f	swi	inh	tba mal 18m24	20.1gm * P<.3 -	
356	M m	swi	inh	lun ade 18m24	.	no dre P=1. -	
	a	M m	swi	inh	lun adc 18m24	no dre P=1. -	
	b	M m	swi	inh	liv hpt 18m24	no dre P=1. -	
	c	M m	swi	inh	tba mix 18m24	no dre P=1. -	
	d	M m	swi	inh	tba mal 18m24	no dre P=1. -	
1,2-PROPYLENE OXIDE***					100ng...1ug...10...100...1mg...10...100...1g...10		
357	R f	wsr	inh	mgf fba 29m29 e	.	92.6mg * P<.003 +	
	a	R f	wsr	inh	mgf adc 29m29 e	813.mg * P<.2	
	b	R f	wsr	inh	liv cho 29m29	2.46gm * P<.5	
	c	R f	wsr	inh	res car 29m29 e	no dre P=1. -	
	d	R f	wsr	inh	tba tum 29m29 e	25.7mg * P<.0005	
	e	R f	wsr	inh	tba mal 29m29 e	150.mg * P<.0005	
358	R m	wsr	inh	res car 29m29 e	.	896.mg * P<.005 +hist	
	a	R m	wsr	inh	liv nnd 29m29	no dre P=1. -	
	b	R m	wsr	inh	liv clic 29m29	no dre P=1. -	
	c	R m	wsr	inh	tba mal 29m29 e	101.mg * P<.002	
	d	R m	wsr	inh	tba tum 29m29 e	79.3mg Z P<.02	
FD & C RED NO. 3***					100ng...1ug...10...100...1mg...10...100...1g...10		
359	M f	cd1	eat	tba mix 24m24 e	.	no dre P=1. -	
	a	M f	cd1	eat	tba ben 24m24 e	no dre P=1. -	
	b	M f	cd1	eat	tba mal 24m24 e	no dre P=1. -	
360	M m	cd1	eat	lcl 24m24 e	.	3.14gm Z P<.02 -	
	a	M m	cd1	eat	tba mix 24m24 e	17.0gm P<.3	
	b	M m	cd1	eat	tba ben 24m24 e	25.9gm * P<.3 -	
	c	M m	cd1	eat	tba mal 24m24 e	87.6gm * P<.8 -	
RETINOL ACETATE***					100ng...1ug...10...100...1mg...10...100...1g...10		
361	R m	f3d	wat	for neo 52w52	.	no dre P=1. -	
	a	R m	f3d	wat	liv tum 52w52	no dre P=1. -	
RETINOL PALMITATE					100ng...1ug...10...100...1mg...10...100...1g...10		
362	R m	cdr	eat	liv tum 28m28 e	.	no dre P=1. -	
ROTENONE***					100ng...1ug...10...100...1mg...10...100...1g...10		
363	M f	b6c	eat	TBA MXB 24m24	.	no dre P=1. -	
	a	M f	b6c	eat	liv MXB 24m24	no dre P=1. -	
	b	M f	b6c	eat	lun MXB 24m24	15.0gm * P<.1	
364	M m	b6c	eat	TBA MXB 24m24	.	no dre P=1. -	
	a	M m	b6c	eat	liv MXB 24m24	no dre P=1. -	
	b	M m	b6c	eat	lun MXB 24m24	no dre P=1. -	
365	R f	f34	eat	TBA MXB 24m24	.	no dre P=1. -	
	a	R f	f34	eat	liv MXB 24m24	no dre P=1. -	
366	R m	f34	eat	pty adn 24m24	.	35.6mg * P<.3 e	
	a	R m	f34	eat	TBA MXB 24m24	no dre P=1. -	
	b	R m	f34	eat	liv MXB 24m24	no dre P=1. -	
SALBUTAMOL***					100ng...1ug...10...100...1mg...10...100...1g...10		
367	R f	cdr	eat	meo ley 80w80 ekr	.	36.3mg P<.0005+	
STYRENE***					100ng...1ug...10...100...1mg...10...100...1g...10		
368	R f	sda	inh	mam mal 12m24	.	57.1mg * P<.002 +	
	a	R f	sda	inh	mam mix 12m24	23.3mg * P<.02 +	
	b	R f	sda	inh	tba mix 12m24	48.7mg * P<.3	

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code						
PHENYLENEDIAMINE 108-45-2															
2	1888	277.mg	n.s.s.	0/50	37.1mg	1/50	74.3mg	2/59	Amo;fctx,26,893-897;1988						
	1888	175.mg	n.s.s.	3/50	37.1mg	0/50	74.3mg	0/59							
	1888	175.mg	n.s.s.	0/50	37.1mg	0/50	74.3mg	0/59							
	1888	406.mg	n.s.s.	4/50	37.1mg	2/50	74.3mg	2/59							
3	1888	165.mg	n.s.s.	4/50	31.0mg	4/50	61.9mg	5/56							
i	1888	112.mg	n.s.s.	20/50	31.0mg	7/50	61.9mg	3/56							
j	1888	98.2mg	n.s.s.	7/50	31.0mg	4/50	61.9mg	1/56							
;	1888	123.mg	n.s.s.	8/50	31.0mg	3/50	61.9mg	1/56							
ROPYL GALLATE*** 121-79-9															
54	1900	206.mg	n.s.s.	0/10	400.mg	0/10			Hirose;carc,8,1731-1735;1987/pers.comm.						
a	1900	206.mg	n.s.s.	0/10	400.mg	0/10									
b	1900	206.mg	n.s.s.	0/10	400.mg	0/10									
PROPYLENE*** 115-07-1															
555	bt702	6.88gm	n.s.s.	6/100	94.7mg	10/100	474.mg	13/100	2.37gm	15/100	Ciliberti;anya,534,235-245;1988				
a	bt702	30.2gm	n.s.s.	0/100	94.7mg	1/100	474.mg	0/100	2.37gm	1/100					
b	bt702	34.8gm	n.s.s.	1/100	94.7mg	1/100	474.mg	0/100	2.37gm	1/100					
c	bt702	3.79gm	n.s.s.	24/100	94.7mg	34/100	474.mg	31/100	2.37gm	39/100					
d	bt702	5.89gm	n.s.s.	18/100	94.7mg	20/100	474.mg	19/100	2.37gm	25/100					
356	bt702	26.0gm	n.s.s.	10/100	78.9mg	8/100	395.mg	9/100	1.97gm	3/100					
a	bt702	29.9gm	n.s.s.	0/100	78.9mg	0/100	395.mg	1/100	1.97gm	0/100					
b	bt702	44.5gm	n.s.s.	4/100	78.9mg	2/100	395.mg	1/100	1.97gm	0/100					
c	bt702	1.99gm	n.s.s.	26/100	78.9mg	17/100	395.mg	19/100	1.97gm	6/100					
d	bt702	2.63gm	n.s.s.	14/100	78.9mg	11/100	395.mg	10/100	1.97gm	2/100					
1,2-PROPYLENE OXIDE*** (1,2-epoxypropane) 75-56-9															
357	1830	46.7mg	602.mg	32/69	5.33mg	30/71	17.8mg	39/69	53.3mg	47/70	Kuper;fctx,29,159-167;1988				
a	1830	235.mg	n.s.s.	3/69	5.33mg	6/71	17.8mg	5/69	53.3mg	8/70					
b	1830	447.mg	n.s.s.	2/69	5.33mg	1/71	17.8mg	2/69	53.3mg	3/70					
c	1830	77.4mg	n.s.s.	0/69	5.33mg	0/71	17.8mg	0/69	53.3mg	0/70					
d	1830	14.0mg	69.4mg	52/69	5.33mg	49/71	17.8mg	61/69	53.3mg	67/70					
e	1830	81.1mg	510.mg	6/69	5.33mg	15/71	17.8mg	14/69	53.3mg	26/70					
358	1830	310.mg	7.93gm	0/70	3.73mg	0/69	12.4mg	0/71	37.3mg	4/70					
a	1830	604.mg	n.s.s.	0/70	3.73mg	0/69	12.4mg	1/71	37.3mg	0/70					
b	1830	630.mg	n.s.s.	1/70	3.73mg	0/69	12.4mg	2/71	37.3mg	0/70					
c	1830	51.3mg	569.mg	19/70	3.73mg	17/69	12.4mg	22/71	37.3mg	34/70					
d	1830	35.9mg	n.s.s.	49/70	3.73mg	28/69	12.4mg	34/71	37.3mg	53/70					
FD & C RED NO. 3*** (erythrosine) 16423-68-0															
359	1811	11.7gm	n.s.s.	67/120	3.90gm	25/60					Borzelleca;fctx,25,735-737;1987				
a	1811	14.4gm	n.s.s.	40/120	390.mg	13/60	1.30gm	9/60	3.90gm	16/60					
b	1811	16.0gm	n.s.s.	35/120	390.mg	14/60	1.30gm	17/60	3.90gm	12/60					
360	1811	1.11gm	n.s.s.	1/120	360.mg	5/60	1.20gm	2/60	3.60gm	2/60					
a	1811	4.50gm	n.s.s.	46/120	3.60gm	28/60									
b	1811	7.34gm	n.s.s.	29/120	360.mg	5/60	1.20gm	12/60	3.60gm	17/60					
c	1811	9.15gm	n.s.s.	17/120	360.mg	18/60	1.20gm	12/60	3.60gm	12/60					
RETINOL ACETATE*** (vitamin A, acetate) 127-47-9															
361	1883	64.4mg	n.s.s.	0/10	125.mg	0/10					Hasegawa;gann,79,320-328;1988/pers.comm.				
a	1883	64.4mg	n.s.s.	0/10	125.mg	0/10									
RETINOL PALMITATE (vitamin A, palmitate) 79-81-2															
362	1833	16.8mg	n.s.s.	0/38	1.60mg	0/39					Arnold;fctx,23,779-793;1985				
ROTENONE*** (tubatoxin) 83-79-4															
363	c55210	345.mg	n.s.s.	26/50	77.3mg	16/50	155.mg	22/50							
a	c55210	658.mg	n.s.s.	4/50	77.3mg	3/50	155.mg	4/50			liv:hpa,hpc,nnd.				
b	c55210	607.mg	n.s.s.	4/50	77.3mg	2/50	155.mg	5/50			lun:a/a,a/c.				
364	c55210	88.4mg	n.s.s.	25/50	71.3mg	26/50	143.mg	18/50							
a	c55210	139.mg	n.s.s.	12/50	71.3mg	12/50	143.mg	1/50			liv:hpa,hpc,nnd.				
b	c55210	346.mg	n.s.s.	6/50	71.3mg	12/50	143.mg	8/50			lun:a/a,a/c.				
365	c55210	2.86mg	n.s.s.	45/50	1.88mg	43/50	3.71mg	45/50							
a	c55210	36.7mg	n.s.s.	1/50	1.88mg	0/50	3.71mg	0/50			liv:hpa,hpc,nnd.				
366	c55210	9.37mg	n.s.s.	1/50	1.51mg	0/50	2.97mg	4/50							
a	c55210	2.98mg	n.s.s.	48/50	1.51mg	36/50	2.97mg	47/50							
b	c55210	12.0mg	n.s.s.	3/50	1.51mg	1/50	2.97mg	3/50			liv:hpa,hpc,nnd.				
SALBUTAMOL*** 18559-94-9															
367	1734m	17.7mg	93.4mg	0/105	20.0mg	10/50					Gopinath;enhp,73,107-113;1987/Jack 1983/pers.comm.				
STYRENE*** 100-42-5															
368	bt101	28.9mg	316.mg	6/60	2.66mg	6/30	5.31mg	4/30	10.6mg	9/30	21.2mg	12/30	31.9mg	9/30	Conti;anya,534,203-234;1988
a	bt101	10.5mg	8.37gm	34/60	2.66mg	24/30	5.31mg	21/30	10.6mg	23/30	21.2mg	24/30	31.9mg	25/30	
b	bt101	13.0mg	n.s.s.	43/60	2.66mg	24/30	5.31mg	25/30	10.6mg	26/30	21.2mg	24/30	31.9mg	25/30	

Spe	Strain	Site	Xpo+Xpt	TD50	2Tailpvl
Sex	Route	Hist	Notes	DR	AuOp
c	R f sda inh tba mal	12m24		205.mg	* P<.5
369	R f sda gav tba mix	12m24	.	12.0mg	P<.03
a	R f sda gav tba mal	12m24		no dre	P=1.
370	R m sda inh tba mix	12m24	.	107.mg	* P<.4
a	R m sda inh tba mal	12m24		no dre	P=1.
371	R m sda gav tba mix	12m24	.	1.22gm	* P<.7
a	R m sda gav tba mal	12m24		1.09gm	* P<.5
STYRENE OXIDE***				100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	
372	R f sda gav for mix	12m36 ej	.	96.5mg	* P<.0005+
a	R f sda gav for sqc	12m36 ej	.	102.mg	* P<.0005+
b	R f sda gav for sqn	12m36 ej	.	129.mg	* P<.0005+
c	R f sda gav for sqi	12m36 ej	.	301.mg	* P<.0005+
d	R f sda gav for ben	12m36 ej	.	503.mg	* P<.009 +
e	R f sda gav tba mix	12m36 j	.	164.mg	* P<.009
f	R f sda gav tba mal	12m36 j	.	166.mg	* P<.002
373	R m sda gav for sqc	12m36 ej	.	63.0mg	P<.0005+
a	R m sda gav for mix	12m36 ej	.	99.6mg	* P<.0005+
b	R m sda gav for sqn	12m36 ej	.	140.mg	* P<.0005+
c	R m sda gav for sqi	12m36 ej	.	267.mg	* P<.004 +
d	R m sda gav for ben	12m36 ej	.	354.mg	* P<.003 +
e	R m sda gav tba mal	12m36 j	.	189.mg	* P<.004
f	R m sda gav tba mix	12m36 j	.	191.mg	* P<.02
TETRACYCLINE.HCl				100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	
374	M f b6c eat TBA MXB	24m24	.	no dre	P=1. -
a	M f b6c eat liv MXB	24m24	.	no dre	P=1.
b	M f b6c eat lun MXB	24m24	.	37.2gm	* P<.4
375	M m b6c eat TBA MXB	24m24	.	no dre	P=1. -
a	M m b6c eat liv MXB	24m24	.	no dre	P=1.
b	M m b6c eat lun MXB	24m24	.	no dre	P=1.
376	R f f34 eat TBA MXB	24m24	.	no dre	P=1. -
a	R f f34 eat liv MXB	24m24	.	no dre	P=1.
377	R m f34 eat TBA MXB	24m24	.	no dre	P=1. -
a	R m f34 eat liv MXB	24m24	.	6.09gm	* P<.06
3,4,5,6-TETRAHYDROQUINOLINE				100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	
378	R m f34 ipj liv tum	52w52 e	.	no dre	P=1.
a	R m f34 ipj tba tum	52w52 e	.	15.7mg	P<.6
THIDACETAMIDE***				100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	
379	R m don eat liv mix	40w80 er	.	11.5mg	P<.02 +
a	R m don eat liv thc	40w80 er	.	21.8mg	P<.08
b	R m don eat liv pac	40w80 er	.	27.6mg	P<.2
DL-alpha-TOCOPHEROL				100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	
380	R m f3d eat eso tum	52w52 er	.	no dre	P=1. -
a	R m f3d eat for tum	52w52 er	.	no dre	P=1. -
b	R m f3d eat liv tum	52w52 er	.	no dre	P=1. -
TRIBROMOMETHANE				100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	
381	M f b6c gav MXA MXA	24m25 s	.	#1.11gm	* P<.04 -
a	M f b6c gav TBA MXB	24m25 s	.	no dre	P=1.
b	M f b6c gav liv MXB	24m25 s	.	570.mg	* P<.3
c	M f b6c gav lun MXB	24m25 s	.	no dre	P=1.
382	M m b6c gav sub MXA	24m25	.	#81.9mg	P<.02 -
a	M m b6c gav TBA MXB	24m25	.	41.0mg	P<.2
b	M m b6c gav liv MXB	24m25	.	53.6mg	P<.07
c	M m b6c gav lun MXB	24m25	.	2.45gm	P<.1.
383	R f f34 gav lgi MXA	24m25	.	469.mg	* P<.002 c
a	R f f34 gav lgi pla	24m25	.	632.mg	* P<.004
b	R f f34 gav TBA MXB	24m25	.	no dre	P=1.
c	R f f34 gav liv MXB	24m25	.	676.mg	* P<.06
384	R m f34 gav tes MXA	24m24 s	.	75.0mg	* P<.03
a	R m f34 gav thy fcc	24m24 s	.	656.mg	* P<.03
b	R m f34 gav lgi MXA	24m24 s	.	+hist 1.05gm	* P<.02 p
c	R m f34 gav TBA MXB	24m24 s	.	513.mg	* P<.7
d	R m f34 gav liv MXB	24m24 s	.	no dre	P=1.
1,1,2-TRICHLORO-1,2,2-TRIFLUOROETHANE, TECHNICAL GRADE			100.....1mg.....10.....100.....1g.....10	
385	R f cdr inh pni isa	24m24 e	.	160.gm	* P<.005 -
386	R m cdr inh pni isa	24m24 e	.	9.14kg	P<.1. -
1,1,1-TRICHLOROETHANE, TECHNICAL GRADE***				..1ug.....10.....100.....1mg.....10.....100.....1g.....10	
387	M f b6c inh liv mix	24m24 e	.	no dre	P=1. -
a	M f b6c inh liv hpc	24m24 e	.	no dre	P=1. -
b	M f b6c inh liv hpa	24m24 e	.	no dre	P=1. -

	RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc							Citation or Pathology	Brkly Code
c	bt101	41.7mg	n.s.s.	16/60	2.66mg	9/30	5.31mg	9/30	10.6mg	13/30	21.2mg	10/30	31.9mg	10/30		
369	bt102	4.97mg	n.s.s.	25/40	16.1mg	34/40	(80.4mg)	19/40)								
a	bt102	176. mg	n.s.s.	9/40	16.1mg	15/40	80.4mg	9/40								
370	bt101	27.7mg	n.s.s.	17/60	1.86mg	12/30	3.72mg	6/30	7.44mg	11/30	14.9mg	10/30	22.3mg	12/30		
a	bt101	75.8mg	n.s.s.	10/60	1.86mg	5/30	3.72mg	5/30	7.44mg	8/30	14.9mg	3/30	22.3mg	4/30		
371	bt102	143. mg	n.s.s.	9/40	16.1mg	8/40	80.4mg	10/40								
a	bt102	206. mg	n.s.s.	2/40	16.1mg	3/40	80.4mg	4/40								
STYRENE OXIDE*** 96-09-3																
372	bt105	60.6mg	167. mg	0/40	10.7mg	7/37	53.6mg	21/38							Conti;anya,534,203-234;1988/Maltoni 1981	
a	bt105	63.7mg	180. mg	0/40	10.7mg	7/37	53.6mg	20/38								
b	bt105	78.0mg	264. mg	0/40	10.7mg	7/37	53.6mg	16/38								
c	bt105	151. mg	755. mg	0/40	10.7mg	1/37	53.6mg	10/38								
d	bt105	217. mg	19.7gm	0/40	10.7mg	2/37	53.6mg	5/38								
e	bt105	74.1mg	7.47gm	10/40	10.7mg	16/40	53.6mg	22/40								
f	bt105	83.2mg	771. mg	7/40	10.7mg	9/40	53.6mg	20/40								
373	bt105	29.6mg	184. mg	0/39	10.7mg	9/39	(53.6mg)	16/39)								
a	bt105	63.2mg	194. mg	0/39	10.7mg	10/39	53.6mg	19/39								
b	bt105	84.3mg	284. mg	0/39	10.7mg	6/39	53.6mg	16/39								
c	bt105	141. mg	2.30gm	0/39	10.7mg	5/39	53.6mg	8/39								
d	bt105	172. mg	2.23gm	0/39	10.7mg	3/39	53.6mg	7/39								
e	bt105	89.2mg	1.75gm	6/40	10.7mg	11/40	53.6mg	18/40								
f	bt105	84.0mg	n.s.s.	9/40	10.7mg	14/40	53.6mg	20/40								
TETRACYCLINE.HCl 64-75-5																
374	c55561	5.96gm	n.s.s.	35/50	1.61gm	19/50	3.22gm	26/50								
a	c55561	36.7gm	n.s.s.	10/50	1.61gm	0/50	3.22gm	0/50							liv:hpa,hpc,nnd.	
b	c55561	8.64gm	n.s.s.	4/50	1.61gm	1/50	3.22gm	7/50							lun:a/a,a/c.	
375	c55561	3.44gm	n.s.s.	31/50	1.49gm	23/50	(2.97gm)	21/50)								
a	c55561	8.76gm	n.s.s.	12/50	1.49gm	12/50	2.97gm	10/50							liv:hpa,hpc,nnd.	
b	c55561	12.9gm	n.s.s.	6/50	1.49gm	6/50	2.97gm	4/50							lun:a/a,a/c.	
376	c55561	712. mg	n.s.s.	46/50	619. mg	44/50	(1.24gm)	41/50)								
a	c55561	15.0gm	n.s.s.	1/50	619. mg	0/50	1.24gm	0/50							liv:hpa,hpc,nnd.	
377	c55561	722. mg	n.s.s.	46/50	495. mg	49/50	990. mg	45/50								
a	c55561	2.28gm	n.s.s.	0/50	495. mg	2/50	990. mg	3/50							liv:hpa,hpc,nnd.	
3,4,5,6-TETRAHYDROURIDINE 18771-50-1																
378	1906	6.07mg	n.s.s.	0/49	11.8mg	0/10									Carr;bjca,57,395-402;1988	
a	1906	2.06mg	n.s.s.	10/49	11.8mg	3/10										
THIOALETAMIDE*** 62-55-5																
379	1836	5.38mg	n.s.s.	0/15	7.00mg	9/41									Kuroda;jnci,79,1047-1051;1987	
a	1836	8.28mg	n.s.s.	0/15	7.00mg	5/41										
b	1836	9.55mg	n.s.s.	0/15	7.00mg	4/41										
DL-alpha-TOCOPHEROL (vitamin E) 10191-41-0																
380	1900	206. mg	n.s.s.	0/10	400. mg	0/10									Hirose;carc,8,1731-1735;1987/pers.comm.	
a	1900	206. mg	n.s.s.	0/10	400. mg	0/10										
b	1900	206. mg	n.s.s.	0/10	400. mg	0/10										
TRIBROMOMETHANE (bromoform) 75-25-2																
381	c55130	311. mg	n.s.s.	0/50	69.4mg	0/50	140. mg	3/50							(iv:hes; spl:hes. S	
a	c55130	109. mg	n.s.s.	24/50	69.4mg	18/50	140. mg	18/50								
b	c55130	152. mg	n.s.s.	4/50	69.4mg	6/50	140. mg	6/50							liv:hpa,hpc,nnd.	
c	c55130	349. mg	n.s.s.	3/50	69.4mg	1/50	140. mg	2/50							lun:a/a,a/c.	
382	c55130	28.0mg	17.5gm	2/50	34.9mg	8/50	(69.7mg)	4/50)							sub: fbs, ser. S	
a	c55130	13.8mg	n.s.s.	34/50	34.9mg	33/50	(69.7mg)	27/50)								
b	c55130	18.1mg	n.s.s.	16/50	34.9mg	19/50	(69.7mg)	14/50)							liv:hpa,hpc,nnd.	
c	c55130	44.0mg	n.s.s.	11/50	34.9mg	7/50	(69.7mg)	2/50)							lun:a/a,a/c.	
383	c55130	219. mg	1.55gm	0/50	69.4mg	1/50	139. mg	8/50							lgi:adc,pla. S	
a	c55130	270. mg	3.60gm	0/50	69.4mg	1/50	139. mg	6/50								
b	c55130	104. mg	n.s.s.	47/50	69.4mg	37/50	139. mg	38/50								
c	c55130	276. mg	n.s.s.	0/50	69.4mg	4/50	139. mg	2/50							liv:hpa,hpc,nnd.	
384	c55130	33.3mg	n.s.s.	46/50	69.7mg	45/50	140. mg	37/50							tes:iab,ica. S	
a	c55130	237. mg	n.s.s.	0/50	69.7mg	3/50	140. mg	2/50								
b	c55130	298. mg	n.s.s.	0/50	69.7mg	0/50	140. mg	3/50							lgi:adc,pla. S	
c	c55130	71.8mg	n.s.s.	45/50	69.7mg	37/50	140. mg	25/50								
d	c55130	541. mg	n.s.s.	5/50	69.7mg	2/50	140. mg	1/50							liv:hpa,hpc,nnd.	
1,1,2-TRICHLORO-1,2,2-TRIFLUOROETHANE, TECHNICAL GRADE (fluorocarbon 113) 76-13-1																
385	1876	60.9gm	1.25kg	0/85	1.15gm	0/36	5.74gm	0/30	11.5gm	5/86					Trochimowicz;faat,11,68-75;1988	
386	1876	95.1gm	n.s.s.	2/88	803. mg	1/64	4.02gm	0/58	8.03gm	2/87						
1,1,1-TRICHLOROETHANE, TECHNICAL GRADE*** (methyl chloroform) 71-55-6																
387	1892	11.4gm	n.s.s.	13/50	257. mg	10/50	858. mg	10/50	2.57gm	7/50					Quast;faat,11,611-625;1988	
a	1892	13.2gm	n.s.s.	4/50	257. mg	1/50	858. mg	5/50	2.57gm	2/50						
b	1892	14.2gm	n.s.s.	10/50	257. mg	9/50	858. mg	5/50	2.57gm	5/50						

Spe	Strain	Site	Xpo+Xpt				TD50	2Tailpvl
Sex	Route	Hist	Notes				DR	AuOp
388	M m b6c	inh liv hpc	24m24 e				.> 66.3gm	* P<.9 -
a	M m b6c	inh liv hpa	24m24 e				no dre	P=1. -
b	M m b6c	inh liv mix	24m24 e				no dre	P=1. -
389	R f f34	inh liv hpc	24m24 e				.> no dre	P=1. -
a	R f f34	inh liv nnd	24m24 e				no dre	P=1. -
390	R m f34	inh liv hpc	24m24 e				. ± 2.07gm	Z P<.03 -
a	R m f34	inh liv nnd	24m24 e				5.12gm	* P<.09 -

TRICHLOROETHYLENE (WITHOUT EPICHLOROHYDRIN)*						10.....100.....1mg.....10.....100.....1g.....10		
391	M f b6c	gav liv MXA	24m24				: + :	411.mg	P<.0005c
a	M f b6c	gav liv hpa	24m24					579.mg	P<.0005c
b	M f b6c	gav liv hpc	24m24					673.mg	P<.0005c
c	M f b6c	gav lun a/a	24m24					2.78gm	P<.009
d	M f b6c	gav MXA MXA	24m24					1.35gm	P<.03
e	M f b6c	gav MXA MXA	24m24					1.47gm	P<.04
f	M f b6c	gav mul mlp	24m24					4.88gm	P<.04
g	M f b6c	gav TBA MXB	24m24					359.mg	P<.0005
h	M f b6c	gav liv MXB	24m24					411.mg	P<.0005
i	M f b6c	gav lun MXB	24m24					3.85gm	P<.1
392	M m b6c	gav liv MXA	24m24				: + :	239.mg	P<.0005
a	M m b6c	gav liv hpc	24m24					294.mg	P<.0005c
b	M m b6c	gav liv hpa	24m24					855.mg	P<.006
c	M m b6c	gav hag MXA	24m24					3.83gm	P<.02
d	M m b6c	gav TBA MXB	24m24					332.mg	P<.002
e	M m b6c	gav liv MXB	24m24					239.mg	P<.0005
f	M m b6c	gav lun MXB	24m24					4.25gm	P<.5
393	R f f34	gav TBA MXB	24m24				:>	5.71gm	* P<.9 -
a	R f f34	gav liv MXB	24m24					9.98gm	* P<.2
394	R m f34	gav kid MXA	24m24 s				: +	#2.78gm	* P<.009
a	R m f34	gav per MXA	24m24 s					1.49gm	P<.04
b	R m f34	gav per msm	24m24 s					1.49gm	P<.04
c	R m f34	gav kid uac	24m24 s					3.92gm	* P<.02
d	R m f34	gav TBA MXB	24m24 s					2.24gm	* P<.6
e	R m f34	gav liv MXB	24m24 s					12.2gm	* P<.2
395	R f aci	gav TBA MXB	24m24 s				:>	61.7gm	* P<.1
a	R f aci	gav liv MXB	24m24 s					no dre	P=1.
396	R m aci	gav TBA MXB	24m24 s				:>	820.mg	* P<.4
a	R m aci	gav liv MXB	24m24 s					9.40gm	* P<.5
397	R f aug	gav TBA MXB	24m24				:>	no dre	P=1.
a	R f aug	gav liv MXB	24m24					no dre	P=1.
398	R m aug	gav sub MXA	24m24				: ±	#3.73gm	* P<.03
a	R m aug	gav TBA MXB	24m24					no dre	P=1.
b	R m aug	gav liv MXB	24m24					6.44gm	* P<.2
399	R f mar	gav TBA MXB	24m24 s				:>	709.mg	* P<.3
a	R f mar	gav liv MXB	24m24 s					no dre	P=1.
400	R m mar	gav tes MXA	24m24 s				: + :	#153.mg	* P<.0005
a	R m mar	gav TBA MXB	24m24 s					199.mg	* P<.002
b	R m mar	gav liv MXB	24m24 s					no dre	P=1.
401	R f osm	gav adr coa	24m24 s				: ±	#556.mg	* P<.04
a	R f osm	gav TBA MXB	24m24 s					372.mg	* P<.07
b	R f osm	gav liv MXB	24m24 s					3.50gm	* P<.05
402	R m osm	gav kid tla	24m24				: + :	#628.mg	* P<.003
a	R m osm	gav kid MXA	24m24					628.mg	* P<.003
b	R m osm	gav TBA MXB	24m24					1.49gm	* P<.6
c	R m osm	gav liv MXB	24m24					8.95gm	* P<.5

TRICHLOROFUOROMETHANE***							100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10		
403	M f swi	inh mam car	18m24					31.6gm	* P<.01 -
a	M f swi	inh --- leu	18m24					23.7gm	* P<.09 -
b	M f swi	inh lun ade	18m24					34.9gm	* P<.06 -
c	M f swi	inh tba mix	18m24					11.1gm	* P<.02 -
d	M f swi	inh tba mal	18m24					14.6gm	* P<.02 -
404	M m swi	inh lun ade	18m24					no dre	P=1. -
a	M m swi	inh tba mal	18m24					7.54gm	* P<.2 -
b	M m swi	inh tba mix	18m24					13.4gm	* P<.6 -
405	M m swi	inh lun ade	18m24					no dre	P=1. -
a	M m swi	inh tba mix	18m24					no dre	P=1. -
b	M m swi	inh tba mal	18m24					no dre	P=1. -
406	R f sda	inh liv ang	24m24					no dre	P=1. -
a	R f sda	inh tba mix	24m24					no dre	P=1. -
b	R f sda	inh tba mal	24m24					no dre	P=1. -
407	R m sda	inh liv ang	24m24				:>	no dre	P=1. -
a	R m sda	inh tba mix	24m24					631.mg	* P<.06 -
b	R m sda	inh tba mal	24m24					no dre	P=1. -

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology		Brkly Code	
388	1892	4.67gm	n.s.s.	12/50	214.mg	10/50	715.mg	12/50	2.14gm	12/50	
a	1892	5.83gm	n.s.s.	26/50	214.mg	13/50	715.mg	19/50	2.14gm	16/50	
b	1892	3.43gm	n.s.s.	29/50	214.mg	22/50	715.mg	28/50	2.14gm	24/50	
389	1892	451.mg	n.s.s.	1/50	61.3mg	0/50	204.mg	0/50	613.mg	0/50	
a	1892	7.94gm	n.s.s.	1/50	61.3mg	1/50	204.mg	0/50	613.mg	0/50	
390	1892	627.mg	n.s.s.	0/50	42.9mg	0/50	143.mg	3/50	(429.mg)	0/50	
a	1892	1.57gm	n.s.s.	1/50	42.9mg	1/50	143.mg	1/50	429.mg	4/50	

TRICHLOROETHYLENE (WITHOUT EPICHLOROHYDRIN)* (TCE. c04547 is NTP TR# 243; 04546 (b,d,e & f) are NTP TR# 273) 79-01-6

391	c04547	215.mg	1.10gm	6/50	704.mg	22/50					liv:hpa,hpc.
a	c04547	283.mg	1.89gm	4/50	704.mg	16/50					
b	c04547	314.mg	2.22gm	2/50	704.mg	13/50					
c	c04547	877.mg	81.4gm	0/50	704.mg	4/50					S
d	c04547	538.mg	n.s.s.	7/50	704.mg	14/50			liv:mlh; mul:mlh,mlm,mlp,mlu,mno,myo; spl:mno.		S
e	c04547	558.mg	n.s.s.	7/50	704.mg	13/50			liv:mlh; mul:mlh,mlm,mlp,mlu,mno; spl:mno.		S
f	c04547	1.48gm	n.s.s.	0/50	704.mg	3/50					S
g	c04547	187.mg	1.19gm	21/50	704.mg	38/50					
h	c04547	215.mg	1.10gm	6/50	704.mg	22/50					liv:hpa,hpc,nnnd.
i	c04547	1.04gm	n.s.s.	1/50	704.mg	4/50					lun:a/a,a/c.
392	c04547	134.mg	539.mg	14/50	701.mg	39/50					liv:hpa,hpc.
a	c04547	163.mg	672.mg	8/50	701.mg	31/50					S
b	c04547	365.mg	11.6gm	7/50	701.mg	14/50					S
c	c04547	1.29gm	n.s.s.	0/50	701.mg	4/50					hag:adn,ana,ppa.
d	c04547	165.mg	1.55gm	33/50	701.mg	45/50					S
e	c04547	134.mg	539.mg	14/50	701.mg	39/50					liv:hpa,hpc,nnnd.
f	c04547	744.mg	n.s.s.	7/50	701.mg	6/50					lun:a/a,a/c.
393	c04547	486.mg	n.s.s.	38/50	354.mg	31/50	714.mg	30/50			
a	c04547	2.46gm	n.s.s.	0/50	354.mg	1/50	714.mg	1/50			liv:hpa,hpc,nnnd.
394	c04547	1.03gm	116.gm	0/50	357.mg	2/50	714.mg	3/50			kid:tla,uac.
a	c04547	497.mg	n.s.s.	1/50	357.mg	5/50	(714.mg)	1/50			per:men,msm.
b	c04547	497.mg	n.s.s.	1/50	357.mg	5/50	(714.mg)	0/50			S
c	c04547	1.19gm	n.s.s.	0/50	357.mg	0/50	714.mg	3/50			S
d	c04547	392.mg	n.s.s.	33/50	357.mg	26/50	714.mg	18/50			
e	c04547	1.99gm	n.s.s.	0/50	357.mg	0/50	714.mg	1/50			liv:hpa,hpc,nnnd.
395	d04546	461.mg	n.s.s.	33/50	349.mg	21/50	707.mg	18/50			
a	d04546	4.26gm	n.s.s.	2/50	349.mg	0/50	707.mg	0/50			liv:hpa,hpc,nnnd.
396	d04546	198.mg	n.s.s.	44/50	354.mg	27/50	707.mg	17/50			
a	d04546	1.47gm	n.s.s.	1/50	354.mg	1/50	707.mg	1/50			liv:hpa,hpc,nnnd.
397	e04546	660.mg	n.s.s.	43/50	354.mg	35/50	707.mg	29/50			
a	e04546	5.95gm	n.s.s.	2/50	354.mg	0/50	707.mg	0/50			liv:hpa,hpc,nnnd.
398	e04546	1.24gm	n.s.s.	0/50	354.mg	1/50	707.mg	3/50			sub:spm,srcn.
a	e04546	347.mg	n.s.s.	45/50	354.mg	32/50	707.mg	27/50			
b	e04546	1.55gm	n.s.s.	0/50	354.mg	1/50	707.mg	1/50			liv:hpa,hpc,nnnd.
399	b04546	196.mg	n.s.s.	47/50	354.mg	32/50	707.mg	22/50			
a	b04546	n.s.s.	n.s.s.	0/50	354.mg	0/50	707.mg	0/50			liv:hpa,hpc,nnnd.
400	b04546	90.6mg	316.mg	17/50	354.mg	21/50	707.mg	32/50			tes:ict,itm.
a	b04546	101.mg	906.mg	38/50	354.mg	23/50	707.mg	32/50			
b	b04546	n.s.s.	n.s.s.	0/50	354.mg	0/50	707.mg	0/50			liv:hpa,hpc,nnnd.
401	f04546	217.mg	n.s.s.	16/50	354.mg	13/50	711.mg	19/50			S
a	f04546	143.mg	n.s.s.	40/50	354.mg	36/50	711.mg	37/50			
b	f04546	839.mg	n.s.s.	0/50	354.mg	0/50	711.mg	2/50			liv:hpa,hpc,nnnd.
402	f04546	253.mg	3.23gm	0/50	354.mg	6/50	(707.mg)	1/50			S
a	f04546	253.mg	3.23gm	0/50	354.mg	6/50	(707.mg)	2/50			kid:tla,uac.
b	f04546	257.mg	n.s.s.	37/50	354.mg	35/50	707.mg	29/50			
c	f04546	1.46gm	n.s.s.	1/50	354.mg	0/50	707.mg	2/50			liv:hpa,hpc,nnnd.

TRICHLOROFUOROMETHANE*** (fluorocarbon 11) 75-69-4

403	bt604m	12.6gm	4.71kg	1/90	883.mg	2/60	4.42gm	6/60	Maltoni;anya,534,261-282;1988	
a	bt604m	8.28gm	n.s.s.	8/90	883.mg	10/60	4.42gm	12/60		
b	bt604m	12.1gm	n.s.s.	2/90	883.mg	4/60	4.42gm	6/60		
c	bt604m	4.82gm	n.s.s.	15/90	883.mg	20/60	4.42gm	22/60		
d	bt604m	6.27gm	n.s.s.	9/90	883.mg	12/60	4.42gm	16/60		
404	bt604m	9.10gm	n.s.s.	3/90	736.mg	0/60				
a	bt604m	2.11gm	n.s.s.	5/90	736.mg	7/60				
b	bt604m	2.23gm	n.s.s.	9/90	736.mg	8/60				
405	bt604n	32.9gm	n.s.s.	4/90	3.68gm	1/60				
a	bt604n	30.7gm	n.s.s.	9/90	3.68gm	2/60				
b	bt604n	35.1gm	n.s.s.	6/90	3.68gm	1/60				
406	bt603	20.8gm	n.s.s.	1/150	280.mg	2/90	1.40gm	0/90		
a	bt603	1.77gm	n.s.s.	124/150	280.mg	65/90	1.40gm	70/90		
b	bt603	9.88gm	n.s.s.	43/150	280.mg	23/90	1.40gm	15/90		
407	bt603	3.03gm	n.s.s.	1/150	196.mg	0/90	981.mg	0/90		
a	bt603	252.mg	n.s.s.	51/150	196.mg	42/90	(981.mg)	25/90		
b	bt603	6.05gm	n.s.s.	25/150	196.mg	16/90	981.mg	11/90		

Spe	Strain	Site	Xpo+Xpt							TD50	ZTailpvl
Sex	Route	Hist	Notes							DR	AuOp
VINYL CHLORIDE***			100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10								
408	R f	sda inh bra neu	18m24 gv							299.mg	P<.0005+
a	R f	sda inh liv ang	18m24 gv							387.mg	P<.0005+
b	R f	sda inh liv hpc	18m24 gv							2.76gm	P<.006 +
c	R f	sda inh tba mal	18m24 gv							85.7mg	P<.0005
d	R f	sda inh tba mix	18m24 gv							111.mg	P<.0005
FD & C YELLOW NO. 5***			100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10								
409	M f	cd1 eat --- mlp	24m24 e							1.43gm Z	P<.0005-
a	M f	cd1 eat liv hpa	24m24 e							200.gm *	P<.2 -
b	M f	cd1 eat liv hpd	24m24 e							no dre	P=1. -
c	M f	cd1 eat lun a/a	24m24 e							no dre	P=1. -
d	M f	cd1 eat lun acb	24m24 e							no dre	P=1. -
e	M f	cd1 eat tba mal	24m24 e							1.56gm Z	P<.0005-
f	M f	cd1 eat tba ben	24m24 e							no dre	P=1. -
410	M m	cd1 eat liv hpa	24m24 e							2.15gm Z	P<.02 -
a	M m	cd1 eat --- mlp	24m24 e							11.8gm Z	P<.02 -
b	M m	cd1 eat lun a/a	24m24 e							42.5gm *	P<.4 -
c	M m	cd1 eat liv hpd	24m24 e							61.1gm *	P<.3 -
d	M m	cd1 eat lun acb	24m24 e							no dre	P=1. -
e	M m	cd1 eat tba ben	24m24 e							388.mg Z	P<.0005-
f	M m	cd1 eat tba mal	24m24 e							1.81gm Z	P<.0005-
411	R f	f3d wat ute esp	24m26 e							5.78gm *	P<.2 -
a	R f	f3d wat liv nnd	24m26 e							no dre	P=1. -
b	R f	f3d wat tba tum	24m26 e							no dre	P=1. -
412	R m	f3d wat abc mso	24m26 e							2.82gm	P<.004 -
a	R m	f3d wat liv hpc	24m26 e							no dre	P=1. -
b	R m	f3d wat liv nnd	24m26 e							no dre	P=1. -
c	R m	f3d wat tba tum	24m26 e							noTD50	P<.4 -

	RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code	
VINYL CHLORIDE*** 75-01-4											
408	bt4001	192.mg	496.mg	0/60	392.mg	32/54			Maltoni;anya,534,145-159;1988		
a	bt4001	242.mg	671.mg	0/60	392.mg	27/54					
b	bt4001	1.05gm	29.9gm	0/60	392.mg	5/54					
c	bt4001	47.0mg	151.mg	9/60	392.mg	52/54					
d	bt4001	53.6mg	270.mg	35/60	392.mg	52/54					
FD & C YELLOW NO. 5*** (tartrazine) 1934-21-0											
409	1869	616.mg	5.36gm	3/120	650.mg	8/28	(1.95gm	4/30	6.50gm	2/60)	Borzelleca;fctx,26,189-194;1988
a	1869	40.6gm	n.s.s.	1/120	650.mg	0/28	1.95gm	0/30	6.50gm	2/60	
b	1869	53.6gm	n.s.s.	3/120	650.mg	0/28	1.95gm	1/30	6.50gm	1/60	
c	1869	44.4gm	n.s.s.	29/120	650.mg	7/28	1.95gm	7/30	6.50gm	6/60	
d	1869	46.9gm	n.s.s.	3/120	650.mg	1/28	1.95gm	2/30	6.50gm	1/60	
e	1869	813.mg	4.84gm	34/120	650.mg	15/28	1.95gm	20/30	(6.50gm	15/60)	
f	1869	32.4gm	n.s.s.	52/120	650.mg	14/28	1.95gm	10/30	6.50gm	15/60	
410	1869	732.mg	n.s.s.	7/120	600.mg	6/27	(1.80gm	3/33	6.00gm	2/60)	Maekawa;fctx,25,891-896;1987
a	1869	3.96gm	n.s.s.	2/120	600.mg	1/27	1.80gm	4/33	(6.00gm	3/60)	
b	1869	10.3gm	n.s.s.	23/120	600.mg	11/27	1.80gm	11/33	6.00gm	17/60	
c	1869	14.8gm	n.s.s.	9/120	600.mg	4/27	1.80gm	7/33	6.00gm	8/60	
d	1869	73.5gm	n.s.s.	3/120	600.mg	0/27	1.80gm	1/33	6.00gm	0/60	
e	1869	182.mg	1.36gm	43/120	600.mg	21/27	(1.80gm	13/33	6.00gm	22/60)	
f	1869	961.mg	5.11gm	27/120	600.mg	6/27	1.80gm	22/33	(6.00gm	20/60)	
411	1857	1.98gm	n.s.s.	5/47	531.mg	13/50	1.06gm	10/49			
a	1857	9.15gm	n.s.s.	1/47	531.mg	1/50	1.06gm	1/49			
b	1857	2.13gm	n.s.s.	39/47	531.mg	41/50	1.06gm	30/49			
412	1857	1.15gm	18.3gm	0/48	464.mg	6/49	(929.mg	0/49			
a	1857	8.82gm	n.s.s.	0/48	464.mg	1/49	929.mg	0/49			
b	1857	9.84gm	n.s.s.	3/48	464.mg	3/49	929.mg	0/49			
c	1857	n.s.s.	n.s.s.	47/48	464.mg	49/49	929.mg	49/49			

APPENDIX 1: CHEMICAL NAMES AND SYNONYMS IN THIS PLOT

CAS NUMBER	CHEMICAL NAME	CAS NUMBER	CHEMICAL NAME
75-07-0	ACETALDEHYDE	121-69-7	N,N-DIMETHYLANILINE
107-29-9	ACETALDOXIME	62-75-9	DIMETHYLNITROSAMINE (see N-NITROSODIMETHYLAMINE)
53-96-3	2-ACETYLAMINOFLUORENE	62-75-9	N,N-DIMETHYLNITROSAMINE (see N-NITROSODIMETHYLAMINE)
---	L-alpha-ACETYLMETHADOL.HCl (see 6-DIMETHYLAMINO-4,4-DIPHENYL-3-HEPTANOL ACETATE.HCl)	121-14-2	2,4-DINITROTOLUENE (PURIFIED)
107-02-8	ACROLEIN	606-20-2	2,6-DINITROTOLUENE
3054-95-3	ACROLEIN DIETHYLACETAL	---	DINITROTOLUENE, TECHNICAL GRADE (2,4 (77%)- and 2,6 (19%)-)
5314-33-0	ACROLEIN OXIME	13256-06-9	DIPENTYLNITROSAMINE
107-13-1	ACRYLONITRILE	147-24-0	DIPHENHYDRAMINE.HCl
1162-65-8	AFLATOXIN B1	57-41-0	5,5-DIPHENYLHYDANTOIN
135-88-6	AGERITE POWDER (see PHENYL-beta-NAPHTHYLAMINE)	756-79-6	DMMP (see DIMETHYL METHYLPHOSPHONATE)
107-18-6	ALLYL ALCOHOL	62-75-9	DMN (see N-NITROSODIMETHYLAMINE)
77500-04-0	2-AMINO-3,8-DIMETHYLIMIDAZO[4,5-f]QUINOXALINE	87-86-5	DOWICIDE 7 (see 2,3,4,5,6-PENTACHLOROPHENOL (Dowicide EC-7))
99-57-0	2-AMINO-4-NITROPHENOL	87-86-5	DOWICIDE EC-7 (see 2,3,4,5,6-PENTACHLOROPHENOL (Dowicide EC-7))
121-88-0	2-AMINO-5-NITROPHENOL	75-21-8	EO (see ETHYLENE OXIDE)
---	4-(2-AMINOETHYL)-6-DIAZO-2,4-CYCLOHEXADIENONE.HCl (see 3-DIAZOTYRAMINE.HCl)	106-88-7	1,2-EPOXYBUTANE
134-03-2	L-ASCORBATE, SODIUM	75-56-9	1,2-EPOXYPROPANE (see 1,2-PROPYLENE OXIDE)
34031-32-8	AURANOFIN	643-22-1	ERYTHROMYCIN STEARATE
320-67-2	5-AZACYTIDINE	16423-68-0	ERYTHROSINE (see FD & C RED NO. 3)
3131-60-0	6-AZACYTIDINE	91-53-2	ETHOXYQUIN
25843-45-2	AZOXYMETHANE	74-96-4	ETHYL BROMIDE (see BROMOETHANE)
17697-55-1	1-AZOXYPROPANE	75-00-3	ETHYL CHLORIDE (see CHLOROETHANE)
17697-53-9	2-AZOXYPROPANE	75-21-8	ETHYLENE OXIDE
147-24-0	BENADRYL (see DIPHENHYDRAMINE.HCl)	117-81-7	DI(2-ETHYLHEXYL)PHTHALATE
71-43-2	BENZENE	297-76-7	ETHYNIODIOL DIACETATE
271-89-6	BENZOFURAN	53-96-3	FLUORENYLACETAMIDE (see 2-ACETYLAMINOFLUORENE)
100-51-6	BENZYL ALCOHOL	53-96-3	N-2-FLUORENYLACETAMIDE (see 2-ACETYLAMINOFLUORENE)
25013-16-5	BHA (see BUTYLATED HYDROXYANISOLE)	75-69-4	FLUOROCARBON 11 (see TRICHLOROFLUOROMETHANE)
128-37-0	BHT (see BUTYLATED HYDROXYTOLUENE)	75-71-8	FLUOROCARBON 12 (see DICHLORODIFLUOROMETHANE)
2784-94-3	HC BLUE NO. 1	75-45-6	FLUOROCARBON 22 (see CHLORODIFLUOROMETHANE)
2784-94-3	HC BLUE NO. 1 (PURIFIED)	50-00-0	FORMALDEHYDE
10043-35-3	BORIC ACID	75-09-2	FREON 30 (see METHYLENE CHLORIDE)
7758-01-2	BROMATE, POTASSIUM	54-31-9	FUROSEMIDE
75-27-4	BROMODICHLOROMETHANE	mixture	GERANYL ACETATE, FOOD GRADE (71% GERANYL ACETATE, 29% CITRONELLYL ACETATE) (CAS NUMBERS 105-87-3 and 150-84-5)
74-96-4	BROMOETHANE	69644-85-5	N2-[gamma-L(+)-GLUTAMYL]-4-CARBOXYPHENYLHYDRAZINE (see N2-gamma-GLUTAMYL-p-HYDRAZINOBENZOIC ACID)
75-25-2	BROMOFORM (see TRIBROMOMETHANE)	69644-85-5	N2-gamma-GLUTAMYL-p-HYDRAZINOBENZOIC ACID
106-99-0	1,3-BUTADIENE	118-74-1	HCb (see HEXACHLOROBENZENE)
128-37-0	2,6-DI-tert-BUTYL-p-CRESOL (see BUTYLATED HYDROXYTOLUENE)	118-74-1	HEXACHLOROBENZENE
25013-16-5	2(3)-tert-BUTYL-4-HYDROXYANISOLE (see BUTYLATED HYDROXYANISOLE)	58-89-9	gamma-1,2,3,4,5,6-HEXACHLOROCYCLOHEXANE
25013-16-5	BUTYLATED HYDROXYANISOLE	67-72-1	HEXACHLOROETHANE
128-37-0	BUTYLATED HYDROXYTOLUENE	136-77-6	4-HEXYLRESORCINOL
35658-65-2	CADMIUM CHLORIDE	10034-93-2	HYDRAZINE SULFATE
149-30-4	CAPTAX (see 2-MERCAPTOBENZOTHAZOLE)	69644-85-5	p-HYDRAZINOBENZOIC ACID, N2-gamma-GLUTAMYL (see N2-gamma-GLUTAMYL-p-HYDRAZINOBENZOIC ACID)
120-80-9	CATECHOL	24589-77-3	p-HYDRAZINOBENZOIC ACID.HCl
20265-96-7	p-CHLOROANILINE.HCl	58-93-5	HYDROCHLOROTHIAZIDE
75-45-6	CHLORODIFLUOROMETHANE	123-31-9	HYDROQUINONE
75-00-3	CHLOROETHANE	1083-57-4	3-HYDROXY-p-BUTYROPHENETIDIDE
150-68-5	3-(p-CHLOROPHENYL)-1, 1-DIMETHYLUREA	24382-04-5	3-HYDROXY-2-PROPENAL, SODIUM SALT (see MALONALDEHYDE, SODIUM SALT)
52214-84-3	CIPROFIBRATE	13743-07-2	1-(2-HYDROXYETHYL)-1-NITROSOUREA
108-94-1	CYCLOHEXANONE	924-42-5	N-(HYDROXYMETHYL)-ACRYLAMIDE (see N-METHYLOLACRYLAMIDE)
62-73-7	DDVP (see DICHLORVOS)	75011-65-3	IBOPAMINE.HCl (see N-METHYLDOPAMINE, O,O'-DIISOBUTYROYL ESTER, HCl)
55-18-5	DEN (see N-NITROSODIETHYLAMINE)	26675-46-7	ISOFURANE
56-53-1	DES (see DIETHYLSTILBESTROL)	---	LAAM (see 6-DIMETHYLAMINO-4,4-DIPHENYL-3-HEPTANOL ACETATE.HCl)
62488-57-7	DHAC (see 5,6-DIHYDRO-5-AZACYTIDINE)	---	LASIOCARPINE
---	3-DIAZOTYRAMINE.HCl	303-34-4	LINDANE (see gamma-1,2,3,4,5,6-HEXACHLOROCYCLOHEXANE)
75-27-4	DICHLOROBROMOMETHANE (see BROMODICHLOROMETHANE)	58-89-9	MACRODANTIN (see 1-[(5-NITROFURFURYLIDENE)AMINO]HYDANTOIN)
75-71-8	DICHLORODIFLUOROMETHANE	67-20-9	MALONALDEHYDE, SODIUM SALT
75-09-2	DICHLOROMETHANE (see METHYLENE CHLORIDE)	24382-04-5	MeIQx (see 2-AMINO-3,8-DIMETHYLIMIDAZO[4,5-f]QUINOXALINE)
120-83-2	2,4-DICHLOROPHENOL	77500-04-0	2-MERCAPTOBENZOTHAZOLE
62-73-7	DICHLORVOS	1095-90-5	DL-METHADONE.HCl (see 6-DIMETHYLAMINO-4,4-DIPHENYL-3-HEPTANONE.HCl)
56-53-1	4,4'-(1,2-DIETHYL-1,2-ETHENEDIYL)BIS-PHENOL (see DIETHYLSTILBESTROL)	298-81-7	8-METHOXYPSORALEN
55-18-5	DIETHYLNITROSAMINE (see N-NITROSODIETHYLAMINE)	25843-45-2	Z-METHYL-O,N,N-AZOXYMETHANE (see AZOXYMETHANE)
55-18-5	N,N-DIETHYLNITROSAMINE (see N-NITROSODIETHYLAMINE)	598-55-0	METHYL CARBAMATE
56-53-1	DIETHYLSTILBESTROL	71-55-6	METHYL CHLOROFORM (see 1,1,1-TRICHLOROETHANE, TECHNICAL GRADE)
62488-57-7	5,6-DIHYDRO-5-AZACYTIDINE	70-25-7	N-METHYL-N'-NITRO-N-NITROSOGUANIDINE
120-80-9	1,2-DIHYDROXYBENZENE (see CATECHOL)	872-50-4	N-METHYL-2-PYRROLIDONE
828-00-2	DIMETHOXANE, COMMERCIAL GRADE		
65176-75-2	5,6-DIMETHOXYSTERIGMATOCYSTIN		
756-79-6	DIMETHYL METHYLPHOSPHONATE		
---	6-DIMETHYLAMINO-4,4-DIPHENYL-3-HEPTANOL ACETATE.HCl		
1095-90-5	6-DIMETHYLAMINO-4,4-DIPHENYL-3-HEPTANONE.HCl		
108-01-0	2-DIMETHYLAMINOETHANOL		

CAS NUMBER	CHEMICAL NAME	CAS NUMBER	CHEMICAL NAME
41372-08-1	alpha-METHYLDOPA SESQUIHYDRATE	79-01-6	TCE (see TRICHLOROETHYLENE (WITHOUT EPICHLOROHYDRIN))
75011-65-3	N-METHYLDOPAMINE, O,O-DIISOBUTYROYL ESTER.HCl	150-68-5	TELVAR (see 3-(p-CHLOROPHENYL)-1,1-DIMETHYLUREA)
75-09-2	METHYLENE CHLORIDE	34031-32-8	2,3,4,6-TETRA-O-ACETYL-L-THIO-L-beta-D-GLUCOPYRANOSATO-S) (TRIETHYLPHOSPHINE) GOLD (see AURANOFIN)
64091-91-4	4-(METHYLNITROSAMINO)-1-(3-PYRRIDYL)-1-BUTANOL	64-75-5	TETRACYCLINE.HCl
924-42-5	4-(METHYLNITROSAMINO)-1-(3-PYRRIDYL)-1-(BUTANONE)	18771-50-1	3,4,5,6-TETRAHYDROURIDINE
622-97-9	N-METHYLOLACRYLAMIDE	62-55-5	THIOACETAMIDE
59122-46-2	p-METHYLSTYRENE	10191-41-0	DL-alpha-TOCOPHEROL
70-25-7	MISOPROSTOL	75-25-2	TRIBROMOMETHANE
150-68-5	MNNG (see N-METHYL-N-NITRO-N-NITROSOGUANIDINE)	76-13-1	1,1,2-TRICHLORO-1,2,2-TRIFLUOROETHANE, TECHNICAL GRADE
298-81-7	MONURON (see 3-(p-CHLOROPHENYL)-1,1-DIMETHYLUREA)	71-55-6	1,1,1-TRICHLOROETHANE, TECHNICAL GRADE
389-08-2	8-MOP (see 8-METHOXYPSORALEN)	79-01-6	TRICHLOROETHYLENE (WITHOUT EPICHLOROHYDRIN) (TCE, c04547 is NTP TR# 243; 04546 (b,d,e & f) are NTP TR# 273)
88385-81-3	NALIDIXIC ACID	75-69-4	TRICHLOROFLUOROMETHANE
13743-07-2	NEOSUGAR	83-79-4	TUBATOXIN (see ROTENONE)
7632-00-0	NHEU (see 1-(2-HYDROXYETHYL)-1-NITROSOUREA))	62-73-7	VAPONA (see DICHLORVOS)
59-87-0	NITRITE, SODIUM	75-01-4	VINYL CHLORIDE
121-19-7	5-NITRO-2-FURALDEHYDE SEMICARBAZONE	127-47-9	VITAMIN A, ACETATE (see RETINOL ACETATE)
67-20-9	3-NITRO-4-HYDROXYPHENYLARSONIC ACID	79-81-2	VITAMIN A, PALMITATE (see RETINOL PALMITATE)
59-87-0	NITROFURANTOIN (see 1-[(5-NITROFURFURYLIDENE)AMINO]HYDANTOIN)	134-03-2	VITAMIN C, SODIUM (see L-ASCORBATE, SODIUM)
108-03-2	NITROFURAZONE (see 5-NITRO-2-FURALDEHYDE SEMICARBAZONE)	10191-41-0	VITAMIN E (see DL-alpha-TOCOPHEROL)
13743-07-2	1-(5-NITROFURFURYLIDENE)AMINO]HYDANTOIN	1934-21-0	FD & C YELLOW NO. 5
38347-74-9	1-NITROPROPANE		
1116-54-7	N-NITROSO-2-HYDROXYETHYLUREA (see 1-(2-HYDROXYETHYL)-1-NITROSOUREA))		
55-18-5	3-NITROSO-2-OXAZOLIDINONE		
62-75-9	N-NITROSODIETHANOLAMINE		
114282-83-6	N-NITROSODIETHYLAMINE		
10595-95-6	N-NITROSODIMETHYLAMINE		
55557-02-3	N-NITROSODITHIAZINE		
26921-68-6	NITROSOETHYLMETHYLAMINE		
70415-59-7	NITROSOETHYLMETHYLAMINE		
10595-95-6	N-NITROSOGUVACOLINE		
59-89-2	N-NITROSOMETHYL-(2-HYDROXYETHYL)AMINE		
59-89-2	N-NITROSOMETHYL-(3-HYDROXYPROPYL)AMINE		
930-55-2	N-NITROSOMETHYL-(2-TOSYLOXYETHYL)AMINE		
930-55-2	N-NITROSOMETHYLETHYLAMINE (see NITROSOETHYLMETHYLAMINE)		
81795-07-5	NITROSOMORPHOLINE (see N-NITROSOMORPHOLINE)		
303-47-9	N-NITROSOMORPHOLINE		
117-81-7	NITROSOPYRROLIDINE (see N-NITROSOPYRROLIDINE)		
6373-74-6	N-NITROSOPYRROLIDINE		
1936-15-8	N-NITROSOTHIALDINE		
297-76-7	OCHRATOXIN A		
132-98-9	DI-sec-OCTYL PHTHALATE (see DI(2-ETHYLHEXYL)PHTHALATE)		
87-86-5	C.I. ACID ORANGE 3		
87-86-5	C.I. ACID ORANGE 10		
87-86-5	OVULEN-50 (see ETHYNODIOL DIACETATE)		
78-11-5	PENICILLIN VK		
57590-20-2	PENTA (see 2,3,4,5,6-PENTACHLOROPHENOL (Dowicide EC-7))		
78-11-5	2,3,4,5,6-PENTACHLOROPHENOL (Dowicide EC-7)		
50-06-6	2,3,4,5,6-PENTACHLOROPHENOL, TECHNICAL GRADE		
50-06-6	PENTAERYTHRITOL TETRANITRATE WITH 80% D-LACTOSE MONOHYDRATE		
135-88-6	PENTANAL METHYLFORMYLHYDRAZONE		
135-88-6	PETN, NF (see PENTAERYTHRITOL TETRANITRATE WITH 80% D-LACTOSE MONOHYDRATE)		
50-33-9	PHENOBARBITAL		
108-45-2	PHENOBARBITONE (see PHENOBARBITAL)		
50-06-6	PHENYL-beta-NAPHTHYLAMINE		
57-41-0	N-PHENYL-2-NAPHTHYLAMINE (see PHENYL-beta-NAPHTHYLAMINE)		
7758-01-2	PHENYLBUTAZONE		
121-79-9	m-PHENYLENEDIAMINE		
115-07-1	PHENYLETHYLBARBITURIC ACID (see PHENOBARBITAL)		
75-56-9	PHENYTOIN (see 5,5-DIPHENYLHYDANTOIN)		
16423-68-0	POTASSIUM BROMATE (see BROMATE, POTASSIUM)		
79-81-2	PROPYL GALLATE		
127-47-9	PROPYLENE		
149-30-4	1,2-PROPYLENE OXIDE		
83-79-4	FD & C RED NO. 3		
121-19-7	RETINOL PALMITATE		
18559-94-9	RETINOL ACETATE		
7632-00-0	ROTAX (see 2-MERCAPTOBENZOTHAZOLE)		
100-42-5	ROTENONE		
96-09-3	ROXARSONE (see 3-NITRO-4-HYDROXYPHENYLARSONIC ACID)		
1934-21-0	SALBUTAMOL		
	SODIUM NITRITE (see NITRITE, SODIUM)		
	STYRENE		
	STYRENE OXIDE		
	TARTRAZINE (see FD & C YELLOW NO. 5)		

APPENDIX 2: CHEMICAL NAMES IN THIS PLOT LISTED BY CAS NUMBER

CAS NUMBER	CHEMICAL NAME	CAS NUMBER	CHEMICAL NAME
mixture	GERANYL ACETATE, FOOD GRADE (71% GERANYL ACETATE, 29% CITRONELLYL ACETATE) (CAS NUMBERS 105-87-3 and 150-84-5)	127-47-9	RETINOL ACETATE (vitamin A, acetate)
50-00-0	FORMALDEHYDE	128-37-0	BUTYLATED HYDROXYTOLUENE (BHT, 2,6-Di-tert-butyl-p-cresol)
50-06-6	PHENOBARBITAL (phenobarbitone)	132-98-9	PENICILLIN VK
50-33-9	PHENYLBUTAZONE	134-03-2	L-ASCORBATE, SODIUM (vitamin C, sodium)
53-96-3	2-ACETYLAMINOFLUORENE (N-2-fluorenylacetamide)	135-88-6	PHENYL-beta-NAPHTHYLAMINE (Agerite powder, N-phenyl-2-naphthylamine)
54-31-9	FUROSEMIDE	136-77-6	4-HEXYLRESORCINOL
55-18-5	N-NITROSODIETHYLAMINE (DEN)	147-24-0	DIPHENHYDRAMINE.HCl (Benadryl)
56-53-1	DIETHYLSTILBESTROL (DES)	149-30-4	2-MERCAPTOBENZOTHAZOLE (Captax, rotax)
57-41-0	5,5-DIPHENYLHYDANTOIN (phenytoin)	150-68-5	3-(p-CHLOROPHENYL)-1,1-DIMETHYLUREA (Telvar, monuron)
58-89-9	gamma-1,2,3,4,5,6-HEXACHLOROCYCLOHEXANE (lindane)	271-89-6	BENZOFURAN
58-93-5	HYDROCHLOROTHIAZIDE	297-76-7	ETHYNODIOL DIACETATE (Ovulen-50)
59-87-0	5-NITRO-2-FURALDEHYDE SEMICARBAZONE (nitrofurazone)	298-81-7	8-METHOXYPSORALEN (8-MOP)
59-89-2	N-NITROSOMORPHOLINE	303-34-4	LASIOCARPINE
62-55-5	THIOACETAMIDE	303-47-9	OCHRATOXIN A
62-73-7	DICHLORVOS (DDVP, Vapona)	320-67-2	5-AZACYTIDINE
62-75-9	N-NITROSODIMETHYLAMINE (DMN)	389-08-2	NALIDIXIC ACID
64-75-5	TETRACYCLINE.HCl	598-55-0	METHYL CARBAMATE
67-20-9	1-[(5-NITROFURFURYLIDENE)AMINO]HYDANTOIN (macrodantin, nitrofurantoin)	606-20-2	2,6-DINITROTOLUENE
67-72-1	HEXACHLOROETHANE	622-97-9	p-METHYLSTYRENE
70-25-7	N-METHYL-N-NITRO-N-NITROSOGUANIDINE (MNNG)	643-22-1	ERYTHROMYCIN STEARATE
71-43-2	BENZENE	756-79-6	DIMETHYL METHYLPHOSPHONATE (DMMP)
71-55-6	1,1,1-TRICHLOROETHANE, TECHNICAL GRADE (methyl chloroform)	828-00-2	DIMETHOXANE, COMMERCIAL GRADE
74-96-4	BROMOETHANE (ethyl bromide)	872-50-4	N-METHYL-2-PYRROLIDONE
75-00-3	CHLOROETHANE (ethyl chloride)	924-42-5	N-METHYLOLACRYLAMIDE
75-01-4	VINYL CHLORIDE	930-55-2	N-NITROSOPYRROLIDINE
75-07-0	ACETALDEHYDE	1083-57-4	3-HYDROXY-p-BUTYROPHENETIDIDE (betadid, buccetin)
75-09-2	METHYLENE CHLORIDE (dichloromethane, Freon 30)	1095-90-5	6-DIMETHYLAMINO-4,4-DIPHENYL-3-HEPTANONE.HCl (DL-methadone.HCl)
75-21-8	ETHYLENE OXIDE (EO)	1116-54-7	N-NITROSODIETHANOLAMINE
75-25-2	TRIBROMOMETHANE (bromoform)	1162-65-8	AFATOXIN BI
75-27-4	BROMODICHLOROMETHANE (dichlorobromomethane)	1934-21-0	FD & C YELLOW NO. 5 (tartrazine)
75-45-6	CHLORODIFLUOROMETHANE (fluorocarbon 22)	1936-15-8	C.I. ACID ORANGE 10
75-56-9	1,2-PROPYLENE OXIDE (1,2-epoxypropane)	2784-94-3	HC BLUE NO. 1
75-69-4	TRICHLOROFLUOROMETHANE (fluorocarbon 11)	2784-94-3	HC BLUE NO. 1 (PURIFIED)
75-71-8	DICHLORODIFLUOROMETHANE (fluorocarbon 12)	3054-95-3	ACROLEIN DIETHYLACETAL
76-13-1	1,1,2-TRICHLORO-1,2,2-TRIFLUOROETHANE, TECHNICAL GRADE (fluorocarbon 113)	3131-60-0	6-AZACYTIDINE
78-11-5	PENTAERYTHRITOL TETRANITRATE WITH 80% D-LACTOSE MONOHYDRATE (PETN, NF)	5314-33-0	ACROLEIN OXIME
79-01-6	TRICHLOROETHYLENE (WITHOUT EPICHLOROHYDRIN) (TCE)	6373-74-6	C.I. ACID ORANGE 3
79-81-2	RETINOL PALMITATE (vitamin A, palmitate)	7632-00-0	NITRITE, SODIUM
83-79-4	ROTENONE (tubatoxin)	7758-01-2	BROMATE, POTASSIUM
87-86-5	2,3,4,5,6-PENTACHLOROPHENOL (Dowicide EC-7) (Dowicide 7, penta, PCP)	10034-93-2	HYDRAZINE SULFATE
87-86-5	2,3,4,5,6-PENTACHLOROPHENOL, TECHNICAL GRADE (penta, PCP)	10043-35-3	BORIC ACID
91-53-2	ETHOXYQUIN	10191-41-0	DL-alpha-TOCOPHEROL (vitamin E)
96-09-3	STYRENE OXIDE	10595-95-6	NITROSOETHYLMETHYLAMINE (N-nitrosomethylethylamine)
99-57-0	2-AMINO-4-NITROPHENOL	13256-06-9	DIPENTYLNITROSAMINE
100-42-5	STYRENE	13743-07-2	1-(2-HYDROXYETHYL)-1-NITROSOUREA (N-nitroso-2-hydroxyethylurea, NHEU)
100-51-6	BENZYL ALCOHOL	16423-68-0	FD & C RED NO. 3 (erythrosine)
106-88-7	1,2-EPOXYBUTANE	17697-53-9	2-AZOXYPROPANE
106-99-0	1,3-BUTADIENE	17697-55-1	1-AZOXYPROPANE
107-02-8	ACROLEIN	18559-94-9	SALBUTAMOL
107-13-1	ACRYLONITRILE	18771-50-1	3,4,5,6-TETRAHYDROURIDINE
107-18-6	ALLYL ALCOHOL	20265-96-7	p-CHLOROANILINE.HCl
107-29-9	ACETALDOXIME	24382-04-5	MALONALDEHYDE, SODIUM SALT (3-hydroxy-2-propenal, sodium salt)
108-01-0	2-DIMETHYLAMINOETHANOL	24589-77-3	p-HYDRAZINOBENZOIC ACID.HCl
108-03-2	1-NITROPROPANE	25013-16-5	BUTYLATED HYDROXYANISOLE (BHA, 2(3)-tert-butyl-4-hydroxyanisole)
108-45-2	m-PHENYLENEDIAMINE	25843-45-2	AZOXYMETHANE (Z-methyl-O,N,N-azoxymethane)
108-94-1	CYCLOHEXANONE	26675-46-7	ISOFURANE
115-07-1	PROPYLENE	26921-68-6	N-NITROSOMETHYL-(2-HYDROXYETHYL)AMINE
117-81-7	Di(2-ETHYLHEXYL)PHTHALATE (di-sec-octyl phthalate)	34031-32-8	AURANOFIN ((2,3,4,6-tetra-O-acetyl-1-thio-1-beta-D-glucopyranosato-S) (triethylphosphine) gold)
118-74-1	HEXACHLOROBENZENE (HCB)	35658-65-2	CADMIUM CHLORIDE
120-80-9	CATECHOL (1,2-dihydroxybenzene)	38347-74-9	3-NITROSO-2-OXAZOLIDINONE
120-83-2	2,4-DICHLOROPHENOL	41372-08-1	alpha-METHYLDOPA SESQUIHYDRATE
121-14-2	2,4-DINITROTOLUENE (PURIFIED)	52214-84-3	CIPROFIBRATE
121-19-7	3-NITRO-4-HYDROXYPHENYLARSONIC ACID (roxarsone)	55557-02-3	N-NITROSOGUACOLINE
121-69-7	N,N-DIMETHYLANILINE	57590-20-2	PENTANAL METHYLFORMYLHYDRAZONE
121-79-9	PROPYL GALLATE	59122-46-2	MISOPROSTOL
121-88-0	2-AMINO-5-NITROPHENOL	62488-57-7	5,6-DIHYDRO-5-AZACYTIDINE (DHAC)
123-31-9	HYDROQUINONE	64091-91-4	4-(METHYLNITROSAMINO)-1-(3-PYRRIDYL)-1-(BUTANONE)
		65176-75-2	5,6-DIMETHOXYSTERIGMATOCYSTIN
		69644-85-5	N2-gamma-GLUTAMYL-p-HYDRAZINOBENZOIC ACID (N2-

APPENDIX 2: *continued.*

CAS NUMBER	CHEMICAL NAME
70415-59-7	[gamma-L(+)-GLUTAMYL]-4-CARBOXYPHENYLHYDRAZINE
75011-65-3	N-NITROSOMETHYL-(3-HYDROXYPROPYL)AMINE N-METHYLDOPAMINE, O,O-DIISOBUTYROYL ESTER.HCl (ibopamine.HCl)
77500-04-0	2-AMINO-3,8-DIMETHYLIMIDAZO[4,5-f]QUINOXALINE (MeIQx)
81795-07-5	N-NITROSOTHIALDINE
88385-81-3	NEOSUGAR
114282-83-6	N-NITROSODITHIAZINE
---	3-DIAZOTYRAMINE.HCl (4-(2-aminoethyl)-6-diazo-2,4-cyclohexadienone.HCl)
---	6-DIMETHYLAMINO-4,4-DIPHENYL-3-HEPTANOL ACETATE.HCl (L-alpha-acetylmethadol.HCl, LAAM)
---	DINITROTOLUENE, TECHNICAL GRADE (2.4 (77%)- and 2.6 (19%)-)
---	4-(METHYLNITROSAMINO)-1-(3-PYRRIDYL)-1-BUTANOL
---	N-NITROSOMETHYL-(2-TOSYLOXYETHYL)AMINE

APPENDIX 3: STRAIN CODES AND DEFINITIONS

Code	Strain
aci	ACI
ain	ACI/n
aug	August
b6c	B6C3F ₁
baa	Black a/a (YS x VY)F ₁
bal	BALB/c
bcn	BALB/c StCr1fC3Hf/Nctr
c3j	C3H/HeJ
c3v	C3H/HeN-MTV-/Nctr
c5n	C57BL/6N
cd1	Charles River CD1
cdf	CDF ₁
cdr	Charles River CD
cen	C3H/HeN
chg	C3H/He germfree
chh	C3H/He
don	Donryu
f34	Fischer 344
f3d	F344/DuCrj
mar	Marshall
mrw	MRC-Wistar
osm	Osborne-Mendel
pva	Lean pseudoagouti Avy/a
sda	Sprague-Dawley
sss	Sprague-Dawley Spartan
swa	Swiss albino
swj	Swiss
sww	Swiss Webster
syg	Syrian Golden
wln	Wistar/NIN
wis	Wistar
wsr	Wistar-random
yva	Obese yellow Avy/a

APPENDIX 4: ROUTE OF ADMINISTRATION CODES AND DEFINITIONS

Code	Route of Administration
eat	diet
gav	gavage
inh	inhalation
ipj	intraperitoneal injection
wat	water

APPENDIX 5: SITE CODES AND DEFINITIONS

Code	Site
---	all target sites
abc	abdominal cavity
acx	adrenal cortex
adr	adrenal gland
amd	adrenal medulla
aof	aorta and large arteries
bon	bone
bra	brain
brm	brain/meninges
cli	clitoral gland
col	colon
duo	duodenum
eso	esophagus
fgr	forestomach, greater curvature
fls	forestomach, lesser curvature
for	forestomach
gam	gastric mucosa
git	gastrointestinal tract
hag	Harderian gland
itn	intestine
k/c	kidney/cortex
k/p	kidney/pelvis
kid	kidney
lgi	large intestine
liv	liver
lmr	lymphoreticular system
mam	mammary tissue (other than or including more than mammary gland)
lun	lung
mds	mediastinum
meo	mesovarium
mgl	mammary gland
mln	mesenteric lymph node
mul	multiple organs
MXA	more than one site, combined by NCI/NTP
MXB	more than one site, combined by Berkeley
nac	nasal mucosa
nas	nasal cavity
ner	nervous system
orc	oral cavity
ova	ovary
pae	pancreas, exocrine
pal	palate
pan	pancreas
per	peritoneum
pit	pituitary gland
pni	pancreatic islets
pre	preputial gland
pta	pituitary gland, anterior
pty	parathyroid
rec	rectum
res	respiratory system
ski	skin
spl	spleen
stg	stomach, glandular
srp	splenic red pulp
sub	subcutaneous tissue
TBA	all tumor bearing animals, NCI/NTP
tba	all tumor bearing animals
tes	testis
thy	thyroid gland

Code	Site
tna	tunica albuginea
tnv	tunica vaginalis
ton	tongue
ubl	urinary bladder
unt	urinary tract
ute	uterus
zym	Zymbal's gland

APPENDIX 6: HISTOPATHOLOGY CODES AND DEFINITIONS

Code	Histopathology
a/a	alveolar/bronchiolar adenoma
a/c	alveolar/bronchiolar carcinoma
acb	adenocarcinoma, bronchalveolar
acc	acinar-cell carcinoma
acn	adenocarcinoma, NOS
act	alveolar-cell tumor
ada	adenocarcinoma, type A
adb	adenocarcinoma, type B
adc	adenocarcinoma
ade	adenoma
adn	adenoma, NOS
adq	adenosquamous carcinoma
ala	alveolar-cell adenoma
alc	alveolar-cell carcinoma
ana	acinar-cell adenoma
anb	adenoma, bilateral
ang	angiosarcoma
aod	adenocarcinoma, acinar or ductal
apn	adenomatous polyp, NOS
asl	astrocytoma, malignant
ast	astrocytoma
ata	atypic adenoma
bcc	basal-cell carcinoma
ben	benign tumor
bhp	hepatoma, benign
bht	hepatocellular tumor, benign
blc	biliary cystadenoma
bsa	basophil adenoma
cab	cholangiocellular tumor, benign
can	carcinoma, NOS
car	carcinoma
cca	c-cell adenoma
ccr	c-cell carcinoma
cgf	cholangiofibroma
cho	cholangioma
clc	cholangiocarcinoma
coa	cortical adenoma
csa	cortical subcapsular adenoma
ena	endometrial adenocarcinoma
ene	esthesioneuroepithelioma
epc	epidermoid carcinoma
esp	endometrial stromal polyp
exa	exocrine adenoma
fa	fibroadenoma
fas	fibrosarcoma
fca	follicular-cell adenoma
fcc	follicular-cell carcinoma
fct	follicular-cell tumor
fib	fibroma
gcb	granulosa-cell tumor, benign

Code	Histopathology
gcc	granulosa-cell carcinoma
gcl	granulosa-cell tumor, NOS
gcm	granulosa-cell tumor, malignant
gct	granulosa-cell tumor
gli	glioma
gln	glioma, NOS
hcs	histiocytic sarcoma
hct	hepatocellular tumor
hem	hemangioma
hes	hemangiosarcoma
hmb	hemangioendothelioma, benign
hmm	hemangioendothelioma, malignant
hms	hemangioendothelial sarcoma
hnd	hyperplastic nodule
hpa	hepatocellular adenoma
hpb	hepatoblastoma
hpc	hepatocellular carcinoma
hpd	hepatocellular adenocarcinoma
hpn	hepatocellular neoplastic nodule
hpt	hepatoma
iab	interstitial-cell adenoma, bilateral
ica	interstitial-cell adenoma
ict	interstitial-cell tumor
isa	islet-cell adenoma
isc	islet-cell carcinoma
itm	interstitial-cell tumor, malignant
kcs	Kupffer-cell sarcoma
ker	keratoacanthoma
lcl	lymphocytic lymphoma
ldc	Leydig-cell tumor
lei	leiomyosarcoma
leu	leukemia
ley	leiomyoma
lkm	lymphoma leukemia
lls	lymphoblastic leukemia-lymphosarcoma
mal	malignant tumor
mec	muco-epidermoid carcinoma
men	mesothelioma, NOS
mhs	histiocytoma, malignant
mix	more than one tumor type; tumor types specified in published paper
mlh	malignant lymphoma, histiocytic type
mlm	malignant lymphoma, mixed type
mlp	malignant lymphoma, lymphocytic type
mlu	malignant lymphoma, undifferentiated type
mly	malignant lymphoma
mng	meningioma
mnl	mononuclear-cell leukemia
mno	malignant lymphoma, NOS
mnp	mesenchymal neoplasm
msm	mesothelioma, malignant
mso	mesothelioma
mtb	mixed tumor, benign
mtm	mixed tumor, malignant
MXA	more than one tumor type, combined by NCI/NTP
MXB	more than one tumor type, combined by Berkeley
myo	myelomonocytic leukemia
neo	neoplasm
neu	neuroblastoma
nfm	neurofibroma
nfs	neurofibrosarcoma
nim	neurilemoma, malignant
nd	neoplastic nodule
oli	oligodendroglioma

Code	Histopathology
ost	osteosarcoma
pac	papillary adenocarcinoma
pam	papilloma
pbb	pheochromocytoma benign, bilateral
pbm	pheochromocytoma, benign/malignant
pcy	papillary cystadenoma, NOS
pda	pars distalis adenoma
phc	pheochromocytoma, complex
phe	pheochromocytoma
phm	pheochromocytoma, malignant
pla	polypoid adenoma
pmb	pheochromocytoma malignant, bilateral
pob	pheochromocytoma, benign
ppa	papillary adenoma
ppc	papillary carcinoma
ppn	papilloma, NOS
pst	stromal polyp
rca	renal-cell adenoma
rcc	renal-cell carcinoma
rct	renal-cell tumor
rts	reticulum-cell sarcoma
rua	tubule adenoma
ruc	tubule carcinoma
rue	tubule epithelium adenoma
sar	sarcoma
sea	sebaceous adenoma
sla	sebaceous gland adenoma
spm	sarcoma, NOS, unclear primary or metastatic
sqa	squamous-cell tumor
sqc	squamous-cell carcinoma
sqp	squamous-cell papilloma
srn	sarcoma, NOS
tcb	tubular-cell carcinoma, bilateral
tcc	transitional-cell carcinoma
tcm	thecoma
thc	hepatocellular carcinoma, trabecular
tla	tubular-cell adenoma
tpa	transitional-cell papilloma
tri	trichoepithelioma
tua	tubular adenoma
tum	tumor or more than one tumor type; tumor types not specified in published paper
uac	tubular-cell adenocarcinoma
ulc	undifferentiated carcinoma

APPENDIX 7: NOTECODES AND DEFINITIONS

Code	Definition
a	The exposure time reported on the plot is an average of the different exposure times of the individual dose groups in the experiment. For NCI/NTP, both exposure and experiment times have been averaged because of differential survival among the dose groups. (In the TD ₅₀ calculation for the NCI/NTP bioassays, full lifetable data have been used.)
b	Diet was specially prepared to be deficient in one or more vitamins.
e	For the general literature we have used an effective number of animals in a group whenever possible. This effective number is either: (1) the number of animals alive at the time of appearance of the first tumor, or if that is not reported, then (2) the number of animals examined.
g	Some or all of the animals were used as breeders during the

Code	Definition
	course of the experiment.
j	The data for this test have been previously published in the database. The experimental results have been revised and re-published by the authors. In the database, we give the same reference number to the test in both publications.
k	For interim and serial sacrifice experiments, we have reported, as a separate experiment with a k notecode, each sacrifice time that otherwise met the inclusion rules of the database. Whenever possible, we have included unscheduled deaths with the terminal sacrifice data, and when this has been done, there is no k notecode for the terminal sacrifice experiment.
n	NTP considered one dose group inadequate for detecting a carcinogenic response.
o	Chemical was administered as an aerosol.
r	Restricted site analysis; the authors either examined or chose to report data for only a few selected tissues.
s	Authors noted that survival was decreased due to toxicity, disease, or accidental death.
v	Variable or irregular dosing schedules have been used, e.g. dose level changed during the experiment.

APPENDIX 8: DOSE-RESPONSE CURVE SYMBOLS AND DEFINITIONS

Code	Dose-Response Curve
*	consistent with linearity
/	significant departure from linearity, upward curvature
\	significant departure from linearity, downward curvature
Z	significant departure from linearity, more than three dose groups including controls
blank	either no dose-related effect, or only two dose groups including controls, so not enough information to determine a curve shape

APPENDIX 9: REFERENCE CODES AND DEFINITIONS

Code	Reference
acnr	Anticancer Research
amih	American Industrial Hygiene
anes	Anesthesiology
anya	Annals of the New York Academy of Sciences
bjca	British Journal of Cancer
canr	Cancer Research
carc	Carcinogenesis
clet	Cancer Letters
enhp	Environmental Health Perspectives
faat	Fundamental and Applied Toxicology
fcix	Food and Chemical Toxicology (formerly Food and Cosmetics Toxicology, until 1982)
gann	Japanese Journal of Cancer Research (formerly Gann through Vol. 75, 1984)
ijbb	Indian Journal of Biochemistry & Biophysics
jact	Journal of the American College of Toxicology
jnci	Journal of the National Cancer Institute (U.S. National Cancer Institute Journal)

Code	Reference
jtxe	Journal of Toxicology and Environmental Health
livt	Laboratory Investigation
made	Mechanisms of Ageing and Development
myco	Mycopathologia
neag	Neurobiology of Aging
nutc	Nutrition and Cancer
pavt	Veterinary Pathology (formerly Pathologia Veterinaria)
txcy	Toxicology
txih	Toxicology and Industrial Health
txpy	Toxicologic Pathology

APPENDIX 10: NCI/NTP BIOASSAYS EVALUATED AS INADEQUATE IN TECHNICAL REPORTS

Chemical Name	Experiments Evaluated as Inadequate
CHLOROETHANE	male mice
DIMETHYL METHYLPHOSPHONATE	male mice
TRICHLOROETHYLENE (WITHOUT EPICHLOROHYDRIN)	rats (b, d, e and f 04546), male rats (c04547)

APPENDIX 11: AUTHOR'S OPINION CODES AND DEFINITIONS

Code	Author's Opinion for Each Site
c	NTP evaluation is <i>clear evidence</i> of carcinogenic activity: studies that are interpreted as showing a dose-related (i) increase of malignant neoplasms, (ii) increase of a combination of malignant and benign neoplasms, or (iii) marked increase of benign neoplasms if there is an indication from this or other studies of the ability of such tumors to progress to malignancy.
e	NTP evaluation is <i>equivocal evidence</i> of carcinogenic activity: studies that are interpreted as showing a marginal increase of neoplasms that may be chemically related.
p	NTP evaluation is <i>some evidence</i> of carcinogenic activity: studies that are interpreted as showing a chemically related increased incidence of neoplasms (malignant, benign, or combined) in which the strength of the response is less than that required for clear evidence.
+	Author in general literature evaluated site as positive.
-	NTP evaluation is <i>no evidence</i> of carcinogenic activity: studies that are interpreted as showing no chemically related increases in malignant or benign neoplasms; or author in general literature evaluated site as negative.
blank	For NTP and general literature: all other sites.

APPENDIX 12 Bibliography: General Literature

1. Amo, H., Matsuyama, M., Amano, H., Yamada, C., Kawai, M., Miyata, N., and Nakadate, M. Carcinogenicity and toxicity study of *m*-phenylenediamine administered in the drinking-water to (C57BL/6 × C3H/He)F₁ mice. *Food Chem. Toxicol.* 26: 893-897(1988).
2. Annapurna, V. V., Mukundan, M. A., Sesikeran, B., and Bamji, M. S. Long-term effects of female sex steroids on female rat liver in an initiator-promoter model of hepato-

3. carcinogenesis. *Indian J. Biochem. Biophys.* 25: 708-713(1988).
3. Arnold, D. L., Moodie, C. A., Charbonneau, S. M., Grice, H. C., McGuire, P. F., Bryce, F. R., Collins, B. T., Zawidzka, Z. Z., Krewski, D. R., Nera, E. A., and Munro, I. C. Long-term toxicity of hexachlorobenzene in the rat and the effect of dietary vitamin A. *Food Chem. Toxicol.* 23: 779-793(1985).
4. Baden, J. M., Kundomal, Y. R., Mazze, R. I., and Kosek, J. C. Carcinogen bioassay of isoflurane in mice. *Anesthesiology* 69: 750-753(1988).
5. Barten, M. The effects of different MNNG (*N*-methyl-*N*-nitro-*N*-nitrosoguanidine)-doses on the stomach and the upper small intestine of the rat. *Exp. Pathol.* 31: 147-152(1987).
6. Berger, M. R., Schmahl, D., and Zerban, H. Combination experiments with very low doses of three genotoxic *N*-nitrosamines with similar organotropic carcinogenicity in rats. *Carcinogenesis* 8: 1635-1643(1987).
7. Borzelleca, J. F., and Hallagan, J. B. A chronic toxicity/carcinogenicity study of FD & C Yellow No. 5 (tartrazine) in mice. *Food Chem. Toxicol.* 26: 189-194(1988).
8. Borzelleca, J. F., and Hallagan, J. B. Lifetime toxicity/carcinogenicity study of FD & C Red No. 3 (erythrosine) in mice. *Food Chem. Toxicol.* 25: 735-737(1987).
9. Bosan, W. S., Shank, R. C., MacEwen, J. D., Gaworski, C. L., and Newberne, P. M. Methylation of DNA guanine during the course of induction of liver cancer in hamsters by hydrazine or dimethylnitrosamine. *Carcinogenesis* 8: 439-444(1987).
10. Burnett, C. M., and Corbett, J. F. Failure of short-term *in vitro* mutagenicity tests to predict the animal carcinogenicity of hair dyes. *Food Chem. Toxicol.* 25: 703-707(1987).
11. Carr, B. I., Rahbar, S., Asmeron, Y., Riggs, A., and Winberg, C. D. Carcinogenicity and haemoglobin synthesis induction by cytidine analogues. *Br. J. Cancer* 57: 395-402(1988).
12. Cavaliere, A., Bufalari, A., and Vitali, R. 5-azacytidine carcinogenesis in BALB/c mice. *Cancer Lett.* 37: 51-58(1987).
13. Ciliberti, A., Maltoni, C., and Perino, G. Long-term carcinogenicity bioassays on propylene administered by inhalation to Sprague-Dawley rats and Swiss mice. *Ann. N. Y. Acad. Sci.* 534: 235-245(1988).
14. Clevenger, M. A., Turnbull, D., Inoue, H., Enomoto, M., Allen, J. A., Henderson, L. M., and Jones, E. Toxicological evaluation of neosugar: Genotoxicity, carcinogenicity, and chronic toxicity. *J. Am. Coll. Toxicol.* 7: 643-662(1988).
15. Conti, B., Maltoni, C., Perino, G., and Ciliberti, A. Long-term carcinogenicity bioassays on styrene administered by inhalation, ingestion and injection and styrene oxide administered by ingestion in Sprague-Dawley rats, and para-methylstyrene administered by ingestion in Sprague-Dawley rats and Swiss mice. *Ann. N. Y. Acad. Sci.* 534: 203-234(1988).
16. Dodd, D. C., Port, C. D., Deslex, P., Regnier, B., Sanders, P., and Indacochea-Redmond, N. Two-year evaluation of misoprostol for carcinogenicity in CD Sprague-Dawley rats. *Toxicol. Pathol.* 15: 125-133(1987).
17. Elashoff, R. M., Fears, T. R., and Schneiderman, M. A. Statistical analysis of a carcinogen mixture experiment. I. Liver carcinogens. *J. Nat. Cancer Inst.* 79: 509-526(1987).
18. Ernst, H., Ohshima, H., Bartsch, H., Mohr, U., and Reichart, P. Tumorigenicity study in Syrian hamsters fed areca nut together with nitrite. *Carcinogenesis* 8: 1843-1845(1987).
19. Fiala, E. S., Czerniak, R., Castonguay, A., Conaway, C. C., and Rivenson, A. Assay of 1-nitropropane, 2-nitropropane, 1-azoxypropane and 2-azoxypropane for carcinogenicity by

- gavage in Sprague-Dawley rats. *Carcinogenesis* 8: 1947-1949(1987).
20. Fujii, K., Nomoto, K., Ishidate, M., Jr., and Nakamura, K. Chronic toxicity of charred fish meat in Wistar rats. *Nutr. Cancer* 9: 185-193(1987).
 21. Fujita, Y., Wakabayashi, K., Takayama, S., Nagao, M., and Sugimura, T. Induction of oral cavity cancer by 3-diazotyramine, a nitrosated product of tyramine present in foods. *Carcinogenesis* 8: 527-529(1987).
 22. Gallagher, G. T., Maull, E. A., Kovacs, K., and Szabo, S. Neoplasms in rats ingesting acrylonitrile for two years. *J. Am. Coll. Toxicol.* 7: 603-615(1988).
 23. Gopinath, C., and Gibson, W. A. Mesovarian leiomyomas in the rat. *Environ. Health Perspect.* 73: 107-113(1987).
 24. Greenman, D. L., Highman, B., Chen, J. J., Schieferstein, G. J., and Norvell, M. J. Influence of age on induction of mammary tumors by diethylstilbestrol in C3H/HeN mice with low murine mammary tumor virus titer. *J. Nat. Cancer Inst.* 77: 891-898(1986).
 25. Hasegawa, R., Takahashi, M., Furukawa, F., Toyoda, K., Sato, H., and Hayashi, Y. Co-carcinogenic effect of retinyl acetate on forestomach carcinogenesis of male F344 rats induced with butylated hydroxyanisole. *Jpn. J. Cancer Res.* 79: 320-328(1988).
 26. Hirose, M., Fukushima, S., Shirai, T., Hasegawa, R., Kato, T., Tanaka, H., Asakawa, E., and Ito, N. Stomach carcinogenicity of caffeic acid, sesamol and catechol in rats and mice. *Jpn. J. Cancer Res.* 81: 207-212(1990).
 27. Hirose, M., Kurata, Y., Tsuda, H., Fukushima, S., and Ito, N. Catechol strongly enhances rat stomach carcinogenesis: A possible new environmental stomach carcinogen. *Jpn. J. Cancer Res.* 78: 1144-1149(1987).
 28. Hirose, M., Masuda, A., Tsuda, H., Uwagawa, S., and Ito, N. Enhancement of bha-induced proliferative rat forestomach lesion development by simultaneous treatment with other antioxidants. *Carcinogenesis* 8: 1731-1735(1987).
 29. Inai, K., Kobuke, T., Nambu, S., Takemoto, T., Kou, E., Nishina, H., Fujihara, M., Yonehara, S., Suehiro, S., Tsuya, T., Horiuchi, K., and Tokuoka, S. Hepatocellular tumorigenicity of butylated hydroxytoluene administered orally to B6C3F₁ mice. *Jpn. J. Cancer Res.* 79: 49-58(1988).
 30. Jack, D., Poynter, D., and Spurling, N. W. Beta-adrenoceptor stimulants and mesovarian leiomyomas in the rat. *Toxicology* 27: 315-320(1983).
 31. Jang, J. J., Takahashi, M., Furukawa, F., Toyoda, K., Hasegawa, R., Sato, H., and Hayashi, Y. Long-term in vivo carcinogenicity study of phenytoin (5,5-diphenylhydantoin) in F344 rats. *Food Chem. Toxicol.* 25: 697-702(1987).
 32. Kato, T., Ohgaki, H., Hasegawa, H., Sato, S., Takayama, S., and Sugimura, T. Carcinogenicity in rats of a mutagenic compound, 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline. *Carcinogenesis* 9: 71-73(1988).
 33. Koepke, S. R., Creasia, D. R., Knutsen, G. L., and Michejda, C. J. Carcinogenicity of hydroxyalkylnitrosamines in F344 rats: Contrasting behavior of β - and γ -hydroxylated nitrosamines. *Cancer Res.* 48: 1533-1536(1988).
 34. Kuper, C. F., Reuzel, P. G. J., Feron, V. J., and Verschuuren, H. Chronic inhalation toxicity and carcinogenicity study of propylene oxide in Wistar rats. *Food Chem. Toxicol.* 29: 159-167(1988).
 35. Kuroda, K., Terao, K., and Akao, M. Inhibitory effect of fumaric acid on hepatocarcinogenesis by thioacetamide in rats. *J. Nat. Cancer Inst.* 79: 1047-1051(1987).
 36. Kurokawa, Y., Aoki, S., Matsushima, Y., Takamura, N., Imazawa, T., and Hayashi, Y. Dose-response studies on the carcinogenicity of potassium bromate in F344 rats after long-term oral administration. *J. Nat. Cancer Inst.* 77: 977-982(1986).
 37. Kurokawa, Y., Matsushima, Y., Takamura, N., Imazawa, T., and Hayashi, Y. Relationship between the duration of treatment and the incidence of renal cell tumors in male F344 rats administered potassium bromate. *Jpn. J. Cancer Res.* 78: 358-364(1987).
 38. Lee, K. P., Chromey, N. C., Culik, R., Barnes, J. R., and Schneider, P. W. Toxicity of *N*-methyl-2-pyrrolidone (NMP): Teratogenic, subchronic, and two-year inhalation studies. *Fundam. Appl. Toxicol.* 9: 222-235(1987).
 39. Leonard, T. B., Graichen, M. E., and Popp, J. A. Dinitrotoluene isomer-specific hepatocarcinogenesis in F344 rats. *J. Nat. Cancer Inst.* 79: 1313-1319(1987).
 40. Lijinsky, W., Kovatch, R. M., and Singer, S. S. Carcinogenesis in F-344 rats induced by nitrosohydroxyalkylchloroethylureas. *Cancer Res. Clin. Oncol.* 112: 221-228(1986).
 41. Lijinsky, W., and Kovatch, R. M. Chronic toxicity study of cyclohexanone in rats and mice. *J. Nat. Cancer Inst.* 77: 941-949(1986).
 42. Lijinsky, W., and Kovatch, R. M. Carcinogenesis by nitrosohydroxyethylurea and nitrosomethoxyethylurea in F344 rats. *Jpn. J. Cancer Res.* 79: 181-186(1988).
 43. Lijinsky, W., Kovatch, R. M., Keefer, L. K., Saavedra, J. E., Hansen, T. J., Miller, A. J., and Fiddler, W. Carcinogenesis in rats by cyclic *N*-nitrosamines containing sulphur. *Food Chem. Toxicol.* 26: 3-7(1988).
 44. Lijinsky, W., Kovatch, R. M., and Riggs, C. W. Carcinogenesis by nitrosodialkylamines and azoxyalkanes given by gavage to rats and hamsters. *Cancer Res.* 47: 3968-3972(1987).
 45. Lijinsky, W., Kovatch, R. M., Riggs, C. W., and Walters, P. T. Dose response study with *N*-nitrosomorpholine in drinking water of F-344 rats. *Cancer Res.* 48: 2089-2095(1988).
 46. Lijinsky, W., and Reuber, M. D. Chronic carcinogenesis studies of acrolein and related compounds. *Toxicol. Ind. Health* 3: 337-345(1987).
 47. Lijinsky, W., and Reuber, M. D. Pathologic effects of chronic administration of hydrochlorothiazide, with and without sodium nitrite, to F344 rats. *Toxicol. Ind. Health* 3: 413-422(1987).
 48. Maeda, T., Sano, N., Toge, K., Shibata, M., Izumi, K., and Otsuka, H. Lack of carcinogenicity of phenytoin in (C57BL/6 \times C3H)F₁ mice. *J. Toxicol. Environ. Health* 24: 111-119(1988).
 49. Maekawa, A., Matsuoka, C., Onodera, H., Tanigawa, H., Furuta, K., Kanno, J., Jang, J. J., Hayashi, Y., and Ogiu, T. Lack of carcinogenicity of tartrazine (FD & C Yellow No. 5) in the F344 rat. *Food Chem. Toxicol.* 25: 891-896(1987).
 50. Maekawa, A., Onodera, H., Tanigawa, H., Furuta, K., Kanno, J., Matsuoka, C., Ogiu, T., and Hayashi, Y. Long-term studies on carcinogenicity and promoting effect of phenylbutazone in Donryu rats. *J. Nat. Cancer Inst.* 79: 577-584(1987).
 51. Maltoni, C. Early results of the experimental assessments of the carcinogenic effects of one epoxy solvent: styrene oxide. *Adv. Mod. Environ. Toxicol.* 2: 97-110(1981).
 52. Maltoni, C., Ciliberti, A., Cotti, G., and Perino G. Long-term carcinogenicity bioassays on acrylonitrile administered by inhalation and by ingestion to Sprague-Dawley rats. *Ann. N. Y. Acad. Sci.* 534: 179-202(1988).
 53. Maltoni, C., Conti, B., Perino, G., and Di Maio, V. Further evidence of benzene carcinogenicity; results on Wistar rats and mice treated by injection. *Ann. N. Y. Acad. Sci.* 534: 412-426(1988).
 54. Maltoni, C., and Cotti, G. Carcinogenicity of vinyl chloride in Sprague-Dawley rats after prenatal and postnatal exposure. *Ann. N. Y. Acad. Sci.* 534: 145-159(1988).
 55. Maltoni, C., Cotti, G., and Perino, G. Long-term carcino-

- genicity bioassays on methylene chloride administered by ingestion to Sprague-Dawley rats and Swiss mice and by inhalation to Sprague-Dawley rats. *Ann. N. Y. Acad. Sci.* 534: 352-366(1988).
56. Maltoni, C., Lefemine, G., Tovoli, D., and Perino, G. Long-term carcinogenicity bioassays on three chlorofluorocarbons (trichlorofluoromethane, FC11; dichlorodifluoromethane, FC12; chlorodifluoromethane, FC22) administered by inhalation to Sprague-Dawley rats and Swiss mice. *Ann. N. Y. Acad. Sci.* 534: 261-282(1988).
 57. Markiewicz, V. R., Saunders, L. Z., Geus, R. J., Payne, B. J., and Hook, J. B. Carcinogenicity study of auranofin, an orally administered gold compound, in mice. *Fundam. Appl. Toxicol.* 11: 277-284(1988).
 58. McManus, B. M., Toth, B., and Patil, K. D. Aortic rupture and aortic smooth muscle tumors in mice: Induction by *p*-mushroom benzoic acid hydrochloride of the cultivated mushroom *Agaricus bisporus*. *Lab. Invest.* 57: 78-83(1987).
 59. Mirvish, S. S., Weisenburger, D. D., Salmasi, S., and Kaplan, P. A. Carcinogenicity of 1-(2-hydroxyethyl)-1-nitrosourea and 3-nitroso-2-oxazolidinone administered in drinking water to male MRC-Wistar rats: Induction of bone, hematopoietic, intestinal, and liver tumors. *J. Nat. Cancer Inst.* 78: 387-393(1987).
 60. Mizutani, T., and Mitsuoka, T. Effect of dietary phenobarbital on spontaneous hepatic tumorigenesis in germfree C3H/He male mice. *Cancer Lett.* 39: 233-237(1988).
 61. Mori, H., Sugie, S., Yoshimi, N., Kuniyasu, T., Iwata, H., Kawai, K., and Hamasaki, T. Potential carcinogenicity of 5,6-dimethoxysterigmatocystin in rats. *Carcinogenesis* 9: 1039-1042 (1988).
 62. Nera, E. A., Iverson, F., Lok, E., Armstrong, C. L., Karpinski, K., and Clayson, D. B. A carcinogenesis reversibility study of the effects of butylated hydroxyanisole on the forestomach and urinary bladder in male Fischer 344 rats. *Toxicology* 53: 251-268 (1988).
 63. Nitschke, K. D., Burek, J. D., Bell, T. J., Kociba, R. J., Rampy, L. W., and McKenna, M. J. Methylene chloride: A 2-year inhalation toxicity and oncogenicity study in rats. *Fundam. Appl. Toxicol.* 11: 48-59(1988).
 64. Nonoyama, T., Fullerton, F., Reznik, G., Buccì, T. J., and Ward, J. M. Mouse hepatoblastomas: A histologic, ultrastructural, and immunohistochemical study. *Pathol. Vet.* 25: 286-296(1988).
 65. Ohgaki, H., Hasegawa, H., Suenaga, M., Sato, S., Takayama, S., and Sugimura, T. Carcinogenicity in mice of a mutagenic compound, 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline (MeIQx) from cooked foods. *Carcinogenesis* 8: 665-668(1987).
 66. Owen, P. E., Glaister, J. R., Gaunt, I. F., and Pullinger, D. H. Inhalation toxicity studies with 1,3-butadiene 3 two year toxicity/carcinogenicity study in rats. *Am. Ind. Hyg. Assoc. J.* 48: 407-413(1987).
 67. Port, C. D., Dodd, D. C., Deslex, P., Regnier, B., Sanders, P., and Indacochea-Redmond, N. Twenty-one month evaluation of misoprostol for carcinogenicity in CD-1 mice. *Toxicol. Pathol.* 15: 134-142(1987).
 68. Quast, J. F., Calhoun, L. L., and Frauson, L. E. 1,1,1-trichloroethane formulation: A chronic inhalation toxicity and oncogenicity study in Fischer 344 rats and B6C3F₁ mice. *Fundam. Appl. Toxicol.* 11: 611-625(1988).
 69. Rao, M. S., Dwivedi, R. S., Subbarao, V., and Reddy, J. K. Induction of peroxisome proliferation and hepatic tumours in C57BL/6N mice by ciprofibrate, a hypolipidaemic compound. *Br. J. Cancer* 58: 46-51(1988).
 70. Rao, M. S., Usuda, N., Subbarao, V., and Reddy, J. K. Absence of γ -glutamyl transpeptidase activity in neoplastic lesions induced in the liver of male F-344 rats by di-(2-ethylhexyl)phthalate, a peroxisome proliferator. *Carcinogenesis* 8: 1347-1350(1987).
 71. Rivenson, A., Hoffmann, D., Prokopczyk, B., Amin, S., and Hecht, S. S. Induction of lung and exocrine pancreas tumors in F344 rats by tobacco-specific and areca-derived *N*-nitrosamines. *Cancer Res.* 48: 6912-6917(1988).
 72. Rosenkrantz, H., and Fleischman, R. W. In vivo carcinogenesis assay of DL-methadone.HCl in rodents. *Fundam. Appl. Toxicol.* 11: 640-651(1988).
 73. Rosenkrantz, H., and Fleischman, R. W. In vivo carcinogenesis assay of *l*- α -acetylmethadol.HCl in rodents. *Fundam. Appl. Toxicol.* 11: 626-639(1988).
 74. Soffritti, M., Maltoni, C., Maffei, F., and Biagi, R. Formaldehyde: An experimental multipotential carcinogen. *Toxicol. Ind. Health* 5: 699-730(1989).
 75. Stenback, F., Weisenburger, J. H., and Williams, G. M. Effect of lifetime administration of dimethylaminoethanol on longevity, aging changes, and cryptogenic neoplasms in C3H mice. *Mech. Ageing Dev.* 42: 129-138(1988).
 76. Togeï, K., Sano, N., Maeda, T., Shibata, M., and Otsuka, H. Carcinogenicity of bucetin in (C57BL/6 \times C3H)F₁ mice. *J. Nat. Cancer Inst.* 79: 1151-1158(1987).
 77. Toth, B. Carcinogenesis by *N*2-[γ -L(+)-glutamyl]-4-carboxy-phenylhydrazine of *Agaricus bisporus* in mice. *Anticancer Res.* 6: 917-920(1986).
 78. Toth, B., and Raha, C. R. Carcinogenesis by pentanal methylformylhydrazone of *Gyromitra esculenta* in mice. *Mycopathologia* 98: 83-89(1987).
 79. Trochimowicz, H. J., Rusch, G. M., Chiu, T., and Wood, C. K. Chronic inhalation toxicity/carcinogenicity study in rats exposed to Fluorocarbon 113 (FC-113). *Fundam. Appl. Toxicol.* 11: 68-75(1988).
 80. Truhaut, R., Le Bourhis, B., Attia, M., Glomot, R., Newman, J., and Caldwell, J. Chronic toxicity/carcinogenicity study of trans-anethole in rats. *Food Chem. Toxicol.* 27: 11-19(1989).
 81. Walker, R. F., Weideman, C. A., and Wheeldon, E. B. Reduced disease in aged rats treated chronically with ibopamine, a catecholaminergic drug. *Neurobiol. Aging* 9: 291-301(1988).
 82. Wolff, G. L., Roberts, D. W., Morrissey, R. L., Greenman, D. L., Allen, R. R., Campbell, W. L., Bergman, H., Nesnow, S., and Frith, C. H. Tumorigenic responses to lindane in mice: Potentiation by a dominant mutation. *Carcinogenesis* 8: 1889-1897(1987).
 83. Woutersen, R. A., Appelman, L. M., Van Gardenen-Hoetmer, A., and Feron, V. J. Inhalation toxicity of acetaldehyde in rats. III. Carcinogenicity study. *Toxicology* 41: 213-231(1986).
 84. Woutersen, R. A., and Feron, V. J. Inhalation toxicity of acetaldehyde in rats. IV. progression and regression of nasal lesions after discontinuation of exposure. *Toxicology* 47: 295-305(1987).

APPENDIX 13

Bibliography: National Cancer Institute/
National Toxicology Program Technical Reports

CHEMICAL NAME	TECHNICAL REPORT NUMBER	PUBLICATION DATE
2-AMINO-4-NITROPHENOL	339	1988
2-AMINO-5-NITROPHENOL	334	1988
BENZOFURAN	370	1989
BENZYL ALCOHOL	343	1989
BORIC ACID	324	1987
BROMODICHLOROMETHANE	321	1987
BROMOETHANE	363	1989
PARA-CHLOROANILINE HYDROCHLORIDE	351	1989
CHLOROETHANE	346	1989
2,4-DICHLOROPHENOL	353	1989
DICHLORVOS	342	1989
DIMETHOXANE	354	1989
DIMETHYL METHYLPHOSPHONATE	323	1987
N,N-DIMETHYLANILINE	360	1989
DIPHENHYDRAMINE HYDROCHLORIDE	355	1989
1,2-EPOXYBUTANE	329	1988
ERYTHROMYCIN STEARATE	338	1988
ETHYLENE OXIDE	326	1987
FUROSEMIDE	356	1989
FOOD GRADE GERANYL ACETATE (71% GERANYL ACETATE, 29% CITRONELLYL ACETATE)	252	1987
HEXACHLOROETHANE	361	1989
4-HEXYLRESORCINOL	330	1988
HYDROCHLOROTHIAZIDE	357	1989
HYDROQUINONE	366	1989
MALONALDEHYDE, SODIUM SALT	331	1988
2-MERCAPTOBENZOTHAZOLE	332	1988
8-METHOXYPBORALEN	359	1989
METHYL CARBAMATE	328	1987
alpha-METHYLDOPA SESQUIHYDRATE	348	1989
N-METHYLOLACRYLAMIDE	352	1989
MONURON	266	1988
NALIDIXIC ACID	368	1989
NITROFURANTOIN	341	1989
NITROFURAZONE	337	1988
OCHRATOXIN A	358	1989
C.I. ACID ORANGE 3	335	1988
C.I. ACID ORANGE 10	211	1987
PENICILLIN VK	336	1988
PENTACHLOROPHENOL, TWO TECHNICAL GRADE MIXTURES	349	1989
PENTAERYTHRITOL TETRANITRATE WITH 80% D-LACTOSE MONOHYDRATE	365	1989
N-PHENYL-2-NAPHTHYLAMINE	333	1988
ROTENONE	320	1988
ROXARSONE	345	1989
TETRACYCLINE HYDROCHLORIDE	344	1989
TRIBROMOMETHANE	350	1989
TRICHLOROETHYLENE (WITHOUT EPICHLOROHYDRIN)	273	1988
TRICHLOROETHYLENE (WITHOUT EPICHLOROHYDRIN)	243	1990

APPENDIX 14: INDEX TO ALL CHEMICALS IN THE FIVE PLOTS OF THE CARCINOGENIC POTENCY DATABASE AND RESULTS FOR POTENCY (TD₅₀) AND POSITIVITY

Appendix 14 is both an index to chemicals in the CPDB and a tabular compilation of results on positivity and potency in rats and mice. Chemical names and common synonyms are listed alphabetically for the 1136 chemicals in the database, Chemical Abstracts Service registry (CAS) number is reported, and the plots that include experimental results on the chemical are listed by plot number.

Positivity. For each chemical, a result is reported in male rats (MR), female rats (FR), male mice (MM), and female mice (FM). If there is no experiment in the CPDB for that sex-species group, this is indicated by "NT." When all four sex-species groups are NT, the chemical was tested only in a species other than rats or mice (see footnotes "g" and "h" below). The classification of positivity is based on a positive result in at least one experiment, and we classify an experiment as either positive or negative on the basis of the author's opinion in the published paper. We use the author's opinion to determine positivity because it often takes into account more information than statistical significance alone, such as historical control rates for particular sites, survival and latency, and/or dose response. Generally, this designation by author's opinion corresponds well with the results of statistical tests for the significance of the dose-response effect. The strongest level of evidence of carcinogenicity in any experiment in the sex-species group is reported in Appendix 14 for each chemical. We indicate whether the compound was tested in each group and list the strongest level of evidence for carcinogenicity based upon any author's evaluation in either the general literature or the NCI/NTP. In the general literature, a (+) indicates a positive author's opinion, and a (-) indicates either that "no opinion" was reported for this experiment or that the opinion was negative. In the NCI/NTP the strongest evaluation is clear evidence of carcinogenicity (+). When there was no such evaluation in one of the sex-species groups, but the compound was tested by NCI/NTP and their evaluation was stronger than "no evidence of carcinogenicity" (-), we indicate whether that NCI/NTP evaluation was "some evidence of carcinogenicity" (P), "equivocal" (E) or "inadequate bioassay" (I). For older NCI/NTP tests the evaluation (A) indicates "associated with carcinogenicity," and we do not interpret this as positive. These evaluations correspond to the opinions reported in our published plots. The abbreviations for positivity in Appendix 14 are as follows:

- NT = No Test in the CPDB in this group
- + = The CPDB contains at least one experiment in which the compound was evaluated as a carcinogen by the published author. For NCI/NTP tests, the evaluation was "clear evidence of carcinogenicity."
- P = The strongest level of evidence in the CPDB was an NTP evaluation of "some evidence of carcinogenicity."
- I = No tests in the CPDB in this sex-species group were

evaluated as positive; however, the NCI/NTP test was evaluated as inadequate.

- A = The strongest level of evidence in the CPDB was an NCI/NTP evaluation of "associated with carcinogenicity."
- E = The strongest level of evidence in the CPDB was an NTP evaluation of "equivocal."
- = All tests in this group were negative.
- B+ = In the only positive test in the sex-species, results were reported only for males and females combined.
- B- = In the only test in the sex-species, results were reported only for males and females combined, and the test was negative.

Carcinogenic Potency. For the purposes of Appendix 14, TD₅₀ values for a chemical are reported only for a species with a positive evaluation of carcinogenicity in at least one test. In any given positive experiment we select the lowest TD₅₀ value from among positively evaluated target sites with a statistically significant dose response (two-tailed $p < 0.1$). If no positive sites have a significant dose response, then we select the most potent (lowest TD₅₀ from among positively evaluated sites with $p \geq 0.1$). This method provides a single TD₅₀ to represent an experiment. For chemicals with more than one positive experiment, we summarize potency in a species by selecting the lowest significant TD₅₀ value from among those representing each experiment. If none is significant, the lowest is chosen from among the non-significant values with a positive author's opinion (see footnote "b" below). In some experiments, no TD₅₀ could be estimated because all dosed animals had the tumor of interest, and the only data available were for crude percentages of animals with a tumor. For these cases we use the 99% upper confidence limit of TD₅₀ as a replacement for the TD₅₀.

In a series of footnotes, we provide additional information about TD₅₀ values and test results in the CPDB. These are as follows:

- a = The CPDB contains more than one positive test in the species.
- b = The reported TD₅₀ is not statistically significant (i.e., $p \geq 0.1$), and all results evaluated as positive in the species are not significant.
- c = Only an upper bound and no TD₅₀ could be estimated because all dosed animals had the tumor of interest and only summary data were available. The reported value is the 99% upper confidence limit.
- d = All positive results for this species in the CPDB are from tests in which the compound was administered by either IP or IV injection.
- e = The reported TD₅₀ from a test in which the compound was administered by IP or IV injection; however, the CPDB also contains a positive test in this species

with a less potent TD₅₀ value from a test where the route was oral or inhalation.

- f = TD₅₀ values from different significant, positive experiments in this species vary by more than 10-fold from one another. The most potent TD₅₀ value is reported here.
- g = The CPDB includes tests in a species other than rats or mice, and at least one test is positive.
- h = The CPDB includes tests in a species other than rats or mice, and all tests are negative.
- i = Data on four NCI bioassays are included in Appendix 14 but are excluded from the analyses and tables in this and previous papers: C.I. Direct Black 38, C.I. Direct Blue 6, and C.I. Direct Brown 95, were only tested subchronically; 3-Amino-9-ethylcarbazole•HCL and 3-amino-9-ethylcarbazole mixture were tested by NCI in one bioassay but we separated them in the CPDB because slightly different chemicals were used for different dose groups; we combined them for our analyses, as NCI had done.

The experimental results used in Appendix 14 appear in the five plots of the CPDB:

- 1 = Gold, L. S., Sawyer, C. B., Magaw, R., Backman, G. M., de Veciana, M., Levinson, R., Hooper, N. K., Havender, W. R., Bernstein, L., Peto, R., Pike, M.

C., and Ames, B. N. A carcinogenic potency database of the standardized results of animal bioassays. *Environ. Health Perspect.* 58: 9-319 (1984).

- 2 = Gold, L. S., de Veciana, M., Backman, G. M., Magaw, R., Lopipero, P., Smith, M., Blumenthal, M., Levinson, R., Bernstein, L., and Ames, B. N. *Chronological supplement to the carcinogenic potency database: standardized results of animal bioassays published through December 1982.* *Environ. Health Perspect.* 67: 161-200 (1986).
- 3 = Gold, L. S., Slone, T. H., Backman, G. M., Magaw, R., Da Costa, M., Lopipero, P., Blumenthal, M., and Ames, B. N. *Second Chronological Supplement to the Carcinogenic Potency Database: Standardized Results of Animal Bioassays Published through December 1984 and by the National Toxicology Program through May 1986.* *Environ. Health Perspect.* 74: 237-329 (1987).
- 4 = Gold, L. S., Slone, T. H., Backman, G. M., Eisenberg, S., Da Costa, M., Wong, M., Manley, N. B., Rohrbach, L., and Ames, B. N. *Third chronological supplement to the Carcinogenic Potency Database: standardized results of animal bioassays published through December 1986 and by the National Toxicology Program through June 1987.* *Environ. Health Perspect.* 84: 215-285 (1990).
- 5 = This publication.

**APPENDIX 14. INDEX TO CHEMICALS IN THE 5 PLOTS OF THE CARCINOGENIC
POTENCY DATABASE AND RESULTS FOR POTENCY (TD₅₀) AND POSITIVITY**

TD ₅₀ (mg/kg/day)		Positivity				Plot	CAS	Chemical Name
Rat	Mouse	MR	FR	MM	FM	Number	Number	
88.5 ^a	NT	+	+	NT	NT	4,5	75-07-0	A-alpha-C (see 2-AMINO-9H-PYRIDO(2,3-b)INDOLE)
NT	1.61 ^a	NT	NT	+	+	2	16568-02-8	ACETALDEHYDE ⁸
-	NT	-	NT	NT	NT	5	107-29-9	ACETALDEHYDE METHYLFORMYLHYDRAZONE
104 ^a	3010	+	+	+	-	1	60-35-5	ACETALDOXIME
440 ^a	1010 ^a	+	+	+	+	1,3,4	103-90-2	ACETAMINOPHEN
-	-	-	-	-	-	1	968-81-0	ACETOHEXAMIDE
6.05	NT	NT	+	NT	NT	1	18523-69-8	ACETONE[4-(5-NITRO-2-FURYL)-2-THIAZOLYL]HYDRAZONE
12.1	NT	+	-	NT	NT	2	127-06-0	ACETOXIME
11.4 ^{af}	72.9 ^{af}	+	+	+	+	1	3688-53-7	AF-2 ⁸
21.1 ^a	-	+	NT	-	NT	1	34627-78-6	1'-ACETOXYSAFROLE
NT	208 ^a	NT	NT	+	+	1	65734-38-5	N'-ACETYL-4-(HYDROXYMETHYL)PHENYLHYDRAZINE
NT	319 ^a	NT	NT	+	+	1	1078-38-2	1-ACETYL-2-ISONICOTINOYLHYDRAZINE
NT	-	NT	NT	-	-	1	520-45-6	3-ACETYL-6-METHYL-2,4-PYRANDIONE
NT	44.8 ^a	NT	NT	+	+	1	114-83-0	1-ACETYL-2-PHENYLHYDRAZINE
1.18	NT	NT	+	NT	NT	1	4075-79-0	4-ACETYLAMINOBIIPHENYL
-	NT	NT	-	NT	NT	1	28314-03-6	1-ACETYLAMINOFLUORENE
0.64 ^a	4.78 ^{af}	+	+	+	+	1-5	53-96-3	2-ACETYLAMINOFLUORENE ⁸
-	NT	NT	-	NT	NT	1	28322-02-3	4-ACETYLAMINOFLUORENE
-	NT	-	-	NT	NT	1	---	ACETYLATED DIAMYLOPECTIN PHOSPHATE
-	NT	-	-	NT	NT	1	68130-14-3	ACETYLATED DISTARCH ADIPATE
-	NT	-	-	NT	NT	1	53123-84-5	ACETYLATED DISTARCH GLYCEROL
-	NT	-	-	NT	NT	1	---	ACETYLATED DISTARCH PHOSPHATE
-	-	-	-	-	-	-	-	L-alpha-ACETYLMETHADOL.HCl (see 6-DIMETHYLAMINO-4,4-DIPHENYL-3-HEPTANOL ACETATE.HCl)
-	-	-	-	-	-	-	-	C.I. ACID RED 14, DISODIUM SALT (see C.I. FOOD RED 3)
-	NT	-	-	NT	NT	5	107-02-8	ACROLEIN
-	NT	-	-	NT	NT	5	3054-95-3	ACROLEIN DIETHYLACETAL
-	NT	-	-	NT	NT	5	5314-33-0	ACROLEIN OXIME
0.395 ^{ad}	NT	+	+	I	I	1	7008-42-6	ACRONYCINE
4.21 ^a	NT	+	+	NT	NT	4	79-06-1	ACRYLAMIDE
5.31 ^{af}	NT	+	+	NT	NT	1,5	107-13-1	ACRYLONITRILE
-	NT	-	NT	NT	NT	1	8052-16-2	ACTINOMYCIN C
7.69E-4 ^{ad}	NT	+	+	NT	NT	1	50-76-0	ACTINOMYCIN D
-	-	-	-	-	-	1	628-94-4	ADIPAMIDE
0.00247	NT	+	NT	NT	NT	1	29611-03-8	AFLATOXICOL
9.32E-4 ^{af}	-	+	+	-	-	1,3,5	1162-65-8	AFLATOXIN B1 ⁸
0.00187 ^a	0.343	+	NT	+	NT	1	---	AFLATOXIN, CRUDE
-	-	-	-	-	-	2	9002-18-0	AGAR
-	-	-	-	-	-	-	-	AGARITINE (see beta-N-[gamma-L(+)-GLUTAMYL]-4-HYDROXYMETHYLPHENYLHYDRAZINE)
-	-	-	-	-	-	-	-	AGERITE 150 (see p-ISOPROPOXYDIPHENYLAMINE)
-	-	-	-	-	-	-	-	AGERITE ALBA (see HYDROQUINONE MONOBENZYL ETHER)
-	-	-	-	-	-	-	-	AGERITE DPPD (see DIPHENYL-p-PHENYLENEDIAMINE)
-	-	-	-	-	-	-	-	AGERITE POWDER (see PHENYL-beta-NAPHTHYLAMINE)
-	-	-	-	-	-	-	-	AGERITE WHITE (see sym.-dibeta-NAPHTHYL-p-PHENYLENEDIAMINE)
-	-	-	-	-	-	-	-	ALDERLIN (see PRONETHALOL)
-	-	-	-	-	-	-	-	ALDERLIN.HCl (see PRONETHALOL.HCl)
-	-	-	-	-	-	1	116-06-3	ALDICARB
-	0.741 ^a	-	-	+	B+	1	309-00-2	ALDRIN

TD ₃₀ (mg/kg/day)		Positivity				Plot	CAS		Chemical Name
Rat	Mouse	MR	FR	MM	FM	Number	Number		
-	NT	-	-	NT	NT	1	---	ALKYLBENZENESULFONATE, LINEAR	
-	NT	-	-	NT	NT	4	mixture	ALKYLDIMETHYLAMINE OXIDES, COMMERCIAL GRADE	
-	NT	-	-	NT	NT	3	97-59-6	ALLANTOIN	
-	NT	-	-	NT	NT	5	107-18-6	ALLYL ALCOHOL	
NT	-	I	I	A	A	1	107-05-1	ALLYL CHLORIDE	
96	-	+	A	-	-	2	57-06-7	ALLYL ISOTHIOCYANATE	
123	62.8	+	-	-	+	3	2835-39-4	ALLYL ISOVALERATE	
								1-ALLYL-3-METHOXY-4-HYDROXYBENZENE (see EUGENOL)	
NT	30.9 ^a	NT	NT	+	+	1	52207-83-7	ALLYLHYDRAZINE.HCl	
-	-	-	-	-	-	1	10043-67-1	ALTAX (see BENZOTHIAZYL DISULFIDE)	
								ALUMINUM POTASSIUM SULFATE	
								AMARANTH (see FD & C RED NO. 2)	
								AMAX (see N-OXYDIETHYLENEBENZOTHIAZOLE-2-SULFENAMIDE)	
0.574 ^a	25 ^a	+	+	+	+	1,4	75104-43-7	2-AMINO-5-AZOTOLUENE (see o-AMINOAZOTOLUENE)	
								3-AMINO-1,4-DIMETHYL-5H-PYRIDO[4,3-b]INDOLE ACETATE	
								4-AMINO-2,3-DIMETHYLAZOBENZENE (see o-AMINOAZOTOLUENE)	
NT	10.7 ^a	NT	NT	+	+	4	77094-11-2	2-AMINO-3,4-DIMETHYLIMIDAZO[4,5-f]QUINOLINE	
1.26 ^a	14.2 ^a	+	+	+	+	5	77500-04-0	2-AMINO-3,8-DIMETHYLIMIDAZO[4,5-f]QUINOXALINE	
-	2070	-	-	+	-	1	17026-81-2	3-AMINO-4-ETHOXYACETANILIDE	
28.1 ^a	33 ^a	+	+	+	+	1	6109-97-3	3-AMINO-9-ETHYL CARBAZOLE.HCl	
11.8 ^a	30.5 ^a	+	+	+	+	1	mixture	3-AMINO-9-ETHYL CARBAZOLE MIXTURE	
								4-AMINO-3-HYDROXYBIPHENYL (see 3-HYDROXY-4-AMINO BIPHENYL)	
								4-AMINO-N10-METHYL-PTEROYLGLUTAMIC ACID (see METHOTREXATE)	
NT	15.6 ^a	NT	NT	+	+	3	68006-83-7	2-AMINO-3-METHYL-9H-PYRIDO-[2,3-b]-INDOLE	
5.32	6.81 ^{af}	-	+	+	+	1	72254-58-1	3-AMINO-1-METHYL-5H-PYRIDO[4,3-b]INDOLE ACETATE	
34.1 ^a	174	+	+	-	+	1	82-28-0	1-AMINO-2-METHYLANTHRAQUINONE	
3.25 ^a	5.08 ^a	+	+	+	+	3	67730-11-4	2-AMINO-6-METHYLDIPYRIDO[1,2-a:3',2'-d]IMIDAZOLE	
3.57 ^a	17.5 ^a	+	+	+	+	3,4	76180-96-6	2-AMINO-3-METHYLIMIDAZO[4,5-f]QUINOLINE	
3.29	NT	NT	+	NT	NT	4	---	2-AMINO-3-METHYLIMIDAZO[4,5-f]QUINOLINE.HCl	
3.67	NT	NT	+	NT	NT	1	3775-55-1	2-AMINO-5-(5-NITRO-2-FURYL)-1,3,4-OXADIAZOLE	
0.662	NT	NT	+	NT	NT	1	712-68-5	2-AMINO-5-(5-NITRO-2-FURYL)-1,3,4-THIADIAZOLE	
5.85	7.87	NT	+	NT	+	1,2	38514-71-5	2-AMINO-4-(5-NITRO-2-FURYL)THIAZOLE	
NT	105 ^a	NT	NT	+	+	3	28754-68-9	trans-5-AMINO-3[2-(5-NITRO-2-FURYL)VINYL-1,2,4-OXADIAZOLE	
839	-	P	-	-	-	5	99-57-0	2-AMINO-4-NITROPHENOL	
111	-	P	-	-	-	5	121-88-0	2-AMINO-5-NITROPHENOL	
309	-	+	A	-	-	1	119-34-6	4-AMINO-2-NITROPHENOL	
NT	9.95	NT	NT	NT	+	1	2104-09-8	2-AMINO-4-(p-NITROPHENYL)THIAZOLE	
44.6	-	A	+	-	-	1	121-66-4	2-AMINO-5-NITROTHIAZOLE	
-	NT	NT	-	NT	NT	1	18968-99-5	2-AMINO-5-PHENYL-2-OXAZOLIN-4-ONE + Mg(OH)2	
NT	35.6 ^a	NT	NT	+	+	3	26148-68-5	2-AMINO-9H-PYRIDO(2,3-b)INDOLE	
101	755 ^a	+	-	+	+	1	117-79-3	2-AMINOANTHRAQUINONE	
3.7 ^a	-	+	+	-	NT	1	97-56-3	o-AMINOAZOTOLUENE	
								AMINOBENZOIC ACID (see ANTHRANILIC ACID)	
								4-AMINO BIPHENYL (see 4-AMINODIPHENYL)	
NT	0.993 ^a	NT	NT	+	+	1	92-67-1	4-AMINODIPHENYL	
0.98	32.6 ^a	NT	+	+	+	4	2113-61-3	4-AMINODIPHENYL.HCl	
NT	3.36 ^{ac}	NT	NT	+	+	1	3693-22-9	2-AMINODIPHENYLENE OXIDE	
33.8 ^a	12 ^a	+	+	+	+	3	67730-10-3	2-AMINODIPYRIDO[1,2-a:3',2'-d]IMIDAZOLE	
								4-(2-AMINOETHYL)-6-DIAZO-2,4-CYCLOHEXADIENONE.HCl (see 3-DIAZOTYRAMINE.HCl)	
								p-AMINONITROPHENOL (see 4-AMINO-2-NITROPHENOL)	
8.75 ^a	24.5 ^a	+	+	+	+	1,3	61-82-5	3-AMINOTRIAZOLE ^h	

TD ₅₀ (mg/kg/day)		Positivity				Plot	CAS	Chemical Name
Rat	Mouse	MR	FR	MM	FM	Number	Number	
833	-	+	-	-	-	2	2432-99-7	11-AMINOUNDECANOIC ACID
NT	-	NT	NT	NT	-	1	12125-02-9	AMITROL (see 3-AMINOTRIAZOLE)
-	NT	-	NT	NT	NT	1	3012-65-5	AMMONIUM CHLORIDE
NT	-	NT	NT	-	-	1	1336-21-6	AMMONIUM CITRATE
-	NT	-	NT	NT	NT	4	57-43-2	AMMONIUM HYDROXIDE
-	-	E	-	-	-	4	7177-48-2	AMOBARBITAL
0.532 ^a	NT	+	+	NT	NT	1	10589-74-9	AMPICILLIN TRIHYDRATE
								1-AMYL-1-NITROSOUREA
								1-AMYL-1-NITROSOURETHAN (see NITROSOAMYLURETHAN)
								n-AMYLHYDRAZINE.HCl (see n-PENTYLHYDRAZINE.HCl)
280 ^a	NT	+	NT	NT	NT	4	9047-13-6	AMYLOPECTIN SULFATE
NT	-	NT	NT	NT	-	3	104-46-1	ANETHOLE
NT	-	NT	NT	-	-	1	15879-93-3	ANHYDROGLUCOCHLORAL
-	-	-	-	-	-	1	101-05-3	ANILAZINE
-	NT	-	NT	NT	NT	1	62-53-3	ANILINE
88 ^{af}	-	+	+	-	-	1	142-04-1	ANILINE.HCl
27.8 ^a	935 ^a	+	+	+	+	1	134-29-2	o-ANISIDINE.HCl
-	-	A	-	-	-	1	20265-97-8	p-ANISIDINE.HCl
-	-	-	-	-	-	1	118-92-3	ANTHRANILIC ACID
NT	-	NT	NT	-	-	1	84-65-1	9,10-ANTHRAQUINONE
NT	-	NT	NT	B-	B-	1	28300-74-5	ANTIMONY POTASSIUM TARTRATE
								ANTIMYCIN (see CITRININ)
								ANTIPYRINE (see PHENAZONE)
								ANTU (see 1-(1-NAPHTHYL)-2-THIOUREA)
								APC (see ASPIRIN, PHENACETIN, AND CAFFEINE)
61.8 ^a	158	B+	B+	+	-	1	140-57-8	ARAMITE
NT	33.6 ^a	NT	NT	+	+	3	61-94-9	ARECOLINE.HCl
-	9.58	A	A	+	NT	1	27323-18-8	AROCLOR 1254
1.04 ^a	NT	+	+	NT	NT	1,3	11096-82-5	AROCLOR 1260
-	NT	B-	B-	NT	NT	1	7631-89-2	ARSENATE, SODIUM
								ARSENIC TRIOXIDE (see ARSENIUS OXIDE)
NT	-	NT	NT	-	-	1	1327-53-3	ARSENIUS OXIDE
-	-	B-	B-	B-	B-	1	7784-46-5	ARSENITE, SODIUM
-	NT	-	NT	NT	NT	5	134-03-2	L-ASCORBATE, SODIUM
-	-	-	-	-	-	3	50-81-7	L-ASCORBIC ACID
-	NT	-	-	NT	NT	1	22839-47-0	ASPARTAME
-	-	-	B-	-	-	1,3,4	50-78-2	ASPIRIN
-	-	-	-	-	-	1	8003-03-0	ASPIRIN, PHENACETIN, AND CAFFEINE
NT	-	NT	NT	-	-	1	1912-24-9	ATRAZINE
-	NT	-	-	NT	NT	1	51-55-8	ATROPINE
11	39.2 ^a	+	NT	+	+	1	2465-27-2	AURAMINE-O
NT	-	NT	NT	-	-	5	34031-32-8	AURANOFIN
								AVADEX (see DIALLATE)
0.17 ^d	0.0569 ^{ad}	+	I	+	+	1,5	320-67-2	5-AZACYTIDINE
-	NT	-	NT	NT	NT	5	3131-60-0	6-AZACYTIDINE
0.793 ^d	NT	B+	B+	NT	NT	1,3	115-02-6	AZASERINE
-	NT	NT	-	NT	NT	3	446-86-6	AZATHIOPRINE
-	NT	-	-	NT	NT	1	26628-22-8	AZIDE, SODIUM
-	-	A	-	-	-	1	86-50-0	AZINPHOSMETHYL
19.2 ^a	-	+	+	-	-	1	103-33-3	AZOBENZENE
0.0302 ^a	NT	+	NT	NT	NT	3,5	25843-45-2	AZOXYMETHANE
2.41E-4 ^c	NT	+	NT	NT	NT	5	---	1-AZOXYPROPANE
0.00268	NT	+	NT	NT	NT	5	---	2-AZOXYPROPANE
-	NT	-	NT	NT	NT	4	67-52-7	BARBITURIC ACID
-	-	-	-	-	-	1	543-80-6	BARIUM ACETATE
								BCME (see BIS-(CHLOROMETHYL)ETHER)
								BENADRYL (see DIPHENHYDRAMINE.HCl)
51.1 ^a	15.1 ^{af}	+	+	+	+	1,3-5	71-43-2	BENZENE
								alpha-BENZENE HEXACHLORIDE (see alpha-1,2,3,4,5,6-HEXACHLOROCYCLOHEXANE)
NT	NT	NT	NT	NT	NT	2	369-57-3	BENZENEDIAZONIUM TETRAFLUOROBORATE ^b

TD ₅₀ (mg/kg/day)		Positivity				Plot	CAS		Chemical Name
Rat	Mouse	MR	FR	MM	FM	Number	Number		
NT	-	NT	NT	NT	-	1	5351-65-5	BENZENESULPHONOHYDRAZIDE BENZHYDRAZIDE (see BENZOYL HYDRAZINE)	
1.73	NT	B+	B+	NT	NT	1	92-87-5	BENZIDINE	
NT	8.99 ^a	NT	NT	+	+	2,3	531-85-1	BENZIDINE.2HCl	
0.956	11	B+	B+	+	-	1-3	50-32-8	BENZO(a)PYRENE	
-	NT	-	-	NT	NT	1	532-32-1	BENZOATE, SODIUM	
424	19.8 ^a	-	P	+	+	5	271-89-6	BENZOFURAN	
-	-	-	NT	-	-	1	91-76-9	BENZOQUANAMINE	
-	-	-	-	-	-	2	119-53-9	BENZOIN	
NT	NT	NT	NT	NT	NT	1	91-64-5	1,2-BENZOPYRONE ^h 1-(2-BENZOTHAZOLYL)-3-METHYL-3-NITROSOUREA (see N-NITROSOBENZTHIAZURON)	
NT	-	NT	NT	-	-	1	120-78-5	BENZOTHAZYL DISULFIDE	
-	-	A	A	-	A	1	95-14-7	1H-BENZOTRIAZOLE	
NT	7.35 ^a	NT	NT	+	+	1	613-94-5	BENZOYL HYDRAZINE BENZPYRENE (see BENZO(a)PYRENE) 3,4-BENZPYRENE (see BENZO(a)PYRENE)	
-	702 ^a	E	-	P	P	4	140-11-4	BENZYL ACETATE	
-	-	-	-	-	-	5	100-51-6	BENZYL ALCOHOL	
-	49.6 ^a	-	-	+	+	4	100-44-7	BENZYL CHLORIDE BENZYL VIOLET 4B (see FD & C VIOLET NO. 1)	
NT	85.3	NT	NT	-	+	1	20570-96-1	BENZYLHYDRAZINE.2HCl	
-	-	-	-	-	-	1	13510-49-1	BERYLLIUM SULFATE BHA (see BUTYLATED HYDROXYANISOLE) BHT (see BUTYLATED HYDROXYTOLUENE)	
NT	-	NT	NT	-	-	1	92-52-4	BIPHENYL	
-	1120	-	-	A	+	2	2185-92-4	2-BIPHENYLAMINE.HCl	
-	138 ^a	-	-	+	+	1,2	108-60-1	BIS(2-CHLORO-1-METHYLETHYL)ETHER	
NT	8.19 ^a	NT	NT	+	-	1	111-44-4	BIS-2-CHLOROETHYLETHER	
NT	-	NT	NT	NT	-	1	13483-19-7	BIS-1,4-(CHLOROMETHOXY)BUTANE	
NT	4.62 ^d	NT	NT	NT	+	1	13483-18-6	BIS-1,2-(CHLOROMETHOXY)ETHANE	
NT	-	NT	NT	NT	-	1	56894-92-9	BIS-1,6-(CHLOROMETHOXY)HEXANE	
NT	3.11 ^d	NT	NT	NT	+	1	56894-91-8	BIS-1,4-(CHLOROMETHOXY)-p-XYLENE	
0.00357	0.182 ^{ac}	+	NT	+	+	1	542-88-1	BIS-(CHLOROMETHYL)ETHER	
3.14	NT	+	NT	NT	NT	1	---	4-BIS(2-HYDROXYETHYL)AMINO-2-(5-NITRO-2-THIENYL)QUINAZOLINE	
-	NT	NT	-	NT	NT	1	58139-47-2	4-BIS(2-HYDROXYETHYL)AMINO-2-(2-THIENYL)QUINAZOLINE	
NT	34.5 ^a	NT	NT	+	-	1	23746-34-1	BIS-2-HYDROXYETHYLDITHIOCARBAMIC ACID, POTASSIUM N-BIS(2-HYDROXYPROPYL)NITROSAMINE (see N-NITROSOBIS(2-HYDROXYPROPYL)AMINE) 2,5-BIS(2,2,2-TRIFLUORETHOXYL)-N-(2-PIPERIDYLMETHYL) BENZAMIDE ACETATE (see FLECAINIDE ACETATE) BISMATE (see BISMUTH DIMETHYLDITHIOCARBAMATE)	
NT	-	NT	NT	-	-	1	21260-46-8	BISMUTH DIMETHYLDITHIOCARBAMATE	
-	NT	B-	B-	NT	NT	1	7787-59-9	BISMUTH OXYCHLORIDE	
-	-	-	-	-	-	2	80-05-7	BISPHENOL A	
-	-	-	-	-	-	1	2519-30-4	BLACK PN	
0.945 ^a	NT	+	+	NT	NT	1	1937-37-7	C.I. DIRECT BLACK 38	
1.18 ^a	NT	+	+	NT	NT	1	2602-46-2	C.I. DIRECT BLUE 6	
89.3 ^a	-	+	+	E	-	3	2475-45-8	C.I. DISPERSE BLUE 1	
-	NT	B-	B-	NT	NT	1	3844-45-9	FD & C BLUE NO. 1	
-	-	B-	B-	-	-	1,4	860-22-0	FD & C BLUE NO. 2	
702	41.3 ^a	E	P	+	+	3,5	2784-94-3	HC BLUE NO. 1	
-	-	-	-	-	-	3	33229-34-4	HC BLUE NO. 2	
NT	70.6 ^a	NT	NT	NT	+	5	2784-94-3	HC BLUE NO. 1 (PURIFIED) BOH (see 2-HYDROXYETHYLHYDRAZINE)	
NT	-	NT	NT	-	-	5	10043-35-3	BORIC ACID BOTRAN (see 2,6-DICHLORO-4-NITROANILINE) BRILLIANT BLACK BN (see BLACK PN)	

TD ₅₀ (mg/kg/day)		Positivity				Plot	CAS		Chemical Name
Rat	Mouse	MR	FR	MM	FM	Number	Number		
								BRILLIANT BLUE FCF (see FD & C BLUE NO. 1)	
								BRILLIANT RED (see D & C RED NO. 9)	
4.81 ^a	-	+	+	-	-	1,3-5	7758-01-2	BROMATE, POTASSIUM	
NT	-	NT	NT	-	-	4	17157-48-1	BROMOACETALDEHYDE	
30.3 ^{af}	28.9 ^a	+	+	+	+	4,5	75-27-4	BROMODICHLOROMETHANE	
								BROMODIETHYLACETYLUREA (see CARBROMAL)	
149 ^b	535	P	E	E	+	5	74-96-4	BROMOETHANE	
NT	69.7 ^a	NT	NT	+	+	4	---	BROMOETHANOL	
								BROMOFORM (see TRIBROMOMETHANE)	
2.07	NT	-	+	NT	NT	1	16071-86-6	C.I. DIRECT BROWN 95	
								BSH (see BENZENESULPHONOHYDRAZIDE)	
								BUSULFAN (see MYLERAN)	
								BUTACIDE (see PIPERONYL BUTOXIDE IN SOLVENT)	
133 ^{af}	28.8 ^a	+	+	+	+	3,5	106-99-0	1,3-BUTADIENE	
								trans-2-BUTENAL (see CROTONALDEHYDE)	
-	-	I	A	-	-	2	85-68-7	BUTYL BENZYL PHTHALATE	
								BUTYL-BUTANOL-NITROSAMINE (see N-BUTYL-N-(4-HYDROXYBUTYL)NITROSAMINE)	
-	-	-	-	-	-	3	109-69-3	N-BUTYL CHLORIDE	
								2,6-DI-tert-BUTYL-p-CRESOL (see BUTYLATED HYDROXYTOLUENE)	
NT	-	NT	NT	-	-	1	88-85-7	2-sec-BUTYL-4,6-DINITROPHENOL	
NT	19.2 ^a	NT	NT	+	+	1	---	N-N-BUTYL-N-FORMYLHYDRAZINE	
								2(3)-tert-BUTYL-4-HYDROXYANISOLE (see BUTYLATED HYDROXYANISOLE)	
NT	-	NT	NT	-	-	4	94-26-8	BUTYL p-HYDROXYBENZOATE	
0.175 ^{af}	NT	+	NT	NT	NT	1,3,4	3817-11-6	N-BUTYL-N-(4-HYDROXYBUTYL)NITROSAMINE	
-	NT	-	-	NT	NT	1	---	DI-tert-BUTYL-4-HYDROXYMETHYL PHENOL	
-	NT	-	NT	NT	NT	1	13010-08-7	N-BUTYL-N-NITRO-N-NITROGUANIDINE	
0.91 ^a	NT	+	+	NT	NT	3	869-01-2	N-N-BUTYL-N-NITROSOUREA	
								BUTYL ZIMATE (see ZINC DIBUTYLDITHIOCARBAMATE)	
349 ^{af}	-	+	+	B-	B-	2-5	25013-16-5	BUTYLATED HYDROXYANISOLE	
-	368 ^a	-	-	+	-	1,2,5	128-37-0	BUTYLATED HYDROXYTOLUENE	
NT	38.1 ^a	NT	NT	+	+	1	---	1,1-DI-N-BUTYLHYDRAZINE	
NT	9.03 ^a	NT	NT	+	+	1	56795-65-4	N-BUTYLHYDRAZINE.HCl	
NT	34.5 ^a	NT	NT	+	+	1	78776-28-0	1,2-DI-N-BUTYLHYDRAZINE.2HCl	
-	-	-	-	-	-	1	592-31-4	N-BUTYLUREA	
13.8	NT	NT	+	NT	NT	1	3068-88-0	beta-BUTYROLACTONE	
								CACODYLIC ACID (see DIMETHYLARSINIC ACID)	
-	-	B-	B-	-	-	1	543-90-8	CADMIUM ACETATE	
0.0127	NT	+	NT	NT	NT	5	10108-64-2	CADMIUM CHLORIDE	
-	NT	-	-	NT	NT	1	35658-65-2	CADMIUM CHLORIDE MONOHYDRATE	
NT	-	NT	NT	-	-	1	14239-68-0	CADMIUM DIETHYLDITHIOCARBAMATE	
-	-	-	NT	-	NT	1	7790-84-3	CADMIUM SULPHATE (1:1) HYDRATE (3:8)	
-	-	-	-	-	-	1-3	58-08-2	CAFFEINE	
								CAFFEINE, ASPIRIN, AND PHENACETIN (see ASPIRIN, PHENACETIN, AND CAFFEINE)	
NT	39.6 ^b	NT	NT	NT	+	1	50-14-6	CALCIFEROL	
-	NT	-	NT	NT	NT	4	62-54-4	CALCIUM ACETATE	
								CALCIUM CYANAMIDE (see CYANAMIDE, CALCIUM)	
-	-	-	-	-	-	2	105-60-2	CAPROLACTAM	
NT	89.4 ^a	NT	NT	+	+	3	2425-06-1	CAPTAFOL	
-	-	-	-	A	A	1	133-06-2	CAPTAN	
								CAPTAX (see 2-MERCAPTOBENZOTHAZOLE)	
NT	223 ^a	NT	NT	+	+	1	563-41-7	CARBAMYL HYDRAZINE.HCl	
NT	155 ^a	NT	NT	+	+	1	103-03-7	1-CARBAMYL-2-PHENYLHYDRAZINE	
-	NT	-	-	NT	NT	1	121-59-5	CARBARSONE	
14.1	-	B+	B+	-	-	1	63-25-2	CARBARYL	
NT	102 ^a	NT	NT	+	+	2	86-74-8	CARBAZOLE	
0.765 ^{abe}	127 ^a	+	+	+	+	1,3	56-23-5	CARBON TETRACHLORIDE	
2.3 ^{af}	NT	+	+	NT	NT	1,3	60391-92-6	CARBOXYMETHYLNITROSOUREA	
-	-	-	-	-	-	1	77-65-6	CARBROMAL	

TD ₅₀ (mg/kg/day)		Positivity				Plot	CAS	
Rat	Mouse	MR	FR	MM	FM	Number	Number	Chemical Name
								CARMOISINE (see C.I. FOOD RED 3)
1490 ^a	NT	+	B+	NT	NT	1,2	---	CAROB SEED GUM (see LOCUST BEAN GUM)
-	NT	-	-	NT	NT	1	9000-07-1	CARRAGEENAN, ACID-DEGRADED
257	NT	+	NT	NT	NT	4,5	120-80-9	CARRAGEENAN, NATIVE ^b
								CATECHOL
								CCC (see (2-CHLOROETHYL)TRIMETHYLAMMONIUM CHLORIDE)
								CDT (see SIMAZINE)
								CELLULOSE CARBOXYMETHYL ETHER, SODIUM (see EDIFAS B)
NT	-	NT	NT	B-	B-	1	474-25-9	CHENODEOXYCHOLIC ACID
-	5230	-	-	A	+	1	133-90-4	alpha-CHLORALOSE (see ANHYDROGLUCOCHLORAL)
0.657 ^a	0.097 ^{ad}	+	+	+	+	1,4	305-03-3	CHLORAMBEN
-	NT	NT	-	NT	NT	1	56-75-7	CHLORAMBUCIL
NT	-	NT	NT	-	-	1	118-75-2	CHLORAMPHENICOL
								CHLORANIL
-	2.15 ^a	-	-	+	+	1,2	57-74-9	4-CHLORANILIC (see p-CHLOROANILINE)
								CHLORDANE
25.4 ^a	141	+	+	+	-	4	115-28-6	CHLORDECONE (see KEPONE)
								CHLORENDIC ACID
110 ^a	86.8 ^a	+	+	+	+	3	63449-39-8	CHLORFENSON (see p-CHLOROPHENYL-p-CHLOROBENZENE SULFONATE)
-	6540	-	E	+	E	3	63449-39-8	CHLORINATED PARAFFINS (C12, 60% CHLORINE)
NT	-	NT	NT	-	-	4	56802-99-4	CHLORINATED PARAFFINS (C23, 43% CHLORINE)
-	NT	B-	B-	NT	NT	1	7782-50-5	CHLORINATED TRISODIUM PHOSPHATE
NT	-	NT	NT	NT	-	1	302-22-7	CHLORINE
37.6	346	+	NT	-	+	1	101-79-1	CHLORMADINONE ACETATE
4.85	NT	+	NT	NT	NT	1	37087-94-8	4-CHLORO-4'-AMINODIPHENYLETHER
								2-CHLORO-5-(3,5-DIMETHYLPYPERIDINOSULPHONYL) BENZOIC ACID
-	-	-	NT	-	-	1	97-00-7	1-CHLORO-2,4-DINITROBENZENE
68.7 ^a	73.5 ^a	+	+	+	+	4	563-47-3	3-CHLORO-2-METHYLPROPENE, TECHNICAL GRADE (CONTAINING 5% DIMETHYLVINYL CHLORIDE)
-	108 ^a	-	NT	+	+	1	88-73-3	1-CHLORO-2-NITROBENZENE
-	430 ^a	-	NT	+	+	1	100-00-5	1-CHLORO-4-NITROBENZENE
315	1230	+	-	-	+	1	5131-60-2	4-CHLORO-m-PHENYLENEDIAMINE
197 ^a	957 ^a	+	+	+	+	1	95-83-0	4-CHLORO-o-PHENYLENEDIAMINE
-	-	-	-	-	-	1	61702-44-1	2-CHLORO-p-PHENYLENEDIAMINE SULFATE
								alpha-CHLORO TOLUENE (see BENZYL CHLORIDE)
-	-	-	-	-	-	1	95-74-9	3-CHLORO-p-TOLUIDINE
-	134 ^a	-	-	+	+	1	95-79-4	5-CHLORO-o-TOLUIDINE
-	15.4 ^{af}	-	-	+	+	1	3165-93-3	4-CHLORO-o-TOLUIDINE.HCl
60 ^a	NT	+	+	NT	NT	3	75-88-7	2-CHLORO-1,1,1-TRIFLUOROETHANE
7.47 ^{ac}	10.8 ^c	+	NT	+	NT	1,3	50892-23-4	[4-CHLORO-6-(2,3-XYLIDINO)-2-PYRIMIDINYLTHTIO] ACETIC ACID
6.49	44.6	+	NT	NT	+	1	---	4-CHLORO-6-(2,3-XYLIDINO)-2-PYRIMIDINYLTHTIO(N-beta-HYDROXYETHYL)ACETAMIDE
NT	-	NT	NT	-	-	1	107-20-0	CHLOROACETALDEHYDE
-	-	-	-	-	A	1	140-49-8	4-(CHLOROACETYL)-ACETANILIDE
-	-	A	-	A	A	1	106-47-8	p-CHLOROANILINE
7.62	89.5	+	E	P	-	5	20265-96-7	p-CHLOROANILINE.HCl
247	-	P	-	-	-	3	108-90-7	CHLOROBENZENE
-	43.8 ^{af}	-	-	+	+	1	510-15-6	CHLOROBENZILATE
-	139	-	-	I	P	3	124-48-1	CHLORODIBROMOMETHANE
-	-	-	-	-	-	5	75-45-6	CHLORODIFLUOROMETHANE
-	1810	E	E	I	+	5	75-00-3	CHLOROETHANE
								2-[3-(2-CHLOROETHYL)-3-NITROSOUREIDO]-D-GLUCOPYRANOSE (see CHLOROZOTOCIN)
-	-	-	-	-	-	1	999-81-5	(2-CHLOROETHYL)TRIMETHYLAMMONIUM CHLORIDE
26.5 ^a	NT	+	+	NT	NT	3	593-70-4	CHLOROFLUOROMETHANE
119 ^a	48 ^a	+	+	+	+	1,4	67-66-3	CHLOROFORM ^b
5.5	NT	+	NT	NT	NT	1	107-30-2	CHLOROMETHYL METHYL ETHER ⁸

TD ₅₀ (mg/kg/day)		Positivity				Plot	CAS	Chemical Name
Rat	Mouse	MR	FR	MM	FM	Number	Number	
-	-	-	-	-	-	1	6959-47-3	2-(CHLOROMETHYL)PYRIDINE.HCl
433	161 ^a	+	-	+	+	1	6959-48-4	3-(CHLOROMETHYL)PYRIDINE.HCl CHLOROMYCETIN (see CHLORAMPHENICOL) p-CHLORONITROBENZENE (see 1-CHLORO-4-NITROBENZENE)
NT	-	NT	NT	-	-	1	80-33-1	p-CHLOROPHENYL-p-CHLOROBENZENE SULFONATE
86.3	-	+	-	-	-	1,5	150-68-5	3-(p-CHLOROPHENYL)-1,1-DIMETHYLUREA
8.78	NT	+	NT	NT	NT	1	10473-70-8	1-(4-CHLOROPHENYL)-1-PHENYL-2-PROPYNYL CARBAMATE
-	NT	-	-	NT	NT	1	2227-13-6	p-CHLOROPHENYL-2,4,5-TRICHLOROPHENYL SULFIDE 1-(p-CHLOROPHENYLSULFONYL)-3-PROPYLUREA (see CHLORPROPAMIDE)
NT	-	I	I	-	-	1	76-06-2	CHLOROPICRIN
NT	12.9	NT	NT	-	+	1	683-50-1	2-CHLOROPROPANAL CHLOROPROPENE (see ALLYL CHLORIDE)
NT	5.05	NT	NT	-	+	1	590-21-6	1-CHLOROPROPENE
2080 ^a	-	+	+	-	-	1	1897-45-6	CHLOROTHALONIL CHLOROWAX 40 (see CHLORINATED PARAFFINS (C23, 43% CHLORINE)) CHLOROWAX 500c (see CHLORINATED PARAFFINS (C12, 60% CHLORINE))
0.0241 ^{ad}	NT	+	+	NT	NT	1	54749-90-5	CHLOROZOTOCIN
-	-	-	-	-	-	3,4	113-92-8	CHLORPHENIRAMINE MALEATE
-	-	-	-	-	-	1	94-20-2	CHLORPROPAMIDE CHLORPROPAM (see ISOPROPYL-N-(3-CHLOROPHENYL)CARBAMATE)
-	-	-	-	-	-	1	12236-46-3	CHLORPYRIFOS (see O,O-DIETHYL-O-(3,5,6-TRICHLORO-2-PYRIDYL)PHOSPHOROTHIOATE)
NT	-	NT	NT	-	-	1	4553-89-3	CHOCOLATE BROWN FB
-	NT	-	NT	NT	NT	4	67-48-1	CHOCOLATE BROWN HT CHOLINE CHLORIDE
-	NT	B-	B-	NT	NT	1	1308-38-9	CHROMIC OXIDE PIGMENT
-	-	B-	B-	-	-	1	1066-30-4	CHROMIUM (III) ACETATE
245	201	+	NT	+	NT	4	117-10-2	CHRYSAZIN
7000	2470 ^a	+	-	+	+	2	87-29-6	CINNAMYL ANTHRANILATE CIPC (see ISOPROPYL-N-(3-CHLOROPHENYL)CARBAMATE)
1.09 ^c	4.17 ^a	+	NT	+	NT	3,5	52214-84-3	CIPROFIBRATE
5.28 ^{ac}	NT	+	NT	NT	NT	3	518-75-2	CITRININ
0.5	NT	B+	B+	NT	NT	1	33979-15-6	CLIVORINE
169	NT	+	NT	NT	NT	1	637-07-0	CLOFIBRATE
NT	-	NT	NT	NT	-	1	43054-45-1	CLOMIPHENE CITRATE
-	-	-	-	I	-	1	1420-04-8	CLONITRALID
157 ^b	NT	+	NT	NT	NT	3	55600-34-5	CLOPHEN A 30 CLOPHEN A 60 (see AROCLOR 1260) CLOROX (see SODIUM HYPOCHLORITE) CMME (see CHLOROMETHYL METHYL ETHER) CMNU (see CARBOXYMETHYLNITROSOUREA)
-	NT	-	NT	NT	NT	1	477-30-5	COLCEMID
-	-	-	-	-	-	3	65765-07-3	COMPOUND 50-892 CONJUGATED EQUINE ESTROGENS (see PREMARIN)
NT	-	NT	NT	-	-	1	137-29-1	COPPER DIMETHYLDITHIOCARBAMATE
NT	-	NT	NT	-	-	1	10380-28-6	COPPER-8-HYDROXYQUINOLINE
-	-	-	-	-	-	1	56-72-4	COUMAPHOS COUMARIN (see 1,2-BENZOPYRONE)
470 ^a	-	+	+	I	-	1	102-50-1	m-CRESIDINE
76.3 ^a	44.7 ^a	+	+	+	+	1	120-71-8	p-CRESIDINE
4.2	NT	+	NT	NT	NT	4	123-73-9	CROTONALDEHYDE CUMATE (see COPPER DIMETHYLDITHIOCARBAMATE)
5.33 ^a	253 ^a	+	+	+	+	1	135-20-6	CUPFERRON
-	-	-	-	-	-	1	156-62-7	CYANAMIDE, CALCIUM CYANO-(3-PHENOXYPHENYL)METHYL-4-CHLORO-

TD ₅₀ (mg/kg/day)		Positivity				Plot	CAS		Chemical Name
Rat	Mouse	MR	FR	MM	FM	Number	Number		
								alpha-(1-METHYLETHYL) BENZENE ACETATE (see FENVALERATE)	
NT	NT	NT	NT	NT	NT	1	mixture	CYCASIN AND METHYLAZOXYMETHANOL ACETATE ^g	
-	587 ^a	B-	B-	+	+	1	139-05-9	CYCLAMATE, SODIUM 2-CYCLO-HEXYL-CARBONYL-1,3,4,6,7,11-b- HEXAHYDRO-2-H-PYRAZINE(2,1-a)ISOQUINOLINE- 4-ONE (see PRAZIQUANTEL)	
NT	23.6	NT	NT	+	NT	1	12663-46-6	CYCLOCHLOROTINE	
-	-	-	-	-	-	5	108-94-1	CYCLOHEXANONE	
NT	-	NT	NT	-	-	1	95-33-0	N-CYCLOHEXYL-2-BENZOTHAZOLE SULFENAMIDE	
-	-	-	-	-	-	1	4998-76-9	CYCLOHEXYLAMINE.HCl	
-	-	-	-	-	-	1	19834-02-7	CYCLOHEXYLAMINE SULFATE	
1.26 ^{ae}	5.78 ^{ad}	+	+	+	+	1,3	50-18-0	CYCLOPHOSPHAMIDE	
1.05 ^{ad}	-	+	+	-	-	2	16170-75-5	CYTEMBENA CYTOXAN (see CYCLOPHOSPHAMIDE) DAAB (see 4,4'-DIAMINOAZOBENZENE) DAB (see N,N-DIMETHYL-4-AMINOAZOBENZENE) DABA (see 4,4'-DIAMINOBENZANILIDE)	
0.71	0.595 ^{ad}	NT	+	+	+	1	4342-03-4	DACARBAZINE DACONIL (see CHLOROTHALONIL)	
1840 ^b	880 ^a	-	+	+	+	1	1596-84-5	DAMINOZIDE DANTHRON (see CHRYSAZIN)	
22.4	-	+	-	-	-	1	80-08-0	DAPSONE DARAPRIN (see PYRIMETHAMINE) DBCP (see 1,2-DIBROMO-3-CHLOROPROPANE) DBM (see DIBROMOMANNITOL) DCB (see 3,3'-DICHLOROBENZIDINE) DCDD (see 2,7-DICHLORODIBENZO-p-DIOXIN)	
NT	-	NT	NT	-	-	1	53-19-0	o,p'-DDD	
-	24.9 ^a	A	-	+	+	1	72-54-8	p,p'-DDD	
-	9.45 ^a	-	-	+	+	1,3	72-55-9	p,p'-DDE ^g	
57.2 ^a	4.55 ^{af}	+	+	+	+	1,3,4	50-29-3	DDT ^h DDVP (see DICHLORVOS)	
2130 ^a	-	P	P	E	-	3	1163-19-5	DECABROMODIPHENYL OXIDE DEGRANOL (see MANNITOL NITROGEN MUSTARD) DEHYDROACETIC ACID (see 3-ACETYL-6-METHYL-2,4- PYRANDIONE) DEN (see N-NITROSODIETHYLAMINE) 6-F-DEN (see N-NITROBIS(2,2,2-TRIFLUOROETHYL) AMINE) beta-2'-DEOXY-6-THIOGUANOSINE MONOHYDRATE (see beta-THIOGUANINE DEOXYRIBOSIDE) DES (see DIETHYLSTILBESTROL)	
-	NT	B-	B-	NT	NT	1	131-01-1	DESERPIDINE	
-	NT	-	-	NT	NT	3	9004-54-0	DEXTRAN	
182 ^a	NT	+	+	NT	NT	2,3	9011-18-1	DEXTRAN SULFATE SODIUM (DS-M-1)	
-	NT	-	-	NT	NT	3	9011-18-1	DEXTRAN SULFATE SODIUM (DST-H)	
-	NT	-	-	NT	NT	3	9011-18-1	DEXTRAN SULFATE SODIUM (KMDS-H) DHAC (see 5,6-DIHYDRO-5-AZACYTIDINE)	
19	NT	NT	+	NT	NT	1	---	N-1-DIACETAMIDOFLUORENE	
NT	-	NT	NT	-	-	3	3148-73-0	DIACETYL HYDRAZINE	
NT	19.4 ^a	NT	NT	+	-	1	2303-16-4	DIALATE	
-	-	-	E	A	A	3	131-17-9	DIALLYL PHTHALATE	
NT	25.7 ^a	NT	NT	+	+	3	5164-11-4	1,1-DIALLYLHYDRAZINE	
NT	33.8 ^a	NT	NT	+	+	2	---	1,2-DIALLYLHYDRAZINE.2HCl	
32.1 ^a	NT	+	+	NT	NT	4	16338-97-9	DIALLYLNITROSAMINE ^g	
1.71	NT	NT	+	NT	NT	1	720-69-4	4,6-DIAMINO-2-(5-NITRO-2-FURYL)-s-TRIAZINE	
72.6 ^a	791 ^a	+	+	+	+	1	39156-41-7	2,4-DIAMINOANISOLE SULFATE	
NT	-	NT	NT	-	-	2	538-41-0	4,4'-DIAMINOAZOBENZENE	
NT	-	NT	NT	-	-	2	785-30-8	4,4'-DIAMINOBENZANILIDE 3,3'-DIAMINOBENZIDINE.4HCl (see 3,3',4,4'- TETRAAMINOBIPHENYL.4HCl)	
								1,5-DIAMINONAPHTHALENE (see	

TD ₅₀ (mg/kg/day)		Positivity				Plot	CAS		Chemical Name
Rat	Mouse	MR	FR	MM	FM	Number	Number		
								1,5-NAPHTHALENEDIAMINE)	
1.43 ^a	26.7	+	+	-	+	1	95-80-7	2,4-DIAMINOTOLUENE	
4.42	201 ^a	+	NT	+	+	1	636-23-7	2,4-DIAMINOTOLUENE.2HCI	
-	-	-	-	-	-	2	15481-70-6	2,6-DIAMINOTOLUENE.2HCI	
-	-	-	-	-	-	1	6369-59-1	2,5-DIAMINOTOLUENE SULFATE	
-	-	-	-	-	-	1	333-41-5	DIAZINON	
37.6	NT	+	NT	NT	NT	5	---	3-DIAZOTYRAMINE.HCI	
NT	5.88	NT	NT	+	NT	1	53-70-3	DIBENZ(a,h)ANTHRACENE	
-	-	-	-	-	-	1	262-12-4	DIBENZO-p-DIOXIN	
2.48	NT	+	NT	NT	NT	1	4106-66-5	3-DIBENZOFURANAMINE	
-	NT	-	-	NT	NT	4	35660-60-7	O,S-DIBENZOYL THIAMINE.HCI	
0.106 ^a	1.28 ^a	+	+	+	+	1	96-12-8	1,2-DIBROMO-3-CHLOROPROPANE	
								DIBROMOCHLOROMETHANE (see CHLORODIBROMOMETHANE)	
8.37 ^d	9.23 ^{ad}	+	NT	+	+	1	10318-26-0	DIBROMODULCITOL	
1.1 ^a	2.34 ^{af}	+	+	+	+	1,4	106-93-4	1,2-DIBROMOETHANE	
24.9 ^{ad}	11.4 ^{ad}	+	+	+	+	1	488-41-5	DIBROMOMANNITOL	
-	NT	-	-	NT	NT	3	3296-90-0	DIBROMONEOPENTYL GLYCOL	
-	NT	-	-	NT	NT	2	34522-69-5	5,7-DIBROMOQUINOLINE	
4.28	NT	NT	+	NT	NT	1	56654-52-5	1,3-DIBUTYL-1-NITROSOUREA	
								DIBUTYLNITROSAMINE (see NITROSODIBUTYLAMINE)	
-	-	-	I	-	-	1	1067-33-0	DIBUTYLTIN DIACETATE	
								DIC (see DACARBAZINE)	
								DICHLONE (see 2,3-DICHLORO-1,4- NAPHTHOQUINONE)	
								DICHLOREN (see NITROGEN MUSTARD)	
								DICHLORICIDE MOTHPROOFER (see STROBANE)	
								3,3'-DICHLORO-4,4'-DIAMINODIPHENYLMETHANE (see 4,4'-METHYLENE-BIS(2-CHLOROANILINE))	
NT	119	NT	NT	+	NT	2	23950-58-5	3,5-DICHLORO(N-1,1-DIMETHYL-2-PROPYNYL) BENZAMIDE	
NT	-	NT	NT	NT	-	1	3883-43-0	2,3-DICHLORO-p-DIOXANE	
NT	-	NT	NT	-	-	1	87-56-9	alpha,beta-DICHLORO-beta-FORMYLACRYLIC ACID	
NT	-	NT	NT	-	-	1	2164-09-2	3,4'-DICHLORO-2-METHYLACRYLANILIDE	
								2,2-DICHLORO-N-METHYLDIETHYLAMINE (see NITROGEN MUSTARD)	
NT	-	NT	NT	-	-	1	117-80-6	2,3-DICHLORO-1,4-NAPHTHOQUINONE	
NT	-	NT	NT	-	-	1	99-30-9	2,6-DICHLORO-4-NITROANILINE	
-	737 ^a	-	-	+	+	2	609-20-1	2,6-DICHLORO-p-PHENYLENEDIAMINE	
3.34 ^a	0.466 ^a	+	+	+	+	3	7572-29-4	DICHLOROACETYLENE	
-	-	-	-	-	-	3	95-50-1	1,2-DICHLOROBENZENE	
644	339 ^a	+	-	+	+	4	106-46-7	1,4-DICHLOROBENZENE	
								o-DICHLOROBENZENE (see 1,2-DICHLOROBENZENE)	
18.3 ^a	NT	+	+	NT	NT	1	91-94-1	3,3'-DICHLOROBENZIDINE ⁸	
								DICHLOROBROMOMETHANE (see BROMODICHLOROMETHANE)	
NT	1.52 ^d	NT	NT	NT	+	1	110-57-6	trans-1,4-DICHLOROBUTENE-2	
-	-	-	-	A	-	1	33857-26-0	2,7-DICHLORODIBENZO-p-DIOXIN	
-	-	-	-	-	-	5	75-71-8	DICHLORODIFLUOROMETHANE	
-	-	-	A	-	A	1	75-34-3	1,1-DICHLOROETHANE	
5.49 ^a	61.2 ^a	+	+	+	+	1	107-06-2	1,2-DICHLOROETHANE	
								DICHLOROMETHANE (see METHYLENE CHLORIDE)	
-	-	-	-	-	-	5	120-83-2	2,4-DICHLOROPHENOL	
								2-(2,4-DICHLOROPHENOXY)PROPIONIC ACID (see alpha-(2,4-DICHLOROPHENOXY)PROPIONIC ACID)	
NT	-	NT	NT	-	-	1	120-36-5	alpha-(2,4-DICHLOROPHENOXY)PROPIONIC ACID	
NT	-	NT	NT	-	-	1	6965-71-5	alpha-(2,5-DICHLOROPHENOXY)PROPIONIC ACID	
NT	-	NT	NT	-	-	1	94-75-7	2,4-DICHLOROPHENOXYACETIC ACID	
NT	-	NT	NT	-	-	1	94-80-4	2,4-DICHLOROPHENOXYACETIC ACID, N-BUTYL ESTER	
NT	-	NT	NT	-	-	1	25168-26-7	2,4-DICHLOROPHENOXYACETIC ACID, ISOCTYL ESTER	

TD ₅₀ (mg/kg/day)		Positivity				Plot	CAS		Chemical Name
Rat	Mouse	MR	FR	MM	FM	Number	Number		
NT	-	NT	NT	-	-	1	94-11-1	2,4-DICHLOROPHENOXYACETIC ACID, ISOPROPYL ESTER	
NT	-	NT	NT	-	-	1	330-54-1	3-(3,4-DICHLOROPHENYL)-1,1-DIMETHYLUREA	
NT	-	NT	NT	-	-	1	97-16-5	2,4-DICHLOROPHENYLBENZENE SULFONATE	
-	229 ^a	-	E	P	P	4	78-87-5	1,2-DICHLOROPROPANE 1,3-DICHLOROPROPENE (see TELONE II) 2-[1-(2,6-DICHLORPHENOXY)-ETHYL]-2-IMIDAZOLINE.HCl (see LOFEXIDINE.HCl)	
3.21	61.3 ^a	P	E	P	+	1,5	62-73-7	DICHLORVOS	
-	32.9	-	-	+	-	1	115-32-2	DICLORAN (see 2,6-DICHLORO-4-NITROANILINE) DICOFOL DICRYL (see 3,4'-DICHLORO-2-METHYLACRYLANILIDE)	
-	-	-	-	-	-	1	1212-29-9	N,N'-DICYCLOHEXYLTHIOUREA	
-	-	-	NT	-	-	1	81-21-0	DICYCLOPENTADIENE DIOXIDE	
-	0.469 ^{ac}	-	-	+	+	1	60-57-1	DIELDRIN ^h	
-	-	-	-	-	-	1	13366-73-9	DIELDRIN, PHOTO-	
-	NT	NT	-	NT	NT	1	298-18-0	D,L-DIEPOXYBUTANE	
NT	-	NT	NT	NT	-	1	7316-37-2	DIETHYL-beta,gamma-EPOXYPROPYLPHOSPHONATE 4,4'-(1,2-DIETHYL-1,2-ETHENEDIYL)BIS-PHENOL (see DIETHYLSTILBESTROL)	
1.63 ^c	NT	+	NT	NT	NT	1	7347-49-1	N,N-DIETHYL-4-(4'-[PYRIDYL-1'-OXIDE]AZO)ANILINE	
-	NT	-	-	NT	NT	1	2921-88-2	O,O-DIETHYL-O-(3,5,6-TRICHLORO-2-PYRIDYL)PHOSPHOROTHIOATE	
8.85 ^b	NT	+	NT	NT	NT	1	685-91-6	DIETHYLACETAMIDE DIETHYLDITHIOCARBAMATE TRIHYDRATE, SODIUM (see SODIUM DIETHYLDITHIOCARBAMATE TRIHYDRATE)	
1660	NT	+	NT	NT	NT	1	111-46-6	DIETHYLENE GLYCOL	
-	NT	-	NT	NT	NT	1	617-84-5	DIETHYLFORMAMIDE DIETHYLNITROSAMINE (see N-NITROSODIETHYLAMINE) N,N-DIETHYLNITROSAMINE (see N-NITROSODIETHYLAMINE)	
0.114	0.0247 ^a	+	-	+	+	1,5	56-53-1	DIETHYLSTILBESTROL	
23.8 ^a	-	+	+	-	-	1	105-55-5	N,N'-DIETHYLTHIOUREA	
NT	571 ^a	NT	NT	+	+	1	628-36-4	1,2-DIFORMYLHYDRAZINE	
NT	852 ^a	NT	NT	+	+	3	21626-89-1	DIFTALONE	
2.33 ^a	17.9 ^a	+	+	+	+	4	101-90-6	DIGLYCIDYL RESORCINOL ETHER, TECHNICAL GRADE	
-	NT	-	NT	NT	NT	5	62488-57-7	5,6-DIHYDRO-5-AZACYTIDINE (2,3-DIHYDRO-1,5-DIMETHYL-3-OXO-2-PHENYL-1H-PYRAZOL-4-YL)METHYLAMINO METHANESULFONATE MONOHYDRATE (see DIPYRONE)	
1.53	NT	NT	+	NT	NT	1	33389-33-2	1,2-DIHYDRO-2-(5-NITRO-2-THIENYL)QUINAZOLIN-4(3H)-ONE	
90.6	NT	B+	B+	NT	NT	1	3276-41-3	3,6-DIHYDRO-2-NITROSO-2H-1,2-OXAZINE 1,2-DIHYDRO-3,6-PYRIDAZINEDIONE (see MALEIC HYDRAZIDE)	
143	90 ^a	B+	B+	+	+	1	94-58-6	DIHYDROSAFROLE 1,2-DIHYDROXYBENZENE (see CATECHOL)	
-	-	-	-	-	-	1	60-51-5	DIMETHOATE	
716	NT	+	NT	NT	NT	1	828-00-2	DIMETHOXANE	
-	-	-	-	E	-	5	828-00-2	DIMETHOXANE, COMMERCIAL GRADE	
0.721	95.9	+	NT	+	-	1	5803-51-0	2,5-DIMETHOXY-4'-AMINOSTILBENE	
-	-	-	-	-	-	1	54150-69-5	2,4-DIMETHOXYANILINE.HCl	
742 ^a	-	+	+	-	-	1	91-93-0	3,3'-DIMETHOXYBENZIDINE-4,4'-DIISOCYANATE	
-	NT	-	NT	NT	NT	1	1146-71-0	5,7-DIMETHOXYCYCLOPENTENE[c]COUMARIN	
-	NT	-	NT	NT	NT	1	1150-37-4	5,7-DIMETHOXYCYCLOPENTENONE[2,3-c]COUMARIN	
-	NT	-	NT	NT	NT	1	1150-42-1	5,7-DIMETHOXYCYCLOPENTENONE[3,2-c]COUMARIN	
1E31	NT	+	NT	NT	NT	5	65176-75-2	5,6-DIMETHOXYSTERIGMATOCYSTIN	
3.31	NT	NT	+	NT	NT	1	60-11-7	N,N-DIMETHYL-4-AMINOAZOBENZENE	

TD ₅₀ (mg/kg/day)		Positivity				Plot	CAS	
Rat	Mouse	MR	FR	MM	FM	Number	Number	Chemical Name
								9,10-DIMETHYL-1,2-BENZANTHRACENE (see 7,12-DIMETHYLBENZ(a)ANTHRACENE)
-	NT	-	NT	NT	NT	1	3851-16-9	N,N'-DIMETHYL-N,N'-DINITROSOPHTHALAMIDE
105	-	+	E	-	-	3	868-85-9	DIMETHYL HYDROGEN PHOSPHITE
520	-	P	-	I	-	5	756-79-6	DIMETHYL METHYLPHOSPHONATE
503 ^a	-	P	P	-	-	3	597-25-1	DIMETHYL MORPHOLINOPHOSPHORAMIDATE
1.39 ^c	NT	NT	+	NT	NT	1	59-35-8	4,6-DIMETHYL-2-(5-NITRO-2-FURYL)PYRIMIDINE
17	NT	NT	+	NT	NT	1	551-92-8	1,2-DIMETHYL-5-NITROIMIDAZOLE
-	-	-	-	-	-	1	120-61-6	DIMETHYL TEREPHTHALATE
								2,2-DIMETHYL-5-(2,5-XYLYLOXY)VALERIC ACID (see GEMFIBROZIL)
60.7 ^a	-	+	+	-	-	5	---	6-DIMETHYLAMINO-4,4-DIPHENYL-3-HEPTANOL ACETATE.HCl
-	-	-	-	-	-	5	1095-90-5	6-DIMETHYLAMINO-4,4-DIPHENYL-3-HEPTANONE.HCl
22.4	NT	NT	+	NT	NT	1	55738-54-0	trans-2-[(DIMETHYLAMINO)METHYLIMINO]-5-[2-(5-NITRO-2-FURYL)VINYL]-1,3,4-OXADIAZOLE
NT	-	NT	NT	-	-	1	6120-10-1	4-DIMETHYLAMINO-3,5-XYLENOL
NT	-	NT	NT	NT	-	5	108-01-0	2-DIMETHYLAMINOETHANOL
125	-	P	-	-	E	5	121-69-7	N,N-DIMETHYLANILINE
NT	-	NT	NT	-	-	1	75-60-5	DIMETHYLARSINIC ACID
NT	0.084	NT	NT	NT	+	1	57-97-6	7,12-DIMETHYLBENZ(a)ANTHRACENE
								DIMETHYLCARBAMOYL CHLORIDE (see DIMETHYLCARBAMYL CHLORIDE)
NT	5.37 ^d	NT	NT	NT	+	1	79-44-7	DIMETHYLCARBAMYL CHLORIDE ^B
NT	-	NT	NT	-	-	1	598-64-1	DIMETHYLDITHIOCARBAMIC ACID, DIMETHYLAMINE
-	NT	-	-	NT	NT	3	1643-20-5	N,N-DIMETHYLDODECYLAMINE-N-OXIDE
NT	2.09 ^a	NT	NT	+	+	1	57-14-7	1,1-DIMETHYLHYDRAZINE ^B
NT	0.102 ^a	NT	NT	+	+	1	306-37-6	1,2-DIMETHYLHYDRAZINE.2HCl ^B
0.41 ^c	NT	NT	+	NT	NT	1	26049-69-4	2-(2,2-DIMETHYLHYDRAZINO)-4-(5-NITRO-2-FURYL)THIAZOLE
0.256 ^a	NT	+	+	NT	NT	1	4164-28-7	DIMETHYLNITRAMINE
								DIMETHYLNITROSAMINE (see N-NITROSODIMETHYLAMINE)
								N,N-DIMETHYLNITROSAMINE (see N-NITROSODIMETHYLAMINE)
17.5 ^a	14.3 ^a	+	+	+	+	4	513-37-1	DIMETHYLVINYL CHLORIDE
NT	-	NT	NT	-	-	1	6119-92-2	DINITRO(1-METHYLHEPTYL)PHENYL CROTONATE
NT	-	NT	NT	B-	B-	1	51-28-5	2,4-DINITROPHENOL
NT	-	NT	NT	NT	-	3	1011-73-0	2,4-DINITROPHENOL, SODIUM
NT	NT	NT	NT	NT	NT	3	55380-34-2	1,4-DINITROSO-2,6-DIMETHYLPYPERAZINE ^B
0.0297 ^a	NT	NT	+	NT	NT	1	55557-00-1	DINITROSOHOMOPIPERAZINE
-	NT	-	NT	NT	NT	1	101-25-7	N,N-DINITROSOPENTAMETHYLENETETRAMINE
NT	2.01 ^a	NT	NT	+	+	1	140-79-4	DINITROSOPIPERAZINE
-	-	A	A	-	-	1	121-14-2	2,4-DINITROTOLUENE
-	NT	-	NT	NT	NT	5	121-14-2	2,4-DINITROTOLUENE (PURIFIED)
0.574	NT	+	NT	NT	NT	5	606-20-2	2,6-DINITROTOLUENE
8.02	NT	+	NT	NT	NT	5	---	DINITROTOLUENE, TECHNICAL GRADE (2,4 (77%)- and 2,6 (19%)-)
126 ^{af}	594 ^a	+	+	+	+	1	123-91-1	1,4-DIOXANE
								p-DIOXANE (see 1,4-DIOXANE)
-	-	-	-	-	-	1	78-34-2	DIOXATHION
								DIOXIN (see 2,3,7,8-TETRACHLORODIBENZO-p-DIOXIN)
NT	-	NT	NT	-	-	1	971-15-3	DIPENTAMETHYLENETHIURAM HEXASULFIDE
2.75 ^a	NT	+	+	NT	NT	5	13256-06-9	DIPENTYLNITROSAMINE
-	-	E	E	-	-	3,5	147-24-0	DIPHENHYDRAMINE.HCl
NT	-	NT	NT	-	-	1	74-31-7	DIPHENYL-p-PHENYLENEDIAMINE
NT	-	NT	NT	-	-	1	86-29-3	DIPHENYLACETONITRILE
NT	-	NT	NT	-	-	1	102-09-0	DIPHENYLCARBONATE
-	-	-	-	-	-	1,5	57-41-0	5,5-DIPHENYLHYDANTOIN
								DIPHENYLNITROSAMINE (see N-NITROSODIPHENYLAMINE)

TD ₃₀ (mg/kg/day)		Positivity				Plot	CAS	Chemical Name
Rat	Mouse	MR	FR	MM	FM	Number	Number	
-	NT	-	NT	NT	NT	1	---	N,N-DIPROPYL-4-(4-[PYRIDYL-1'-OXIDE]AZO)ANILINE DIPROPYLNITROSAMINE (see N-NITROSODIPROPYLAMINE)
-	547 ^a	-	-	+	+	3,4	68-89-3	DIPYRONE DISODIUM ETHYLENEBISDITHIOCARBAMATE (see ETHYLENEBISDITHIOCARBAMATE, DISODIUM) DISODIUM SULFATE (see SULFATE, SODIUM) DISULFIRAM (see TETRAETHYLTHIURAM DISULFIDE) DITHANE (see ETHYLENEBISDITHIOCARBAMATE, DISODIUM)
-	-	-	-	-	A	1	142-46-1	2,5-DITHIOBIUREA
-	NT	NT	-	NT	NT	1	79-40-3	DITHIOOXAMIDE DIURON (see 3-(3,4-DICHLOROPHENYL)-1,1-DIMETHYLUREA) DMASA (see DAMINOZIDE) DMBA (see 7,12-DIMETHYLBENZ(a)ANTHRACENE) DMHP (see DIMETHYL HYDROGEN PHOSPHITE) DMMP (see DIMETHYL METHYLPHOSPHONATE) DMN (see N-NITROSODIMETHYLAMINE) DMT (see DIMETHYL TEREPHTHALATE)
NT	-	NT	NT	-	-	1	2439-10-3	1,1a,2,2,3,3a,4,5,5,5a,5b,6-DODECACHLOROOCCTAHYDRO-1,3,4-METHENO-1H-CYCLOBUTA[cd]PENTALENE (see MIREX) N-DODECYLGUANIDINE ACETATE DODINE (see N-DODECYLGUANIDINE ACETATE) DOWICIDE 1 (see o-PHENYLPHENOL) DOWICIDE 2S (see 2,4,6-TRICHLOROPHENOL) DOWICIDE 7 (see 2,3,4,5,6-PENTACHLOROPHENOL (Dowicide EC-7)) DOWICIDE EC-7 (see 2,3,4,5,6-PENTACHLOROPHENOL (Dowicide EC-7)) DS-M-1 (see DEXTRAN SULFATE SODIUM (DS-M-1)) DST-H (see DEXTRAN SULFATE SODIUM (DST-H)) DURAX (see N-CYCLOHEXYL-2-BENZOTHAZOLE SULFENAMIDE) EDB (see 1,2-DIBROMOETHANE) EDC (see 1,2-DICHLOROETHANE)
-	-	-	-	-	-	1	9004-59-5	EDIFAS A
-	-	-	-	-	-	1	9004-32-4	EDIFAS B
-	-	-	-	-	-	1	150-38-9	EDTA (see EDTA, TRISODIUM SALT TRIHYDRATE)
NT	NT	I	I	I	I	1	316-42-7	EDTA, TRISODIUM SALT TRIHYDRATE
-	-	-	-	-	-	1	55965-13-4	EMETINE.2HCI
-	-	I	-	I	-	1	115-29-7	EMULSIFIER YN ENDOSULFAN ENDOXAN (see CYCLOPHOSPHAMIDE)
-	-	-	-	-	-	1	72-20-8	ENDRIN
NT	-	NT	NT	-	-	3	13838-16-9	ENFLURANE
NT	0.151 ^{af}	NT	NT	-	+	1	8015-30-3	ENOVID
NT	-	NT	NT	-	-	1	8015-30-3	ENOVID-E ENU (see 1-ETHYL-1-NITROSOUREA)
-	-	-	-	-	-	3	134-72-5	EO (see ETHYLENE OXIDE)
2.55 ^a	-	+	+	NT	-	1,4	106-89-8	EPHEDRINE SULPHATE
106	-	+	E	-	-	5	106-88-7	EPICHLOROXYDRIN 1,2-EPOXYBUTANE 1,2-EPOXYPROPANE (see 1,2-PROPYLENE OXIDE)
-	NT	-	-	NT	NT	3	6381-77-7	ERYTHORBATE, SODIUM
-	-	-	-	-	-	5	643-22-1	ERYTHROMYCIN STEARATE
NT	0.282 ^b	NT	NT	NT	+	1	50-28-2	ERYTHROSINE (see FD & C RED NO. 3) ESTRADIOL ESTRADIOL-17beta (see ESTRADIOL)
-	0.682 ^a	-	-	+	+	1	22966-79-6	ESTRADIOL MUSTARD
NT	51.8	NT	NT	NT	+	3	140-67-0	ESTRAGOLE

TD ₅₀ (mg/kg/day)		Positivity				Plot	CAS	Chemical Name
Rat	Mouse	MR	FR	MM	FM	Number	Number	
-	69.3	-	-	-	+	1	536-33-4	ETHENZAMIDE (see o-ETHOXYBENZAMIDE)
4.97 ^c	NT	+	NT	NT	NT	1	13073-35-3	ETHIONAMIDE
5.24 ^a	33.8 ^{af}	+	NT	+	+	2,4	67-21-0	ETHIONINE
NT	513	NT	NT	+	-	4	938-73-8	DL-ETHIONINE
-	NT	-	NT	NT	NT	3,5	91-53-2	o-ETHOXYBENZAMIDE
71.9 ^a	260 ^a	+	+	+	+	4	140-88-5	ETHOXYQUIN
9110	-	+	-	NT	-	1-4	64-17-5	ETHYL ACRYLATE
0.022	NT	+	NT	NT	NT	4	16301-26-1	ETHYL ALCOHOL
0.0189	NT	+	NT	NT	NT	4	57497-29-7	Z-ETHYL-O,N,N-AZOXYETHANE
1210 ^a	NT	+	+	NT	NT	4	100-41-4	Z-ETHYL-O,N,N-AZOXYMETHANE
NT	-	NT	NT	NT	-	1	105-36-2	ETHYL BENZENE
-	NT	-	NT	NT	NT	1	2629-59-6	ETHYL BROMIDE (see BROMOETHANE)
-	-	-	-	-	A	1	72-56-0	ETHYL BROMOACETATE
NT	2.49 ^a	NT	NT	+	+	1	74920-78-8	ETHYL CADMATE (see CADMIUM DIETHYLDITHIOCARBAMATE)
-	NT	-	-	NT	NT	2	77-83-8	ETHYL CHLORIDE (see CHLOROETHANE)
NT	2.84	NT	NT	B+	B+	1	63885-23-4	ETHYL-alpha-p-CHLOROPHENOXYISOBUTYRATE (see CLOFIBRATE)
0.904 ^a	NT	+	+	NT	NT	3	759-73-9	S-ETHYL-L-CYSTEINE
-	-	A	-	A	-	1	20941-65-5	p,p'-ETHYL-DDD
-	-	-	-	-	-	1	74920-78-8	N-ETHYL-N-FORMYLHYDRAZINE
-	NT	-	-	NT	NT	2	77-83-8	ETHYL METHYLPHENYLGLYCIDATE
NT	2.84	NT	NT	B+	B+	1	63885-23-4	N-ETHYL-N-NITRO-N-NITROSOGUANIDINE
0.904 ^a	NT	+	+	NT	NT	3	759-73-9	1-ETHYL-1-NITROSOUREA
-	-	A	-	A	-	1	20941-65-5	N-ETHYL-N-NITROSOUREA (see 1-ETHYL-1- NITROSOUREA)
-	-	A	-	A	-	1	20941-65-5	1-ETHYL-1-NITROSOURETHAN (see NITROSOETHYLURETHAN)
-	-	A	-	A	-	1	20941-65-5	ETHYL SELENAC (see SELENIUM DIETHYLDITHIOCARBAMATE)
-	-	A	-	A	-	1	20941-65-5	ETHYL TELLURAC
-	-	A	-	A	-	1	20941-65-5	ETHYL TUADS (see TETRAETHYLTHIURAM DISULFIDE)
-	-	A	-	A	-	1	20941-65-5	ETHYL ZIMATE (see ZINC DIETHYLDITHIOCARBAMATE)
-	-	A	-	A	-	1	20941-65-5	ETHYLENE DIBROMIDE (see 1,2-DIBROMOETHANE)
-	-	A	-	A	-	1	20941-65-5	ETHYLENE DICHLORIDE (see 1,2-DICHLOROETHANE)
NT	-	NT	NT	NT	-	1	1072-53-3	ETHYLENE GLYCOL
NT	0.283 ^a	NT	NT	+	+	1	151-56-4	ETHYLENE IMINE
7.43 ^{af}	39.2 ^a	+	+	+	+	2,3,5	75-21-8	ETHYLENE OXIDE
10.8 ^a	16.9	+	+	+	-	1	96-45-7	ETHYLENE THIOUREA
NT	-	NT	NT	-	-	1	120-93-4	ETHYLENE UREA
NT	-	NT	NT	-	-	1	142-59-6	ETHYLENEBISDITHIOCARBAMATE, DISODIUM
-	NT	NT	-	NT	NT	1	106-87-6	1-ETHYLENEOXY-3,4-EPOXYCYCLOHEXANE
-	3050 ^a	-	-	+	+	2	103-23-1	DI(2-ETHYLHEXYL)ADIPATE
499 ^a	825 ^a	+	+	+	+	2,5	117-81-7	DI(2-ETHYLHEXYL)PHTHALATE
NT	5.22 ^a	NT	NT	+	+	1	18413-14-4	ETHYLHYDRAZINE.HCl
2.91 ^a	NT	+	+	NT	NT	1	38434-77-4	ETHYLNITROSOYANAMIDE
NT	15.3 ^a	NT	NT	NT	+	1	842-00-2	ETHYLNITROSOUREA (see 1-ETHYL-1-NITROSOUREA)
-	-	NT	-	NT	-	1,5	297-76-7	4-ETHYLSULPHONYLNAPHTHALENE-1-SULFONAMIDE
-	-	NT	-	NT	-	1,5	297-76-7	ETHYNODIOL DIACETATE
-	-	NT	-	NT	-	1,5	297-76-7	ETHYNODIOL DIACETATE/ETHINYL ESTRADIOL [10:1] (see OVULEN)
-	-	NT	-	NT	-	1,5	297-76-7	ETU (see ETHYLENE THIOUREA)
NT	-	NT	NT	-	NT	1	470-82-6	EUCALYPTOL
-	-	-	-	E	E	3	97-53-0	EUGENOL
-	-	-	-	-	-	1	140-56-7	FANFT (see N-[4-(5-NITRO-2-FURYL)-2-THIAZOLYL] FORMAMIDE)
-	-	-	-	-	-	1	140-56-7	FAST GREEN FCF (see FD & C GREEN NO. 3)
-	-	-	-	A	-	1	55-38-9	FENAMINOSULF, FORMULATED
-	NT	-	-	NT	NT	3	51630-58-1	FENTHION
-	NT	-	-	NT	NT	3	51630-58-1	FENVALERATE
-	NT	-	-	NT	NT	3	51630-58-1	FERRAM (see FERRIC DIMETHYLDITHIOCARBAMATE)

TD ₅₀ (mg/kg/day)		Positivity				Plot	CAS		Chemical Name
Rat	Mouse	MR	FR	MM	FM	Number	Number		
NT	-	NT	NT	-	-	1	14484-64-1	FERRIC DIMETHYLDITHIOCARBAMATE FERRIC NITROSODIMETHYLDITHIOCARBAMATE AND TETRAMETHYLTHIURAM DISULFIDE (see VANGUARD GF) FIREMASTER BP-6 (see POLYBROMINATED BIPHENYLS) FIREMASTER FF-1 (see POLYBROMINATED BIPHENYL MIXTURE)	
-	-	-	-	-	-	3	54143-56-5	FLECAINIDE ACETATE	
-	-	-	-	A	-	2	2164-17-2	FLUOMETURON FLUORENE-2,7-DIACETIMIDE (see 2,7-BIS- ACETYLAMINOFLUORENE)	
1.62	NT	NT	+	NT	NT	1	363-17-7	N-(2-FLUORENYL)-2,2,2-TRIFLUOROACETAMIDE FLUORENYLACETAMIDE (see 2- ACETYLAMINOFLUORENE) N-1-FLUORENYLACETAMIDE (see 1-ACETYLAMINOFLUORENE) N-2-FLUORENYLACETAMIDE (see 2-ACETYLAMINOFLUORENE) N-4-FLUORENYLACETAMIDE (see 4-ACETYLAMINOFLUORENE) N-1-FLUORENYLDIACETAMIDE (see N-1- DIACETAMIDOFUORENE)	
NT	-	NT	NT	B-	-	1,3	7681-49-4	FLUORIDE, SODIUM	
NT	1.09 ^a	NT	NT	+	+	1	324-93-6	4-FLUORO-4-AMINODIPHENYL N-(4'-FLUORO-4-BIPHENYLYL)ACETAMIDE (see N-4-(4'- FLUOROBIPHENYL)ACETAMIDE)	
1.01	NT	+	NT	NT	NT	1	398-32-3	N-4-(4'-FLUOROBIPHENYL)ACETAMIDE FLUOROCARBON 31 (see CHLOROFLUOROMETHANE) FLUOROCARBON 11 (see TRICHLOROFLUOROMETHANE) FLUOROCARBON 113 (see 1,1,2-TRICHLORO-1,2,2- TRIFLUOROETHANE, TECHNICAL GRADE) FLUOROCARBON 12 (see DICHLORODIFLUOROMETHANE) FLUOROCARBON 133a (see 2-CHLORO-1,1,1- TRIFLUOROETHANE) FLUOROCARBON 22 (see CHLORODIFLUOROMETHANE)	
-	NT	-	NT	NT	NT	1	51-21-8	5-FLUOROURACIL FNT (see FORMIC ACID 2-[4-(5-NITRO-2-FURYL)-2- THIAZOLYL]HYDRAZIDE) FOLPET (see N-(TRICHLOROMETHYLTHIO) PHTHALIMIDE)	
0.798 ^{af}	43.9	+	+	+	-	2-5	50-00-0	FORMALDEHYDE ^h	
-	NT	NT	-	NT	NT	1	31873-81-1	FORMIC ACID 2-[4-(2-FURYL)-2-THIAZOLYL] HYDRAZIDE	
14.4	NT	NT	+	NT	NT	1	32852-21-4	FORMIC ACID 2-(4-METHYL-2-THIAZOLYL) HYDRAZIDE	
3.54 ^a	8.85 ^a	+	+	NT	+	1	3570-75-0	FORMIC ACID 2-[4-(5-NITRO-2-FURYL)-2-THIAZOLYL] HYDRAZIDE ^b FORMULATED FENAMINOSULF (see FENAMINOSULF, FORMULATED)	
-	NT	NT	-	NT	NT	1	2302-84-3	1-FORMYL-3-THIOSEMICARBAZIDE	
NT	36 ^a	NT	NT	+	+	1	624-84-0	FORMYLHYDRAZINE FREON 30 (see METHYLENE CHLORIDE)	
-	NT	NT	-	NT	NT	1	2411-74-7	2-FURALDEHYDE SEMICARBAZONE	
NT	NT	NT	NT	NT	NT	1	98-01-1	FURFURAL ^h	
-	732	E	-	-	P	5	54-31-9	FUROSEMIDE 2-(2-FURYL)-3-(5-NITRO-2-FURYL)ACRYLAMIDE (see AF-2)	
-	NT	-	NT	NT	NT	3	23255-69-8	FURYL FURAMIDE (see AF-2) FUSARENON-X	

TD ₅₀ (mg/kg/day)		Positivity				Plot	CAS		Chemical Name
Rat	Mouse	MR	FR	MM	FM	Number	Number		
-	NT	-	-	NT	NT	4	35449-36-6	GEMCADIOL	
-	-	-	-	-	-	2	25812-30-0	GEMFIBROZIL GENITE-R99 (see 2,4-DICHLOROPHENYLBENZENE SULFONATE)	
NT	57.9 ^a	NT	NT	+	+	4	548-62-9	GENTIAN VIOLET	
-	-	E	-	-	-	5	mixture	GERANYL ACETATE, FOOD GRADE (71% GERANYL ACETATE, 29% CITRONELLYL ACETATE)	
-	-	B-	B-	B-	B-	1	12025-19-3	GERMANATE, SODIUM GESAMIL (see PROPAZINE)	
NT	-	NT	NT	-	-	1	77-06-5	GIBBERELIC ACID GLU-P-1 (see 2-AMINO-6-METHYLDIPYRIDO[1,2-a:3',2'-d]IMIDAZOLE)	
NT	-	NT	NT	-	NT	3	56-86-0	GLU-P-2 (see 2-AMINODIPYRIDO[1,2-a:3',2'-d]IMIDAZOLE) L-GLUTAMIC ACID N2-[gamma-L(+)-GLUTAMYL]-4-	
NT	277	NT	NT	+	-	5	---	CARBOXYPHENYLHYDRAZINE (see N2-gamma-GLUTAMYL-p-HYDRAZINOBENZOIC ACID)	
NT	-	NT	NT	-	-	2	2757-90-6	GLUTAMYL-p-HYDRAZINOBENZOATE (see N2-gamma-GLUTAMYL-p-HYDRAZINOBENZOIC ACID)	
-	NT	-	-	NT	NT	1	96-24-2	N2-gamma-GLUTAMYL-p-HYDRAZINOBENZOIC ACID beta-N-[gamma-L(+)-GLUTAMYL]-4-	
-	NT	NT	-	NT	NT	1	765-34-4	HYDROXYMETHYLPHENYLHYDRAZINE GLYCEROL alpha-MONOCHLOROHYDRIN	
NT	-	NT	NT	NT	-	1	3741-38-6	GLYCIDALDEHYDE GLYCOL SULFATE (see ETHYLENE GLYCOL)	
NT	-	NT	NT	-	-	4	71277-79-7	GLYCOL SULFITE GLYCYRRHIZINATE, DISODIUM	
3920 ^a	-	+	+	-	-	1	4680-78-8	FD & C GREEN NO. 1	
5640	-	B+	B+	-	-	1	5141-20-8	FD & C GREEN NO. 2	
-	-	-	-	-	-	1	2353-45-9	FD & C GREEN NO. 3	
NT	1660 ^b	NT	NT	+	-	1	126-07-8	GRISEOFULVIN ^h	
-	-	-	-	-	-	2	9000-30-0	GUAR GUM GUINEA GREEN B (see FD & C GREEN NO. 1)	
-	-	-	-	-	-	2	9000-01-5	GUM ACACIA (see GUM ARABIC) GUM ARABIC GUSATHION (see AZINPHOSMETHYL)	
5.96E-4	876E-4 ^a	-	+	+	+	1	mixture	HCB (see HEXACHLOROBENZENE) HCDD MIXTURE	
1000	NT	B+	B+	NT	NT	1	517-28-2	HEMATOXYLIN	
-	1.09 ^a	-	-	+	+	1	76-44-8	HEPTACHLOR	
-	NT	-	-	NT	NT	1	1121-92-2	HEPTAMETHYLENEIMINE	
-	NT	-	NT	NT	NT	1	1241-27-6	HEPTYLAMINE HERCULES-7531 (see 3-(HEXAHYDRO-4,7-METHANOINDAN-5-YL)-1,1-DIMETHYLUREA)	
1.65 ^{acf}	46.4 ^a	+	+	+	+	1,4,5	118-74-1	HETEROAUXIN (see INDOLE-3-ACETIC ACID) HEXACHLOROBENZENE ^g	
50.5 ^a	NT	+	+	NT	NT	1	87-68-3	HEXACHLOROBUTADIENE	
NT	25.3	NT	NT	+	NT	3	608-73-1	HEXACHLOROCYCLOHEXANE	
11.2	6.62 ^c	+	NT	+	NT	1	319-84-6	alpha-1,2,3,4,5,6-HEXACHLOROCYCLOHEXANE	
NT	17.7 ^a	NT	NT	+	+	1	319-85-7	beta-1,2,3,4,5,6-HEXACHLOROCYCLOHEXANE	
-	15.4 ^a	-	-	+	+	1,5	58-89-9	gamma-1,2,3,4,5,6-HEXACHLOROCYCLOHEXANE	
55.4	319 ^a	+	-	+	+	1,5	67-72-1	HEXACHLOROETHANE	
-	-	-	-	-	-	1	70-30-4	HEXACHLOROPHENE	
NT	-	NT	NT	-	-	1	2163-79-3	3-(HEXAHYDRO-4,7-METHANOINDAN-5-YL)-1,1-DIMETHYLUREA	
-	-	-	-	-	-	1	100-97-0	HEXAMETHYLENETETRAMINE	
10.2	NT	NT	+	NT	NT	1	531-18-0	HEXAMETHYLMELAMINE	
-	1950	-	-	+	-	1	628-02-4	HEXANAMIDE	
-	-	-	-	E	-	5	136-77-6	4-HEXYLRESORCINOL HNT (see 2-HYDRAZINO-4-(5-NITRO-2-FURYL)THIAZOLE)	
NT	-	NT	NT	-	-	4	1415-93-6	HUMIC ACIDS, COMMERCIAL GRADE	

TD ₃₀ (mg/kg/day)		Positivity				Plot	CAS		Chemical Name
Rat	Mouse	MR	FR	MM	FM	Number	Number		
0.194 ^a	2.2 ^a	+	+	+	+	1,4	302-01-2	HYDRAZINE ^g	
39.4 ^a	3.35 ^{af}	+	+	+	+	1,2,3,5	10034-93-2	HYDRAZINE SULFATE ^g	
1.03	11.3	NT	+	NT	+	1	26049-71-8	2-HYDRAZINO-4-(p-AMINOPHENYL)THIAZOLE	
2.83 ^a	16.4	NT	+	NT	+	1	26049-68-3	2-HYDRAZINO-4-(5-NITRO-2-FURYL)THIAZOLE	
1.97 ^a	10.6	NT	+	NT	+	1	26049-70-7	2-HYDRAZINO-4(p-NITROPHENYL)THIAZOLE	
-	NT	NT	-	NT	NT	1	34176-52-8	2-HYDRAZINO-4-PHENYLTHIAZOLE	
NT	-	NT	NT	NT	-	1	619-67-0	p-HYDRAZINOBENZOATE (see p-HYDRAZINOBENZOIC ACID) p-HYDRAZINOBENZOIC ACID p-HYDRAZINOBENZOIC ACID, N2-gamma-GLUTAMYL (see N2-gamma-GLUTAMYL-p-HYDRAZINOBENZOIC ACID)	
NT	380 ^a	NT	NT	+	+	5	24589-77-3	p-HYDRAZINOBENZOIC ACID.HCl	
3.55 ^a	26	+	+	-	+	1	122-66-7	HYDRAZOBENZENE	
-	NT	-	NT	NT	NT	4	7647-01-0	HYDROCHLORIC ACID	
-	-	-	-	E	-	5	58-93-5	HYDROCHLOROTHIAZIDE	
-	NT	-	-	NT	NT	1	50-23-7	HYDROCORTISONE	
NT	9010	NT	NT	B+	B+	1	7722-84-1	HYDROGEN CHLORIDE (see HYDROCHLORIC ACID) HYDROGEN PEROXIDE	
55.8 ^a	122	P	P	-	P	5	123-31-9	HYDROQUINONE	
NT	-	NT	NT	-	-	1	103-16-2	HYDROQUINONE MONOBENZYL ETHER	
-	NT	NT	-	NT	NT	1	4463-22-3	N-HYDROXY-N-ACETYL-2-AMINOFLUORENE (see N-HYDROXY-2-ACETYLAMINOFLUORENE) 3-HYDROXY-4-ACETYLAMINOBIIPHENYL	
6.9E-4 ^a	6.23	+	+	NT	+	1,3	53-95-2	N-HYDROXY-2-ACETYLAMINOFLUORENE ^g	
-	NT	NT	-	NT	NT	1	4363-03-5	3-HYDROXY-4-AMINOBIIPHENYL	
NT	5530	NT	NT	+	-	5	1083-57-4	3-HYDROXY-p-BUTYROPHENETIDIDE 2-HYDROXY-1,2-DIPHENYLETHANONE (see BENZOIN) HYDROXY-N-2-FLUORENYLACETAMIDE (see N-HYDROXY-2-ACETYLAMINOFLUORENE) 3-HYDROXY-2-PROPENAL, SODIUM SALT (see MALONALDEHYDE, SODIUM SALT) p-HYDROXYACETANILIDE (see ACETAMINOPHEN)	
NT	57.8	NT	NT	NT	+	3	51410-44-7	1'-HYDROXYESTRAGOLE	
16.7	NT	NT	+	NT	NT	1	5036-03-3	1-(2-HYDROXYETHYL)-3-[(5-NITROFURFURYLIDENE)AMINO]-2-IMIDAZOLIDINONE	
0.046 ^{af}	NT	+	+	NT	NT	1,4,5	13743-07-2	1-(2-HYDROXYETHYL)-1-NITROUREA	
1.87	NT	NT	+	NT	NT	1	33389-36-5	4-(2-HYDROXYETHYLAMINO)-2-(5-NITRO-2-THIENYL)QUINAZOLINE	
NT	0.314 ^a	NT	NT	+	-	1	109-84-2	2-HYDROXYETHYLHYDRAZINE ^h N-(HYDROXYMETHYL)-ACRYLAMIDE (see N-METHYLOLACRYLAMIDE)	
-	NT	-	-	NT	NT	1	---	HYDROXYPROPYL DISTARCH GLYCEROL	
-	-	-	-	-	-	1-3	148-24-3	8-HYDROXYQUINOLINE	
12.1 ^a	49.1 ^a	+	NT	+	+	1,3	5208-87-7	1'-HYDROXYSAFROLE HYPOCHLOROUS ACID, SODIUM SALT (see SODIUM HYPOCHLORITE) IBOPAMINE.HCl (see N-METHYLDOPAMINE, O,O'-DIISOBUTYROYL ESTER.HCl)	
10.7 ^d	23.7 ^d	-	+	-	+	1	21416-87-5	ICRF-159 2-IMIDAZOLIDINONE (see ETHYLENE UREA)	
-	-	A	A	-	-	1	3458-22-8	3,3'-IMINOBIS-1-PROPANOL DIMETHANESULFONATE (ESTER).HCl	
-	NT	-	-	NT	NT	1	32607-00-4	IMINODIACETIC ACID, MONOSODIUM INDIGO CARMINE (see FD & C BLUE NO. 2)	
NT	-	NT	NT	-	-	1	87-51-4	INDOLE-3-ACETIC ACID INH (see ISONIAZID)	
-	NT	-	NT	NT	NT	4	144-48-9	IODOACETAMIDE	
-	-	-	-	-	-	1	75-47-8	IODOFORM IPC (see ISOPROPYL-N-PHENYL CARBAMATE) IPD (see 3,3'-IMINOBIS-1-PROPANOL DIMETHANESULFONATE(ESTER).HCl) IQ (see 2-AMINO-3-METHYLIMIDAZO[4,5-f]QUINOLINE)	

TD ₅₀ (mg/kg/day)		Positivity				Plot	CAS		Chemical Name
Rat	Mouse	MR	FR	MM	FM	Number	Number		
								IQ.HCl (see 2-AMINO-3-METHYLIMIDAZO[4,5-f] QUINOLINE.HCl)	
								ISOASCORBATE (see ERYTHORBATE, SODIUM)	
								ISOBENZAN (see TELODRIN)	
NT	-	NT	NT	-	-	4	4247-02-3	ISOBUTYL p-HYDROXYBENZOATE	
-	NT	-	NT	NT	NT	1	5461-85-8	N-ISOBUTYL-N-NITRO-N-NITROSOGUANIDINE	
								N-ISOBUTYL-N-NITROSOUREA (see N-NITROSO-N-ISOBUTYLUREA)	
NT	-	NT	NT	-	-	5	26675-46-7	ISOFLURANE	
								ISOLAN (see 1-ISOPROPYL-3-METHYL-s-PYRAZOLYLDIMETHYL CARBAMATE)	
120 ^a	11.2 ^{af}	+	+	+	+	1-3	54-85-3	ISONIAZID ^h	
NT	-	NT	NT	-	-	3	1453-82-3	ISONICOTINAMIDE	
NT	-	NT	NT	-	-	1	55-22-1	ISONICOTINIC ACID ^h	
								ISONICOTINIC ACID HYDRAZIDE (see ISONIAZID)	
NT	27.4	NT	NT	B+	B+	1	149-17-7	ISONICOTINIC ACID VANILLYLIDENEHYDRAZIDE	
1210	-	P	-	E	-	3	78-59-1	ISOPHORONE	
0.739 ^d	5.06 ^d	-	+	-	+	1	3778-73-2	ISOPHOSPHAMIDE	
NT	-	NT	NT	-	-	1	101-73-5	p-ISOPROPOXYDIPHENYLAMINE	
-	-	-	-	-	-	1	101-21-3	ISOPROPYL-N-(3-CHLOROPHENYL)CARBAMATE ^h	
								1-ISOPROPYL-4-(m-METHOXYPHENYL)-7-METHYL-2(1H)-QUINAZOLINONE (see COMPOUND 50-892)	
								1-ISOPROPYL-7-METHYL-4-PHENYL-2(1H)-QUINAZOLINONE (see PROQUAZONE)	
NT	-	NT	NT	-	-	1	119-38-0	1-ISOPROPYL-3-METHYL-s-PYRAZOLYLDIMETHYL CARBAMATE	
NT	-	NT	NT	-	-	1	122-42-9	ISOPROPYL-N-PHENYL CARBAMATE ^h	
								4,4'-ISOPROPYLDENEDIPHENOL (see BISPENOL A)	
NT	-	NT	NT	-	-	1	120-58-1	ISOSAFROLE	
-	NT	-	-	NT	NT	3	520-18-3	KAEMPFEROL	
-	NT	NT	-	NT	NT	4	12737-87-0	KANECHLOR 400	
								KARATHANE (see DINITRO(1-METHYLHEPTYL) PHENYL CROTONATE)	
								KARMEX (see 3-(3,4-DICHLOROPHENYL)-1,1-DIMETHYLUREA)	
								KELTHANE (see DICOFOL)	
2.96	0.705 ^a	-	+	+	+	1	143-50-0	KEPONE	
								KMDS-H (see DEXTRAN SULFATE SODIUM (KMDS-H))	
								LAAM (see 6-DIMETHYLAMINO-4,4-DIPHENYL-3-HEPTANOL ACETATE.HCl)	
0.141 ^a	NT	+	+	NT	NT	1,5	303-34-4	LASIOCARPINE	
28.4	-	+	B-	-	-	1,4	301-04-2	LEAD ACETATE	
107 ^a	472 ^a	+	+	+	+	1,4	1335-32-6	LEAD ACETATE, BASIC ^h	
-	-	-	-	-	-	1	19010-66-3	LEAD DIMETHYLDITHIOCARBAMATE	
								LEAD SUBACETATE (see LEAD ACETATE, BASIC)	
								LEDATE (see LEAD DIMETHYLDITHIOCARBAMATE)	
NT	55.8	NT	NT	+	-	1	24365-47-7	LEUPEPTIN	
								LIGHT GREEN SF YELLOWISH (see FD & C GREEN NO. 2)	
								LINDANE (see gamma-1,2,3,4,5,6-HEXACHLOROCHLOROCYCLOHEXANE)	
-	-	-	-	-	-	1	434-13-9	LITHOCHOLIC ACID	
-	-	-	-	-	-	2	9000-40-2	LOCUST BEAN GUM	
-	NT	-	-	NT	NT	3	21498-08-8	LOFEXIDINE.HCl	
NT	14.8 ^a	NT	NT	+	+	1	21884-44-6	LUTEOSKYRIN	
NT	-	NT	NT	-	-	1	8065-91-6	LUTESTRAL	
								MACRODANTIN (see 1-[(5-NITROFURFURYLIDENE) AMINO]HYDANTOIN)	
								MAGENTA I (see ROSANILINE.HCl)	
								p-MAGENTA (see p-ROSANILINE.HCl)	
								MAGNESIUM PEMOLINE (see 2-AMINO-5-PHENYL-2-OXAZOLIN-4-ONE + Mg(OH)2)	
-	-	-	-	-	-	1	1634-78-2	MALAOXON	

TD ₅₀ (mg/kg/day)		Positivity				Plot	CAS		Chemical Name
Rat	Mouse	MR	FR	MM	FM	Number	Number		
-	-	-	-	-	-	1	121-75-5	MALATHION	
-	-	-	-	-	-	1,2	123-33-1	MALATHION-O-ANALOG (see MALAOXON)	
67.7 ^a	14.1	+	+	-	+	2,5	24382-04-5	MALEIC HYDRAZIDE	
								MALONALDEHYDE, SODIUM SALT	
								MAM ACETATE AND CYCASIN MIXTURE (see CYCASIN AND METHYL AZOXYMETHANOL ACETATE)	
								MANEB (see MANGANESE ETHYLENEBISTHIOCARBAMATE)	
157	-	B+	B+	-	-	1	12427-38-2	MANGANESE ETHYLENEBISTHIOCARBAMATE	
-	-	-	-	-	-	2	69-65-8	D-MANNITOL	
-	NT	-	NT	NT	NT	1	576-68-1	MANNITOL NITROGEN MUSTARD	
								MeA-alpha-C (see 2-AMINO-3-METHYL-9H-PYRIDO-[2,3-b]-INDOLE)	
								MeIQ (see 2-AMINO-3,4-DIMETHYLIMIDAZO[4,5-f]QUINOLINE)	
								MeIQx (see 2-AMINO-3,8-DIMETHYLIMIDAZO[4,5-f]QUINOXALINE)	
735	-	+	-	-	-	3	108-78-1	MELAMINE	
0.0719 ^{ad}	0.137 ^{ad}	+	+	+	+	1	148-82-3	MELPHALAN	
-	-	-	-	-	-	1	15356-70-4	DL-MENTHOL	
-	NT	NT	-	NT	NT	1	67-98-1	MER-25	
157 ^a	-	P	P	-	E	1,5	149-30-4	2-MERCAPTOBENZOTHAZOLE	
NT	-	NT	NT	-	-	1	155-04-4	2-MERCAPTOBENZOTHAZOLE, ZINC	
-	NT	-	NT	NT	NT	3	19767-45-4	2-MERCAPTOETHANESULFONATE, SODIUM	
-	NT	-	NT	NT	NT	1	50-44-2	6-MERCAPTOPURINE	
NT	-	NT	NT	-	-	1	7487-94-7	MERCURIC CHLORIDE	
NT	-	NT	NT	-	-	1	115-09-3	MERCURY METHYLCHLORIDE	
NT	-	NT	NT	-	-	1	72-33-3	MESTRANOL	
4.46	NT	+	NT	NT	NT	1	57-39-6	METEPA	
								DL-METHADONE.HCl (see 6-DIMETHYLAMINO-4,4-DIPHENYL-3-HEPTANONE.HCl)	
-	NT	-	-	NT	NT	4	531-06-6	METHAFURYLENE	
-	NT	-	-	NT	NT	4	493-78-7	METHAPHENILENE	
7.65 ^a	NT	+	+	NT	NT	3	135-23-9	METHAPYRILENE.HCl ^b	
0.9 ^a	NT	+	+	NT	NT	1	60-56-0	METHIMAZOLE	
-	NT	-	NT	NT	NT	4	59-51-8	DL-METHIONINE	
-	-	-	-	-	-	1	59-05-2	METHOTREXATE ^h	
NT	-	NT	NT	-	-	2	80830-39-3	2-METHOXY-4-AMINOAZOBENZENE	
NT	60.2	NT	NT	-	+	2	3544-23-8	3-METHOXY-4-AMINOAZOBENZENE	
25.7 ^a	NT	+	+	NT	NT	1	5834-17-3	2-METHOXY-3-AMINODIBENZOFURAN	
								2-METHOXY-3-DIBENZOFURANAMINE (see 2-METHOXY-3-AMINODIBENZOFURAN)	
-	-	-	-	-	-	1	72-43-5	METHOXYCHLOR	
NT	-	NT	NT	-	-	1	1701-77-5	METHOXYPHENYLACETIC ACID	
27.3	NT	+	-	NT	NT	5	298-81-7	8-METHOXYPSORALEN	
								METHYL ALLYL CHLORIDE (see 3-CHLORO-2-METHYLPROPENE, TECHNICAL GRADE (CONTAINING 5% DIMETHYL VINYL CHLORIDE))	
11.5	NT	+	NT	NT	NT	4	57497-34-4	Z-METHYL-O,N,N-AZOXYETHANE	
								Z-METHYL-O,N,N-AZOXYMETHANE (see AZOXYMETHANE)	
839 ^a	-	+	+	-	-	5	598-55-0	METHYL CARBAMATE	
-	NT	-	-	NT	NT	1	6294-89-9	METHYL CARBAZATE	
								METHYL CHLOROFORM (see 1,1,1-TRICHLOROETHANE, TECHNICAL GRADE)	
9.17 ^c	NT	+	NT	NT	NT	2	21340-68-1	METHYL CLOFENAPATE	
NT	8.03	NT	NT	B+	B+	1	---	1-METHYL-1,4-DIHYDRO-7-[2-(5-NITROFURYL)VINYL]-4-OXO-1,8-NAPHTHYRIDINE-3-CARBOXYLATE, POTASSIUM	
3.28 ^a	NT	+	NT	NT	NT	4	55-80-1	3'-METHYL-4-DIMETHYLAMINOAZOBENZENE	
1.3 ^{bd}	NT	+	NT	NT	NT	1	99-80-9	N-METHYL-N,4-DINITROSOANILINE	
								METHYL ETHYL CELLULOSE (see EDIFAS A)	

TD ₅₀ (mg/kg/day)		Positivity				Plot	CAS		Chemical Name
Rat	Mouse	MR	FR	MM	FM	Number	Number		
NT	0.745 ^{af}	NT	NT	+	+	1,2	758-17-8	N-METHYL-N-FORMYLHYDRAZINE ^b	
-	NT	-	NT	NT	NT	2	27323-65-5	METHYL LINOLEATE HYDROPEROXIDE	
-	NT	-	NT	NT	NT	2	---	METHYL LINOLEATE, NATIVE	
-	-	-	-	-	-	4	80-62-6	METHYL METHACRYLATE	
NT	31.8	NT	NT	+	NT	1	66-27-3	METHYL METHANESULFONATE	
0.403 ^a	NT	+	+	NT	NT	1-5	70-25-7	N-METHYL-N-NITRO-N-NITROSOGUANIDINE	
48.8 ^a	1.34 ^a	+	+	+	+	1	129-15-7	2-METHYL-1-NITROANTHRAQUINONE	
5.34	NT	NT	+	NT	NT	1	21638-36-8	4-METHYL-1-[(5-NITROFURFURYLIDENE)AMINO]-2-IMIDAZOLIDINONE	
0.468 ^a	NT	+	+	NT	NT	1	16699-10-8	4-(4-N-METHYL-N-NITROSAMINOSTYRYL)QUINOLINE	
3.23 ^a	NT	+	+	NT	NT	1	63412-06-6	N-METHYL-N-NITROSOBENZAMIDE	
0.633 ^{ad}	NT	+	+	NT	NT	1	---	N-(N-METHYL-N-NITROSO-CARBAMOYL)-L-ORNITHINE	
20.4	NT	B+	B+	NT	NT	1	14026-03-0	R(-)-2-METHYL-N-NITROSOPIPERIDINE	
13.2	NT	B+	B+	NT	NT	1	36702-44-0	S(+)-2-METHYL-N-NITROSOPIPERIDINE	
								N-METHYL-N-NITROSOUREA (see N-NITROSO-N-METHYLUREA)	
								METHYL ORANGE B (see FENAMINOSULF, FORMULATED)	
NT	-	NT	NT	B-	B-	3	21308-79-2	METHYL 12-OXO-trans-10-OCTADECENOATE	
-	-	-	-	-	-	1	298-00-0	METHYL PARATHION	
								METHYL-PHENYL-NITROSAMINE (see NITROSOMETHYLANILINE)	
-	NT	-	-	NT	NT	5	872-50-4	N-METHYL-2-PYRROLIDONE	
								METHYL SELENAC (see SELENIUM DIMETHYLDITHIOCARBAMATE)	
								METHYL ZIMATE (see ZINC DIMETHYLDITHIOCARBAMATE)	
NT	-	NT	NT	-	-	1	443-72-1	(N-6)-METHYLADENINE	
NT	-	NT	NT	-	-	1	1867-73-8	(N-6)-METHYLADENOSINE	
								METHYL AZOXYMETHANOL ACETATE AND CYCASIN MIXTURE (see CYCASIN AND METHYL AZOXYMETHANOL ACETATE)	
								METHYLCHOLANTHRENE (see 3-METHYLCHOLANTHRENE)	
0.202 ^a	NT	-	+	NT	NT	1,2	56-49-5	3-METHYLCHOLANTHRENE	
-	-	-	-	E	-	5	41372-08-1	alpha-METHYLDOPA SESQUIHYDRATE	
-	NT	-	-	NT	NT	5	75011-65-3	N-METHYLDOPAMINE, O,O-DIISOBUTYROYL ESTER.HCl	
9.09 ^a	NT	+	+	NT	NT	1	101-14-4	4,4'-METHYLENE-BIS(2-CHLOROANILINE) ^b	
-	66.6	-	NT	-	+	1	64049-29-2	4,4'-METHYLENE-BIS(2-CHLOROANILINE).2HCl	
6.91 ^a	NT	+	+	NT	NT	1	838-88-0	4,4'-METHYLENE-BIS(2-METHYLANILINE)	
598 ^a	817 ^a	P	+	+	+	3-5	75-09-2	METHYLENE CHLORIDE	
16.4 ^a	207	+	+	-	+	1	101-61-1	4,4'-METHYLENEBIS(N,N-DIMETHYL)BENZENAMINE	
12.5 ^a	22.3 ^a	+	+	+	+	3	13552-44-8	4,4'-METHYLENEDIANILINE.2HCl	
-	NT	-	NT	NT	NT	1	471-29-4	METHYLGUANIDINE	
-	NT	B-	B-	NT	NT	1	578-76-7	7-METHYLGUANINE	
NT	4.58 ^a	NT	NT	+	+	1	60-34-4	METHYLHYDRAZINE ^b	
NT	2.51 ^a	NT	NT	+	+	1	302-15-8	METHYLHYDRAZINE SULFATE	
								METHYLMERCURIC ACETATE (see MERCURYMETHYLCHLORIDE)	
								METHYLMERCURY CHLORIDE (see MERCURYMETHYLCHLORIDE)	
0.103	NT	+	NT	NT	NT	5	---	4-(METHYLNITROSAMINO)-1-(3-PYRRIDYL)-1-BUTANOL	
0.182	NT	+	NT	NT	NT	5	64091-91-4	4-(METHYLNITROSAMINO)-1-(3-PYRRIDYL)-1-(BUTANONE)	
NT	18	NT	NT	+	-	1	---	(N-6)-(METHYLNITROSO)ADENINE	
NT	15.8 ^a	NT	NT	+	+	1	21928-82-5	(N-6)-(METHYLNITROSO)ADENOSINE	
0.48	NT	NT	+	NT	NT	3	33868-17-6	METHYLNITROSO-CYANAMIDE	
-	13.3 ^a	-	-	+	+	5	924-42-5	N-METHYLOLACRYLAMIDE	
-	NT	-	-	NT	NT	2	91-62-3	6-METHYLQUINOLINE	
-	NT	-	-	NT	NT	2	611-32-5	8-METHYLQUINOLINE	
NT	-	NT	NT	-	-	5	622-97-9	p-METHYLSTYRENE	

TD ₅₀ (mg/kg/day)		Positivity				Plot	CAS		Chemical Name
Rat	Mouse	MR	FR	MM	FM	Number	Number		
NT	-	NT	NT	B-	B-	1,3	56-04-2	METHYLTHIOURACIL ⁸	
-	NT	-	-	NT	NT	1	5800-19-1	METIAPINE	
431 ^a	347 ^a	+	+	+	+	1	443-48-1	METRONIDAZOLE	
-	-	-	-	-	-	1	315-18-4	MEXACARBATE	
4.87 ^a	53 ^a	+	+	+	+	1	90-94-8	MICHLERS KETONE	
-	1.1 ^a	-	NT	+	+	1	2385-85-5	MILBAM (see ZINC DIMETHYLDITHIOCARBAMATE)	
1.46	NT	+	NT	NT	NT	1	39801-14-4	MIREX	
-	-	-	-	-	-	5	59122-46-2	MIREX, PHOTO-MISOPROSTOL	
9.81E-4 ^{ad}	NT	+	+	NT	NT	1	50-07-7	MITOMEN (see NITROGEN MUSTARD N-OXIDE)	
								MITOMYCIN-C	
								MMS (see METHYL METHANESULFONATE)	
								MNNG (see N-METHYL-N'-NITRO-N-NITROGUANIDINE)	
								MNU (see N-NITROSO-N-METHYLUREA)	
								MOCA (see 4,4'-METHYLENE-BIS(2-CHLOROANILINE))	
NT	4.48 ^a	NT	NT	+	+	3	1068-57-1	MONOACETYL HYDRAZINE	
NT	-	NT	NT	-	-	1	79-11-8	MONOCHLOROACETIC ACID	
0.79 ^a	NT	+	NT	NT	NT	3	315-22-0	MONOCHLOROBENZENE (see CHLOROBENZENE)	
								MONOCROTALINE	
								MONOMETHYL BENZENE (see TOLUENE)	
NT	-	NT	NT	-	NT	3	32221-81-1	DL-MONOSODIUM GLUTAMATE	
NT	-	NT	NT	-	NT	3	142-47-2	L-MONOSODIUM GLUTAMATE	
								MONOSODIUM IMINODIACETIC ACID (see IMINODIACETIC ACID, MONOSODIUM)	
								MONURON (see 3-(p-CHLOROPHENYL)-1,1-DIMETHYLUREA)	
								8-MOP (see 8-METHOXYPSORALEN)	
5.03	NT	NT	+	NT	NT	1	58139-48-3	4-MORPHOLINO-2-(5-NITRO-2-THIENYL)QUINAZOLINE	
6.33	NT	NT	+	NT	NT	1	3031-51-4	L-5-MORPHOLINOMETHYL-3-[(5-NITROFURFURYLIDENE)AMINO]-2-OXAZOLIDINONE.HCl	
								MUCOCHLORIC ACID (see alpha,beta-DICHLORO-beta-FORMYLACRYLIC ACID)	
-	NT	-	NT	NT	NT	1	55-98-1	MYLERAN	
								NABAM (see ETHYLENEBISDITHIOCARBAMATE, DISODIUM)	
138 ^a	-	+	+	E	-	5	389-08-2	NALIDIXIC ACID	
NT	-	NT	NT	-	-	1	86-86-2	1-NAPHTHALENE ACETAMIDE	
NT	-	NT	NT	-	-	1	86-87-3	1-NAPHTHALENE ACETIC ACID	
50.8	66.6 ^a	-	+	+	+	1	2243-62-1	1,5-NAPHTHALENEDIAMINE	
-	-	-	-	-	-	1	1465-25-4	N-(1-NAPHTHYL)ETHYLENEDIAMINE.2HCl	
NT	-	NT	NT	-	-	1	93-46-9	sym.-dibeta-NAPHTHYL-p-PHENYLENEDIAMINE	
NT	-	NT	NT	-	-	1	86-88-4	1-(1-NAPHTHYL)-2-THIOUREA	
61.6	20.5 ^a	B-	+	B+	+	1,2	91-59-8	2-NAPHTHYLAMINE ⁸	
								beta-NAPHTHYLAMINE (see 2-NAPHTHYLAMINE)	
NT	-	NT	NT	-	-	2	81-16-3	2-NAPHTHYLAMINO,1-SULFONIC ACID	
								NAS (see 2-NAPHTHYLAMINO,1-SULFONIC ACID)	
-	NT	-	-	NT	NT	5	88385-81-3	NEOSUGAR	
								NEW COCCINE (see SX PURPLE)	
								NFTA (see N-[4-(5-NITRO-2-FURYL)-2-THIAZOLYL]ACETAMIDE)	
								NHEU (see 1-(2-HYDROXYETHYL)-1-NITROSOUREA)	
-	NT	-	-	NT	NT	1	7440-02-0	NICKEL	
NT	-	NT	NT	-	-	1	373-02-4	NICKEL (II) ACETATE	
NT	-	NT	NT	-	-	1	13927-77-0	NICKEL DIBUTYLDITHIOCARBAMATE	
								NICLOSAMIDE (see CLONITRALID)	
NT	-	NT	NT	-	-	3	98-92-0	NICOTINAMIDE	
-	NT	-	-	NT	NT	1	54-11-5	NICOTINE	
NT	-	NT	NT	-	-	2	636-79-3	NICOTINE.HCl	
NT	-	NT	NT	-	-	2	59-67-6	NICOTINIC ACID	
NT	145 ^a	NT	NT	+	+	1	553-53-7	NICOTINIC ACID HYDRAZIDE	
-	NT	-	-	NT	NT	1	---	NIGROSINE	

TD ₅₀ (mg/kg/day)		Positivity				Plot	CAS		Chemical Name
Rat	Mouse	MR	FR	MM	FM	Number	Number		
NT	-	NT	NT	B-	B-	1	12034-09-2	NIOBATE, SODIUM	
131	758	-	+	+	-	1	139-94-6	NITHIAZIDE	
-	NT	-	-	NT	NT	1,2	7631-99-4	NITRATE, SODIUM	
NT	-	NT	NT	NT	-	1	10102-43-9	NITRIC OXIDE	
1450 ^a	1470 ^a	+	+	+	+	1	139-13-9	NITRILOTRIACETIC ACID	
224 ^a	-	+	+	-	-	1	18662-53-8	NITRILOTRIACETIC ACID, TRISODIUM SALT, MONOHYDRATE	
124 ^a	-	+	+	-	-	1,2,3,5	7632-00-0	NITRITE, SODIUM ^b	
-	2270	-	-	+	-	1	1777-84-0	3-NITRO-p-ACETOPHENETIDE	
28.1 ^a	3720	+	+	-	+	1	99-59-2	5-NITRO-o-ANISIDINE	
4.64 ^{ac}	22.4	E	+	-	+	1,5	59-87-0	5-NITRO-2-FURALDEHYDE SEMICARBAZONE	
-	NT	NT	-	NT	NT	1	772-43-0	5-NITRO-2-FURAMIDOXIME	
-	NT	NT	-	NT	NT	1	92-55-7	5-NITRO-2-FURANMETHANEDIOL DIACETATE	
11.9 ^a	20.3 ^{ac}	+	+	+	+	1	75198-31-1	3-(5-NITRO-2-FURYL)-IMIDAZO(1,2-alpha)PYRIDINE	
8.61	NT	NT	+	NT	NT	1	2122-86-3	5-(5-NITRO-2-FURYL)-1,3,4-OXADIAZOLE-2-OL	
59.6 ^b	NT	NT	+	NT	NT	1	36133-88-7	N-([3-(5-NITRO-2-FURYL)-1,2,4-OXADIAZOLE-5-YL]-METHYL)ACETAMIDE	
8.84	6.74	NT	+	NT	+	1	2578-75-8	N-[5-(5-NITRO-2-FURYL)-1,3,4-THIADIAZOL-2-YL]ACETAMIDE	
7.68	NT	NT	+	NT	NT	2	53757-28-1	4-(5-NITRO-2-FURYL)THIAZOLE	
10.5 ^a	NT	NT	+	NT	NT	1	531-82-8	N-[4-(5-NITRO-2-FURYL)-2-THIAZOLYL]ACETAMIDE ^g	
1.31 ^{af}	7.72 ^{af}	+	+	+	+	1-4	24554-26-5	N-[4-(5-NITRO-2-FURYL)-2-THIAZOLYL]FORMAMIDE ^g	
14.1	NT	NT	+	NT	NT	1	51325-35-0	N,N'-[6-(5-NITRO-2-FURYL)-s-TRIAZINE-2,4-DIYL]BISACETAMIDE	
8.66	0.346	B+	B+	B+	B+	1	4812-22-0	3-NITRO-3-HEXENE	
-	-	E	-	-	-	1,5	121-19-7	3-NITRO-4-HYDROXYPHENYLARSONIC ACID	
-	614	-	-	-	+	1	5307-14-2	2-NITRO-p-PHENYLENEDIAMINE	
-	-	-	-	-	-	1	99-56-9	4-NITRO-o-PHENYLENEDIAMINE	
-	242 ^a	-	-	+	+	1	99-55-8	5-NITRO-o-TOLUIDINE	
5.98 ^a	45.3	+	+	-	+	1	602-87-9	5-NITROACENAPHTHENE ^h	
-	-	-	-	-	-	1	619-17-0	4-NITROANTHRANILIC ACID	
-	354 ^a	-	-	+	+	1	94-52-0	6-NITROBENZIMIDAZOLE	
420	64.2 ^a	I	+	+	+	1	1836-75-5	NITROFEN NITROFURANTOIN (see 1-[(5-NITROFURFURYLIDENE)AMINO]HYDANTOIN) NITROFURAZONE (see 5-NITRO-2-FURALDEHYDE SEMICARBAZONE)	
698	866	P	-	-	+	1,3,5	67-20-9	1-[(5-NITROFURFURYLIDENE)AMINO]HYDANTOIN	
5.26	NT	NT	+	NT	NT	1	555-84-0	1-[(5-NITROFURFURYLIDENE)AMINO]-2-IMIDAZOLIDINONE	
0.0114 ^d	NT	+	NT	NT	NT	1	51-75-2	NITROGEN MUSTARD	
0.764 ^d	NT	+	NT	NT	NT	1	126-85-2	NITROGEN MUSTARD N-OXIDE	
-	-	-	-	-	-	1	86-57-7	NITROGEN OXIDE (see NITROUS OXIDE) 1-NITRONAPHTHALENE D-(-)-threo-1-(p-NITROPHENYL)-2-DICHLOROACETAMIDO-1,3-PROPANEDIOL (see CHLORAMPHENICOL)	
-	NT	-	-	NT	NT	3,5	108-03-2	1-NITROPROPANE	
-	NT	-	-	NT	NT	1	79-46-9	2-NITROPROPANE	
-	-	A	-	-	-	1	504-88-1	3-NITROPROPIONIC ACID	
-	NT	-	-	NT	NT	2	613-50-3	6-NITROQUINOLINE	
9.55 ^a	NT	+	+	NT	NT	2	607-35-2	8-NITROQUINOLINE	
0.364	NT	+	NT	NT	NT	1	38777-13-8	NITROSO-BAYGON	
0.707 ^a	NT	+	+	NT	NT	2	83335-32-4	N-NITROSO-BIS-(4,4,4-TRIFLUORO-N-BUTYL)AMINE N-NITROSO-3,6-DIHYDROOXAZINE-1,2 (see 3,6-DIHYDRO-2-NITROSO-2H-1,2-OXAZINE)	
-	NT	-	-	NT	NT	3	62641-67-2	1-NITROSO-5,6-DIHYDROTHYMINE	
0.0932 ^a	NT	+	+	NT	NT	1	16813-36-8	1-NITROSO-5,6-DIHYDROURACIL	
0.0535	NT	NT	+	NT	NT	3	89911-79-5	N-NITROSO-2,3-DIHYDROXYPROPYL-2-HYDROXYPROPYLAMINE ^g	
0.0352	NT	NT	+	NT	NT	3	92177-50-9	NITROSO-2,3-DIHYDROXYPROPYL-2-OXOPROPYLAMINE ^g	
5.98	NT	NT	+	NT	NT	3	89911-78-4	N-NITROSO-2,3-DIHYDROXYPROPYLETHANOLAMINE ^h	

TD ₅₀ (mg/kg/day)		Positivity				Plot	CAS		Chemical Name
Rat	Mouse	MR	FR	MM	FM	Number	Number		
9.66	NT	NT	+	NT	NT	2	61034-40-0	1-NITROSO-3,5-DIMETHYL-4-BENZOYLPIPERAZINE	
NT	NT	NT	NT	NT	NT	1	1456-28-6	NITROSO-2,6-DIMETHYLMORPHOLINE ⁸	
0.15 ^a	NT	+	+	NT	NT	4	---	1-NITROSO-1-HYDROXYETHYL-3-CHLOROETHYLUREA N-NITROSO-2-HYDROXYETHYLUREA (see 1-(2-HYDROXYETHYL)-1-NITROSOUREA)	
0.861 ^a	NT	+	+	NT	NT	4	---	1-NITROSO-1-(2-HYDROXYPROPYL)-3-CHLOROETHYLUREA	
1.02	NT	NT	+	NT	NT	3	75896-33-2	N-NITROSO-(2-HYDROXYPROPYL)-(2-HYDROXYETHYL)AMINE	
7.65	NT	B+	B+	NT	NT	3	56222-35-6	N-NITROSO-3-HYDROXYPYRROLIDINE	
4.73	NT	NT	+	NT	NT	3	760-60-1	N-NITROSO-N-ISOBUTYLUREA	
0.487 ^a	NT	+	+	NT	NT	2,3	55090-44-3	N-NITROSO-N-METHYL-N-DODECYLAMINE	
0.255	NT	+	NT	NT	NT	3	937-25-7	N-NITROSO-N-METHYL-4-FLUOROANILINE	
-	NT	-	NT	NT	NT	3	943-41-9	N-NITROSO-N-METHYL-4-NITROANILINE	
0.00788 ^a	NT	+	NT	NT	NT	1	13256-11-6	NITROSO-N-METHYL-N-(2-PHENYL)ETHYLAMINE	
1.65 ^c	NT	+	NT	NT	NT	2	75881-20-8	N-NITROSO-N-METHYL-N-TETRADECYLAMINE	
1.26	NT	+	NT	NT	NT	2	75881-22-0	N-NITROSO-N-METHYLDECYLAMINE	
NT	NT	NT	NT	NT	NT	4	79624-33-2	NITROSO-5-METHYLOXAZOLIDONE ⁸	
NT	NT	NT	NT	NT	NT	1	684-93-5	N-NITROSO-N-METHYLUREA ⁸	
NT	NT	NT	NT	NT	NT	1	615-53-2	N-NITROSO-N-METHYLURETHAN ⁸	
NT	NT	NT	NT	NT	NT	3,4	39884-52-1	N-NITROSO-1,3-OXAZOLIDINE ⁸	
0.262 ^{ac}	NT	+	NT	NT	NT	5	38347-74-9	3-NITROSO-2-OXAZOLIDINONE	
1.8	NT	NT	+	NT	NT	3	92177-49-6	NITROSO-2-OXOPROPYLETHANOLAMINE ⁸	
0.166 ^d	NT	+	NT	NT	NT	3	15973-99-6	DI(N-NITROSO)-PERHYDROPYRIMIDINE	
0.0374 ^a	NT	NT	+	NT	NT	1	55556-92-8	NITROSO-1,2,3,6-TETRAHYDROPYRIDINE	
2.52	NT	+	NT	NT	NT	3	82018-90-4	N-NITROSO(2,2,2-TRIFLUOROETHYL)ETHYLAMINE	
3.31 ^d	NT	+	NT	NT	NT	1	29929-77-9	N-NITROSO-2,2,4-TRIMETHYL-1,2-DIHYDROQUINOLINE POLYMER	
0.151	NT	NT	+	NT	NT	3	75881-18-4	1-NITROSO-3,4,5-TRIMETHYLPIPERAZINE ⁸	
0.825	NT	NT	+	NT	NT	3	88208-16-6	N-NITROSOALLYL-2,3-DIHYDROXYPROPYLAMINE	
0.877	NT	NT	+	NT	NT	3	91308-70-2	N-NITROSOALLYL-2-HYDROXYPROPYLAMINE	
0.335	NT	NT	+	NT	NT	3	91308-71-3	N-NITROSOALLYL-2-OXOPROPYLAMINE ⁸	
0.491	NT	NT	+	NT	NT	3	91308-69-9	N-NITROSOALLYLETHANOLAMINE	
1.01	NT	NT	+	NT	NT	2	---	NITROSOAMYLURETHAN	
11 ^a	NT	+	+	NT	NT	1	1133-64-8	NITROSOANABASINE	
NT	NT	NT	NT	NT	NT	3	15216-10-1	N-NITROSOAZETIDINE ⁸	
1.13	NT	B+	B+	NT	NT	1	51542-33-7	N-NITROSOBENZTHIAZURON	
0.813 ^a	NT	+	+	NT	NT	1,3	53609-64-6	N-NITROSOBIS(2-HYDROXYPROPYL)AMINE	
0.232 ^a	NT	+	+	NT	NT	2,3	60599-38-4	N-NITROSOBIS(2-OXOPROPYL)AMINE	
-	NT	-	-	NT	NT	1	625-89-8	N-NITROSOBIS(2,2,2-TRIFLUOROETHYL)AMINE	
NT	-	NT	NT	-	-	1	51715-17-4	NITROSOCHLORDIAZEPOXIDE	
-	NT	-	-	NT	NT	3	73785-40-7	N-NITROSOCIMETIDINE	
0.691	1.09	+	NT	+	NT	1,3	924-16-3	NITROSODIBUTYLAMINE	
1.9 ^{af}	NT	+	+	NT	NT	2,3,5	1116-54-7	N-NITROSODIETHANOLAMINE	
0.00787 ^{af}	NT	+	+	NT	NT	1,3,5	55-18-5	N-NITROSODIETHYLAMINE ⁸	
0.0587 ^{af}	0.153 ^a	+	+	+	+	1,2,3,5	62-75-9	N-NITROSODIMETHYLAMINE	
116 ^a	-	+	+	-	-	1	86-30-6	N-NITROSODIPHENYLAMINE	
201	340	+	-	+	-	1	156-10-5	p-NITROSODIPHENYLAMINE	
0.186	NT	NT	+	NT	NT	3	621-64-7	N-NITROSODIPROPYLAMINE	
-	NT	NT	-	NT	NT	5	114282-83-6	N-NITROSODITHIAZINE	
10.9 ^a	NT	+	+	NT	NT	3	40580-89-0	NITROSODODECAMETHYLENEIMINE	
95.2	NT	+	NT	NT	NT	1	17608-59-2	N-NITROSOEPHEDRINE NITROSOETHANECARBAMONITRILE (see ETHYLNITROSOCYANAMIDE)	
0.0503	NT	+	-	NT	NT	3,5	10595-95-6	NITROSOETHYLMETHYLAMINE	
0.248	NT	NT	+	NT	NT	2	614-95-9	NITROSOETHYLURETHAN	
-	NT	-	NT	NT	NT	5	55557-02-3	N-NITROSOGUVACOLINE	
0.0292 ^a	NT	+	NT	NT	NT	1	20917-49-1	NITROSOHEPTAMETHYLENEIMINE	
NT	0.313 ^a	NT	NT	+	+	3	932-83-2	N-NITROSOHEXAMETHYLENEIMINE	
43.8 ^a	NT	+	+	NT	NT	1	42579-28-2	1-NITROSOHYDANTOIN	
-	NT	-	-	NT	NT	1	30310-80-6	NITROSOHYDROXYPROLINE	
-	NT	-	-	NT	NT	1	25081-31-6	NITROSOIMINODIACETIC ACID	

TD ₅₀ (mg/kg/day)		Positivity				Plot	CAS	Chemical Name
Rat	Mouse	MR	FR	MM	FM	Number	Number	
0.646	NT	NT	+	NT	NT	3	86451-37-8	N-NITROSOMETHYL-2,3-DIHYDROXYPROPYLAMINE ^g NITROSOMETHYL-N-DODECYLAMINE (see N-NITROSO-N-METHYL-N-DODECYLAMINE)
1.29	NT	+	NT	NT	NT	5	26921-68-6	N-NITROSOMETHYL-(2-HYDROXYETHYL)AMINE
1.09 ^a	NT	+	+	NT	NT	5	70415-59-7	N-NITROSOMETHYL-(3-HYDROXYPROPYL)AMINE
0.0442 ^a	NT	+	+	NT	NT	3	75411-83-5	N-NITROSOMETHYL-2-HYDROXYPROPYLAMINE
3.47 ^a	NT	+	+	NT	NT	5	---	N-NITROSOMETHYL-(2-TOSYLOXYETHYL)AMINE
0.214	NT	NT	+	NT	NT	1	16219-98-0	2-NITROSOMETHYLAMINOPYRIDINE
-	NT	NT	-	NT	NT	1	69658-91-9	3-NITROSOMETHYLAMINOPYRIDINE
-	NT	NT	-	NT	NT	1	16219-99-1	4-NITROSOMETHYLAMINOPYRIDINE
0.0343 ^{af}	NT	+	+	NT	NT	1,3	614-00-6	NITROSOMETHYLANILINE N-NITROSOMETHYLETHYLAMINE (see NITROSOETHYLMETHYLAMINE)
NT	-	NT	NT	-	-	1	55557-03-4	NITROSOMETHYLPHENIDATE
2.37	NT	+	NT	NT	NT	1	68107-26-6	NITROSOMETHYLUDECYLAMINE NITROSOMETHYLUREA (see N-NITROSO-N-METHYLUREA)
0.127 ^a	NT	NT	+	NT	NT	3,5	59-89-2	NITROSOMORPHOLINE (see N-NITROSOMORPHOLINE) N-NITROSOMORPHOLINE ^g
NT	NT	NT	NT	NT	NT	3	16543-55-8	N'-NITROSONORNICOTINE ^g
0.573 ^a	NT	+	+	NT	NT	3	78246-24-9	N'-NITROSONORNICOTINE-1-N-OXIDE ^h NITROSOOXAZOLIDONE (see N-NITROSO-1,3-OXAZOLIDINE)
-	NT	-	-	NT	NT	1	4515-18-8	NITROSOPIPECOLIC ACID NITROSOPIPERAZINE (see N-NITROSOPIPERAZINE) 1-NITROSOPIPERAZINE (see N-NITROSOPIPERAZINE)
5.51 ^{ab}	NT	+	+	NT	NT	1	5632-47-3	N-NITROSOPIPERAZINE
1.57	1.3	B+	B+	+	NT	1,3	100-75-4	N-NITROSOPIPERIDINE ^g
-	NT	-	-	NT	NT	1	7519-36-0	NITROSOPROLINE NITROSOPYRROLIDINE (see N-NITROSOPYRROLIDINE)
0.409 ^{ac}	0.679	+	+	+	NT	1,2,4,5	930-55-2	N-NITROSOPYRROLIDINE ^g
0.483	NT	NT	+	NT	NT	5	81795-07-5	N-NITROSOTHIALDINE
4.15 ^a	NT	+	+	NT	NT	1	26541-51-5	N-NITROSOTHIOMORPHOLINE
50.7	NT	+	NT	NT	NT	2	611-23-4	o-NITROSOTOLUENE beta-NITROSTYRENE AND STYRENE MIXTURE (see STYRENE AND beta-NITROSTYRENE MIXTURE)
NT	-	NT	NT	-	-	4	10024-97-2	NITROUS OXIDE
NT	-	NT	NT	-	-	1	68-23-5	NORETHYNODREL NORETHYNODREL/MESTRANOL [25:1] (see ENOVID-E) NORETHYNODREL/MESTRANOL [66:1] (see ENOVID)
-	NT	-	NT	NT	NT	1	244-63-3	NORHARMAN
1.94	1.34 ^b	B+	B+	NT	+	1,2	8015-12-1	NORLESTRIN ^h
-	-	B-	B-	B-	B-	1	---	NOVADELOX
0.0579 ^a	3.53 ^a	+	+	+	+	1,4,5	303-47-9	OCHRATOXIN A
-	NT	-	-	NT	NT	4	29082-74-4	OCTACHLOROSTYRENE DI-sec-OCTYL PHTHALATE (see DI(2-ETHYLHEXYL)PHTHALATE) 17beta-OESTRADIOL (see ESTRADIOL)
-	NT	-	-	NT	NT	4	143-19-1	OLEATE, SODIUM
-	-	-	-	-	-	4	73590-58-6	OMEPRAZOLE
1710	-	-	+	-	-	5	6373-74-6	C.I. ACID ORANGE 3
-	-	-	-	-	-	5	1936-15-8	C.I. ACID ORANGE 10 ORTHOXENOL (see o-PHENYLPHENOL) OTOS (see N-OXYDIETHYLENE THIOCARBAMYL-N-OXYDIETHYLENE SULFENAMIDE) OVEX (see p-CHLOROPHENYL-p-CHLOROBENZENE SULFONATE)
NT	-	NT	NT	-	-	1	8056-92-6	OVULEN OVULEN-50 (see ETHYNODIOL DIACETATE)
-	-	-	-	-	-	4	23135-22-0	OXAMYL
6.17	NT	NT	+	NT	NT	1	3096-50-2	N-(9-OXO-2-FLUORENYL)ACETAMIDE
-	NT	-	NT	NT	NT	1	30418-53-2	1'-OXOSAFROLE

TD ₅₀ (mg/kg/day)		Positivity				Plot	CAS		Chemical Name
Rat	Mouse	MR	FR	MM	FM	Number	Number		
-	-	-	-	-	-	1	6452-73-9	OXPRENOLOL.HCl	
6.65 ^a	19.7 ^a	+	+	+	+	2	101-80-4	4,4'-OXYDIANILINE	
85.5 ^a	NT	+	+	NT	NT	4	13752-51-7	N-OXYDIETHYLENE THIOCARBAMYL-N-OXYDIETHYLENE SULFENAMIDE	
NT	-	NT	NT	-	-	1	102-77-2	N-OXYDIETHYLENEBENZOTHAZOLE-2-SULFENAMIDE	
-	-	E	E	-	-	4	2058-46-0	OXYTETRACYCLINE.HCl	
-	-	A	A	-	-	1	56-38-2	PARACETAMOL (see ACETAMINOPHEN)	
-	NT	NT	-	NT	NT	1	149-29-1	PARATHION	
-	-	-	-	-	-	5	132-98-9	PARAXENOL (see p-PHENYLPHENOL)	
-	-	-	-	-	-	5	132-98-9	PATULIN	
-	39.8 ^a	A	-	+	+	3	76-01-7	PCBs (see AROCLOR 1254)	
-	71.1	-	-	+	-	1,4	82-68-8	PCBs (see AROCLOR 1260)	
NT	-	NT	NT	NT	-	3	87-86-5	PCBs (see KANECHLOR 400)	
-	17.5 ^a	-	-	+	+	1,5	87-86-5	PCNB (see PENTACHLORONITROBENZENE)	
NT	10.5 ^a	NT	NT	+	P	5	87-86-5	PCP (see 2,3,4,5,6-PENTACHLOROPHENOL)	
-	-	E	E	-	-	5	78-11-5	PENICILLIN VK	
NT	3.12 ^a	NT	NT	+	+	5	57590-20-2	PENTA (see 2,3,4,5,6-PENTACHLOROPHENOL (Dowicide EC-7))	
-	NT	-	NT	NT	NT	1	13010-10-1	PENTACHLOROETHANE	
NT	5.87	NT	NT	-	+	1	1119-68-2	PENTACHLORONITROBENZENE	
NT	-	NT	NT	-	NT	1	8006-90-4	2,3,4,5,6-PENTACHLOROPHENOL	
0.662 ^a	NT	+	+	NT	NT	1	60102-37-6	2,3,4,5,6-PENTACHLOROPHENOL (Dowicide EC-7)	
741 ^a	1100 ^{af}	+	+	+	+	1-3	62-44-2	2,3,4,5,6-PENTACHLOROPHENOL, TECHNICAL GRADE	
1230	NT	+	NT	NT	NT	1	60-80-0	PENTAERYTHRITOL TETRANITRATE WITH 80% D-LACTOSE MONOHYDRATE	
303 ^a	71.1	+	+	-	+	1	136-40-3	D-LACTOSE MONOHYDRATE	
0.523	0.211 ^a	-	+	+	+	1	3546-10-9	PERCHLOROETHYLENE (see TETRACHLOROETHYLENE)	
-	-	-	-	-	-	1	834-28-6	PERTHANE (see p,p'-ETHYL-DDD)	
-	4.18 ^a	-	-	+	+	1-5	50-06-6	PETASITENINE	
74.3 ^a	34.6 ^a	+	+	+	+	1,4	57-30-7	PETN, NF (see PENTAERYTHRITOL TETRANITRATE WITH 80% D-LACTOSE MONOHYDRATE)	
-	-	-	-	-	-	2	108-95-2	PHENACETIN	
NT	-	NT	NT	-	-	1	92-84-2	PHENACETIN, ASPIRIN, AND CAFFEINE (see ASPIRIN, PHENACETIN, AND CAFFEINE)	
0.71 ^{ad}	4.9 ^{ad}	+	+	+	+	1	63-92-3	PHENAZONE	
2.31	NT	B+	B+	NT	NT	1	7227-91-0	PHENAZOPYRIDINE.HCl	
NT	-	NT	NT	-	-	1	103-72-0	PHENESTERIN	
-	-	-	-	-	-	1	89-25-8	PHENFORMIN.HCl	
-	-	-	-	-	E	1,2,5	135-88-6	PHENOBARBITAL ^h	
-	-	-	-	-	-	1	2198-59-6	PHENOBARBITAL, SODIUM	
-	-	-	-	-	-	1	103-85-5	PHENOBARBITONE (see PHENOBARBITAL)	
17.7 ^a	-	+	+	-	-	1,2	842-07-9	PHENOBARBITONE, SODIUM (see PHENOBARBITAL, SODIUM)	
-	-	-	-	-	-	2	108-95-2	PHENOL	
NT	-	NT	NT	-	-	1	92-84-2	PHENOTHIAZINE	
0.71 ^{ad}	4.9 ^{ad}	+	+	+	+	1	63-92-3	PHENOXYBENZAMINE.HCl	
2.31	NT	B+	B+	NT	NT	1	7227-91-0	1-PHENYL-3,3-DIMETHYLTRIAZENE	
NT	-	NT	NT	-	-	1	103-72-0	PHENYL ISOTHIOCYANATE	
-	-	-	-	-	-	1	89-25-8	1-PHENYL-3-METHYL-5-PYRAZOLONE	
-	-	-	-	-	E	1,2,5	135-88-6	PHENYL-beta-NAPHTHYLAMINE ^h	
-	-	-	-	-	-	1	2198-59-6	N-PHENYL-2-NAPHTHYLAMINE (see PHENYL-beta-NAPHTHYLAMINE)	
-	-	-	-	-	-	1	103-85-5	N-PHENYL-p-PHENYLENEDIAMINE.HCl	
17.7 ^a	-	+	+	-	-	1,2	842-07-9	1-PHENYL-2-THIOUREA	
-	-	-	-	-	-	1	103-85-5	4-PHENYLACETANILIDE (see 4-ACETYLAMINOBIOPHENYL)	
17.7 ^a	-	+	+	-	-	1,2	842-07-9	1-PHENYL-2-NAPHTHOL	

TD ₅₀ (mg/kg/day)		Positivity				Plot	CAS		Chemical Name
Rat	Mouse	MR	FR	MM	FM	Number	Number		
-	NT	-	-	NT	NT	5	50-33-9	PHENYLBUTAZONE	
NT	-	NT	NT	-	-	5	108-45-2	m-PHENYLENEDIAMINE	
-	NT	-	-	NT	NT	3	106-50-3	p-PHENYLENEDIAMINE	
-	-	-	NT	-	-	1	541-69-5	m-PHENYLENEDIAMINE.2HCl	
248	611 ^a	+	NT	+	+	1	615-28-1	o-PHENYLENEDIAMINE.2HCl	
-	-	-	-	-	-	1	624-18-0	p-PHENYLENEDIAMINE.2HCl	
-	-	-	-	-	-	4	61-76-7	PHENYLEPHRINE.HCl	
								PHENYLETHYLBARBITURIC ACID (see PHENOBARBITAL)	
NT	14.6	NT	NT	-	+	1	156-51-4	PHENYLETHYLHYDRAZINE SULFATE	
29.1 ^a	NT	+	+	NT	NT	3	122-60-1	PHENYLGLYCIDYL ETHER	
NT	-	NT	NT	NT	-	1	100-63-0	PHENYLHYDRAZINE	
NT	70.6 ^a	NT	NT	+	+	1	59-88-1	PHENYLHYDRAZINE.HCl	
NT	-	NT	NT	-	-	3	66-05-7	beta-PHENYLISOPROPYLHYDRAZINE.HCl	
NT	-	NT	NT	-	-	1	62-38-4	PHENYLMERCURIC ACETATE	
195 ^{af}	-	+	+	-	-	1,3,4	132-27-4	o-PHENYLPHENATE, SODIUM	
232	-	+	NT	-	-	1,3	90-43-7	o-PHENYLPHENOL	
NT	-	NT	NT	-	-	1	92-69-3	p-PHENYLPHENOL	
								PHENYTOIN (see 5,5-DIPHENYLHYDANTOIN)	
NT	2.21 ^d	NT	NT	-	+	1	17673-25-5	PHORBOL	
NT	-	I	I	-	-	1	13171-21-6	PHOSPHAMIDON	
-	NT	-	-	NT	NT	1	-	PHOSPHATED DISTARCH PHOSPHATE	
-	NT	-	-	NT	NT	4	7803-51-2	PHOSPHINE	
								PHOTODIELDRIN (see DIELDRIN, PHOTO-)	
								PHOTOMIREX (see MIREX, PHOTO-)	
-	-	-	-	-	-	1	88-96-0	PHTHALAMIDE	
-	-	-	-	-	-	1	85-44-9	PHTHALIC ANHYDRIDE	
								PHTJVAZID (see ISONICOTINIC ACID VANILLYLIDENEHYDRAZIDE)	
-	-	-	A	-	-	1	1918-02-1	PICLORAM	
NT	-	NT	NT	-	-	3	56393-22-7	PILDALAZINE	
-	NT	-	-	NT	NT	1	92-13-7	PILOCARPINE	
-	NT	-	-	NT	NT	1	7681-93-8	PIMARICIN	
								PIP (see N-NITROSOPIPERIDINE)	
-	NT	-	-	NT	NT	1	110-85-0	PIPERAZINE	
-	NT	-	-	NT	NT	1	110-89-4	PIPERIDINE	
-	-	-	-	-	-	1,4	51-03-6	PIPERONYL BUTOXIDE	
NT	-	NT	NT	-	-	1	51-03-6	PIPERONYL BUTOXIDE IN SOLVENT	
-	62.2	-	-	+	-	1	120-62-7	PIPERONYL SULFOXIDE	
154 ^a	-	+	+	-	-	1	1955-45-9	PIVALOLACTONE	
								PLANOFIX (see 1-NAPHTHALENE ACETIC ACID)	
0.148 ^a	0.381 ^a	+	+	+	+	3	67774-32-7	POLYBROMINATED BIPHENYL MIXTURE	
-	NT	NT	-	NT	NT	1	59536-65-1	POLYBROMINATED BIPHENYLS	
								POLYCHLORINATED BIPHENYLS (see AROCLOR 1254)	
								POLYCHLORINATED BIPHENYLS (see AROCLOR 1260)	
								POLYCHLORINATED BIPHENYLS (see KANECHLOR 400)	
-	-	NT	-	NT	-	1	-	POLYVINYLPIRIDINE-N-OXIDE	
								PONCEAU 3R (see FD & C RED NO. 1)	
								PONCEAU 4R (see SX PURPLE)	
								PONCEAU MX (see D & C RED NO. 5)	
								PONCEAU SX (see FD & C RED NO. 4)	
								POTASSIUM BROMATE (see BROMATE, POTASSIUM)	
-	NT	-	NT	NT	NT	4	7447-40-7	POTASSIUM CHLORIDE	
								POTASSIUM METABISULFITE (see SULFITE, POTASSIUM METABI-)	
-	NT	-	-	NT	NT	2	55268-74-1	PRAZIQUANTEL ^b	
19.2	NT	NT	+	NT	NT	4	29069-24-7	PREDNIMUSTINE	
-	NT	NT	-	NT	NT	4	50-24-8	PREDNISOLONE	
-	NT	-	-	NT	NT	1	-	PREMARIN	
NT	-	NT	NT	-	-	3	40778-40-3	PRIMIDOLOL.HCl	
4.01 ^d	NT	+	NT	NT	NT	1	671-16-9	PROCARBAZINE	
0.284 ^{ad}	0.194 ^{ad}	+	+	+	+	1	366-70-1	PROCARBAZINE.HCl ⁸	

TD ₅₀ (mg/kg/day)		Positivity				Plot	CAS		Chemical Name
Rat	Mouse	MR	FR	MM	FM	Number	Number		
NT	NT	I	I	I	I	1	952-23-8	PROFLAVINE.HCl HEMIHYDRATE	
NT	-	NT	NT	-	-	1	54-80-8	PRONETHALOL	
NT	-	NT	NT	-	-	1	51-02-5	PRONETHALOL.HCl	
3.64 ^a	NT	+	+	NT	NT	1	1120-71-4	PROPANE SULTONE	
NT	-	NT	NT	-	-	1	139-40-2	PROPABINE	
								2-PROPENAMIDE (see ACRYLAMIDE)	
								p-PROPENYLANISOLE (see ANETHOLE)	
1.34 ^a	1.16 ^a	NT	+	+	+	1,2	57-57-8	beta-PROPIOLACTONE	
-	-	-	-	-	-	3	318-98-9	PROPRANOLOL.HCl	
NT	-	NT	NT	-	-	1	1114-71-2	PROPYL N-ETHYL-N-BUTYLTHIOCARBAMATE	
NT	8.74 ^a	NT	NT	+	+	1	77337-54-3	N-N'-PROPYL-N-FORMYLHYDRAZINE	
-	-	-	-	-	-	2,5	121-79-9	PROPYL GALLATE	
NT	-	NT	NT	-	-	1	83-59-0	N-PROPYL ISOME	
0.919 ^a	NT	+	NT	NT	NT	1	13010-07-6	N-PROPYL-N-NITRO-N-NITROGUANIDINE	
-	-	-	-	-	-	3,5	115-07-1	PROPYLENE	
								PROPYLENE DICHLORIDE (see 1,2-DICHLOROPROPANE)	
-	NT	-	-	NT	NT	1	57-55-6	PROPYLENE GLYCOL	
35.1 ^{af}	732 ^a	+	+	+	+	2,3,5	75-56-9	1,2-PROPYLENE OXIDE	
NT	41.4 ^a	NT	NT	+	+	1	56795-66-5	PROPYLHYDRAZINE.HCl	
								DI-N-PROPYLNITROSAMINE (see N-NITROSODIPROPYLAMINE)	
10.3 ^a	409	+	+	B+	B+	1	51-52-5	PROPYLTHIOURACIL	
NT	-	NT	NT	-	-	3	22760-18-5	PROQUAZONE	
-	NT	-	NT	NT	NT	1	1508-45-8	PRORESID	
24500	NT	B+	B+	NT	NT	1	2611-82-7	SX PURPLE	
-	-	-	-	-	I	1	98-96-4	PYRAZAPON (see RIPAPEPAM)	
								3-PYRIDOYL HYDRAZINE (see NICOTINIC ACID HYDRAZIDE)	
175 ^a	NT	+	+	NT	NT	3	59-33-6	PYRILAMINE MALEATE	
-	-	-	-	I	-	1	58-14-0	PYRIMETHAMINE	
5.12 ^a	-	+	+	-	-	1,3	117-39-5	QUERCETIN	
-	NT	-	-	NT	NT	1-3	6151-25-3	QUERCETIN DIHYDRATE ^b	
-	-	-	-	-	-	1,2	---	QUILLAIA EXTRACT	
								8-QUINOLINOL (see 8-HYDROXYQUINOLINE)	
106	-	-	+	-	-	1	105-11-3	p-QUINONE DIOXIME	
								QUINTOZENE (see PENTACHLORONITROBENZENE)	
								C.I. BASIC RED 9.HCl (see p-ROSANILINE.HCl)	
-	-	-	-	-	-	1,2	3567-69-9	C.I. FOOD RED 3	
233 ^a	659 ^a	+	+	+	+	1,3	3761-53-3	D & C RED NO. 5	
104	-	+	A	-	-	1,2	5160-02-1	D & C RED NO. 9	
-	NT	-	-	NT	NT	1	1248-18-6	D & C RED NO. 10	
225 ^{af}	NT	+	+	NT	NT	1	3564-09-8	FD & C RED NO. 1	
632 ^a	NT	B+	B+	NT	NT	1	915-67-3	FD & C RED NO. 2	
-	-	-	-	-	-	1,5	16423-68-0	FD & C RED NO. 3	
6130 ^a	-	B+	B+	B-	B-	1	4548-53-2	FD & C RED NO. 4 ^h	
-	-	-	-	E	I	3	2871-01-4	HC RED NO. 3	
								REDAX (see N-NITROSODIPHENYLAMINE)	
								RENARDINE (see SENKIRKINE)	
0.306	3.58 ^a	+	-	+	+	1	50-55-5	RESERPINE	
-	NT	-	-	NT	NT	1	302-79-4	RETINOIC ACID	
-	NT	-	-	NT	NT	4,5	127-47-9	RETINOL ACETATE	
-	NT	-	NT	NT	NT	5	79-81-2	RETINOL PALMITATE	
-	33.6	-	-	-	+	1	13292-46-1	RIFAMPICIN	
-	67.8 ^a	-	-	+	+	3	26308-28-1	RIPAPEPAM	
-	NT	-	-	NT	NT	1,2	632-99-5	ROSANILINE.HCl ^h	
21.2 ^a	28.8 ^a	+	+	+	+	1-3	569-61-9	p-ROSANILINE.HCl ^h	
								ROTAX (see 2-MERCAPTOBENZOTHIAZOLE)	
-	-	E	-	-	-	1,5	83-79-4	ROTENONE	
								ROXARSONE (see 3-NITRO-4-HYDROXYPHENYLARSONIC ACID)	
								RUTIN (see RUTIN TRIHYDRATE)	

TD ₅₀ (mg/kg/day)		Positivity				Plot	CAS		Chemical Name
Rat	Mouse	MR	FR	MM	FM	Number	Number		
-	NT	-	-	NT	NT	3	12768-44-4	RUTIN SULFATE	
-	NT	-	-	NT	NT	1,2	153-18-4	RUTIN TRIHYDRATE ^h	
NT	-	NT	NT	-	-	1	81-07-2	SACCHARIN	
1110 ^{af}	-	+	-	-	-	1-4	128-44-9	SACCHARIN, SODIUM	
340 ^a	27 ^a	+	B+	+	+	1-3	94-59-7	SAFROLE	
36.3 ^a	NT	NT	+	NT	NT	3,5	18559-94-9	SALBUTAMOL SANAMYCIN (see ACTINOMYCIN C) L-SARCOLYSIN (see MELPHALAN) SDDC (see SODIUM DIETHYLDITHIOCARBAMATE TRIHYDRATE)	
NT	-	NT	NT	NT	-	1	7782-49-2	SELENIUM	
NT	1.49	NT	NT	+	-	1	5456-28-0	SELENIUM DIETHYLDITHIOCARBAMATE	
NT	-	NT	NT	-	-	1	144-34-3	SELENIUM DIMETHYLDITHIOCARBAMATE	
6.14 ^a	46.8	+	+	-	+	1	7446-34-6	SELENIUM SULFIDE	
1.7 ^d	NT	+	NT	NT	NT	1	2318-18-5	SENKIRKINE	
NT	-	NT	NT	-	-	1	122-34-9	SEVIN (see CARBARYL) SIMAZINE	
NT	-	NT	NT	-	-	1	6385-58-6	SODIUM ARSENITE (see ARSENITE, SODIUM)	
-	-	-	NT	-	-	4	7647-14-5	SODIUM AZIDE (see AZIDE, SODIUM)	
-	-	-	-	-	-	4	7758-19-2	SODIUM BENZOATE (see BENZOATE, SODIUM) SODIUM BITHIONOLATE	
-	-	-	-	-	-	1	148-18-5	SODIUM CHLORIDE	
-	-	-	-	-	-	4	7681-52-9	SODIUM CHLORITE SODIUM CYCLAMATE (see CYCLAMATE, SODIUM) SODIUM DIETHYLDITHIOCARBAMATE TRIHYDRATE SODIUM FLUORIDE (see FLUORIDE, SODIUM) SODIUM HYPOCHLORITE	
-	-	-	-	-	-	1	110-44-1	SODIUM NIOBATE (see NIOBATE, SODIUM)	
-	-	-	-	-	-	3	959-24-0	SODIUM NITRATE (see NITRATE, SODIUM)	
-	NT	-	-	NT	NT	1	8002-43-5	SODIUM NITRITE (see NITRITE, SODIUM) SODIUM SULFATE (see SULFATE, SODIUM) SODIUM TETRAFLUOROBORATE (see TETRAFLUOROBORATE, SODIUM) SODIUM TUNGSTATE (see TUNGSTATE, SODIUM)	
0.0825 ^{af}	0.689 ^a	-	-	NT	NT	1	9045-28-7	SORBIC ACID	
-	NT	+	B+	NT	+	1,2	10048-13-2	SOTALOL.HCl SOYBEAN LECITHIN SQ 18506 (see trans-5-AMINO-3[2-(5-NITRO-2-FURYL) VINYL-1,2,4-OXADIAZOLE]) STANNOUS CHLORIDE (see TIN (II) CHLORIDE) STARCH ACETATE STERIGMATOCYSTIN	
0.776 ^{ad}	0.193 ^{ad}	+	+	+	+	1	18883-66-4	STRAWBERRY ALDEHYDE (see ETHYL METHYLPHENYLGLYCIDATE)	
NT	0.644 ^a	NT	NT	+	-	1	8001-50-1	STREPTOZOTOCIN	
23.3	-	-	+	A	-	1,5	100-42-5	STROBANE	
-	-	-	-	-	-	1	mixture	STYRENE	
30.7 ^a	90 ^a	+	+	+	+	3-5	96-09-3	STYRENE AND beta-NITROSTYRENE MIXTURE STYRENE OXIDE	
NT	-	NT	NT	NT	-	1	57-50-1	SUCCINIC ACID 2,2-DIMETHYLHYDRAZIDE (see DAMINOZIDE)	
17.2 ^a	27.3 ^a	+	+	+	+	1	95-06-7	SUCROSE	
NT	-	NT	NT	NT	-	1	7757-82-6	SULFADS (see DIPENTAMETHYLENETHIURAM HEXASULFIDE)	
-	-	-	-	-	-	1	127-69-5	SULFALLATE	
NT	-	NT	NT	-	-	1	4429-42-9	SULFATE, SODIUM	
-	-	-	-	-	-	1	77-79-2	SULFISOXAZOLE	
55.6 ^b	NT	NT	+	NT	NT	1	77-46-3	SULFITE, POTASSIUM METABI-3-SULFOLENE	
1.91 ^d	NT	+	NT	NT	NT	1	22571-95-5	4,4'-SULFONYLBISACETANILIDE SULPYRIN (see DIPYRONE) SUNSET YELLOW FCF (see FD & C YELLOW NO. 6) SYMPHYTINE	

TD ₅₀ (mg/kg/day)		Positivity				Plot	CAS		Chemical Name
Rat	Mouse	MR	FR	MM	FM	Number	Number		
-	NT	-	-	NT	NT	1	569-57-3	2,4,5-T (see 2,4,5-TRICHLOROPHENOXYACETIC ACID)	
-	-	-	-	-	-	2	39300-88-4	TACE TARA GUM TARTRAZINE (see FD & C YELLOW NO. 5) TBP (see 2,2-THIOBIS(4,6-DICHLOROPHENOL)) TCDD (see 2,3,7,8-TETRACHLORODIBENZO-p-DIOXIN) TCE (see TRICHLOROETHYLENE) TCE (see TRICHLOROETHYLENE (WITHOUT EPICHLOROHYDRIN)) TDE (see p,p'-DDD)	
NT	-	NT	NT	-	-	1	297-78-9	TELODRIN	
33.2 ^a	36.3	+	P	I	+	3	542-75-6	TELONE II TELVAR (see 3-(p-CHLOROPHENYL)-1,1-DIMETHYLUREA) TEMIK (see ALDICARB)	
410	NT	NT	+	NT	NT	3	23031-25-6	TERBUTALINE 2,3,4,6-TETRA-O-ACETYL-1-THIO-1-beta-D-GLUCOPYRANOSATO-S) (TRIETHYLPHOSPHINE) GOLD (see AURANOFIN)	
395	288	+	NT	+	-	1	7411-49-6	3,3',4,4'-TETRAAMINOBIIPHENYL.4HCI	
-	-	-	-	-	-	1	2438-88-2	TETRACHLORO-p-BENZOQUINONE (see CHLORANIL)	
-	-	-	-	NT	-	1	15721-02-5	2,2',5,5'-TETRACHLOROBENZIDINE	
6.67E-6 ^{af}	8.68E-5 ^a	+	+	+	+	1	1746-01-6	2,3,7,8-TETRACHLORODIBENZO-p-DIOXIN	
NT	-	NT	NT	-	-	1	116-29-0	2,4,5,4'-TETRACHLORODIPHENYL SULFONE	
-	175 ^a	-	-	+	+	3	630-20-6	1,1,1,2-TETRACHLOROETHANE	
-	35.4 ^a	-	-	+	+	1	79-34-5	1,1,2,2-TETRACHLOROETHANE	
90.8 ^a	75.6 ^a	+	P	+	+	1,3	127-18-4	TETRACHLOROETHYLENE	
-	228	-	A	+	A	1,4	961-11-5	TETRACHLORVINPHOS	
-	-	-	-	-	-	5	64-75-5	TETRACYCLINE.HCI	
-	-	-	-	-	-	1	97-77-8	TETRAETHYLTHIURAM DISULFIDE	
-	-	-	-	-	-	1	97-77-8	TETRAFIDON (see 2,4,5,4'-TETRACHLORODIPHENYL SULFONE)	
-	86.3	-	NT	+	-	1	63886-77-1	TETRAFLUORO-m-PHENYLENEDIAMINE.2HCI	
NT	NT	NT	NT	NT	NT	2	13755-29-8	TETRAFLUOROBORATE, SODIUM ^b	
24.3	NT	B+	B+	NT	NT	1	40548-68-3	TETRAHYDRO-2-NITROSO-2H-1,2-OXAZINE	
-	NT	-	NT	NT	NT	5	18771-50-1	3,4,5,6-TETRAHYDROURIDINE	
-	-	-	-	-	-	4	124-64-1	TETRAKIS(HYDROXYMETHYL)PHOSPHONIUM CHLORIDE	
-	-	-	-	-	-	4	55566-30-8	TETRAKIS(HYDROXYMETHYL)PHOSPHONIUM SULFATE	
-	-	-	-	-	-	1,3	137-26-8	2,2,9,9-TETRAMETHYL-1,10-DECANEDIOL (see GEMCADIOL) TETRAMETHYLTHIURAM DISULFIDE TETRAMETHYLTHIURAM DISULFIDE AND FERRIC NITROSODIMETHYLDITHIOCARBAMATE (see VANGUARD GF)	
NT	-	NT	NT	-	-	1	97-74-5	TETRAMETHYLTHIURAM MONOSULFIDE	
-	NT	-	-	NT	NT	4	91-79-2	TETRASUL (see p-CHLOROPHENYL-2,4,5-TRICHLOROPHENYL SULFIDE) beta-TGdR (see beta-THIOGUANINE DEOXYRIBOSIDE)	
-	NT	-	-	NT	NT	4	148-79-8	THENYLDIAMINE THIABENDAZOLE 2-(4-THIAZOLYL)-BENZIMAZOLE (see THIABENDAZOLE)	
0.122 ^{ad}	0.21 ^{ad}	+	+	+	+	1	52-24-4	THIO-TEPA	
11.5	5.36 ^a	+	NT	+	+	1,5	62-55-5	THIOACETAMIDE	
NT	-	NT	NT	-	-	1	97-18-7	2,2-THIOBIS(4,6-DICHLOROPHENOL) THIOCARBAMYLHYDRAZINE (see THIOSEMICARBAZIDE) THIODAN (see ENDOSULFAN)	
5.52 ^a	32.7 ^a	+	+	+	+	1	139-65-1	4,4'-THIODIANILINE	
2.1 ^d	NT	A	+	I	I	1	64039-27-6	beta-THIOGUANINE DEOXYRIBOSIDE	

TD ₅₀ (mg/kg/day)		Positivity				Plot	CAS		Chemical Name
Rat	Mouse	MR	FR	MM	FM	Number	Number		
-	-	NT	-	-	-	1,3	79-19-6	THIOSEMICARBAZIDE	
NT	48.6 ^a	NT	NT	+	+	1	141-90-2	THIOURACIL	
93.5 ^a	-	+	-	NT	-	1	62-56-6	THIOUREA	
								THIRAM (see TETRAMETHYLTHIURAM DISULFIDE)	
								THPC (see TETRAKIS(HYDROXYMETHYL) PHOSPHONIUM CHLORIDE)	
								THPS (see TETRAKIS(HYDROXYMETHYL) PHOSPHONIUM SULFATE)	
								TIBRIC ACID (see 2-CHLORO-5-(3,5-DIMETHYLPYPERIDINOSULPHONYL)BENZOIC ACID)	
-	-	-	-	-	-	4	55567-81-2	TILIDINE FUMARATE	
								TILLAM-6-E (see PROPYL N-ETHYL-N-BUTYLTHIOCARBAMATE)	
-	-	-	-	-	-	1,2	7772-99-8	TIN (II) CHLORIDE	
-	-	-	-	-	-	1	13463-67-7	TITANIUM DIOXIDE	
NT	-	NT	NT	-	-	1	14481-26-6	TITANIUM OXALATE, POTASSIUM	
								TMTD (see TETRAMETHYLTHIURAM DISULFIDE)	
-	NT	-	NT	NT	NT	5	10191-41-0	DL-alpha-TOCOPHEROL	
-	NT	-	-	NT	NT	3	58-95-7	DL-alpha-TOCOPHERYL ACETATE	
-	-	-	-	-	-	1	1156-19-0	TOLAZAMIDE	
-	-	-	-	-	-	1	64-77-7	TOLBUTAMIDE	
578 ^a	NT	+	+	NT	NT	3,4	108-88-3	TOLUENE	
25.4 ^a	181	+	+	-	+	4	26471-62-5	TOLUENE DIISOCYANATE, COMMERCIAL GRADE (2,4 (80%)- AND 2,6 (20%)-)	
								2,4-TOLUENEDIAMINE.2HCl (see 2,4-DIAMINOTOLUENE.2HCl)	
								2,6-TOLUENEDIAMINE.2HCl (see 2,6-DIAMINOTOLUENE.2HCl)	
								2,5-TOLUENEDIAMINE SULFATE (see 2,5-DIAMINOTOLUENE SULFATE)	
3960	NT	B+	B+	NT	NT	1	88-19-7	o-TOLUENESULFONAMIDE	
-	1440 ^b	-	NT	+	-	1	638-03-9	m-TOLUIDINE.HCl	
23.3 ^a	646 ^a	+	+	+	+	1,2	636-21-5	o-TOLUIDINE.HCl	
-	49.1 ^a	-	NT	+	+	1	540-23-8	p-TOLUIDINE.HCl	
-	206	-	-	+	-	1	622-51-5	p-TOLYLUREA	
-	4.08 ^a	A	A	+	+	1	8001-35-2	TOXAPHENE	
0.00504 ^d	NT	+	NT	NT	NT	1	68-76-8	TRENIMON	
469 ^a	-	P	+	-	-	5	75-25-2	TRIBROMOMETHANE	
NT	-	NT	NT	-	-	1	6379-46-0	1,2,3-TRICHLORO-4,6-DINITROBENZENE	
-	NT	-	-	NT	NT	5	76-13-1	1,1,2-TRICHLORO-1,2,2-TRIFLUOROETHANE, TECHNICAL GRADE	
-	259	-	NT	+	-	1	634-93-5	2,4,6-TRICHLOROANILINE	
-	47.6 ^a	-	-	+	+	1	79-00-5	1,1,2-TRICHLOROETHANE	
-	-	I	I	I	I	1,5	71-55-6	1,1,1-TRICHLOROETHANE, TECHNICAL GRADE	
557 ^a	421 ^{af}	+	-	+	+	1,3,4	79-01-6	TRICHLOROETHYLENE ^h	
-	294 ^a	I	I	+	+	5	79-01-6	TRICHLOROETHYLENE (WITHOUT EPICHLOROHYDRIN)	
-	-	I	I	-	-	1,5	75-69-4	TRICHLOROFUOROMETHANE	
NT	-	NT	NT	-	-	1	133-07-3	N-(TRICHLOROMETHYLTHIO)PHTHALIMIDE	
405	856 ^a	+	-	+	+	1	88-06-2	2,4,6-TRICHLOROPHENOL	
NT	-	NT	NT	-	-	1	93-72-1	2-(2,4,5-TRICHLOROPHENOXY)PROPIONIC ACID	
-	-	-	-	-	-	1	93-76-5	2,4,5-TRICHLOROPHENOXYACETIC ACID	
-	100 ^a	-	-	+	+	1,4	102-71-6	TRIEHANOLAMINE	
-	NT	-	NT	NT	NT	1	112-27-6	TRIEHTYLENE GLYCOL	
6.79	9.98	NT	+	NT	+	1	42011-48-3	2,2,2-TRIFLUORO-N-[4-(5-NITRO-2-FURYL)-2-THIAZOLYL]ACETAMIDE	
-	330	-	-	-	+	1	1582-09-8	TRIFLURALIN, TECHNICAL GRADE	
								TRIODOMETHANE (see IODOFORM)	
20.4 ^a	6.13	+	+	-	+	1	137-17-7	2,4,5-TRIMETHYLANILINE	
98.5 ^b	40 ^a	+	NT	+	+	1	21436-97-5	2,4,5-TRIMETHYLANILINE.HCl	
5.17	19.3 ^a	+	NT	+	+	1	6334-11-8	2,4,6-TRIMETHYLANILINE.HCl	
-	335	A	-	-	+	1	512-56-1	TRIMETHYLPHOSPHATE	
25.8	-	-	+	-	-	1	2489-77-2	TRIMETHYLTHIOUREA	

TD ₅₀ (mg/kg/day)		Positivity				Plot	CAS		Chemical Name
Rat	Mouse	MR	FR	MM	FM	Number	Number		
NT	-	NT	NT	-	-	1	900-95-8	TRIPHENYLTIN ACETATE	
-	-	-	-	-	-	1	76-87-9	TRIPHENYLTIN HYDROXIDE	
NT	3.44 ^d	NT	NT	NT	+	1	38571-73-2	TRIS (see TRIS(2,3-DIBROMOPROPYL)PHOSPHATE)	
1.57 ^a	80.1 ^a	+	+	+	+	1,3	126-72-7	TRIS-1,2,3-(CHLOROMETHOXY)PROPANE	
-	2560	E	-	-	P	3	78-42-2	TRIS(2,3-DIBROMOPROPYL)PHOSPHATE	
								TRIS(2-ETHYLHEXYL)PHOSPHATE	
								TRISODIUM ETHYLENEDIAMINETETRAACETATE	
								TRIHYDRATE (see EDTA, TRISODIUM SALT	
								TRIHYDRATE)	
								TRP-P-1 ACETATE (see 3-AMINO-1,4-DIMETHYL-5H-	
								PYRIDO[4,3-b]INDOLE ACETATE)	
								TRP-P-2 ACETATE (see 3-AMINO-1-METHYL-5H-	
								PYRIDO[4,3-b]INDOLE ACETATE)	
-	NT	-	NT	NT	NT	3	54-12-6	DL-TRYPTOPHAN	
-	-	-	-	-	-	1-3	73-22-3	L-TRYPTOPHAN	
								TUBATOXIN (see ROTENONE)	
-	NT	-	-	NT	NT	1	13472-45-2	TUNGSTATE, SODIUM	
								TYLENOL (see ACETAMINOPHEN)	
								UDMH (see 1,1-DIMETHYLHYDRAZINE)	
								UNADS (see TETRAMETHYLTHIURAM	
								MONOSULFIDE)	
-	-	-	-	-	-	1	57-13-6	UREA	
41.3	12.5 ^a	B+	B+	+	+	1	51-79-6	URETHANE ^b	
								VALORON (see TILIDINE FUMARATE)	
NT	-	NT	NT	-	-	1	27774-13-6	VANADYL SULFATE	
								VANCIDE BL (see 2,2-THIOBIS(4,6-DICHLOROPHENOL))	
								VANCIDE BN (see SODIUM BITHIONOLATE)	
								VANCIDE PB (see 1,2,3-TRICHLORO-4,6-	
								DINITROBENZENE)	
NT	-	NT	NT	-	-	1	mixture	VANGUARD GF	
								VANGUARD N (see NICKEL	
								DIBUTYLDITHIOCARBAMATE)	
								VAPONA (see DICHLORVOS)	
-	NT	-	NT	NT	NT	1	865-21-4	VINBLASTINE	
132 ^a	NT	+	+	NT	NT	3	108-05-4	VINYL ACETATE	
17.9 ^a	NT	+	+	NT	NT	1	593-60-2	VINYL BROMIDE	
3.69 ^{af}	10.6 ^a	+	+	+	+	1-5	75-01-4	VINYL CHLORIDE ^b	
NT	94.4	I	I	I	+	4	100-40-3	4-VINYLCYCLOHEXENE	
-	22 ^a	-	-	+	+	1-4	75-35-4	VINYLDENE CHLORIDE	
418 ^a	-	-	+	-	-	1,3	1694-09-3	FD & C VIOLET NO. 1	
								VITAMIN A ACID (see RETINOIC ACID)	
								VITAMIN A, ACETATE (see RETINOL ACETATE)	
								VITAMIN A, PALMITATE (see RETINOL PALMITATE)	
								VITAMIN C (see L-ASCORBIC ACID)	
								VITAMIN C, SODIUM (see L-ASCORBATE, SODIUM)	
								VITAMIN D2 (see CALCIFEROL)	
								VITAMIN E (see DL-alpha-TOCOPHERYL)	
								VITAMIN E ACETATE (see DL-alpha-TOCOPHERYL	
								ACETATE)	
-	-	-	-	-	-	4	1330-20-7	XYLENE MIXTURE (60% m-XYLENE, 9% o-XYLENE,	
								14% p-XYLENE, 17% ETHYLBENZENE)	
524 ^a	NT	+	+	NT	NT	4	mixture	XYLENE MIXTURE (m-XYLENE, o-XYLENE,	
								p-XYLENE)	
-	12.4	-	NT	-	+	1	21436-96-4	2,4-XYLIDINE.HCl	
152	552 ^a	+	NT	+	+	1	51786-53-9	2,5-XYLIDINE.HCl	
380	1020	+	-	-	+	2	2832-40-8	C.I. DISPERSE YELLOW 3	
-	-	-	-	-	-	1	6358-85-6	C.I. PIGMENT YELLOW 12	
-	-	B-	B-	B-	B-	1	5979-28-2	C.I. PIGMENT YELLOW 16	
-	-	B-	B-	B-	B-	1	5567-15-7	C.I. PIGMENT YELLOW 83	
								C.I. SOLVENT YELLOW 14 (see 1-PHENYLAZO-2-	
								NAPHTHOL)	
-	10900	-	-	+	-	1	128-66-5	C.I. VAT YELLOW 4	
								DIARYLANILIDE YELLOW (see C.I. PIGMENT	

TD ₅₀ (mg/kg/day)		Positivity				Plot	CAS	Chemical Name
Rat	Mouse	MR	FR	MM	FM	Number	Number	
								YELLOW 12)
-	-	-	-	-	-	1,5	1934-21-0	FD & C YELLOW NO. 5
-	-	-	-	-	-	1,2	2783-94-0	FD & C YELLOW NO. 6
-	22 ^a	-	-	+	+	2	17924-92-4	ZEARALENONE
								ZECTRAN (see MEXACARBATE)
								ZETAX (see 2-MERCAPTOBENZOTHIAZOLE, ZINC)
NT	-	NT	NT	-	-	1	136-23-2	ZINC DIBUTYLDITHIOCARBAMATE
NT	-	NT	NT	-	-	1	14324-55-1	ZINC DIETHYLDITHIOCARBAMATE
25.8 ^a	-	+	B+	-	E	1,3	137-30-4	ZINC DIMETHYLDITHIOCARBAMATE
255	-	B+	B+	-	-	1	12122-67-7	ZINC ETHYLENEBISTHIOCARBAMATE
								ZINEB (see ZINC ETHYLENEBISTHIOCARBAMATE)
								ZIRAM (see ZINC DIMETHYLDITHIOCARBAMATE)
NT	-	NT	NT	B-	B-	1	14644-61-2	ZIRCONIUM (IV) SULFATE